MTS Trials - BreastCancerTrials.org

1

Virtual Support and Navigation for People with Stage I-IV Breast Cancer

Show Scientific Title

The Patient Care Outreach, Navigation, Technology and Support 2.0 Study (COUNTS2)

Purpose: To study a virtual patient navigation program to support people with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet started treatment or are currently receiving treatment. You must speak English, Mandarin/Cantonese/Chinese, or Spanish. View full eligibility criteria

What's involved?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Participate in patient navigation program, online or in-person</li> <li class="seamTextUnorderedListItem">Participate in focus groups</li> <li class="seamTextUnorderedListItem">Complete questionnaires, 2 times in 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The focus groups will be used to develop parts of the program specific to culture and language.</li> <li class="seamTextUnorderedListItem">While not able to entirely replace in-person interactions, virtual patient navigation may be used to expand reach and availability of navigation services to a much greater segment of the population.</li> <li class="seamTextUnorderedListItem">Your family member may also be asked to participate in this study.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06648278' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://patientcounts.ucsf.edu/s/About?language=en_CA' target='_blank'>University of California San Francisco: Patient COUNTS</a> </li></ul>

1

Virtual Support and Navigation for People with Stage I-IV Breast Cancer

Show Scientific Title

The Patient Care Outreach, Navigation, Technology and Support 2.0 Study (COUNTS2)

Nearest Location from 94107:
2 miles
Zuckerberg San Francisco General Hospital
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06648278

Phase NA

2

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Show Scientific Title

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Purpose: To compare a technology-based supportive cancer care approach with a team-based supportive cancer care approach.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV breast cancer that is newly diagnosed or whose cancer has come back. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials, virtual, weekly for 4 months, then every 2 weeks for 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials, in person or by phone, weekly for 4 months, then every 2 weeks for 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The educational materials are designed to assist with advance care planning and symptom management. Topics include surrogate decision-makers, advance directives, and physician orders for life-sustaining treatment. The education is delivered to the participant by an electronic health record message or email, or by a lay health worker. </li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05297734' target='_blank'>ClinicalTrials.gov</a> </li></ul>

2

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Show Scientific Title

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Nearest Location from 94107:
2 miles
Zuckerberg San Francisco General
San Francisco, CA

Visits:
Up to 2 to 4 times per month for 1 year

ClinicalTrials.gov: NCT05297734

Phase NA

3

Alisertib Targeted Therapy with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Purpose: To study the safety, best dose, and effects (good and bad) of alisertib, an experimental AURKA inhibitor, with standard of care hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received at least two hormone therapies including a CDK4/6 inhibitor with hormone therapy for advanced disease. You must not have received chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alisertib, by mouth, daily</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alisertib is an experimental targeted therapy called an Aurora Kinase A (AURKA) inhibitor. Blocking AURKA may slow or stop cancer cells from growing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06369285' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pumabiotechnology.com/clinical-trials/alisca_breast1.html' target='_blank'>Puma Biotechnology: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/the-role-of-mtor-aurora-a-kinase-combination-therapy-requires-further-elucidation-in-solid-tumors' target='_blank'>OncLive: Alisertib for Advanced Solid Tumors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alisertib' target='_blank'>National Cancer Institute: Alisertib</a> </li></ul>

3

Alisertib Targeted Therapy with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Nearest Location from 94107:
3 miles
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
4 visits in 1 month, then 1 visit every month

ClinicalTrials.gov: NCT06369285

Phase II

4

Experimental Anti-Estrogen Therapy Alone or with Targeted Therapy or Chemotherapy for Women with Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)

Purpose: To study the anti-cancer activity and safety of giving the experimental anti-estrogen therapy giredestrant alone or with a CDK 4/6 inhibitor, an AKT inhibitor, a PI3K inhibitor, or chemotherapy.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) estrogen-receptor positive (ER+), HER2-negative (HER2-) breast cancer whose disease progressed while taking anti-hormone therapy with a CDK 4/6 inhibitor and who have not received chemotherapy for metastatic disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 6 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, ongoing</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice daily, ongoing</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Ipatasertib, by mouth, daily (3 weeks on, 1 week off), ongoing</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Inavolisib, by mouth, daily, ongoing</li> </ul> Group 5 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> </ul> Group 6 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth, daily, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant is an experimental anti-estrogen therapy you take by mouth. It is a type of anti-estrogen therapy called a SERD (selective estrogen receptor degrader).</li> <li class="seamTextUnorderedListItem">SERDs work by binding to and breaking down estrogen receptors. The only SERD currently approved to treat breast cancer is fulvestrant (Faslodex®). Faslodex is given by injection. </li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor -- it blocks two enzymes, CDK4 and CDK6, that help cancer grow. It is already approved to treat some metastatic breast cancer, but its use in this trial is experimental.</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) is also a CDK 4/6 inhibitor. It is already approved to treat some metastatic breast cancer, but its use in this trial is experimental.</li> <li class="seamTextUnorderedListItem">Ipatasertib is an experimental type of targeted therapy called an AKT inhibitor. It may slow or stop cancer cells from growing by blocking the enzyme (protein) AKT. </li> <li class="seamTextUnorderedListItem">Inavolisib is an experimental type of targeted therapy called a PI3K inhibitor. If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated, allowing cancer cells to grow. Inavolisib may slow or stop cancer cells from growing by blocking this pathway. </li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®) is a type of targeted therapy called an mTOR inhibitor. It works by interfering with a cancer cell's ability to divide and grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04802759' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.genentechoncology.com/pipeline-molecules/serd-3.html' target='_blank'>Genentech Drug Information Page: Giredestrant (GDC-9545)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors (Abemaciclib & Ribociclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.genentechoncology.com/pipeline-molecules/ipatasertib.html' target='_blank'>Genentech Drug Information Page: Ipatasertib (AKT Inhibitor)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.genentechoncology.com/pipeline-molecules/inavolisib.html' target='_blank'>Genentech Drug Information Page: Inavolisib (P13K Alpha Inhibitor)</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/everolimus.aspx' target='_blank'>Chemocare: Everolimus (Afinitor)</a> </li></ul>

4

Experimental Anti-Estrogen Therapy Alone or with Targeted Therapy or Chemotherapy for Women with Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)

Nearest Location from 94107:
3 miles
University of California, San Francisco (UCSF)
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04802759

Phase I-II

5

Niraparib Targeted Therapy and Irinotecan Chemotherapy for Advanced Breast Cancer with BRCA1, BRCA2, ATM, and PALB2 Mutations

Show Scientific Title

Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of niraparib PARP inhibitor with irinotecan chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a BRCA1, BRCA2, ATM, and/or PALB2 mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®), by mouth, 1 week on, 2 weeks off</li> <li class="seamTextUnorderedListItem">Irinotecan (Camptosar®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®) is a type of targeted therapy called a PARP inhibitor. It works by blocking poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA.</li> <li class="seamTextUnorderedListItem">Irinotecan (Camptosar®) is a type of chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Niraparib (Zejula®) and irinotecan (Camptosar®) are approved to treat certain types of cancer. Their use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, ATM, PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05694715' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a617007.html' target='_blank'>Medline Plus: Niraparib (Zejula®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a608043.html' target='_blank'>Medline Plus: Irinotecan (Camptosar®)</a> </li></ul>

5

Niraparib Targeted Therapy and Irinotecan Chemotherapy for Advanced Breast Cancer with BRCA1, BRCA2, ATM, and PALB2 Mutations

Show Scientific Title

Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes

Nearest Location from 94107:
3 miles
University of California, San Francisco
San Francisco, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT05694715

Phase I

6

Talazoparib in Women With Metastatic Triple Negative or HR+, HER2- Breast Cancer with a Tumor (Not Inherited) BRCA1/2 Mutation

Show Scientific Title

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Purpose: To study the anti-cancer activity of the PARP inhibitor Talazoparib (Talzenna®) in breast cancer tumors that test positive for a tumor (not inherited) BRCA 1 or BRCA 2 mutation.

Who is this for?: Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. Your tumor must test positive for a BRCA 1 or a BRCA 2 tumor (not inherited) mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is a type of targeted therapy called a PARP inhibitor. It prevents the PARP protein from repairing damaged DNA in tumor cells.</li> <li class="seamTextUnorderedListItem">BRCA1/2 mutations are called germline when they are inherited. </li> <li class="seamTextUnorderedListItem">BRCA1/2 mutations are called somatic when they are not inherited.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA 1 (tumor), BRCA 2 (tumor)</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03990896' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/somatic-mutation' target='_blank'>NCI Drug Dictionary: Somatic Mutation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com/?source=google&HBX_PK=s_talazoparib&skwid=43700039109817433' target='_blank'>Pfizer Oncology: Talzenna®</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2016/07/how-do-parp-inhibitors-work-in-cancer/' target='_blank'>Dana-Farber Cancer Institue: How Do PARP Inhibitors Work In Cancer? (Video)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/publications/oncology-live/2017/vol-18-no-13/blurring-the-lines-between-germline-and-somatic-mutations-in-cancer' target='_blank'>OncLive: Blurring the Lines Between Germline and Somatic Mutations in Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nature.com/articles/s41416-018-0127-5' target='_blank'>Journal Article: BRCA1/2 Testing: Therapeutic Implications for Breast Cancer Management</a> </li></ul>

6

Talazoparib in Women With Metastatic Triple Negative or HR+, HER2- Breast Cancer with a Tumor (Not Inherited) BRCA1/2 Mutation

Show Scientific Title

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Nearest Location from 94107:
3 miles
UCSF Medical Center-Mission Bay/Benioff Children's Hospital
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT03990896

Phase II

7

BBO-10203 Targeted Therapy with Trastuzumab for Advanced HER2+ or HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Purpose: To study the safety, best dose, and effects (good and bad) of BBO-10203, an experimental targeted therapy, with trastuzumab (Herceptin®) anti-HER2 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received at least 2 lines of anti-HER2 targeted therapy or hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BBO-10203, by mouth, daily</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, weekly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BBO-10203 is an experimental targeted therapy called a PI3Kα/AKT inhibitor. Blocking PI3Kα and AKT may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06625775' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://bridgebiooncology.com/platform/' target='_blank'>BridgeBio: BBO-10203 Drug Information Page</a> </li></ul>

7

BBO-10203 Targeted Therapy with Trastuzumab for Advanced HER2+ or HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
At least 1 visit every week

ClinicalTrials.gov: NCT06625775

Phase I

8

Experimental Therapy PF-07248144 for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.

Purpose: To study the safety, side effects, dose, and anti-cancer activity of giving PF-07248144 alone, in combination with fulvestrant, or with palbociclib and letrozole.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen-receptor positive (ER+), HER2-negative (HER2-) breast cancer whose disease progressed after receiving a CDK 4/6 inhibitor and anti-estrogen therapy. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-07248144, ongoing</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-07248144, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, ongoing</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-07248144, ongoing</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-07248144 is a KAT6 Inhibitor</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. It is commonly used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is commonly used with anti-estrogen therapy for metastatic, hormone-positive (ER+ and/or PR+), HER2-negative (HER2-) breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04606446' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pfizerclinicaltrials.com/find-a-trial/nct04606446' target='_blank'>Pfizer Trial Information Page: PF-07248144</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/update-on-hormone-receptor-positive-mbc-2021/' target='_blank'>Metastatic Trial Talk: Update on Hormone Receptor-Positive MBC</a> </li></ul>

8

Experimental Therapy PF-07248144 for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.

Nearest Location from 94107:
3 miles
UCSF Medical Center at Mission Bay
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04606446

Phase II

9

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

Show Scientific Title

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of using a tumor's genetic profile to select an FDA-approved targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options. You must have results from a genomic or immunohistochemistry test approved by TAPUR. View full eligibility criteria

What's involved?

You will receive an FDA-approved targeted therapy based on your tumor's genetic profile.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted therapy you receive will be selected based on your tumor's genetic profile.</li> <li class="seamTextUnorderedListItem">Your treatment may include one or more of the following: Abemaciclib, Futibatinib, Nivolumab, Ipilimumab, Olaparib, Palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab, Pertuzumab, Vemurafenib, Cobimetinib</li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ALK, ATM, BRAF, BRAF V600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, FGFR1/2/3/4, HER2 (ERBB2), high mutational load and others, KIT, MET, MSI-H, mTOR, NRG1, PALB2, PDGFR, POLD1, POLE, RAF-1, RET, ROS1, TSC, VEGFR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02693535' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.tapur.org/' target='_blank'>ASCO: TAPUR Study Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/clinical-trials/what-tapur-study' target='_blank'>Cancer.Net (Video): What is the TAPUR Study?</a> </li><li class='seamTextUnorderedListItem'><a href='https://old-prod.asco.org/research-data/tapur-study/study-participation' target='_blank'>ASCO: TAPUR Study Participation</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/conference-coverage/asco-2016/dr-edward-kim-on-ascos-tapur-trial' target='_blank'>OncLive (Video): About TAPUR</a> </li></ul>

9

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

Show Scientific Title

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Nearest Location from 94107:
3 miles
Sutter Cancer Research Consortium
San Francisco, CA

Visits:
Coincides with targeted therapy

ClinicalTrials.gov: NCT02693535

Phase II

10

ASTX727 Targeted Therapy with Olaparib for Advanced Breast Cancer with Certain Mutations

Show Scientific Title

A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ASTX727, an experimental targeted therapy, with olaparib (Lynparza®) PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with BRCA1, BRCA2, PALB2, ATM, and/or CHEK2 inherited or tumor mutations who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASTX727, by mouth</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASTX727 is an experimental targeted therapy called a DNMT inhibitor. Blocking DNMT may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">ASTX727 is a combination of decitabine with cedazuridine.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">BRCA1, BRCA2, PALB2, ATM, and CHEK2 gene mutations are homologous recombination repair (HRR) or homologous recombination deficient (HRD) mutations.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06177171' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://astx.com/research-development/clinical-pipeline/oral-decitabine-and-cedazuridine-astx727-hematological-malignancies/' target='_blank'>Astex Pharmaceuticals: ASTX727 Drug Information Page</a> </li></ul>

10

ASTX727 Targeted Therapy with Olaparib for Advanced Breast Cancer with Certain Mutations

Show Scientific Title

A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors

Nearest Location from 94107:
3 miles
University of California, San Francisco
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06177171

Phase I

11

AZD9574 Targeted Therapy for Advanced HER2 Negative Breast Cancer With Certain Mutations

Show Scientific Title

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AZD9574, an experimental PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer with a tumor or inherited BRCA1, BRCA2, PALB2, RAD51C, or RAD51D mutation. You must not have received treatment with a PARP inhibitor. You must have at least 1 tumor that has not been treated with radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD9574, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD9574 is an experimental targeted therapy called a PARP inhibitor. PARP inhibitors stop the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP).</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">The mutations can be inherited (also called germline) or in a tumor (also called somatic).</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PALB2, RAD51C, RAD51D</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05417594' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://aacrjournals.org/cancerres/article/82/12_Supplement/2609/702588' target='_blank'>Abstract: AZD9574</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/parp-inhibitors/' target='_blank'>Susan G. Komen: PARP Inhibitors</a> </li></ul>

11

AZD9574 Targeted Therapy for Advanced HER2 Negative Breast Cancer With Certain Mutations

Show Scientific Title

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Nearest Location from 94107:
3 miles
Research Site
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05417594

Phase I-II

12

MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer

Show Scientific Title

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of MEN2312, an experimental KAT6 inhibitor, alone or with elacestrant (Orserdu®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. You must have received no more than 6 lines of therapy for advanced disease, including no more than 2 lines of chemotherapy and/or antibody drug conjugates (ADC). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312, by mouth</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312, by mouth</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312 is an experimental targeted therapy called a KAT6 inhibitor. Blocking KAT6 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is a hormone therapy called a selective estrogen receptor degrader (SERD). SERDs work by binding to and breaking down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06638307' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://stemline.com/product-pipeline/' target='_blank'>Stemline Therapeutics: MEN2312 Drug Information Page</a> </li></ul>

12

MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer

Show Scientific Title

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06638307

Phase I

13

Capivasertib, Palbociclib, and Fulvestrant for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Purpose: To study the dose, safety, side effects, and anti-cancer activity of giving the targeted therapies capivasertib and palbociclib (Ibrance®) with the anti-estrogen therapy fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer. Your cancer must have progressed on anti-estrogen therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capivasertib, by mouth, daily (4 days on, 3 days off), ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, once a month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capivasertib is a targeted therapy that blocks the Akt protein. The Akt protein helps cancer cells divide and grow.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. It is approved for treating metastatic hormone-positive, HER2-negative breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04862663' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/capivasertib?redirect=true' target='_blank'>NCI Drug Dictionary: Capivasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30857-5/fulltext' target='_blank'>Journal Article: Capivasertib Inhibits a Key Pathway in Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a615013.html' target='_blank'>Medline Plus: Palbociclib</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Fulvestrant' target='_blank'>Wikipedia: Fulvestrant</a> </li></ul>

13

Capivasertib, Palbociclib, and Fulvestrant for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Nearest Location from 94107:
3 miles
Research Site
San Francisco, CA

Visits:
1 visit per month, ongoing

ClinicalTrials.gov: NCT04862663

Phase III

14

GDC-4198 CDK2/4/6 Inhibitor Plus Giredestrant Oral SERD Versus Abemaciclib Plus Giredestrant for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progre...

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of GDC-4198 CDK2/4/6 inhibitor and giredestrant oral SERD compared with abemaciclib (Verzenio®) CDK4/6 inhibitor and giredestrant.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have experienced disease progression during or after receiving a CDK4/6 inhibitor and hormone therapy. You must not have received more than 1 line of therapy or chemotherapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-4198, by mouth, daily, up to 3 years</li> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, up to 3 years</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily, up to 3 years</li> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily, up to 3 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-4198 is an experimental CDK2/4/6 inhibitor.</li> <li class="seamTextUnorderedListItem">Giredestrant is an experimental hormone therapy called a SERD (selective estrogen receptor degrader). SERDs work by binding to and breaking down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07100106' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://regor.com/#pipeline' target='_blank'>Regor Therapeutics: GDC-4198</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gene.com/medical-professionals/pipeline/giredestrant' target='_blank'>Genentech: Giredestrant</a> </li></ul>

14

GDC-4198 CDK2/4/6 Inhibitor Plus Giredestrant Oral SERD Versus Abemaciclib Plus Giredestrant for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progre...

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family CCC
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07100106

Phase I-II

15

177Lu-FAP-2286 Radioactive Drug for Advanced Breast Cancer

Show Scientific Title

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

Purpose: To study the safety, best dose, and effects (good and bad) of 177Lu-FAP-2286, an experimental radioactive drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received at least 2 lines of therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">177Lu-FAP-2286, by IV, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are developing a new class of drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells.</li> <li class="seamTextUnorderedListItem">177Lu-FAP-2286 is an experimental radiopharmaceutical or radioactive drug.</li> <li class="seamTextUnorderedListItem">177Lu-FAP-2286 targets fibroblast activation protein (FAP) which is on cells near tumor cells and on some tumor cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04939610' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/177lu-fap-2286-yields-promising-preliminary-anti-tumor-activity-in-advanced-metastatic-solid-malignancies' target='_blank'>CancerNetwork: 177Lu-FAP-2286 Yields Promising Preliminary Anti-Tumor Activity in Advanced Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy#:~:text=Once%20a%20radiopharmaceutical%20has%20stuck,irreparably%20damaged%2C%20that%20cell%20dies' target='_blank'>National Cancer Institute: Radiopharmaceuticals</a> </li></ul>

15

177Lu-FAP-2286 Radioactive Drug for Advanced Breast Cancer

Show Scientific Title

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

Nearest Location from 94107:
3 miles
UCSF Medical Center
San Francisco, CA

Visits:
1 visit every 2 weeks

ClinicalTrials.gov: NCT04939610

Phase I-II

16

RLY-2608 PI3Kα Inhibitor Plus Fulvestrant Versus Capivasertib AKT Inhibitor Plus Fulvestrant for Advanced PIK3CA-Mutant HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Tr...(ReDiscover-2)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of RLY-2608 PI3Kα inhibitor plus fulvestrant (Faslodex®) hormone therapy versus capivasertib (Truqap®) AKT inhibitor plus fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation whose cancer has progressed while receiving 1 or 2 lines of hormone therapy and a CDK4/6 inhibitor. You must not have received certain treatments that are listed below. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RLY-2608, by mouth, daily</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capivasertib (Truqap®), by mouth, daily, 4 days on 3 days off</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Capivasertib (Truqap®) is used to treat HR+, HER2- advanced breast cancer with a mutation in PIK3CA, AKT1, or PTEN.</li> <li class="seamTextUnorderedListItem">RLY-2608 is an experimental treatment being tested to treat HR+, HER2- advanced breast cancer with a mutation in PIK3CA.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li> <li class="seamTextUnorderedListItem">To be eligible for this trial, you must not have received any of the following treatments: alpelisib (Piqray®), capivasertib (Truqap®), pembrolizumab (Keytruda®), dostarlimab-gxly (Jemperli®), fam-trastuzumab deruxtecan-nxki (Enhertu®), sacituzumab govitecan-hziy (Trodelvy®), or datopotamab deruxtecan (Dato-DXd; Datroway®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06982521' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://relaytx.com/pipeline/#hero-scroll' target='_blank'>Relay Therapeutics: RLY-2608</a> </li></ul>

16

RLY-2608 PI3Kα Inhibitor Plus Fulvestrant Versus Capivasertib AKT Inhibitor Plus Fulvestrant for Advanced PIK3CA-Mutant HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Tr...(ReDiscover-2)

Nearest Location from 94107:
3 miles
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
Monthly

ClinicalTrials.gov: NCT06982521

Phase III

17

MBRC-201 Antibody-Drug Conjugate for Metastatic Breast Cancer

Show Scientific Title

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of MBRC-201 antibody-drug conjugate.

Who is this for?: People with metastatic (stage IV) breast cancer that is resistant to standard therapies. You must not have received trastuzumab deruxtecan (Enhertu®), datopotamab deruxtecan (Datroway®), or sacituzumab govitecan (Trodelvy®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBRC-201</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07145255' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbracetrx.com/clinical-program-mbrc-201/' target='_blank'>MBrace Therapeutics: MBRC-201</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates (ADC)</a> </li></ul>

17

MBRC-201 Antibody-Drug Conjugate for Metastatic Breast Cancer

Show Scientific Title

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
Number of visits unavailable, up to 2 years

ClinicalTrials.gov: NCT07145255

Phase I-II

18

Studying Cannabis to Improve Symptoms for People with Stage I-IV Breast Cancer

Show Scientific Title

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

Purpose: To study the potential benefits and harms of cannabis products for cancer-related symptoms.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive or are receiving (within 2 months) treatment with chemotherapy, targeted therapy, and/or an immune checkpoint inhibitor (pembrolizumab (Keytruda®) or dostarlimab (Jemperli®)). You must be using cannabis products. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys, at home or in person, monthly for 1 year</li> <li class="seamTextUnorderedListItem">Blood sample, 3 times in 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cannabis may help ease symptoms of cancer and side effects of treatment.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06418204' target='_blank'>ClinicalTrials.gov</a> </li></ul>

18

Studying Cannabis to Improve Symptoms for People with Stage I-IV Breast Cancer

Show Scientific Title

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

Nearest Location from 94107:
3 miles
Kaiser Permanente-San Francisco
San Francisco, CA

Visits:
3 visits in 1 year

ClinicalTrials.gov: NCT06418204

Phase NA

19

OP-1250 Hormone Therapy with Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of OP-1250, an experimental hormone therapy, with ribociclib (Kisqali®) CDK 4/6 inhibitor or alpelisib (Piqray®) PI3K inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received 1-2 hormone therapies for advanced or metastatic disease. You must not have received more than 1 chemotherapy for advanced or metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OP-1250</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®)</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OP-1250</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OP-1250 is an experimental hormone therapy called a selective estrogen receptor downregulator (SERD) and complete estrogen receptor antagonist (CERAN). SERDs bind to and break down estrogen receptors, and CERANs block estrogen receptors.</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05508906' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://olema.com/science/' target='_blank'>Olema Oncology Drug Information Page: OP-1250</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/kisqali' target='_blank'>Breastcancer.org: Ribociclib (Kisqali®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li></ul>

19

OP-1250 Hormone Therapy with Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer

Nearest Location from 94107:
3 miles
University of California San Francisco Health
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05508906

Phase I

20

CLSP-1025 Immunotherapy for Advanced HLA-A*02:01 Positive Breast Cancer with p53 R175H Mutations

Show Scientific Title

GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Purpose: To study the safety, best dose, and effects (good and bad) of CLSP-1025, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HLA-A*02:01 positive breast cancer with p53 R175H mutations who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CLSP-1025, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CLSP-1025 is an experimental immunotherapy called a T cell engager (TCE).</li> <li class="seamTextUnorderedListItem">A T cell engager (TCE) is a drug that binds to proteins on the surface of T cells (a type of immune cell) and, at the same time, to a different protein on cancer cells.</li> <li class="seamTextUnorderedListItem">This brings the T cells and cancer cells close together so the T cells can more effectively kill the cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06778863' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html' target='_blank'>AstraZeneca: T Cell Engagers</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.clasptx.com/home#science' target='_blank'>Clasp Therapeutics: CLSP-1025 Drug Information Page</a> </li></ul>

20

CLSP-1025 Immunotherapy for Advanced HLA-A*02:01 Positive Breast Cancer with p53 R175H Mutations

Show Scientific Title

GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Nearest Location from 94107:
3 miles
University of California San Francisco
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06778863

Phase I

21

STX-478 Targeted Therapy for Advanced HR+, HER2- Breast Cancer with a PI3K Mutation

Show Scientific Title

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of STX-478, an experimental PI3K inhibitor, alone or with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PI3K mutation. You must not have a PTEN, AKT, or mTOR mutation. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">STX-478</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">STX-478</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">STX-478 is an experimental targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PI3K</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05768139' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.scorpiontx.com/pipeline/' target='_blank'>Scorpion Therapeutics: STX-478 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li></ul>

21

STX-478 Targeted Therapy for Advanced HR+, HER2- Breast Cancer with a PI3K Mutation

Show Scientific Title

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Nearest Location from 94107:
3 miles
UCSF Medical Center at Mission Bay
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05768139

Phase I-II

22

XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of XMT-1660, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-1660, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-1660 is an experimental antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XMT-1660's antibody targets B7-H4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called dolasynthen.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05377996' target='_blank'>ClinicalTrials.gov</a> </li></ul>

22

XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05377996

Phase I-II

23

ETX-636 Targeted Therapy for Advanced HR+, HER2- Breast Cancer With PIK3CA Mutations

Show Scientific Title

A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ETX-636, an experimental targeted therapy, with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with PIK3CA mutations who have received at least 1 CDK4/6 inhibitor and hormone therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ETX-636, by mouth, daily</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ETX-636 is an experimental targeted therapy called a PI3K alpha inhibitor that blocks the growth of cancer cells with a PIK3CA mutation.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06993844' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ensemtx.com/science/pipeline/' target='_blank'>Ensem Therapeutics: ETX-636 Drug Information Page</a> </li></ul>

23

ETX-636 Targeted Therapy for Advanced HR+, HER2- Breast Cancer With PIK3CA Mutations

Show Scientific Title

A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Visits:
At least 1 visit every month

ClinicalTrials.gov: NCT06993844

Phase I-II

24

PLUMB Registry for Metastatic Lobular Breast Cancer

Show Scientific Title

Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer

Purpose: To create a registry to study metastatic lobular breast cancer, treatment patterns, and overall survival.

Who is this for?: People with stage IV (metastatic) lobular breast cancer. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples will be used to study the relationship between ctDNA and disease progression.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">This trial will also develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05964504' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.ucsf.edu/trial/NCT05964504' target='_blank'>University of California, San Francisco: Trial Information Page</a> </li></ul>

24

PLUMB Registry for Metastatic Lobular Breast Cancer

Show Scientific Title

Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer

Nearest Location from 94107:
5 miles
University of California, San Francisco
San Francisco, CA

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT05964504

Phase NA

25

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Show Scientific Title

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703)

Purpose: To study if blood tests that look for tumor markers are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a tumor is growing.

Who is this for?: People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated tumor marker. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), at least every 3 months, ongoing</li> <li class="seamTextUnorderedListItem">Tumor Marker Test, if ordered by your doctor</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Marker Tests, every 1 to 2 months, ongoing</li> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), only if need is shown by a Tumor Marker Test</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This imaging trial will compare using blood tests to PET/CT scans for monitoring tumor growth. </li> <li class="seamTextUnorderedListItem">The tumor markers that will be tested for in this study are CA 15-3, CA27.29, and CEA.</li> <li class="seamTextUnorderedListItem">The imaging tests will be those ordered by your doctor.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03723928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/blood_marker' target='_blank'>Breastcancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/about-us/collaborations/top-five-list-oncology/choosing-wisely®-top-five-cancer-related-tests-procedures-and-treatments-many-patients-do-not-need/topic-4-follow-tumor-marker-tests-and-imaging-tests-people-treated-breast-cancer' target='_blank'>ASCO Cancer.net: Follow-up Tumor Marker Tests and Imaging Tests for People Treated for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet' target='_blank'>NCI: Tumor Markers</a> </li><li class='seamTextUnorderedListItem'><a href='https://ozarkscancerresearch.org/wp-content/uploads/2019/04/SWOG-S1703.pdf' target='_blank'>Cancer Research for the Ozarks: Trial Information Page</a> </li></ul>

25

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Show Scientific Title

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703)

Nearest Location from 94107:
8 miles
Epic Care Partners in Cancer Care
Emeryville, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT03723928

Phase NA

26

Inavolisib Targeted Therapy with CDK4/6 Inhibitor and Hormone Therapy for HR+, HER2- Advanced Breast Cancer with PIK3CA Mutations

Show Scientific Title

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of inavolisib (Itovebi®) PI3K inhibitor with palbociclib (Ibrance®) CDK4/6 inhibitor and letrozole (Femara®) aromatase inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation. You must have been diagnosed with de novo advanced/metastatic breast cancer or received at least 2 years of hormone therapy and completed hormone therapy at least 1 year before your advanced/metastatic diagnosis. You must have not yet received treatment for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inavolisib (Itovebi®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for inavolisib (Itovebi®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inavolisib (Itovebi®) is a type of targeted therapy called a PI3K inhibitor. It can stop cancer cell growth of tumors with a PIK3CA mutation.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06790693' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.itovebi.com/?c=ina-192c045e973&gad_source=1&gad_campaignid=22379686314&gclid=CjwKCAjw3_PCBhA2EiwAkH_j4vPWHwf18zpyVOBvHcRP6iHfngpGw_isqNXvAvPlr2i6vJ0TAA8mdxoCtHYQAvD_BwE&gclsrc=aw.ds' target='_blank'>Hoffman-La Roche: Inavolisib (Itovebi®)</a> </li></ul>

26

Inavolisib Targeted Therapy with CDK4/6 Inhibitor and Hormone Therapy for HR+, HER2- Advanced Breast Cancer with PIK3CA Mutations

Show Scientific Title

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123)

Nearest Location from 94107:
14 miles
Palo Alto Medical Foundation Research Center
San Mateo, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06790693

Phase III

27

BMS-986500 CDK4/6 Inhibitor for Advanced HR+ Breast Cancer

Show Scientific Title

A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BMS-986500, a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986500</li> <li class="seamTextUnorderedListItem">Palbociblib (Ibrance®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986500 is a CDK4/6 inhibitor. </li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors block two enzymes, CDK 4 and CDK 6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06997029' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: CDK4/6 Inhibitors</a> </li></ul>

27

BMS-986500 CDK4/6 Inhibitor for Advanced HR+ Breast Cancer

Show Scientific Title

A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer

Nearest Location from 94107:
15 miles
Marin Cancer Care
Greenbrae, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06997029

Phase I

28

Tersolisib PI3Ka Inhibitor For HR+, HER2- or HER2 Low Advanced Breast Cancer with a PIK3CA Mutation

Show Scientific Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of Tersolisib (LY4064809), an experimental PI3Ka inhibitor, with standard of care CDK4/6 inhibitor and hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer with a PIK3CA mutation. You may have received 0-2 prior treatments for advanced or metastatic breast cancer. View full eligibility criteria

What's involved?

You will receive the following: Part 1: For people who have received prior treatment: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tersolisib (LY4064809), by mouth, once or twice a day</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor determined by your physician, by mouth</li> <li class="seamTextUnorderedListItem">Hormone therapy determined by your physician, by mouth or injection</li> </ul> Part 2: For people who have not yet received treatment, you will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tersolisib (LY4064809), by mouth, once or twice a day</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor determined by your physician, by mouth</li> <li class="seamTextUnorderedListItem">Hormone therapy determined by your physician, by mouth or injection</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, once or twice a day</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor determined by your physician, by mouth</li> <li class="seamTextUnorderedListItem">Hormone therapy determined by your physician, by mouth or injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tersolisib (LY4064809) is an experimental type of targeted therapy called a PI3K inhibitor. </li> <li class="seamTextUnorderedListItem">If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated, allowing cancer cells to grow. Tersolisib may slow or stop cancer cells from growing by blocking this pathway.</li> <li class="seamTextUnorderedListItem">Standard of care treatment for hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer is treatment with hormone therapy along with a CDK inhibitor.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07174336' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/mbc-biomarkers-part-1/' target='_blank'>Metastatic Trial Talk: Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1</a> </li></ul>

28

Tersolisib PI3Ka Inhibitor For HR+, HER2- or HER2 Low Advanced Breast Cancer with a PIK3CA Mutation

Show Scientific Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Nearest Location from 94107:
15 miles
Marin Cancer Care
Greenbrae, CA

Visits:
Every 2 weeks for 2 months; then monthly visits thereafter

ClinicalTrials.gov: NCT07174336

Phase III

29

Giredestrant Hormone Therapy with a CDK Inhibitor for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of giredestrant, an experimental hormone therapy, compared with fulvestrant (Faslodex®) hormone therapy in combination with a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who not have received treatment (except for surgery or radiation) for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giredestrant, by mouth, daily</li> <li class="seamTextUnorderedListItem">CDK inhibitor, by mouth, daily</li> <li class="seamTextUnorderedListItem">FoundationOne Liquid CDx Assay blood test</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li> <li class="seamTextUnorderedListItem">CDK inhibitor, by mouth, daily</li> <li class="seamTextUnorderedListItem">FoundationOne Liquid CDx Assay blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) and giredestrant are a type of hormone therapy called selective estrogen receptor degraders (SERDs). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Giredestrant is an experimental SERD.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), abemaciclib (Verzenio®), ribociclib (Kisqali®) are a type of targeted therapy called CDK 4/6 inhibitors. CDK 4/6 inhibitors block two enzymes, CDK 4 and CDK 6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">The FoundationOne Liquid CDx Assay blood test will identify ctDNA mutations.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06065748' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.genentechoncology.com/pipeline-molecules/serd-3.html#:~:text=This%20compound%20and%20its%20use,US%20Food%20and%20Drug%20Administration.' target='_blank'>Genentech: Giredestrant Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK4/6 Inhibitors</a> </li></ul>

29

Giredestrant Hormone Therapy with a CDK Inhibitor for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Nearest Location from 94107:
15 miles
Marin Cancer Care Inc
Greenbrae, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06065748

Phase III

30

Mobile Health Tools to Help Take Medication as Prescribed for People with Metastatic Breast Cancer

Show Scientific Title

Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)

Purpose: To study if WiseBag and CONCURxP mobile health tools will improve the ability of people to take their medication as prescribed compared to WiseBag alone.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to receive a CDK4/6 inhibitor or started receiving a CDK4/6 inhibitor within the past month. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Enhanced Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">WiseBag, 1 year</li> <li class="seamTextUnorderedListItem">Educational materials, monthly for 1 year</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">WiseBag, 1 year</li> <li class="seamTextUnorderedListItem">CONCURxP, 1 year</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li> <li class="seamTextUnorderedListItem">Interviews, 6 months after completing study</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors need to be taken as prescribed to receive the best benefit.</li> <li class="seamTextUnorderedListItem">Using WiseBag and CONCURxP may reduce forgetfulness for taking medications.</li> <li class="seamTextUnorderedListItem">WiseBag is a lunch box sized medication monitoring device that holds and monitors medications.</li> <li class="seamTextUnorderedListItem">The CONnected CUstomized Treatment Platform (CONCURxP) includes personalized text message reminders for missed medications, monitoring of the medications you take, and notifications to doctors about missed doses.</li> <li class="seamTextUnorderedListItem">CONCURxP sends a text message when a medication is not taken when it should be.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06112613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/staying-on-track-with-treatment' target='_blank'>Breastcancer.org: Following Your Treatment Plan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK4/6 Inhibitors</a> </li></ul>

30

Mobile Health Tools to Help Take Medication as Prescribed for People with Metastatic Breast Cancer

Show Scientific Title

Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)

Nearest Location from 94107:
22 miles
Contra Costa Regional Medical Center
Martinez, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06112613

Phase NA

31

LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer

Show Scientific Title

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4337713 radiopharmaceutical.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that is positive for fibroblast activation protein (FAP) who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4337713, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4337713 targets fibroblast activation protein (FAP) on cells near cancer cells. LY4337713 contains a radioactive molecule that kills the nearby cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07213791' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lillyoncologypipeline.com/molecule/Fibroblast-Activation-Protein-Radioligand/' target='_blank'>Eli Lilly: LY4337713</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>Metastatic Trial Talk: Radiopharmaceuticals</a> </li></ul>

31

LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer

Show Scientific Title

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

Nearest Location from 94107:
27 miles
Stanford University Medical Center
Stanford, CA

Visits:
Number of visits unavailable, 5 years

ClinicalTrials.gov: NCT07213791

Phase I

32

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

Show Scientific Title

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4257496 GRPR radiopharmaceutical with or without standard of care therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer. Your tumor must be positive for gastrin-releasing peptide receptor (GRPR). View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496, by IV, up to 9 months</li> <li class="seamTextUnorderedListItem">Standard of care therapy</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496, by IV, up to 9 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496 is a radiopharmaceutical that targets GRPR. A radiopharmaceutical is a type of therapy that combines a molecule that targets cancer cells with a radioactive molecule that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Gastrin Releasing Peptide Receptor (GRPR) is a G protein coupled receptor activated by the peptide gastrin-releasing peptide (GRP), which regulates various bodily functions, including gastrointestinal activity and central nervous system processes. GRPR plays a role in normal functions like hormone release and smooth muscle contraction.</li> <li class="seamTextUnorderedListItem">Standard of care options in this trial are fulvestrant (Faslodex®), imlunestrant (Inluriyo®), capecitabine (Xeloda®), abemaciclib (Verzenio®) and aromatase inhibitors- letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07114601' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>Metastatic Trial Talk: Radiopharmaceuticals</a> </li></ul>

32

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

Show Scientific Title

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

Nearest Location from 94107:
27 miles
Stanford University Medical Center
Stanford, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07114601

Phase I

33

Usual Radiation Therapy Compared to Longer Radiation Therapy for People with Brain Metastases

Show Scientific Title

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of standard of care stereotactic radiosurgery (SRS) to experimental fractionated stereotactic radiosurgery (FSRS).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have not yet received brain radiation. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS), 1 session</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated stereotactic radiosurgery (FSRS), 3 sessions</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. </li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS) is a type of radiation that uses special equipment to precisely give a single large dose of radiation to a tumor. </li> <li class="seamTextUnorderedListItem">Fractionated stereotactic radiosurgery (FSRS) delivers a high dose of radiation to the tumor over 3 treatments.</li> <li class="seamTextUnorderedListItem">FSRS may be more effective compared to SRS in treating people with cancer that has spread to the brain.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06500455' target='_blank'>ClinicalTrials.gov</a> </li></ul>

33

Usual Radiation Therapy Compared to Longer Radiation Therapy for People with Brain Metastases

Show Scientific Title

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Nearest Location from 94107:
28 miles
Stanford Cancer Institute Palo Alto
Palo Alto, CA

Visits:
At least 1-3 visits

ClinicalTrials.gov: NCT06500455

Phase III

34

Radioactive Drug for Advanced HR+, HER2- or Triple Negative Breast Cancer

Show Scientific Title

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Purpose: To study the safety, best dose, and effects (good and bad) of [177Lu]Lu-NNS309, an experimental radioactive drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or triple negative (ER-, PR-, HER2-) breast cancer who have received at least 2 lines of therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT or PET/MRI scan with 68Ga-Ga-NNS309, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">177Lu-Lu-NNS309, by IV, every 1-1.5 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are developing a new class of drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells.</li> <li class="seamTextUnorderedListItem">177Lu-Lu-NNS309 is an experimental radiopharmaceutical or radioactive drug.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">68Ga-Ga-NNS309 is a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06562192' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.novartis.com/clinicaltrials/study/nct06562192' target='_blank'>Novartis: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy#:~:text=Once%20a%20radiopharmaceutical%20has%20stuck,irreparably%20damaged%2C%20that%20cell%20dies' target='_blank'>National Cancer Institute: Radiopharmaceuticals</a> </li></ul>

34

Radioactive Drug for Advanced HR+, HER2- or Triple Negative Breast Cancer

Show Scientific Title

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Nearest Location from 94107:
28 miles
Stanford University Medical Center
Palo Alto, CA

Visits:
At least 1 visit every 1-1.5 months

ClinicalTrials.gov: NCT06562192

Phase I

35

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

Show Scientific Title

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Purpose: To use genetic testing to match people to treatments and help doctors plan better treatments.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received at least 1 line of therapy for advanced disease or who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy based on genetic testing</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic tests look at the unique genetic material (genes) of tumor cells.</li> <li class="seamTextUnorderedListItem">People with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: AKT, ERK, MEK, NF1, RAF, RAS</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05564377' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/press-releases/2023/combomatch-precision-medicine-cancer-initiative' target='_blank'>National Cancer Institute: ComboMATCH</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/precision-medicine-breast-cancer/about/pac-20385240' target='_blank'>Mayo Clinic: Precision Medicine for Breast Cancer</a> </li></ul>

35

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

Show Scientific Title

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Nearest Location from 94107:
28 miles
Stanford Cancer Institute Palo Alto
Palo Alto, CA

Visits:
Please contact research site

ClinicalTrials.gov: NCT05564377

Phase II

36

Lasofoxifene Hormone Therapy with CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer With an ESR1 Mutation

Show Scientific Title

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of lasofoxifene, an experimental hormone therapy, with abemaciclib (Verzenio®) CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer with an ESR1 mutation. You must have received an aromatase inhibitor with palbociclib (Ibrance®) or ribociclib (Kisqali®) CDK4/6 inhibitor as your first line of hormone therapy for advanced disease. You must not have received more than 1 line of chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lasofoxifene, by mouth, daily</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lasofoxifene is an experimental hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. It blocks two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05696626' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://sermonixpharma.com/lasofoxifene/' target='_blank'>Sermonix Pharmaceuticals: Lasofoxifene Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li></ul>

36

Lasofoxifene Hormone Therapy with CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer With an ESR1 Mutation

Show Scientific Title

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

Nearest Location from 94107:
53 miles
Providence Medical Foundation - Santa Rosa, CA
Santa Rosa, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05696626

Phase III

37

PRO1184 Antibody Drug Conjugate for Advanced HER2- Breast Cancer that Expresses FRA

Show Scientific Title

Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of PRO1184, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer that expresses folate receptor alpha (FRA) who have received standard treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRO1184, by IV</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRO1184 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">BB-1701's antibody targets folate receptor alpha (FRA), a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called exatecan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FRA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05579366' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/profoundbio-receives-fda-study-may-proceed-letter-for-pro1184-a-folate-receptor-alpha-directed-adc-with-a-topoisomerase-1-inhibitor-payload-and-welcomes-naomi-hunder-md-as-chief-medical-officer-301598943.html?tc=em' target='_blank'>ProfoundBio Press Release: PRO1184</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>

37

PRO1184 Antibody Drug Conjugate for Advanced HER2- Breast Cancer that Expresses FRA

Show Scientific Title

Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

Nearest Location from 94107:
53 miles
Providence Medical Foundation
Santa Rosa, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05579366

Phase I-II

38

RE104 for People with Stage 0-IV Breast Cancer and Adjustment Disorder With Anxiety and Depression

Show Scientific Title

A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses

Purpose: To study the safety and effects (good and bad) of RE104 for Injection to reduce depression and/or anxiety.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer with adjustment disorder that includes depression and/or anxiety that has lasted for at least 1 month. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: High Dose <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High dose of RE104, by injection</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Low Dose <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low dose of RE104, by injection</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RE104 is a psilocybin-like compound that may help with depression.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer and other serious diseases.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07002034' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://reunionneuro.com/programs/#approach' target='_blank'>Reunion Neuroscience: RE104</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rekindlestudies.com/' target='_blank'>Reunion Neuroscience: REKINDLE Study Information</a> </li></ul>

38

RE104 for People with Stage 0-IV Breast Cancer and Adjustment Disorder With Anxiety and Depression

Show Scientific Title

A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses

Nearest Location from 94107:
53 miles
Providence Medical Foundation
Santa Rosa, CA

Visits:
9 visits within 2.5 months

ClinicalTrials.gov: NCT07002034

Phase II

39

Genomic Test Studying the Tumor Microenvironment for Advanced Breast Cancer

Show Scientific Title

BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting

Purpose: To study the ability of the BostonGene Tumor Portrait test to provide information about tumors and their microenvironment and help make treatment decisions.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, blood, saliva, and cheek swab samples for the BostonGene Tumor Portrait test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tumor microenvironment describes the cells that surround a tumor and plays a role in both how tumors grow and how they respond to treatment. </li> <li class="seamTextUnorderedListItem">The BostonGene Tumor Portrait test may help make treatment decisions for people with advanced cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06272864' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/breast-cancer-and-tumor-microenvironment/' target='_blank'>Metastatic Trial Talk: The Tumor Microenvironment</a> </li></ul>

39

Genomic Test Studying the Tumor Microenvironment for Advanced Breast Cancer

Show Scientific Title

BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting

Nearest Location from 94107:
61 miles
Stockton Hematology Oncology Medical Group
Stockton, CA

Visits:
Up to 2 years

ClinicalTrials.gov: NCT06272864

Phase NA

40

DB-1310 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of DB-1310, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1310, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1310 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">DB-1310's antibody targets HER3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05785741' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dualitybiologics.com/approach.html?md=1' target='_blank'>DualityBio: ADC Information Page</a> </li></ul>

40

DB-1310 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

Nearest Location from 94107:
74 miles
University of California, Davis Comprehensive Cancer Center
Sacramento, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT05785741

Phase I-II

41

PET/CT Scans with 68Ga-Ga DOTA-5G for Advanced Lobular Breast Cancer

Show Scientific Title

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Purpose: To study if PET/CT scans with 68Ga-Ga DOTA-5G, an experimental radioactive tracer, improve the ability to detect lobular breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) lobular breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 68Ga-Ga DOTA-5G, by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">68Ga-Ga DOTA-5G is an experimental tracer that can look for and attach to cancer cells during PET/CT scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07020806' target='_blank'>ClinicalTrials.gov</a> </li></ul>

41

PET/CT Scans with 68Ga-Ga DOTA-5G for Advanced Lobular Breast Cancer

Show Scientific Title

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Nearest Location from 94107:
74 miles
University of California Davis
Sacramento, CA

Visits:
1 visit

ClinicalTrials.gov: NCT07020806

Phase I

42

Adding Radiation to Treatment for People with Metastatic Oligoprogressive Breast Cancer

Show Scientific Title

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of adding radiation to metastatic breast cancer treatment.

Who is this for?: People with metastatic (stage IV) oligoprogressive breast cancer who have received at least 1 line of therapy for metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation or interventional radiology ablation</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Interventional radiology ablation uses heat or cold to kill cancer cells.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Oligoprogressive disease refers to progression of only a few sites of metastasis.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06103669' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://studypages.com/en/s/a-study-of-ablative-therapy-in-people-with-progressive-solid-tumors-valorous-278307/?ref=gallery' target='_blank'>University of California, Davis: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation-therapy' target='_blank'>Breastcancer.org: Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.columbiaradiology.org/patients/services/interventional-radiology/tumor-ablation' target='_blank'>Columbia University: Interventional Radiology Ablation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/treatment/radiotherapy/external/types/stereotactic-body-radiotherapy-sbrt' target='_blank'>Cancer Research UK: Stereotactic Radiotherapy</a> </li></ul>

42

Adding Radiation to Treatment for People with Metastatic Oligoprogressive Breast Cancer

Show Scientific Title

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

Nearest Location from 94107:
74 miles
University of California, Davis
Sacramento, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06103669

Phase NA

43

Tart Cherry Juice to Prevent Nerve Pain During Chemotherapy for People with Stage I-IV Breast Cancer

Show Scientific Title

A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Purpose: To study the ability of tart cherry juice to prevent nerve pain during chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive paclitaxel (Taxol®). You must not have received docetaxel (Taxotere®), nab-paclitaxel (Abraxane®), eribulin (Halaven®), or cisplatin (Platinol®). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: High Dose Tart Cherry Juice <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 oz tart cherry juice concentrate mixed with water, by mouth, daily for 2 weeks</li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> Group 2: Low Dose Tart Cherry Juice <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1/4 oz tart cherry juice concentrate mixed with water, by mouth, daily for 2 weeks</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy induced peripheral neuropathy (CIPN), or paclitaxel induced peripheral neuropathy (PIPN), is nerve pain in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06268665' target='_blank'>ClinicalTrials.gov</a> </li></ul>

43

Tart Cherry Juice to Prevent Nerve Pain During Chemotherapy for People with Stage I-IV Breast Cancer

Show Scientific Title

A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Nearest Location from 94107:
80 miles
University of California Davis Comprehensive Cancer Center
Sacramento, CA

Visits:
2 visits within 3 months

ClinicalTrials.gov: NCT06268665

Phase II

44

BMS-986340 Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BMS-986340, an experimental CCR8 inhibitor, alone or with nivolumab (Opdivo®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. You must have received at least 1 PD-1 inhibitor. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986340</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986340</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986340 is an experimental immunotherapy called a CCR8 inhibitor. BMS-986340 blocks the activity of CCR8 on immune cells to activate the immune system to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04895709' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bolderscience.com/trial/NCT04895709/' target='_blank'>Bristol-Myers Squibb: Clinical Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bmsscience.com/?s=BMS-986340+%26plusmn%3B+Nivolumab&search_cat=bms' target='_blank'>Bristol-Myers Squibb: BMS-986340 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bms.com/assets/bms/us/en-us/pdf/CCR8-Immune-Pathway-Fact-Sheet.pdf' target='_blank'>Bristol-Myers Squibb: CCR8 Immune Pathway</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ccr8-monoclonal-antibody-bms-986340?redirect=true' target='_blank'>National Cancer Institute: BMS-986340 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://chemocare.com/chemotherapy/drug-info/opdivo.aspx' target='_blank'>Chemocare: Nivolumab (Opdivo®)</a> </li></ul>

44

BMS-986340 Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Nearest Location from 94107:
164 miles
Community Cancer Institute
Clovis, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04895709

Phase I-II

45

RLY-2608 Alone and With Fulvestrant for Advanced Breast Cancer with a PIK3CA Mutation

Show Scientific Title

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of RLY-2608 alone and in combination with fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups based on when you enroll: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RLY-2608, by mouth</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RLY-2608, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require a biopsy</li> </ul> Please contact research site for treatment schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RLY-2608 is an experimental targeted therapy called a PI3K inhibitor.</li> <li class="seamTextUnorderedListItem">If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated which allows cancer cells to grow.</li> <li class="seamTextUnorderedListItem">RLY-2608 may block the PI3K pathway.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05216432' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-dosing-first-patient-first-human-0' target='_blank'>Relay Therapeutics Press Release: RLY-2608</a> </li></ul>

45

RLY-2608 Alone and With Fulvestrant for Advanced Breast Cancer with a PIK3CA Mutation

Show Scientific Title

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Nearest Location from 94107:
186 miles
Renown Regional Medical Center
Reno, NV

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05216432

Phase I

46

Bria-IMT Cell Therapy for Advanced Breast Cancer

Show Scientific Title

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of the Bria-IMT regimen, an experimental cell therapy, alone and with retifanlimab (Zynyz®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 3 groups: Group 1: Bria-IMT Regimen with Immunotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, 1 day every 3 weeks</li> <li class="seamTextUnorderedListItem">SV-BR-1-GM, by injection, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Interferon, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®), by infusion, every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-2 months</li> </ul> Group 2: Bria-IMT Regimen Alone <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, 1 day every 3 weeks</li> <li class="seamTextUnorderedListItem">SV-BR-1-GM, by injection, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Interferon, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-2 months</li> </ul> Group 3: Chemotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Bria-IMT regimen is an experimental cell therapy with SV-BR-1-GM cells.</li> <li class="seamTextUnorderedListItem">Before you receive the cell therapy, you will receive cyclophosphamide (Cytoxan®) chemotherapy to prepare your body to receive the cells.</li> <li class="seamTextUnorderedListItem">Interferon is an immunotherapy used to regulate your immune response to the cell therapy.</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also called the BRIA-ABC trial.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06072612' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapy-2-2/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies: A Type of Immunotherapy for MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://briacell.com/briaimt/' target='_blank'>BriaCell Therapeutics: Bria-IMT Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/retifanlimab-dlwr' target='_blank'>National Cancer Institute: Retifanlimab (Zynyz®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

46

Bria-IMT Cell Therapy for Advanced Breast Cancer

Show Scientific Title

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Nearest Location from 94107:
250 miles
Comprehensive Blood and Cancer Center
Bakersfield, CA

Visits:
May require hospitalization

ClinicalTrials.gov: NCT06072612

Phase III

47

Utidelone Chemotherapy for Metastatic HER2- or HER2 Low Breast Cancer with Brain Metastases

Show Scientific Title

A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients with Brain Metastases

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of utidelone (UTD1), an experimental chemotherapy, with capecitabine (Xeloda®) chemotherapy.

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) or HER2 low breast cancer that has spread to the brain (brain metastases) who have received no more than 3 lines of chemotherapy for metastatic disease. You must not have leptomeningeal metastasis (leptomeningeal disease). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Utidelone (UTD1), by injection, daily for 5 days, every 3 weeks</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Utidelone (UTD1) is an experimental chemotherapy drug that may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is an FDA approved chemotherapy drug.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06764940' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/utd1-receives-fda-orphan-drug-designation-in-breast-cancer-brain-metastasis' target='_blank'>OncLive: UTD1 for Breast Cancer Brain Metastasis</a> </li></ul>

47

Utidelone Chemotherapy for Metastatic HER2- or HER2 Low Breast Cancer with Brain Metastases

Show Scientific Title

A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients with Brain Metastases

Nearest Location from 94107:
304 miles
FOMAT Medical Research (Network)
Oxnard, CA

Visits:
At least 5 visits every 3 weeks

ClinicalTrials.gov: NCT06764940

Phase II

48

Eniluracil Targeted Therapy with Chemotherapy for Advanced HER2- Breast Cancer

Show Scientific Title

A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of eniluracil (PCS6422), an experimental DPD inhibitor, with capecitabine (Xeloda®) compared to capecitabine (Xeloda®) alone.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer who have received chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eniluracil (PCS6422), 1 time</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eniluracil (PCS6422) is an experimental targeted therapy called a DPD inhibitor that, when combined with capecitabine (Xeloda®), may make the immune response more active against cancer.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06568692' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/fixed-dose-eniluracil-under-investigation-in-advanced-refractory-gastrointestinal-cancers' target='_blank'>OncLive: Eniluracil for Advanced Gastrointestinal Cancers</a> </li></ul>

48

Eniluracil Targeted Therapy with Chemotherapy for Advanced HER2- Breast Cancer

Show Scientific Title

A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Nearest Location from 94107:
304 miles
FOMAT Medical Research
Oxnard, CA

Visits:
1 visit every 3 months

ClinicalTrials.gov: NCT06568692

Phase II

49

Stereotactic Radiation or Memory Sparing Whole-Brain Radiation for Patients with 5-15 Brain Metastases

Show Scientific Title

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases

Purpose: To compare the anti-cancer activity and side effects of stereotaxic radiation with memory-sparing, whole-brain radiation, To preserve memory, radiation will avoid the hippocampus, an area of the brain associated with memory, and be given with Memantine, a drug used to treat memory loss caused by dementia.

Who is this for?: People with metastatic (stage IV) breast cancer and 5-15 brain metastases. You must not have received prior radiation or surgery for brain metastases (mets). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-brain radiation</li> <li class="seamTextUnorderedListItem">Memantine, by mouth, twice a day, for 4 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation to metastatic brain metastases</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to kill tumor cells that remain after surgery.</li> <li class="seamTextUnorderedListItem">Whole-brain radiation therapy (WBR) typically targets the entire brain, including the hippocampus. By avoiding the hippocampus, researchers hope to lessen the side effects of WBR.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery) delivers focused radiation to each metastasis (met/tumor).</li> <li class="seamTextUnorderedListItem">Memantine is a medication approved for use in people with dementia, but its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that have spread to the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03550391' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-77932-377/memantine-oral/memantine-oral/details' target='_blank'>Memantine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verywellmind.com/what-is-the-hippocampus-2795231' target='_blank'>What is the Hippocampus?</a> </li></ul>

49

Stereotactic Radiation or Memory Sparing Whole-Brain Radiation for Patients with 5-15 Brain Metastases

Show Scientific Title

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases

Nearest Location from 94107:
318 miles
City of Hope Antelope Valley
Lancaster, CA

Visits:
1 to 10 visits over 1 month

ClinicalTrials.gov: NCT03550391

Phase III

50

MRI Scans to Tell the Difference Between Brain Tumors That Have Come Back and Tumor Destruction Due to Radiation for Metastatic Breast Cancer That Has Spread to the Brain

Show Scientific Title

Advanced Dual-Nuclei MRI for Differentiation of Recurrent Brain Metastases and Radiation Necrosis

Purpose: To study the ability of advanced MRI methods to tell the difference between a brain tumor that has come back and destruction of the tumor due to radiation.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery or radiation to remove the tumor. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups depending on your treatment plan: Group 1: Surgery <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, before surgery</li> <li class="seamTextUnorderedListItem">Brain surgery to remove the tumor or biopsy</li> </ul> Group 2: Radiation <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation</li> <li class="seamTextUnorderedListItem">MRI scans, before radiation and 2 weeks, 3 months, and 6 months after radiation</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Current imaging methods have a limited ability to tell the difference between a brain tumor that has come back and destruction of the tumor due to radiation.</li> <li class="seamTextUnorderedListItem">This trial is studying advanced MRI methods that may be able to tell the difference.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07339085' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

50

MRI Scans to Tell the Difference Between Brain Tumors That Have Come Back and Tumor Destruction Due to Radiation for Metastatic Breast Cancer That Has Spread to the Brain

Show Scientific Title

Advanced Dual-Nuclei MRI for Differentiation of Recurrent Brain Metastases and Radiation Necrosis

Nearest Location from 94107:
336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, CA

Visits:
Up to 5 visits within 6 months

ClinicalTrials.gov: NCT07339085

Phase NA

51

Saruparib PARP1 Inhibitor with Camizestrant Hormone Therapy for Advanced HR+, HER2- or HER2 Low Breast Cancer with BRCA1, BRCA2, or PALB2 Mutations

Show Scientific Title

EvoPAR-BR01: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Br...

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of saruparib, an experimental PARP1 inhibitor, with camizestrant, an experimental hormone therapy, to standard of care CDK4/6 inhibitor with hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer with BRCA1, BRCA2, or PALB2 mutations. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 3 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Saruparib (AZD5305), by mouth</li> <li class="seamTextUnorderedListItem">Camizestrant, by mouth</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor, by mouth</li> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth</li> </ul> Group 3: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor, by mouth</li> <li class="seamTextUnorderedListItem">Camizestrant, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Saruparib (AZD5305) is an experimental targeted therapy called a PARP1 inhibitor. PARP inhibitors stop the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP).</li> <li class="seamTextUnorderedListItem">Camizestrant is an experimental hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Exemestane (Aromasin®), letrozole (Femara®), and anastrozole (Arimidex®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block production of estrogen that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), ribociclib (Kisqali®) and palbociclib (Ibrance®) are a type of targeted therapy called CDK4/6 inhibitors. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06380751' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazenecaclinicaltrials.com/study/D9722C00001/' target='_blank'>AstraZeneca: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aacr.org/about-the-aacr/newsroom/news-releases/next-generation-parp-inhibitor-demonstrates-clinical-benefit-in-patients-with-homologous-recombination-repair-deficient-breast-cancer/' target='_blank'>AACR: Saruparib for Homologous Recombination Repair Deficient Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aacr.org/about-the-aacr/newsroom/news-releases/camizestrant-may-be-superior-to-fulvestrant-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer/' target='_blank'>AACR: Camizestrant for Hormone Receptor Positive, HER2 Negative Breast Cancer</a> </li></ul>

51

Saruparib PARP1 Inhibitor with Camizestrant Hormone Therapy for Advanced HR+, HER2- or HER2 Low Breast Cancer with BRCA1, BRCA2, or PALB2 Mutations

Show Scientific Title

EvoPAR-BR01: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Br...

Nearest Location from 94107:
336 miles
Research Site
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06380751

Phase III

52

GTAEXS617 for Advanced HR+ HER2- Breast Cancer

Show Scientific Title

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of GTAEXS617-001 CDK7 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed while receiving palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®). View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GTAEXS617, by mouth</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GTAEXS617, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blocking CDK7 is expected to slow cancer cell growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05985655' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.exscientia.com/wp-content/uploads/2024/09/Exscientia_617_Sept24.pdf' target='_blank'>Exscientia: GTAEXS617</a> </li></ul>

52

GTAEXS617 for Advanced HR+ HER2- Breast Cancer

Show Scientific Title

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Nearest Location from 94107:
336 miles
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Visits:
Number of visits unavailable, up to 2 years

ClinicalTrials.gov: NCT05985655

Phase I-II

53

PET Scan to Predict Response to Immunotherapy for People with Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors

Purpose: To study how well PET scans with an experimental tracer can identify immune cell activity, which may help predict response to immunotherapy.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. View full eligibility criteria

What's involved?

You will receive the following before standard of care surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zr-89 crefmirlimab berdoxam, by IV, 1 time</li> </ul> followed 1 day later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The presence of immune cells in or near a tumor can help predict response to immunotherapy.</li> <li class="seamTextUnorderedListItem">Zr-89 crefmirlimab berdoxam is an experimental radioactive tracer that can identify immune cells in and near a tumor with a PET scan.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cells of interest.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06650163' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

53

PET Scan to Predict Response to Immunotherapy for People with Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors

Nearest Location from 94107:
336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, CA

Visits:
2 visits in 2 days

ClinicalTrials.gov: NCT06650163

Phase I

54

AVZO-023 Plus Hormone Therapy and an Experimental CDK2 Inhibitor for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of AVZO-023 CDK4 inhibitor in combination with hormone therapy and an experimental CDK2 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. You must not have received CDK2, 4, and/or 6 inhibitors. You must not have active, untreated brain metastases. View full eligibility criteria

What's involved?

You will be assigned to 1 of 4 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVZO-023, by mouth</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVZO-023, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVZO-023, by mouth</li> <li class="seamTextUnorderedListItem">AVZO-021, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVZO-023, by mouth</li> <li class="seamTextUnorderedListItem">AVZO-021, by mouth</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).</li> <li class="seamTextUnorderedListItem">AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK2). CDK inhibitors block enzymes that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. It is commonly used to treat hormone receptor positive breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06998407' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://avenzotx.com/pipeline-and-science/#moa' target='_blank'>Avenzo Therapeutics: AVZO-023</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: CDK4/6 Inhibitors</a> </li></ul>

54

AVZO-023 Plus Hormone Therapy and an Experimental CDK2 Inhibitor for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

Nearest Location from 94107:
336 miles
Avenzo Therapeutics Recruiting Site
Los Angeles, CA

Visits:
Number of visits unavailable, up to 2 years

ClinicalTrials.gov: NCT06998407

Phase I-II

55

Invikafusp Alfa Immunotherapy with ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of STAR0602, an experimental immunotherapy, with sacituzumab govitecan (Trodelvy®) antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Invikafusp alfa (STAR0602), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Invikafusp alfa (STAR0602) is an experimental bispecific antibody that may target immune cells to stimulate anti-cancer activity.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06827613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>

55

Invikafusp Alfa Immunotherapy with ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)

Nearest Location from 94107:
336 miles
UCLA Health
Los Angeles, CA

Visits:
At least 1 visit every 3 weeks

ClinicalTrials.gov: NCT06827613

Phase I-II

56

ECI830 CDK2 Inhibitor with CDK4/6 Inhibitor and Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of ECI830, an experimental; CDK2 inhibitor, with ribociclib (Kisqali®) CDK4/6 inhibitor and fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received an aromatase inhibitor or tamoxifen (Nolvadex®) with a CDK4/6 inhibitor. You must not have received more than 2 lines of hormone therapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 3 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ECI830</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ECI830</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li> </ul> Group 3: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ECI830 is an experimental targeted therapy called a CDK2 inhibitor. CDK2 inhibitors block an enzyme, CDK2, that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor-positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®). are letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06726148' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.novartis.com/clinicaltrials/study/nct06726148' target='_blank'>Novartis: Trial Information Page</a> </li></ul>

56

ECI830 CDK2 Inhibitor with CDK4/6 Inhibitor and Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Nearest Location from 94107:
336 miles
University of California LA
Los Angeles, CA

Visits:
At least 1 visit every month

ClinicalTrials.gov: NCT06726148

Phase I-II

57

SGN-B6A in Advanced Breast Cancer

Show Scientific Title

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Purpose: To study the safety, side-effects, anti-cancer activity, and best dose of the antibody-drug conjugate SGN-B6A.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-B6A, by IV</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-B6A is an investigational therapy. This means it is only available in a clinical trial.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a cancer therapy that combines an antibody that targets cancer cells with a drug that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">SGN-B6A is an antibody-drug conjugate (ADC) targeting integrin beta-6. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced or metastatic cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04389632' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org' target='_blank'>Metastatic Breast Cancer Network</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biospace.com/article/releases/seattle-genetics-announces-initiation-of-phase-1-clinical-trials-for-two-novel-antibody-based-drug-candidates/' target='_blank'>BioSpace Press Release: Seagen Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates</a> </li></ul>

57

SGN-B6A in Advanced Breast Cancer

Show Scientific Title

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Nearest Location from 94107:
336 miles
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04389632

Phase I

58

Laser Interstitial Thermal Therapy for Brain Metastasis

Show Scientific Title

REMASTer: REcurrent Brain Metastases After SRS Trial

Purpose: To study the effects (good and bad) and anti-cancer activity of NeuroBlate® Laser Interstitial Thermal Therapy alone or with stereotactic radiation.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have received stereotactic radiation. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeuroBlate® Laser Interstitial Thermal Therapy (LITT)</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeuroBlate® Laser Interstitial Thermal Therapy (LITT)</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation</li> </ul> Please contact research site for treatment schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeuroBlate® Laser Interstitial Thermal Therapy (LITT) is a minimally invasive surgical tool designed to remove brain metastases during surgery.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation, also called stereotactic radiosurgery or hypofractionated radiation therapy, delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05124912' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.monteris.com/patients-caregivers/what-is-neuroblate/' target='_blank'>Monteris Medical: NeuroBlate® Laser Interstitial Thermal Therapy (LITT)</a> </li></ul>

58

Laser Interstitial Thermal Therapy for Brain Metastasis

Show Scientific Title

REMASTer: REcurrent Brain Metastases After SRS Trial

Nearest Location from 94107:
336 miles
UCLA
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05124912

Phase NA

59

XB010 ADC for Advanced HR+ or Triple Negative Breast Cancer

Show Scientific Title

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of XB010, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) or triple negative (ER-, PR-, HER2-) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XB010, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XB010 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XB0101's antibody targets 5T4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06545331' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.exelixis.com/clinical-trials-pipeline/' target='_blank'>Exelixis: XB010 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>

59

XB010 ADC for Advanced HR+ or Triple Negative Breast Cancer

Show Scientific Title

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Nearest Location from 94107:
336 miles
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06545331

Phase I

60

BRIA-OTS Cell Therapy for Metastatic Breast Cancer

Show Scientific Title

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of the Bria-OTS regimen, an experimental cell therapy, with tislelizumab (Tevimbra®) PD-1 inhibitor.

Who is this for?: People with metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following as part of the Bria-OTS regimen: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 2-3 days before BC1 cells</li> </ul> followed 2-3 days later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BC1 cells, by injection, every 3 weeks</li> <li class="seamTextUnorderedListItem">Peginterferon, every 3 weeks</li> <li class="seamTextUnorderedListItem">Tislelizumab (Tevimbra®), every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Bria-OTS regimen is an experimental cell therapy with BC1 cells.</li> <li class="seamTextUnorderedListItem">Before you receive the cell therapy, you will receive cyclophosphamide (Cytoxan®) chemotherapy to prepare your body to receive the cells.</li> <li class="seamTextUnorderedListItem">Tislelizumab (Tevimbra®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Tislelizumab (Tevimbra®) is approved to treat other cancers. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Peginterferon is an immunotherapy used to regulate your immune response to the cell therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06471673' target='_blank'>ClinicalTrials.gov</a> </li></ul>

60

BRIA-OTS Cell Therapy for Metastatic Breast Cancer

Show Scientific Title

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Nearest Location from 94107:
338 miles
Sarcoma Oncology Center
Santa Monica, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06471673

Phase I-II

61

AMXT 1501 and DFMO in Combination With Standard Therapies for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of AMXT 1501 and DFMO when combined with standard treatments.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with alterations in the genes, PIK3CA, AKT1, or PTEN, whose cancer has progressed on at least 2 hormone therapies. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMXT 1501, by mouth, daily</li> <li class="seamTextUnorderedListItem">DFMO, by mouth, daily</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li> <li class="seamTextUnorderedListItem">Capivasertib (Truqap®), by mouth, 4 days on, 3 days off</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Biopsies, 2 times within 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMXT 1501 and DFMO block molecules involved in tumor growth and survival. Together, they may improve tumor response to standard cancer treatments, reduce tumor growth, and reverse tumor-induced immunosuppression.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Capivasertib (Truqap®) is a targeted therapy for people with abnormal changes in PIK3CA, AKT1, and/or PTEN genes and whose cancer has progressed on or after hormone therapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with melanoma (skin cancer).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07287917' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://aminextx.com/science/' target='_blank'>Aminex Therapeutics: AMXT 1501 and DFMO</a> </li></ul>

61

AMXT 1501 and DFMO in Combination With Standard Therapies for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

Nearest Location from 94107:
339 miles
START Los Angeles
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07287917

Phase I-II

62

BL-B01D1 ADC for Advanced HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors (BL-B01D1-LUNG-101)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BL-B01D1, an experimental antibody drug conjugate.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2- breast cancer. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-B01D1, by IV, weekly, 2 weeks on, 1 week off</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-B01D1, by IV, weekly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-B01D1 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in BL-B01D1 targets EGFR and HER3 proteins and delivers a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05983432' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://systimmune.com/bl-m01d1' target='_blank'>SystImmune: BL-B01D1 Drug Information Page</a> </li></ul>

62

BL-B01D1 ADC for Advanced HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors (BL-B01D1-LUNG-101)

Nearest Location from 94107:
339 miles
UCLA Santa Monica
Santa Monica, CA

Visits:
1 visit every 1-2 weeks

ClinicalTrials.gov: NCT05983432

Phase I

63

MGC026 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of MGC026, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have not received trastuzumab deruxtecan (Enhertu®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGC026, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGC026 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">MGC026's antibody targets B7-H3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06242470' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://macrogenics.com/pipeline/mgc026/' target='_blank'>MacroGenics: MGC026 Drug Information Page</a> </li></ul>

63

MGC026 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Nearest Location from 94107:
339 miles
The Angeles Clinic and Research Institute
Los Angeles, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06242470

Phase I

64

Targeted Therapy for Advanced Breast Cancer With a TP53 Y220C Mutation

Show Scientific Title

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of PC14586, an experimental p53 reactivator, alone or with pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a TP53 Y220C mutation who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PC14586, by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PC14586, by mouth, daily</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PC14586 is an experimental targeted therapy called a p53 reactivator which may stop the mutated p53 protein from working and cause cancer cell death.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: TP53 Y220C</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04585750' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pmvpharma.com/pipeline/' target='_blank'>PMV Pharmaceuticals: PC14586 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>

64

Targeted Therapy for Advanced Breast Cancer With a TP53 Y220C Mutation

Show Scientific Title

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

Nearest Location from 94107:
339 miles
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04585750

Phase I-II

65

Gedatolisib Targeted Therapy with CDK4/6 Inhibitor and Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of gedatolisib, an experimental targeted therapy, with standard of care CDK4/6 inhibitor and hormone therapy compared to standard of care alone.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who were diagnosed with advanced disease during or within 1 year of completing hormone therapy. You must have not yet received treatment for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gedatolisib, by IV, weekly, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) or ribociclib (Kisqali®), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) or ribociclib (Kisqali®), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gedatolisib is an experimental targeted therapy called a pan-PI3K/mTOR inhibitor. Blocking PI3K/mTOR may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) and ribociclib (Kisqali®) are types of targeted therapies called CDK4/6 inhibitors. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06757634' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.celcuity.com/our-approach/viktoria-2-2/' target='_blank'>Celcuity: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.celcuity.com/gedatolisib/' target='_blank'>Celcuity: Gedatolisib Drug Information Page</a> </li></ul>

65

Gedatolisib Targeted Therapy with CDK4/6 Inhibitor and Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

Nearest Location from 94107:
339 miles
UCLA Hematology Oncology Santa Monica
Los Angeles, CA

Visits:
1 visit every 1-2 weeks

ClinicalTrials.gov: NCT06757634

Phase III

66

BBI-940 Alone or with Fulvestrant for Advanced or Metastatic Breast Cancer

Show Scientific Title

An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BBI-940, a new type of targeted treatment, alone or in combination with fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or triple negative (ER-, PR-, HER2-) breast cancer that is also androgen receptor positive (AR+). You must have already received standard treatment. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BBI-940, by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BB1-940, by mouth, daily,</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by Injection, as scheduled</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BBI-940 is an investigational (still being studied) medicine that targets and breaks down specific proteins inside cancer cells, which may help slow or stop tumor growth.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">Treatment is organized into repeating 28-day periods (called cycles). Each cycle includes days when you take the treatment and days for rest, then the cycle starts again.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07408089' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Faslodex (fulvestrant) for Breast Cancer: What to Expect, Side Effects, and More</a> </li></ul>

66

BBI-940 Alone or with Fulvestrant for Advanced or Metastatic Breast Cancer

Show Scientific Title

An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)

Nearest Location from 94107:
339 miles
The START Center for Cancer Research
Los Angeles, CA

Visits:
1 visit every 1 or 2 months

ClinicalTrials.gov: NCT07408089

Phase I

67

Targeted Therapy with Hormone Therapy for Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Show Scientific Title

Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a targeted therapy, PIKTOR (Sapanisertib and Serabelisib), with fulvestrant( Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor–positive (ER+ and/or PR+), HER2‑negative (HER2‑) breast cancer. You must have received at least one prior line of chemotherapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sapanisertib, by mouth </li> <li class="seamTextUnorderedListItem">Serabelisib, by mouth </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">The study is testing different dose levels of the targeted therapies combined with hormone therapy.</li> <li class="seamTextUnorderedListItem">PIKTOR is a targeted therapy designed to find and block a specific growth signal that cancer cells use to multiply.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07558733' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li></ul>

67

Targeted Therapy with Hormone Therapy for Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Show Scientific Title

Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer

Nearest Location from 94107:
339 miles
START Los Angeles
Los Angeles, CA

Visits:
Number of visits unavailable, up to 3 months

ClinicalTrials.gov: NCT07558733

Phase I-II

68

Dual PARP and Microtubule Polymerization Inhibitor AMXI-5001 for Advanced Breast Cancer.

Show Scientific Title

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

Purpose: To study the best dose, safety, and anti-cancer activity of AMXI-5001--an experimental PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMXI-5001, by mouth, twice daily (4 days on, 3 days off), ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMX-5001 is an experimental PARP inhibitor.</li> <li class="seamTextUnorderedListItem">PARP inhibitors block poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04503265' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://atlasmedx.com/product-pipeline/' target='_blank'>AtlasMedx Drug Information Page: AMXI-5001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor' target='_blank'>NCI Drug Dictionary: PARP Inhibitor</a> </li></ul>

68

Dual PARP and Microtubule Polymerization Inhibitor AMXI-5001 for Advanced Breast Cancer.

Show Scientific Title

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

Nearest Location from 94107:
339 miles
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04503265

Phase I-II

69

RGT-419B Targeted Therapy for HR+, HER2- Advanced Breast Cancer

Show Scientific Title

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of RGT-419B, an experimental type of targeted therapy called a CDK 2/4/6 inhibitor, alone and with hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has progressed after treatment with a CDK 4/6 inhibitor and hormone therapy. You must not have received more than 1 line of chemotherapy. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups based on when you enroll: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RGT-419B, by mouth</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RGT-419B, by mouth</li> <li class="seamTextUnorderedListItem">Hormone therapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RGT-419B is an experimental type of targeted therapy called a CDK 2/4/6 inhibitor. It is designed to block three enzymes, CDK2, CDK4, and CDK6, that help cancer cells grow.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will receive one of the following types of hormone therapy that you have already received: selective estrogen receptor degrader (SERD), selective estrogen receptor modulator (SERM), or aromatase inhibitor.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05304962' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biospace.com/article/releases/regor-therapeutics-announces-u-s-fda-authorization-to-conduct-regor-s-first-in-human-clinical-trial-with-the-next-generation-targeted-inhibitor-rgt-419b-for-oncology/' target='_blank'>Regor Therapeutics Press Release: RGT-419B</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html' target='_blank'>American Cancer Society: CDK Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>

69

RGT-419B Targeted Therapy for HR+, HER2- Advanced Breast Cancer

Show Scientific Title

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Nearest Location from 94107:
339 miles
University California, Los Angeles
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05304962

Phase I

70

NT-175 TCR Immunotherapy for Advanced HLA Positive Breast Cancer with the TP53 R175H Mutation

Show Scientific Title

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of NT-175, an experimental T cell receptor (TCR) immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HLA positive breast cancer with the TP53 R175H mutation who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis procedure</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fludarabine (Fludara®)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®)</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NT-175 T cell receptor (TCR) immunotherapy, by IV</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interleukin-2 (IL-2)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NT-175 T cell receptor (TCR) immunotherapy is an experimental immunotherapy that trains the immune system to attack cancer cells with the TP53 R175H mutation.</li> <li class="seamTextUnorderedListItem">Leukapheresis is the removal of blood by a machine to collect specific immune cells called T cells that will be modified to target cancer cells.</li> <li class="seamTextUnorderedListItem">The T cells will be grown in a lab, modified, and given back to you through an infusion.</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and fludarabine (Fludara®) are chemotherapy drugs. The main purpose of chemotherapy drugs in this trial is to make the T cells more effective in fighting cancer cells.</li> <li class="seamTextUnorderedListItem">Interleukin-2 (IL-2) may help the T cells live longer in your body.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05877599' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapy-2-2/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies: A Type of Immunotherapy for MBC</a> </li></ul>

70

NT-175 TCR Immunotherapy for Advanced HLA Positive Breast Cancer with the TP53 R175H Mutation

Show Scientific Title

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Nearest Location from 94107:
339 miles
Research Site
Santa Monica, CA

Visits:
May require hospitalization

ClinicalTrials.gov: NCT05877599

Phase I

71

Targeted Therapy for Advanced HR+, HER2 Negative Breast Cancer With a PIK3CA Mutation

Show Scientific Title

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

Purpose: To study the safety, side effects (good and bad), and anti-cancer activity of a targeted therapy called RGT‑490.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor‑positive (ER+ and/or PR+), HER2‑negative breast cancer that has a PIK3CA gene mutation and has progressed after at least one prior line of treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RGT‑490, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RGT‑490 is an experimental targeted therapy called a PI3K alpha inhibitor that blocks the growth of cancer cells with a PIK3CA mutation.</li> <li class="seamTextUnorderedListItem">This is a dose finding study meaning that some people will receive different doses of RGT-490 as researchers determine the safest dose.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07524322' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/pik3ca-mbc-2/' target='_blank'>Metastatic Trial Talk: New Targeted Treatment Options for Metastatic Breast Cancer: Updates on PIK3CA</a> </li></ul>

71

Targeted Therapy for Advanced HR+, HER2 Negative Breast Cancer With a PIK3CA Mutation

Show Scientific Title

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

Nearest Location from 94107:
339 miles
START Los Angeles
Los Angeles, CA

Visits:
At least 1 visit every month

ClinicalTrials.gov: NCT07524322

Phase I

72

CX-5461 for Advanced Breast Cancer with a BRCA2 or PALB2 Mutation

Show Scientific Title

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

Purpose: To determine the safety and best dose of CX-5461, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have a BRCA2 or PALB2 germline (genetic) mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-5461, by IV, 2 times per month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-5461 is an experimental targeted therapy. </li> <li class="seamTextUnorderedListItem">It targets cells with a Homologous Recombination Deficiency (HRD) mutation. </li> <li class="seamTextUnorderedListItem">It works by slowing down the growth of cancer cells or causing cancer cells to die.</li> <li class="seamTextUnorderedListItem">This trial also is enrolling patients with other types of advanced cancers.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA2, PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04890613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/senhwa-biosciences-receives-us-fda-study-may-proceed-letter-to-treat-brca2-or-palb2-solid-tumors-with-cx-5461-301198347.html' target='_blank'>Senhwa Biosciences Press Release: CX-5461</a> </li></ul>

72

CX-5461 for Advanced Breast Cancer with a BRCA2 or PALB2 Mutation

Show Scientific Title

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

Nearest Location from 94107:
339 miles
University of California, Los Angeles
Santa Monica, CA

Visits:
2 visits per month

ClinicalTrials.gov: NCT04890613

Phase I

73

INCB123667 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of INCB123667, an experimental type of targeted therapy called a CDK 2 inhibitor.

Who is this for?: For people with advanced (some stage III) or metastatic (stage IV) breast cancer that has progressed on standard treatment. If you have hormone receptor positive (ER+ and/or PR+) breast cancer, you must not have received treatment with a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INCB0123667, by mouth, daily</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require at least 1 biopsy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INCB123667 is an experimental type of targeted therapy called a CDK 2/CDK2 inhibitor.</li> <li class="seamTextUnorderedListItem">CDK 2 inhibitors block the enzyme/protein CDK2 that helps cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05238922' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.incyteclinicaltrials.com/study/?id=INCB%20123667-101' target='_blank'>Incyte Corporation Clinical Trial Page: INCB123667</a> </li><li class='seamTextUnorderedListItem'><a href='https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2022-first-quarter-financial-results-and-provides' target='_blank'>Incyte Corporation Press Release: INCB123667</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html' target='_blank'>American Cancer Society: CDK Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li></ul>

73

INCB123667 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

Nearest Location from 94107:
340 miles
Valkyrie Clinical Trials
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05238922

Phase I

74

MBQ-167 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of MBQ-167, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBQ-167, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBQ-167 is an experimental targeted therapy called a Rac and Cdc42 inhibitor. Blocking Rac and Cdc42 may slow or stop cancer cells from growing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06075810' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbqpharma.com/science/' target='_blank'>MBQ Pharma: MBQ-167 Drug Information Page</a> </li></ul>

74

MBQ-167 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer

Nearest Location from 94107:
340 miles
Precision Next Gen Oncology & Research Center
Beverly Hills, CA

Visits:
About 1 visit every week

ClinicalTrials.gov: NCT06075810

Phase I

75

BNT323 ADC and BNT327 Immunotherapy for Advanced HER2 Low, HER2 Ultra Low, and HER2 Negative Breast Cancer

Show Scientific Title

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BNT323, an experimental antibody drug conjugate (ADC), and/or BNT327, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 low, HER2 ultralow, and HER2 negative (HER2-) breast cancer. You must not have received treatment with trastuzumab deruxtecan (Enhertu®) or sacituzumab govitecan (Trodelvy®) ADCs or irinotecan (Camptosr®) chemotherapy. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BNT323, by IV</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BNT327, by IV</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BNT323, by IV</li> <li class="seamTextUnorderedListItem">BNT327, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BNT323 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in BNT323 targets HER2 proteins. It delivers a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">BNT327 is an experimental targeted therapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to 2 distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">BNT327 binds to PD-L1 and VEGF.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC1+ or IHC 2+/ISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06827236' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.biontech.com/trials/BNT323-03?utm_source=chatgpt.com' target='_blank'>BioNTech: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='file:///Users/alexandraburd/Downloads/BNT_Factsheet_BNT323DB_1303_RZ_EN.pdf' target='_blank'>BioNTech: BNT323 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li></ul>

75

BNT323 ADC and BNT327 Immunotherapy for Advanced HER2 Low, HER2 Ultra Low, and HER2 Negative Breast Cancer

Show Scientific Title

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Nearest Location from 94107:
341 miles
Beverly Hills Cancer Center
Beverly Hills, CA

Visits:
At least 11 visits every 2 weeks

ClinicalTrials.gov: NCT06827236

Phase I-II

76

LCB84 Antibody Drug Conjugate With and Without Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of LCB84, an experimental antibody drug conjugate (ADC), with or without a PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84, by IV, every 3 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">PD-1 inhibitor, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">LCB84's antibody targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called MMAE.</li> <li class="seamTextUnorderedListItem">PD-1 inhibitors are a type of immunotherapy called immune checkpoint inhibitors. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05941507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/?utm_medium=email&utm_source=subscribers&utm_campaign=Oct2023&utm_content=Email102023' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors' target='_blank'>National Cancer Institute: Immune Checkpoint Inhibitors</a> </li></ul>

76

LCB84 Antibody Drug Conjugate With and Without Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

Nearest Location from 94107:
341 miles
Cedars Sinai Medical Center
Los Angeles, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT05941507

Phase I-II

77

QXL138AM Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Purpose: To study the safety, best dose, and effects (good and bad) of QXL138AM, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">QXL138AM, by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">QXL138AM is an experimental immunotherapy called an immunocytokine (MIC).</li> <li class="seamTextUnorderedListItem">Immunocytokines such as QXL138AM may support the immune system's ability to target and kill cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06582017' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-qxl138am-for-pancreatic-cancers' target='_blank'>Targeted Oncology: QXL138AM for Pancreatic Cancer</a> </li></ul>

77

QXL138AM Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Nearest Location from 94107:
341 miles
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer
Los Angeles, CA

Visits:
1 visit every 2 weeks

ClinicalTrials.gov: NCT06582017

Phase I

78

Palazestrant Hormone Therapy for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 3 Randomized, Open-Label Study Of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of palazestrant (OP-1250), an experimental hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. You must not have received chemotherapy or more than 2 lines of hormone therapy for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palazestrant (OP-1250)</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care hormone therapy: fulvestrant (Faslodex®), anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palazestrant (OP-1250) and fulvestrant (Faslodex®) are types of hormone therapy called selective estrogen receptor degraders (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is approved, and palazestrant (OP-1250) is experimental.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women and men will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06016738' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://opera01study.com/' target='_blank'>Olema Pharmaceuticals: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://olema.com/pipeline/' target='_blank'>Olema Pharmaceuticals: Palazestrant (OP-1250) Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oral-serds/' target='_blank'>Metastatic Trial Talk: Update on Oral SERDs for Estrogen Receptor-Positive MBC</a> </li></ul>

78

Palazestrant Hormone Therapy for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 3 Randomized, Open-Label Study Of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Nearest Location from 94107:
342 miles
Clinical Trial Site
Los Angeles, CA

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT06016738

Phase III

79

Elacestrant Hormone Therapy and Abemaciclib CDK 4/6 Inhibitor for ER+, HER2- Breast Cancer with Brain Metastasis

Show Scientific Title

An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of elacestrant, an experimental hormone therapy, alone or with abemaciclib (Verzenio®) CDK 4/6 inhibitor.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or HER2 low breast cancer that has spread to the brain (brain metastasis) who have received at least 1 hormone therapy, up to 2 chemotherapies, and up to 2 CDK 4/6 inhibitors for metastatic disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®)</li> <li class="seamTextUnorderedListItem">Elacestrant, daily</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant is an experimental hormone therapy called a selective estrogen receptor degrader (SERD). SERDs work by binding to and breaking down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women and men will also be given a drug that will put women in temporary menopause.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05386108' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/benefit-of-elacestrant-improves-with-longer-duration-of-cdk4-6-inhibition-in-patients-with-er-her2-metastatic-breast-cancer' target='_blank'>OncLive: Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in People With ER+/HER2- Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/the-emerald-trial-elacestrant-mechanism-of-action-study-design-and-outcomes' target='_blank'>Targeted Oncology: Elacestrant for ER+, HER2- MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oral-serds/' target='_blank'>Metastatic Trial Talk: Update on Oral SERDs for Estrogen Receptor-Positive MBC</a> </li></ul>

79

Elacestrant Hormone Therapy and Abemaciclib CDK 4/6 Inhibitor for ER+, HER2- Breast Cancer with Brain Metastasis

Show Scientific Title

An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Nearest Location from 94107:
342 miles
California Research Institute
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05386108

Phase I-II

80

ZEN003694 and Abemaciclib Targeted Therapies for Advanced Breast Cancer

Show Scientific Title

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ZEN003694, an experimental BET bromodomain Inhibitor, with abemaciclib (Verzenio®) CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZEN003694, by mouth, daily, 5 days on, 2 days off</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZEN003694 is an experimental targeted therapy called a BET bromodomain inhibitor. It may prevent the growth of tumor cells that overproduce BET protein.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05372640' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zenithepigenetics.com/programs/pipeline' target='_blank'>Zenith Epigenetics Drug Information Page: ZEN-3694</a> </li></ul>

80

ZEN003694 and Abemaciclib Targeted Therapies for Advanced Breast Cancer

Show Scientific Title

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

Nearest Location from 94107:
343 miles
Keck Medicine of USC Koreatown
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05372640

Phase I

81

Patritumab Deruxtecan ADC Compared to Chemotherapy or Trastuzumab Deruxtecan for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of patritumab deruxtecan antibody-drug conjugate (ADC) compared to chemotherapy or trastuzumab deruxtecan (T-DXd; Enhertu®) ADC.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed while receiving a CDK4/6 inhibitor and hormone therapy. You must not have a BRCA mutation and be eligible for treatment with a PARP inhibitor. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks for 13 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy or trastuzumab deruxtecan (T-DXd; Enhertu®), for 13 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells. Patritumab deruxtecan is an ADC that binds to HER3, which is found on many breast cancer cells.</li> <li class="seamTextUnorderedListItem">For participants in the control group, the schedule for receiving the drug will vary depending on the drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07060807' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: Patritumab deruxtecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates</a> </li></ul>

81

Patritumab Deruxtecan ADC Compared to Chemotherapy or Trastuzumab Deruxtecan for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Nearest Location from 94107:
346 miles
Los Angeles Hematology Oncology Medical Group ( Site 0026)
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07060807

Phase III

82

Inavolisib With Fulvestrant for Advanced HR+, HER2- Breast Cancer with PIK3CA Mutations

Show Scientific Title

A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of inavolisib (Itovebi®) PI3K inhibitor with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation whose disease progressed while taking anti-hormone therapy with a CDK 4/6 inhibitor. You must not have received more than 1 line of anti-hormone therapy with a CDK 4/6 inhibitors for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inavolisib (Itovebi®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">To find out how well inavolisib with fulvestrant works, and how safe inavolisib is at different doses. </li> <li class="seamTextUnorderedListItem">If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated which allows cancer cells to grow.</li> <li class="seamTextUnorderedListItem">Inavolisib (Itovebi®) is a type of targeted therapy called a PI3K inhibitor. It can stop cancer cell growth of tumors with a PIK3CA mutation.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07368998' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/health/metastatic-breast-cancer/pik3ca-mutation-and-breast-cancer#what-is-the-pik-3-ca-gene' target='_blank'>Healthline: PIK3CA Mutations in Breast Cancer: What Does It Mean?</a> </li></ul>

82

Inavolisib With Fulvestrant for Advanced HR+, HER2- Breast Cancer with PIK3CA Mutations

Show Scientific Title

A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Nearest Location from 94107:
346 miles
Los Angeles Cancer Network
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07368998

Phase II

83

Ifinatamab Deruxtecan ADC for Advanced HER2 Low or HER2 Negative Breast Cancer

Show Scientific Title

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Purpose: To study the safety, best dose, and effects (good and bad) of ifinatamab deruxtecan (I-DXd), an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 low or HER2 negative (HER2-) breast cancer who have received at least 1 line of therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ifinatamab deruxtecan (I-DXd), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ifinatamab deruxtecan (I-DXd) is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Ifinatamab deruxtecan (I-DXd)'s antibody targets B7-H3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 2+/ISH- or IHC 1+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06330064' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/news/january-2024/antibody-drug-conjugate-ifinatamab-deruxtecan-shows-robust-activity-in-refractory-small-cell-lung-cancer/' target='_blank'>ASCO: Antibody-Drug Conjugate Ifinatamab Deruxtecan for Small Cell Lung Cancer</a> </li></ul>

83

Ifinatamab Deruxtecan ADC for Advanced HER2 Low or HER2 Negative Breast Cancer

Show Scientific Title

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Nearest Location from 94107:
346 miles
Los Angeles Cancer Network
Los Angeles, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06330064

Phase II

84

Effects of Abemaciclib in People 70 or Older With Metastatic Hormone Positive Breast Cancer

Show Scientific Title

A Phase IIA Trial Assessing the Tolerability of Abemaciclib Monotherapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer

Purpose: To study the side effects (good and bad) of abemaciclib (Verzenio®).

Who is this for?: People with metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are age 70 or older and have already received treatment for metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04305834' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verzenio.com' target='_blank'>Drug Company Information Page: Verzenio® (Abemaciclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/blog/breast-cancer-elderly-how-bcrf-researchers-are-treating-growing-patient-population' target='_blank'>Breast Cancer Research Foundation: Breast Cancer in the Elderly</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249663/' target='_blank'>Journal Article: Use of Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors in Older Patients</a> </li></ul>

84

Effects of Abemaciclib in People 70 or Older With Metastatic Hormone Positive Breast Cancer

Show Scientific Title

A Phase IIA Trial Assessing the Tolerability of Abemaciclib Monotherapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer

Nearest Location from 94107:
347 miles
City of Hope South Pasadena
South Pasadena, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04305834

Phase II

85

MT-4561 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of MT-4561, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MT-4561, by IV, weekly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MT-4561 is an experimental targeted therapy called a BRD4 inhibitor. Blocking BRD4 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06943521' target='_blank'>ClinicalTrials.gov</a> </li></ul>

85

MT-4561 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

Nearest Location from 94107:
348 miles
University of Southern California
Los Angeles, CA

Visits:
1 visit every week

ClinicalTrials.gov: NCT06943521

Phase I-II

86

FT836 With or Without Chemotherapy and/or Targeted Therapy for Metastatic Breast Cancer

Show Scientific Title

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of FT836 cell therapy alone or with chemotherapy or targeted therapy.

Who is this for?: People with stage IV (metastatic) breast cancer who have received at least one line of therapy. View full eligibility criteria

What's involved?

You will be assigned to 1 of 6 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836, by IV</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 times</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836, by IV</li> <li class="seamTextUnorderedListItem">Cetuximab (Erbitux®), by IV</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 times</li> <li class="seamTextUnorderedListItem">Cetuximab (Erbitux®), by IV</li> </ul> Group 5 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836, by IV</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV</li> </ul> Group 6 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 times</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT836 is a type of cell therapy designed to kill cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07216105' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft836/' target='_blank'>Fate Therapeutics: FT836</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immunotherapy-mbc-2-2/' target='_blank'>Metastatic Trial Talk: Cell-Based Therapy</a> </li></ul>

86

FT836 With or Without Chemotherapy and/or Targeted Therapy for Metastatic Breast Cancer

Show Scientific Title

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Nearest Location from 94107:
348 miles
University of Southern California
La Jolla, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07216105

Phase I

87

Genetic Testing Education for People with Stage 0-IV Breast Cancer

Show Scientific Title

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

Purpose: To gather feedback about genetic testing education with a computer-generated character as an alternative to standard of care genetic testing education with a human genetic counselor.

Who is this for?: People diagnosed with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer before age 50, people with breast cancer in both breasts, people with triple negative (ER-, PR-, HER2-) breast cancer, or men with breast cancer. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing education with PERLA, computer-generated character, 1 time before testing</li> <li class="seamTextUnorderedListItem">Genetic counseling with genetic counselor, 1 time after testing</li> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Survey</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing education with genetic counselor, 1 time before testing</li> <li class="seamTextUnorderedListItem">Genetic counseling with genetic counselor, 1 time after testing</li> <li class="seamTextUnorderedListItem">Survey</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The computer-generated character in Group 1 is called a patient-facing relational agent (PERLA).</li> <li class="seamTextUnorderedListItem">Many people with cancer are recommended to receive genetic testing as standard of care.</li> <li class="seamTextUnorderedListItem">Lack of access to genetic counseling and testing is one reason people may not receive genetic testing.</li> <li class="seamTextUnorderedListItem">Education about genetic testing before recieving testing in both English and Spanish may lead to better access to genetic testing.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06422455' target='_blank'>ClinicalTrials.gov</a> </li></ul>

87

Genetic Testing Education for People with Stage 0-IV Breast Cancer

Show Scientific Title

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

Nearest Location from 94107:
348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06422455

Phase NA

88

Cemiplimab Immunotherapy and Blockade of Tumor Blood Vessels for Metastatic Breast Cancer That Has Spread to the Liver

Show Scientific Title

Pilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cemiplimab (Libtayo®) immunotherapy and a new type of procedure called transarterial radioembolization (TARE) with Y90 SIR-S Spheres.

Who is this for?: People with stage IV (metastatic) breast cancer that has spread to the liver and who have received at least one line of chemotherapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cemiplimab (Libtayo®), by IV, every 3 weeks for 1 year</li> <li class="seamTextUnorderedListItem">Y90 SIR-Spheres, by injection into the tumor, 2 times within 2 months</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 1.5 months</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">CT scan or MRI scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cemiplimab (Libtayo®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Transarterial radioembolization (TARE) is a treatment that uses radioactive microspheres, such as Y90 SIR-S Spheres, to block liver tumor arteries and deliver radiotherapy to kill or slow tumor growth.</li> <li class="seamTextUnorderedListItem">Y90 SIR-S Spheres are a medical device used in selective internal radiation therapy (SIRT). They work from the inside, targeting radiation to the tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06860815' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.libtayo.com/cscc/what-is-libtayo?gclsrc=aw.ds&gad_source=1&gad_campaignid=21818392314&gclid=CjwKCAjw-svEBhB6EiwAEzSdrqVrcE526ont6BY7LSTfDrcWHrRlNbq3aKo67h3-MT7X9HJ1CwupdBoCOCwQAvD_BwE' target='_blank'>Regeneron: Cemiplimab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sirtex.com/us/patients/sir-spheres-y-90-resin-microspheres/about-sir-spheres/' target='_blank'>Sirtex: Y90 SIR-Spheres</a> </li></ul>

88

Cemiplimab Immunotherapy and Blockade of Tumor Blood Vessels for Metastatic Breast Cancer That Has Spread to the Liver

Show Scientific Title

Pilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Breast Cancer

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Visits:
Every 3 weeks for 1 year

ClinicalTrials.gov: NCT06860815

Phase II

89

Stereotactic Body Radiation Therapy and FES PET/CT Scans for Oligoprogressive Metastatic ER+ Breast Cancer

Show Scientific Title

A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of stereotactic body radiation therapy (SBRT) for oligoprogressive metastatic breast cancer.

Who is this for?: People with oligoprogressive metastatic (stage IV) estrogen receptor positive (ER+) breast cancer who have received 1-3 lines of therapy for metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT), 3-5 sessions within 3 weeks</li> <li class="seamTextUnorderedListItem">PET/CT scan with FES, by IV, 3-4 times within 6 months</li> <li class="seamTextUnorderedListItem">Bone scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Oligoprogression refers to limited disease progression (1-4 metastases).</li> <li class="seamTextUnorderedListItem">Currently, the standard of care treatment for oligoprogressive disease is to change treatment when progression occurs.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors.</li> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses special equipment to position a patient and precisely deliver radiation. The total dose of radiation is divided into smaller doses (fractions) given over several days.</li> <li class="seamTextUnorderedListItem">SBRT helps keep normal tissue healthy and has been shown to improve survival.</li> <li class="seamTextUnorderedListItem">This trial also tests how well PET/CT scans with FES works in identifying progressive disease.</li> <li class="seamTextUnorderedListItem">FES is a radioactive substance that binds to estrogen receptors and gives off radiation that can be detected by a PET scan.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06260033' target='_blank'>ClinicalTrials.gov</a> </li></ul>

89

Stereotactic Body Radiation Therapy and FES PET/CT Scans for Oligoprogressive Metastatic ER+ Breast Cancer

Show Scientific Title

A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Visits:
At least 6-9 visits within 6 months

ClinicalTrials.gov: NCT06260033

Phase II

90

Biomarker Testing to Select an Antibody-Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of using biomarkers to select an antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have had a type of blood test called an RNA test. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups depending on your RNA blood test and biopsy results: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, weekly, 2 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enfortumab vedotin (Padcev®), by IV, weekly, 3 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Echocardiography or multigated acquisition scan (heart scans), 2 times</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing the person's blood and tumor for the presence of the biomarkers, TROP-2, nectin 4, or HER2 to match them to one of three ADCs.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a TROP-2-targeted ADC approved for triple-negative or HR+, HER2- MBC.</li> <li class="seamTextUnorderedListItem">Enfortumab vedotin (Padcev®) is a nectin4-targeted ADC approved for use in other cancers. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a HER2-targeted ADC approved for HER2+ or HER2-low MBC.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06311214' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.trodelvy.com/?utm_source=google&utm_medium=cpc&utm_campaign=us_sem_trmd_onc_dtp_ex_mtnbc_go_na_na_b_standard_branded_1432nn&utm_content=17054576844%3B136230621779%3Bkwd-946345024054&utm_term=trodelvy&gclsrc=aw.ds&gad_source=1&gad_campaignid=17' target='_blank'>Gilead: Sacituzumab Govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.padcev.com/' target='_blank'>Astellas Pharma: Enfortumab Vedotin (Padcev®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://enhertu.com/en/mbc?utm_source=google&utm_medium=cpc&utm_term=trastuzumab%20deruxtecan&utm_campaign=|CN|DTCB|BR|mBC|ENH|AZ|Core|Alone&utm_source=google&utm_medium=cpc&utm_campaign=%7CCN%7CDTCB%7CBR%7CmBC%7CENH%7CAZ%7CCore%7CAlone&utm_content=Alone%' target='_blank'>Daiichi Sankyo: Trastuzumab Deruxtecan (Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates (ADCs)</a> </li></ul>

90

Biomarker Testing to Select an Antibody-Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

Nearest Location from 94107:
353 miles
City of Hope Comprehensive Cancer Center
Duarte, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06311214

Phase II

91

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for MUC 1*

Show Scientific Title

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*)

Purpose: To look at the safety, best dose and effects of an experimental CAR T-cell immunotherapy that targets cancer cells that test positive for MUC1*, a special type of the MUC1 protein.

Who is this for?: People with metastatic (stage IV) breast cancer that tests positive for MUC1 and who have already received at least one standard therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your personalized CAR T-cell therapy (leukapheresis)</li> <li class="seamTextUnorderedListItem">Chemotherapy to deplete your lymph cells</li> <li class="seamTextUnorderedListItem">huMNC2-CAR44 CAR T-cells, by IV</li> </ul> Please contact research site for treatment schedule. Hospital stay may be required.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR T cell or CAR-T cell therapy is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein. </li> <li class="seamTextUnorderedListItem">The CAR T-cells are then infused back into you while you are hospitalized </li> <li class="seamTextUnorderedListItem">The CAR T-cell therapy being used in this study trains the immune system to attack MUC1 on cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04020575' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html' target='_blank'>MD Anderson Cancer Center: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/research/car-t-cells' target='_blank'>NCI: Car T-Cells</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.minervabio.com/clinical-trial-humnc2-car44-in-mbc/' target='_blank'>Minerva Biotechnologies: Study Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>

91

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for MUC 1*

Show Scientific Title

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*)

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Visits:
May require hospitalization

ClinicalTrials.gov: NCT04020575

Phase I

92

PF-08032562 for Advanced Breast Cancer

Show Scientific Title

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of PF-08032562 and fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose cancer has progressed after receiving prior treatment or for whom no standard treatment options are available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-08032562, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07318805' target='_blank'>ClinicalTrials.gov</a> </li></ul>

92

PF-08032562 for Advanced Breast Cancer

Show Scientific Title

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Nearest Location from 94107:
353 miles
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, CA

Visits:
Number of visits unavailable, up to 2 years

ClinicalTrials.gov: NCT07318805

Phase I

93

225Ac-Ac-AKY-1189 Radioactive Drug for Advanced Triple Negative or HR+ Breast Cancer That is Nectin-4 Positive

Show Scientific Title

NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of 225Ac-Ac-AKY-1189, an experimental radioactive drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor positive (ER+ and/or PR+) breast cancer that is Nectin-4 positive. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">225Ac-Ac-AKY-1189, by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are developing a new type of drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells.</li> <li class="seamTextUnorderedListItem">225Ac-Ac-AKY-1189 is an experimental radiopharmaceutical or radioactive drug.</li> <li class="seamTextUnorderedListItem">225Ac-Ac-AKY-1189 targets Nectin-4 which is on some tumor cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07020117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aktisoncology.com/our-science/' target='_blank'>Aktis Oncology: Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>Metastatic Trial Talk: What Are Radiopharmaceuticals and How Are They Used in MBC?</a> </li></ul>

93

225Ac-Ac-AKY-1189 Radioactive Drug for Advanced Triple Negative or HR+ Breast Cancer That is Nectin-4 Positive

Show Scientific Title

NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

Nearest Location from 94107:
353 miles
City of Hope
Duarte, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07020117

Phase I

94

NKT5097 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of NKT5097, an experimental CDK2/4 degrader.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKT5097, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKT5097 is an experimental targeted therapy called a CDK2/4 degrader. It breaks down two enzymes, CDK2 and CDK4, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07029399' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2023/12/what-is-protein-degradation/' target='_blank'>Dana-Farber Cancer Institute: Protein Degraders for Cancer</a> </li></ul>

94

NKT5097 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors

Nearest Location from 94107:
353 miles
City of Hope
Duarte, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07029399

Phase I

95

Photon Craniospinal Irradiation for Metastatic Breast Cancer with Leptomeningeal Disease

Show Scientific Title

Phase II Trial of Photon Craniospinal Irradiation for Leptomeningeal Disease Secondary to Solid Tumor Malignancy

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of craniospinal irradiation (CSI) for leptomeningeal disease.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal metastasis or leptomeningeal disease). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Craniospinal irradiation (CSI), 10 sessions within 2-3 weeks</li> <li class="seamTextUnorderedListItem">CSF samples</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times in 1 month, then every 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the fluid surrounding the brain (cerebrospinal fluid or CSF).</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.</li> <li class="seamTextUnorderedListItem">Craniospinal irradiation (CSI) is radiation therapy directed at the brain and spinal cord to kill tumor cells.</li> <li class="seamTextUnorderedListItem">CSI may be able to target all of the areas of possible leptomeningeal tumor spread.</li> <li class="seamTextUnorderedListItem">CSF is collected during a procedure called a lumbar puncture (spinal tap) or with an Ommaya reservoir.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to CSF.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06910761' target='_blank'>ClinicalTrials.gov</a> </li></ul>

95

Photon Craniospinal Irradiation for Metastatic Breast Cancer with Leptomeningeal Disease

Show Scientific Title

Phase II Trial of Photon Craniospinal Irradiation for Leptomeningeal Disease Secondary to Solid Tumor Malignancy

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Visits:
At least 10 visits within 2-3 weeks

ClinicalTrials.gov: NCT06910761

Phase II

96

Patritumab Deruxtecan for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received treatment with chemotherapy, a CDK 4/6 inhibitor, and hormone therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan (HER3-DXd), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate that targets HER3.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06172478' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.daiichisankyo.com/rd/pipeline/' target='_blank'>Daiichi Sankyo: Patritumab Deruxtecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates</a> </li></ul>

96

Patritumab Deruxtecan for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Nearest Location from 94107:
353 miles
City of Hope
Duarte, CA

Visits:
Every 3 weeks

ClinicalTrials.gov: NCT06172478

Phase II

97

Sacituzumab Tirumotecan ADC for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of sacituzumab tirumotecan, an experimental antibody drug conjugate (ADC), alone or with pembrolizumab (Keytruda®) PD-1 inhibitor, compared to standard of care chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received hormone therapy with a CDK4/6 inhibitor for advanced disease. You must not have received chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 3 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (MK-2870), by IV, every 2 weeks</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (MK-2870), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 1.5 months</li> </ul> Group 3: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (MK-2870) is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in sacituzumab tirumotecan (MK-2870) targets TROP2 proteins. It delivers the chemotherapy belotecan.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06312176' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: Sacituzumab Tirumotecan (MK-2870) Drug Information Page</a> </li></ul>

97

Sacituzumab Tirumotecan ADC for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Nearest Location from 94107:
366 miles
Cancer and Blood Specialty Clinic ( Site 0001)
Los Alamitos, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06312176

Phase III

98

Hormone Therapy and Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of fulvestrant (Faslodex®) and anastrozole (Arimidex®) hormone therapies with abemaciclib (Verzenio®) CDK 4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that is newly diagnosed or that progressed at least 1 year after finishing standard treatment. You must not have received treatment with fulvestrant (Faslodex®) or a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®) is type of hormone therapy called an aromatase inhibitor. It is commonly used to treat early-stage and metastatic hormone-positive (ER+ and/or PR+) breast cancer.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women and men will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05524584' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/arimidex' target='_blank'>Breastcancer.org: Anastrozole (Arimidex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/arimidex' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li></ul>

98

Hormone Therapy and Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer

Nearest Location from 94107:
374 miles
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, CA

Visits:
2 visits in 1 month, then monthly

ClinicalTrials.gov: NCT05524584

Phase II

99

Riluzole to Prevent Memory and Thinking Problems in People who Receiving Chemotherapy

Show Scientific Title

RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)

Purpose: To study if riluzole (Rilutek®) can help prevent problems with memory, thinking, and concentration (often called “chemo brain”).

Who is this for?: People with stage I, stage II, stage III, or stage IV breast cancer who are receiving or planning to receive anthracycline or platinum chemotherapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Riluzole (Rilutek®), by mouth, 2 times a day, up to 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> Group 2: Placebo <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for riluzole, by mouth, 2 times a day, up to 6 months </li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some people who receive treatments for breast cancer experience cognitive problems.</li> <li class="seamTextUnorderedListItem">Problems with thinking, called cognitive impairment, can happen during and after breast cancer treatment.</li> <li class="seamTextUnorderedListItem">These problems can last for years and can affect a person's ability to work or participate in social activities.</li> <li class="seamTextUnorderedListItem">Riluzole (Rilutek®) is a drug used to treat ALS (Lou Gehrig's disease), but it may also be helpful to improve cognition. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Researchers want to learn if this drug can protect brain function during cancer treatment.</li> <li class="seamTextUnorderedListItem">Anthracycline chemotherapy drugs are doxorubicin (Doxil®), epirubicin (Ellence®), mitoxantrone (Novantrone®), and idarubicin (Idamycin®).</li> <li class="seamTextUnorderedListItem">Platinum chemotherapy drugs are cisplatin, oxaliplatin (Eloxatin®), and carboplatin (Paraplatin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07447050' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/managing-cancer/side-effects/changes-in-mood-or-thinking/chemo-brain.html' target='_blank'>American Cancer Society: Changes in Memory, Thinking, and Focus (Chemo Brain)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/chemo-brain' target='_blank'>BreastCancer.org: Chemo Brain: Understanding Brain Fog and How to Treat It</a> </li></ul>

99

Riluzole to Prevent Memory and Thinking Problems in People who Receiving Chemotherapy

Show Scientific Title

RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)

Nearest Location from 94107:
374 miles
Chao Family Comprehensive Cancer Center, University of California Irvine
Orange, CA

Visits:
Coincides with usual care, up to 6 months

ClinicalTrials.gov: NCT07447050

Phase II

100

LNCB74 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors (LNCB74-01)

Purpose: To study the safety, best dose, and effects (good and bad) of LNCB74, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LNCB74, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LNCB74 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in LNCB74 targets B7-H4 proteins. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06774963' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nextcure.com/pipeline/' target='_blank'>NextCure: LNCB74 Drug Information Page</a> </li></ul>

100

LNCB74 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors (LNCB74-01)

Nearest Location from 94107:
381 miles
Hoag Family Cancer Institute
Newport Beach, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06774963

Phase I

101

SLV-154 for Metastatic Breast Cancer

Show Scientific Title

A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of SLV-154.

Who is this for?: People with stage IV (metastatic) breast cancer. You must have received at least one line of therapy for your breast cancer. You must not have brain metastases that are unstable or untreated. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SLV-154, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06771219' target='_blank'>ClinicalTrials.gov</a> </li></ul>

101

SLV-154 for Metastatic Breast Cancer

Show Scientific Title

A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors

Nearest Location from 94107:
381 miles
Hoag Memorial Hospital Presbyterian
Newport Beach, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06771219

Phase I

102

Evexomostat for Women with Advanced HR+, HER2- Breast Cancer with a PIK3CA Mutation and High Blood Sugar

Show Scientific Title

Phase 1b/2 Study of the Safety and Efficacy of Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Advanced Breast Cancer and a PIK3CA Mutation Following Endocrine Therapy and a CDK4/6 Inhibitor

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of evexomostat (SDX-7320), an experimental polymer drug conjugate, with fulvestrant (Faslodex®) hormone therapy and alpelisib (Piqray®) PI3K inhibitor.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation who have high blood sugar. You must have received hormone therapy and a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®)</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320) is an experimental polymer drug conjugate (PDC), which is similar to an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320) releases fumagillol, a type of targeted therapy called a MetAP2 inhibitor. Blocking MetAP2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women will also be given a drug that will put women in temporary menopause.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05455619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.amelia1.com/' target='_blank'>SynDevRx: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://syndevrx.com/lead-compound-sdx-7320/' target='_blank'>SynDevRx Drug Information Page: Evexomostat (SDX-7320)</a> </li><li class='seamTextUnorderedListItem'><a href='https://syndevrx.com/science/polymer-drug-conjugation/' target='_blank'>SynDevRx: Polymer Drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li></ul>

102

Evexomostat for Women with Advanced HR+, HER2- Breast Cancer with a PIK3CA Mutation and High Blood Sugar

Show Scientific Title

Phase 1b/2 Study of the Safety and Efficacy of Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Advanced Breast Cancer and a PIK3CA Mutation Following Endocrine Therapy and a CDK4/6 Inhibitor

Nearest Location from 94107:
381 miles
Hoag Memorial Hospital Presbyterian
Newport, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05455619

Phase I-II

103

TOS-358 Targeted Therapy for Advanced HER2- Breast Cancer With a PIK3CA Mutation

Show Scientific Title

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of TOS-358, an experimental PI3K inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer with a PIK3CA mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TOS-358, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TOS-358 is an experimental targeted therapy called a PI3K inhibitor.</li> <li class="seamTextUnorderedListItem">If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated, allowing cancer cells to grow. TOS-358 may slow or stop cancer cells from growing by blocking this pathway.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05683418' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.totusmedicines.com/pipeline' target='_blank'>Totus Medicines: TOS-358 Drug Information Page</a> </li></ul>

103

TOS-358 Targeted Therapy for Advanced HER2- Breast Cancer With a PIK3CA Mutation

Show Scientific Title

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

Nearest Location from 94107:
421 miles
Comprehensive Cancer Centers of Nevada
Las Vegas, NV

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05683418

Phase I

104

CID-078 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

Purpose: To study the safety, best dose, and effects (good and bad) of CID-078, an experimental cyclin A/B-RxL inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CID-078, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CID-078 is an experimental targeted therapy called a cyclin A/B-RxL inhibitor. Blocking cyclin A/B-RxL may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06577987' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://circlepharma.com/our-pipeline' target='_blank'>Circle Pharma: CID-078 Drug Information Page</a> </li></ul>

104

CID-078 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

Nearest Location from 94107:
421 miles
Comprehensive Cancer Centers of Nevada
Las Vegas, NV

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06577987

Phase I

105

Proton Craniospinal Irradiation for Metastatic Breast Cancer with Leptomeningeal Metastasis

Show Scientific Title

A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients With Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (RADIATE-LM)

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of proton craniospinal irradiation (pCSI), an experimental radiation therapy, and involved-field radiation therapy (IFRT).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal metastasis or leptomeningeal disease) who have not yet received treatment for leptomeningeal metastasis. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Involved-field radiation therapy (IFRT)</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton craniospinal irradiation (pCSI), 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the fluid surrounding the brain (cerebrospinal fluid or CSF).</li> <li class="seamTextUnorderedListItem">Radiation therapy (RT) uses high energy x-rays to kill cancer cells and shrink tumors.</li> <li class="seamTextUnorderedListItem">Involved-field radiation therapy (IFRT) is standard of care radiation that uses x-rays to treat specific areas of leptomeningeal metastases (LM) and to reduce and/or prevent symptoms.</li> <li class="seamTextUnorderedListItem">Proton craniospinal irradiation (pCSI) uses protons which may be more accurate than x-rays.</li> <li class="seamTextUnorderedListItem">pCSI may also treat the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06500481' target='_blank'>ClinicalTrials.gov</a> </li></ul>

105

Proton Craniospinal Irradiation for Metastatic Breast Cancer with Leptomeningeal Metastasis

Show Scientific Title

A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients With Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (RADIATE-LM)

Nearest Location from 94107:
436 miles
UC San Diego Health System - Encinitas
Encinitas, CA

Visits:
10 visits within 2 weeks

ClinicalTrials.gov: NCT06500481

Phase III

106

ENV-501 Antibody Drug Conjugate for Advanced HR+, HER2-, HER3+ Breast Cancer

Show Scientific Title

A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ENV-501, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-), HER3 positive (HER3+) breast cancer who have no standard treatment options available. You must not have received trastuzumab deruxtecan (Enhertu®) as your most recent line of therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ENV-501, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ENV-501 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in disitamab vedotin targets HER3 proteins. It delivers the chemotherapy exatecan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06956690' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://endeavorbiomedicines.com/our-science/env-501/' target='_blank'>Endeavor Biomedicines: ENV-501 Drug Information Page</a> </li></ul>

106

ENV-501 Antibody Drug Conjugate for Advanced HR+, HER2-, HER3+ Breast Cancer

Show Scientific Title

A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors

Nearest Location from 94107:
441 miles
Research Site
La Jolla, CA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06956690

Phase I-II

107

Artificial Intelligence Guided Treatment Selection for Advanced HR+/HER2- Breast Cancer

Show Scientific Title

Artificial Intelligence and Machine Learning-Enhanced Biomarker-dRiven CDK4/6 Inhibitor Rechallenge in HR+ HER2- Advanced Breast Tumors.

Purpose: To see if using an artificial intelligence (AI) tool can help identify who may benefit from taking a second CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has progressed after treatment with a CDK4/6 inhibitor. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor that is different from the one you previously took</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly</li> <li class="seamTextUnorderedListItem">Checkups, tests, and questionnaires, monthly</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Treatment chosen by the doctor, but will not include CDK4/6 inhibitors</li> <li class="seamTextUnorderedListItem">Checkups, tests, and questionnaires, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), abemaciclib (Verzenio®), ribociclib (Kisqali®) are a type of targeted therapy called CDK 4/6 inhibitors.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). It is approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Researchers believe that the AI tool will be able to predict who will respond to a second CDK4/6 inhibitor combined with fulvestrant (Faslodex) and that they will have better outcomes (longer progression free survival, higher overall response rate, higher clinical benefit rate, and better quality of life).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07227233' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-resistance/' target='_blank'>Metastatic Trial Talk: Overcoming Resistance to CDK4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li></ul>

107

Artificial Intelligence Guided Treatment Selection for Advanced HR+/HER2- Breast Cancer

Show Scientific Title

Artificial Intelligence and Machine Learning-Enhanced Biomarker-dRiven CDK4/6 Inhibitor Rechallenge in HR+ HER2- Advanced Breast Tumors.

Nearest Location from 94107:
441 miles
University of California, San Diego
La Jolla, CA

Visits:
Monthly for up to 6 months

ClinicalTrials.gov: NCT07227233

Phase II

108

Registry of Wearable Device Data to Study Brain Metastasis

Show Scientific Title

Study of Clinical Biomarkers in Human Health and Disease (Healthiomics)

Purpose: To collect wearable device data and biological samples to study brain metastasis and develop new ways to treat brain metastasis.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and people that do not have cancer or a brain disorder. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wearable device</li> <li class="seamTextUnorderedListItem">Collection of biological samples: blood, tumor, cerebrospinal fluid, urine</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wearable devices such as FitBits are used to track your physical activity.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF is typically collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">If you do not have cancer or a brain disorder, your data will be compared to data collected by people with brain metastasis.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05106725' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

108

Registry of Wearable Device Data to Study Brain Metastasis

Show Scientific Title

Study of Clinical Biomarkers in Human Health and Disease (Healthiomics)

Nearest Location from 94107:
446 miles
CureScience Institute
San Diego, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05106725

Phase NA

109

Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastasis

Show Scientific Title

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cognitive-sparing stereotactic radiosurgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have at least 1 brain tumor that has not been treated with radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive-sparing stereotactic radiosurgery</li> <li class="seamTextUnorderedListItem">MRI scans, 4 scans within 6 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive tests</li> </ul> Please contact research site for treatment schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Cognitive-sparing stereotactic radiosurgery is a targeted radiation therapy that avoids the white matter and hippocampus (parts of the brain that control memory, language, attention, and cognition).</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04343157' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

109

Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastasis

Show Scientific Title

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions

Nearest Location from 94107:
447 miles
Moores Cancer Center
San Diego, CA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04343157

Phase II

110

FMISO PET/CT and PET/MRI Scans for Brain Metastasis

Show Scientific Title

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors

Purpose: To study how well FMISO works with imaging techniques to detect tumor behavior and predict cancer progression.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FMISO tracer, by IV</li> <li class="seamTextUnorderedListItem">PET/CT scan or PET/MRI scan, 2 scans within 1 week, then 2 scans within 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called ¹⁸F-fluoromisonidazole (FMISO).</li> <li class="seamTextUnorderedListItem">FMISO with PET/CT and PET/MRI imaging techniques produce images of the brain that may help investigators see how much oxygen is getting in the brain tumors.</li> <li class="seamTextUnorderedListItem">The imaging techniques will study if brain tumor cells have low oxygen levels, called tumor hypoxia, which helps cancer cells grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03649880' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

110

FMISO PET/CT and PET/MRI Scans for Brain Metastasis

Show Scientific Title

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors

Nearest Location from 94107:
533 miles
OHSU Knight Cancer Institute
Portland, OR

Visits:
2 visits within 1 week, then 2 visits within 2 months

ClinicalTrials.gov: NCT03649880

Phase II

111

Gadolinium and Ferumoxytol with MRI Scans for Brain Metastasis

Show Scientific Title

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS

Purpose: To use ferumoxytol and gadolinium to improve the ability of MRI scans to image, diagnose, and study brain metastasis.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gadolinium, by IV</li> <li class="seamTextUnorderedListItem">Ferumoxytol, by IV</li> <li class="seamTextUnorderedListItem">MRI scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Ferumoxytol and gadolinium can increase the visibility of body structures in imaging such as MRI scans.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03270059' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://mriquestions.com/ferumoxytol.html' target='_blank'>MRI Questions: Ferumoxytol</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-gadolinium-based-contrast-agents' target='_blank'>Food and Drug Administration: Gadolinium</a> </li></ul>

111

Gadolinium and Ferumoxytol with MRI Scans for Brain Metastasis

Show Scientific Title

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS

Nearest Location from 94107:
533 miles
OHSU Knight Cancer Institute
Portland, OR

Visits:
3 visits within 6 weeks

ClinicalTrials.gov: NCT03270059

Phase II

112

ARTS-021 CDK2 Inhibitor for Advanced HR+, HER2- or HER2 Low Breast Cancer

Show Scientific Title

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, MTD/RP2D, and Antitumor Activity of ARTS-021 as a Single Agent and in Combination Therapy in Patients With Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ARTS-021, an experimental CDK2 inhibitor, alone or with other anti-cancer drugs.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ARTS-021, by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ARTS-021, by mouth, daily</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) or letrozole (Femara®)</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ARTS-021, by mouth, daily</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ARTS-021 is an experimental targeted therapy called a CDK2 inhibitor. CDK2 inhibitors block the enzyme/protein CDK2 that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called selective estrogen receptor degraders (SERDs). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) is a chemotherapy drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05867251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://avenzotx.com/pipeline-and-science/' target='_blank'>Avenzo Therapeutics: ARTS-021 Drug and Trial Information Page</a> </li></ul>

112

ARTS-021 CDK2 Inhibitor for Advanced HR+, HER2- or HER2 Low Breast Cancer

Show Scientific Title

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, MTD/RP2D, and Antitumor Activity of ARTS-021 as a Single Agent and in Combination Therapy in Patients With Solid Tumors

Nearest Location from 94107:
538 miles
Providence Cancer Institute
Portland, OR

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05867251

Phase I-II

113

NKT3964 Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of NKT3964, an experimental CDK2 PROTAC degrader.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have no standard treatment options available. You must have received 0-1 line of chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKT3964, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKT3964 is an experimental targeted therapy called a CDK2 PROTAC degrader that breaks down CDK2 to slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06586957' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nikangtx.com/science-and-pipeline/' target='_blank'>NiKang Therapeutics: NKT3964 Drug Information Page</a> </li></ul>

113

NKT3964 Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

Nearest Location from 94107:
590 miles
Intermountain Health
Salt Lake City, UT

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06586957

Phase I

114

OP-3136 Targeted Therapy for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants with Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of OP-3136, an experimental KAT6A/B inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received 1-3 lines of hormone therapy (including 1 line with a CDK4/6 inhibitor) and no more than 1 line of chemotherapy or antibody-drug conjugate for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OP-3136, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OP-3136 is an experimental targeted therapy called a KAT6A/B inhibitor. Blocking KAT6A/B may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06784193' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://olema.com/pipeline/' target='_blank'>Olema Pharmaceuticals: OP-3136 Drug Information Page</a> </li></ul>

114

OP-3136 Targeted Therapy for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants with Advanced or Metastatic Solid Tumors

Nearest Location from 94107:
595 miles
START - Mountain Region
West Valley City, UT

Visits:
10-12 visits in the first 2 months, then 2 visits every month

ClinicalTrials.gov: NCT06784193

Phase I

115

BNT326 Alone or with Immunotherapy for Advanced HER2- Breast Cancer

Show Scientific Title

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), best dose, and anti-cancer activity of BNT326, combined with pumitamig (BNT327) immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2-negative breast cancer that has come back or progressed after treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BNT326, by IV, every 2–3 weeks</li> <li class="seamTextUnorderedListItem">BNT327 (Pumitamig), by IV, every 2–3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BNT326 is a type of drug called an antibody-drug conjugate (ADC). </li> <li class="seamTextUnorderedListItem">Researchers are studying BNT326 both on its own, and in combination with other immunotherapy drugs (like BNT327.)</li> <li class="seamTextUnorderedListItem">BNT327 binds to one protein on the surface of cancer cells and another on the surface of immune cells. It may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07070232' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/adcs' target='_blank'>Breastcancer.org: Antibody-Drug Conjugates (ADCs)</a> </li></ul>

115

BNT326 Alone or with Immunotherapy for Advanced HER2- Breast Cancer

Show Scientific Title

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

Nearest Location from 94107:
595 miles
START Mountain Region
West Valley City, UT

Visits:
Every 2-3 weeks, up to 2 years

ClinicalTrials.gov: NCT07070232

Phase I-II

116

Targeted Therapy With or Without Hormone Therapy for Advanced ER Positive, HER2 Negative Breast Cancer

Show Scientific Title

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a new targeted therapy (IDE574), given alone or together with hormone therapy (fulvestrant).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+), HER2 negative (HER2-) breast cancer. You must have received at least one prior hormone (endocrine) therapy, with a CDK4/6 inhibitor therapy for advanced disease. View full eligibility criteria

What's involved?

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IDE574 is an experimental targeted therapy that works by blocking two proteins in cancer cells called KAT6 and KAT7. These proteins help cancer cells grow, survive, and keep multiplying. </li> <li class="seamTextUnorderedListItem">Researchers are interested to see if this therapy is safe and effective and if it may help cancers that no longer respond to standard treatments.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07540572' target='_blank'>ClinicalTrials.gov</a> </li></ul>

116

Targeted Therapy With or Without Hormone Therapy for Advanced ER Positive, HER2 Negative Breast Cancer

Show Scientific Title

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

Nearest Location from 94107:
595 miles
START Mountain Region, LLC
West Valley City, UT

Visits:
Every 3 weeks, up to 2 years

ClinicalTrials.gov: NCT07540572

Phase I

117

BTX-9341 CDK4/6 Inhibitor with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of BTX-9341, an experimental CDK4/6 inhibitor, with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: Advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received 1-2 lines of hormone therapy with CDK4/6 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BTX-9341, by mouth, daily</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BTX-9341 is an experimental targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06515470' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biotheryx.com/pipeline/' target='_blank'>Biotheryx: BTX-9341 Drug Information Page</a> </li></ul>

117

BTX-9341 CDK4/6 Inhibitor with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer

Nearest Location from 94107:
595 miles
Biotheryx Investigative Site
West Valley City, UT

Visits:
1-2 visits every month

ClinicalTrials.gov: NCT06515470

Phase I

118

Increasing Dose of CDK4/6 Inhibitors with Hormone Therapy to Manage Side Effects for People with Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Purpose: To study increasing the dose of CDK4/6 inhibitors to help people manage side effects and continue taking CDK4/6 inhibitors as prescribed.

Who is this for?: People at least 65 years old with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to receive a CDK4/6 inhibitor with hormone therapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Regular dose of palbociclib (Ibrance®) or ribociclib (Kisqali®), by mouth, daily for 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Increasing low dose of palbociclib (Ibrance®) or ribociclib (Kisqali®), by mouth, daily for 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) and ribociclib (Kisqali®) are a type of targeted therapy called CDK4/6 inhibitors. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">If you are in group 1, you will continue the normal dose (unless you need to decrease the dose due to challenging side effects).</li> <li class="seamTextUnorderedListItem">If you are in group 2, you will increase your dose every month (unless you have challenging side effects) up to the normal dose.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06377852' target='_blank'>ClinicalTrials.gov</a> </li></ul>

118

Increasing Dose of CDK4/6 Inhibitors with Hormone Therapy to Manage Side Effects for People with Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Nearest Location from 94107:
600 miles
Ironwood Cancer & Research Centers
Goodyear, AZ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06377852

Phase III

119

PF-07248144 Plus Fulvestrant for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of PF-07248144 plus fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed while receiving hormone therapy and/or palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®). You must not have received more than 2 prior lines of therapy for your advanced or metastatic cancer or prior chemotherapy, including antibody-drug conjugates (ADCs). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-07248144, by mouth </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth</li> <li class="seamTextUnorderedListItem">Exemestane (Aromasin®), by mouth or fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-07248144 is a KAT6 inhibitor. KAT6 allows tumor growth to continue.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07062965' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pfizeroncologydevelopment.com/molecule/kat6-inhibitor#:~:text=PF%2D07248144%20is%20an%20investigational,for%20a%20more%20localized%20activity' target='_blank'>Pfizer: PF-07248144</a> </li></ul>

119

PF-07248144 Plus Fulvestrant for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

Nearest Location from 94107:
600 miles
Ironwood Cancer & Research Centers
Goodyear, AZ

Visits:
Number of visits unavailable, up to 5 years

ClinicalTrials.gov: NCT07062965

Phase III

120

Guided Meditation During Radiation for People with Brain Metastases

Show Scientific Title

An Interventional Trial Using Guided Meditation During Radiation Therapy for Brain Tumors (Med-RT)

Purpose: To study the ability of guided meditation to decrease anxiety.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation to the brain. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guided meditation during radiation sessions, 2 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The guided meditation practice involves a series of 5 audio recordings with the following topics: body scan, mindful breathing, mindfulness of discomfort, savoring memories, and loving-kindness.</li> <li class="seamTextUnorderedListItem">Each audio recording is 5 minutes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06165653' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

120

Guided Meditation During Radiation for People with Brain Metastases

Show Scientific Title

An Interventional Trial Using Guided Meditation During Radiation Therapy for Brain Tumors (Med-RT)

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute
Salt Lake City, UT

Visits:
Coincides with radiation sessions, for 2 months

ClinicalTrials.gov: NCT06165653

Phase NA

121

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Show Scientific Title

Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Purpose: To determine the maximal dose of stereotaxic radiation for treating brain metastases, while protecting the healthy tissues around the abnormal areas.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). You must have 1-5 untreated brain metastases and no prior history of whole or partial brain irradiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation to brain metastases</li> <li class="seamTextUnorderedListItem">One metastatic site will receive the experimental dose</li> <li class="seamTextUnorderedListItem">Other sites will receive standard doses</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02390518' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

121

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Show Scientific Title

Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute
Salt Lake City, UT

Visits:
At least 1 visit

ClinicalTrials.gov: NCT02390518

Phase I

122

ETX-19477 PARG Inhibitor for Advanced Breast Cancer

Show Scientific Title

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ETX-19477, an experimental PARG inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ETX-19477, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ETX-19477 is experimental targeted therapy called a PARG (poly ADP ribose glycohydrolase) inhibitor.</li> <li class="seamTextUnorderedListItem">Blocking PARG may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06395519' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://8five8tx.com/pipeline' target='_blank'>858 Therapeutics: ETX-19477 Drug Information Page</a> </li></ul>

122

ETX-19477 PARG Inhibitor for Advanced Breast Cancer

Show Scientific Title

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Nearest Location from 94107:
602 miles
START Center for Cancer Care - Mountain Region
Salt Lake City, UT

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06395519

Phase I-II

123

Exercise for Fatigue for People with Advanced Breast Cancer Receiving Trastuzumab Deruxtecan

Show Scientific Title

ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study

Purpose: To study the safety and effects (good and bad) of a home-based, unsupervised exercise program for cancer-related fatigue.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+), HER2-low, or hormone receptor-positive (HR+), HER2-low or HER2-ultralow breast cancer who are receiving trastuzumab deruxtecan (Enhertu®) and experiencing fatigue. You must not be participating in an exercise program as defined by the study investigators. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, at home, for 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Physical function tests</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No exercise</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Physical function tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The exercise program is an individualized, home-based, unsupervised, whole-body resistance training and aerobic exercise program.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07203378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/special-topics/enhertu-hrpos-her2low/' target='_blank'>Metastatic Trial Talk: Trastuzumab Deruxtecan (Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/fatigue-2/' target='_blank'>Metastatic Trial Talk: Fatigue</a> </li></ul>

123

Exercise for Fatigue for People with Advanced Breast Cancer Receiving Trastuzumab Deruxtecan

Show Scientific Title

ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Visits:
Number of visits unavailable, 3 months

ClinicalTrials.gov: NCT07203378

Phase II

124

JAB-2485 Targeted Therapy for Advanced ER+, Triple Negative, or ARID1A Mutated Breast Cancer

Show Scientific Title

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of JAB-2485, an experimental Aurora A inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) ER positive (ER+), triple negative (ER-, PR-, HER2-), or ARID1A mutated breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">JAB-2485, by mouth</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">JAB-2485 is an experimental targeted therapy called an Aurora A inhibitor. Aurora A inhibitors may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ARID1A</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05490472' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aurora-a-kinase-inhibitor-jab-2485' target='_blank'>National Cancer Institute: JAB-2485</a> </li></ul>

124

JAB-2485 Targeted Therapy for Advanced ER+, Triple Negative, or ARID1A Mutated Breast Cancer

Show Scientific Title

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

Nearest Location from 94107:
602 miles
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05490472

Phase I-II

125

Dato-DXd for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of datopotamab deruxtecan (Dato-DXd; Datroway®) antibody-drug conjugate.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has become resistant to hormone therapy. You must not have received chemotherapy, fam-trastuzumab deruxtecan-nxki (Enhertu®), sacituzumab govitecan-hziy (Trodelvy®), or datopotamab deruxtecan (Dato-DXd; Datroway®) for your advanced cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd; Datroway®), by IV, every 3 weeks, up to 5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In this study, HER2- is defined as IHC 0 (no staining or incomplete and faint/barely perceptible membrane staining in ≤10% of tumor cells).</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd; Datroway®) is an antibody-drug conjugate (ADC). An ADC is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07205822' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://datroway.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=22411693368&gbraid=0AAAAA-nL_-fHlfedCQ0wuAVgecBaDMC80&gclid=CjwKCAiA0eTJBhBaEiwA-Pa-hbSesNEE7n09CdOw1ZrQBMl6NMyWMeF6MMPq4fD30xu3Pn1CBF7EIRoCWUsQAvD_BwE' target='_blank'>Daiichi Sankyo: Datopotamab Deruxtecan (Dato-DXd; Datroway®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates</a> </li></ul>

125

Dato-DXd for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

Nearest Location from 94107:
649 miles
Research Site
Puyallup, WA

Visits:
Every 3 weeks up to 5 years

ClinicalTrials.gov: NCT07205822

Phase III

126

INX-315 CDK2 Inhibitor for Advanced ER+, HER2- or CCNE1 Amplified Breast Cancer

Show Scientific Title

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of INX-315, an experimental CDK2 inhibitor, alone or with other anti-cancer therapies.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received treatment with a CDK4/6 inhibitor or CCNE1 amplified breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups based on your type of cancer: Group 1: CCNE1 Amplified Breast Cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INX-315, by mouth</li> </ul> Group 2: ER Positive, HER2 Negative Breast Cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INX-315, by mouth</li> <li class="seamTextUnorderedListItem">Selective estrogen receptor degrader (SERD) hormone therapy (standard of care)</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitor (standard of care)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INX-315 is an experimental targeted therapy called a CDK2 inhibitor. CDK2 inhibitors block the enzyme/protein CDK2 that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Selective estrogen receptor degraders (SERD) are a type of hormone therapy that bind to and break down estrogen receptors. </li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are a type of targeted therapy that block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: CCNE1</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05735080' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://incyclixbio.com/our-science/' target='_blank'>Incyclix Bio Drug Information Page: INX-315</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy and SERDs</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: The Latest Research on CDK 4/6 Inhibitors</a> </li></ul>

126

INX-315 CDK2 Inhibitor for Advanced ER+, HER2- or CCNE1 Amplified Breast Cancer

Show Scientific Title

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Nearest Location from 94107:
656 miles
Northwest Medical Specialties, PLLC
Tacoma, WA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05735080

Phase I-II

127

2 Types of Stereotactic Radiosurgery for Brain Metastasis

Show Scientific Title

Phase IIR Trial of Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS (FSRS) for Intact Metastatic Brain Disease (FRACTIONATE)

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of two different types of stereotactic radiosurgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) that has not been treated with whole brain radiation. You are eligible if you have at least one brain lesion that has not been yet been treated with radiation. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Single Fraction Stereotactic Radiosurgery, 1 session</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated Stereotactic Radiosurgery, 2-5 sessions</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery or stereotactic radiotherapy) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Single Fraction Stereotactic Radiosurgery (SFSR) is stereotactic radiation received in one higher dose of radiation given on one day of treatment.</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated Stereotactic Radiation Therapy (FSRT) is stereotactic radiation is divided into several smaller doses (typically 2-5 sessions) of radiation given on separate days of treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05222620' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/radiotherapy/external/types/stereotactic-body-radiotherapy-sbrt' target='_blank'>CancerResearchUK: Stereotactic Radiotherapy (SRT)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526' target='_blank'>Mayo Clinic: Stereotactic Radiosurgery</a> </li></ul>

127

2 Types of Stereotactic Radiosurgery for Brain Metastasis

Show Scientific Title

Phase IIR Trial of Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS (FSRS) for Intact Metastatic Brain Disease (FRACTIONATE)

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Visits:
1-5 radiation sessions, then 1 visit every 3-6 months for 5 years

ClinicalTrials.gov: NCT05222620

Phase II

128

Delivery of Stereotactic Radiation Before or After Brain Surgery for Metastatic Brain Tumors

Show Scientific Title

Pre-Operative vs. Post-Operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors

Purpose: To study whether delivering stereotactic radiation before surgery is more effective for treating brain metastases than delivering stereotactic radiation after surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). View full eligibility criteria

What's involved?

You will be randomly assigned to one of two groups: Group 1 (Experimental group) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive stereotactic radiosurgery followed by brain surgery within 4 weeks</li> </ul> Group 2 (Control Group) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will undergo brain surgery followed by stereotactic radiosurgery within 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation, also known as stereotactic radiosurgery, delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation.</li> <li class="seamTextUnorderedListItem">Brain surgery to remove metastases.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03750227' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

128

Delivery of Stereotactic Radiation Before or After Brain Surgery for Metastatic Brain Tumors

Show Scientific Title

Pre-Operative vs. Post-Operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Visits:
Please contact the research site

ClinicalTrials.gov: NCT03750227

Phase III

129

GI-102 Bispecific Antibody Alone or With Immunotherapy for Advanced Breast Cancer

Show Scientific Title

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patient...(KEYNOTE-G08)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of GI-102, an experimental bispecific antibody, alone or with other anti-cancer drugs.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will be assigned to 1 of 5 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV or injection, every 3 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), by IV, every 3 weeks</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy, by IV, every 1-3 weeks</li> </ul> Group 5 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102 is an experimental immunotherapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two different targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd) is an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s antibody targets HER2 and delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">The chemotherapies being used in this study are doxorubicin (Doxil®), paclitaxel (Taxol®), and eribulin (Halaven®).</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®) is a targeted therapy called a VEGF inhibitor. Blocking VEGF may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05824975' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li></ul>

129

GI-102 Bispecific Antibody Alone or With Immunotherapy for Advanced Breast Cancer

Show Scientific Title

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patient...(KEYNOTE-G08)

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Visits:
At least 1 visit every 3 weeks

ClinicalTrials.gov: NCT05824975

Phase I-II

130

Genetic Testing for Diverse Groups of People with Breast Cancer

Show Scientific Title

Gemini - Cancer Genetic Testing in Ethnic Populations

Purpose: To use genetic testing to identify genetic mutations and make treatment decisions.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing looks for changes, sometimes called mutations or variants, in your DNA.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04475640' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease and Control: Genetic Testing</a> </li></ul>

130

Genetic Testing for Diverse Groups of People with Breast Cancer

Show Scientific Title

Gemini - Cancer Genetic Testing in Ethnic Populations

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04475640

Phase NA

131

Changing the Dose of Capecitabine According to Scans to Control Metastatic ER+, HER2- Breast Cancer

Show Scientific Title

Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of changing the dose of capecitabine (Xeloda®) chemotherapy according to the results of scans.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer. You must not have received chemotherapy or fam-trastuzumab deruxtecan-nxki (Enhertu®), sacituzumab govitecan-hziy (Trodelvy®), or datopotamab deruxtecan (Dato-DXd; Datroway®) for your metastatic breast cancer. You must not have uncontrolled brain metastases. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth</li> <li class="seamTextUnorderedListItem">Bone scan</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Changing the dose of capecitabine (Xeloda®) according to how the tumor is growing on a scan may allow someone to live longer. This is called <q>adaptive therapy</q>. The goal of adaptive therapy is not to get rid of the entire tumor but to control its growth in a way that helps the patient live longer with a better quality of life.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06525766' target='_blank'>ClinicalTrials.gov</a> </li></ul>

131

Changing the Dose of Capecitabine According to Scans to Control Metastatic ER+, HER2- Breast Cancer

Show Scientific Title

Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Visits:
Number of visits unavailable, up to 5 years

ClinicalTrials.gov: NCT06525766

Phase II

132

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Show Scientific Title

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)

Purpose: To study if radiation therapy can delay treatment changes and if circulating tumor cells (CTCs) can help guide treatment options.

Who is this for?: Women with stage IV (metastatic) breast cancer who have been receiving their first line of therapy for metastatic disease for at least 1 year or have been receiving their second or later line of therapy for at least 6 months. You must have 1-3 sites of oligoprogressive disease that have not received radiation and must not have triple negative breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery or stereotactic body radiotherapy) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">In this trial, CTCs may be used to help you and your doctor guide treatment options.</li> <li class="seamTextUnorderedListItem">Oligoprogressive disease refers to progression of only a few sites of metastasis.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06055881' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20555625' target='_blank'>Mayo Clinic: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/sbrt/pyc-20446794' target='_blank'>Mayo Clinic: Stereotactic Body Radiotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20071218' target='_blank'>Breastcancer.org: Circulating Tumor Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oligometastatic-breast-cancer/' target='_blank'>Metastatic Trial Talk: What is Oligometastatic Breast Cancer?</a> </li></ul>

132

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Show Scientific Title

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06055881

Phase NA

133

Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer

Show Scientific Title

Inflammatory Breast Cancer (IBC) Registry

Purpose: To collect and study blood and tissue samples and clinical data from people with newly diagnosed and untreated breast cancer, including inflammatory breast cancer.

Who is this for?: People with newly diagnosed and untreated stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Additional blood drawn during a routine blood draw</li> <li class="seamTextUnorderedListItem">Core, breast tissue, and skin biopsy (performed for diagnosis)</li> <li class="seamTextUnorderedListItem">Medical history interview</li> <li class="seamTextUnorderedListItem">Clinical data collected from your medical records</li> <li class="seamTextUnorderedListItem">Photographs of both breasts</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inflammatory breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen.</li> <li class="seamTextUnorderedListItem">Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for inflammatory breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00477100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2006-1072.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/sites-types/ibc' target='_blank'>NCI: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li></ul>

133

Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer

Show Scientific Title

Inflammatory Breast Cancer (IBC) Registry

Nearest Location from 94107:
671 miles
Banner - MD Anderson Cancer Center
Gilbert, AZ

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT00477100

Phase NA

134

TUB-030 Antibody Drug Conjugate for Advanced Triple Negative and HR+, HER2- Breast Cancer

Show Scientific Title

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)

Purpose: To study the safety, best dose, and effects (good and bad) of TUB-030, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) and hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TUB-030, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TUB-030 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in TUB-030 targets 5T4 proteins. It delivers the chemotherapy exatecan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06657222' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tubulis.com/our-pipeline/' target='_blank'>Tubulis: TUB-030 Drug Information Page</a> </li></ul>

134

TUB-030 Antibody Drug Conjugate for Advanced Triple Negative and HR+, HER2- Breast Cancer

Show Scientific Title

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)

Nearest Location from 94107:
682 miles
Fred Hutchinson Cancer Center
Seattle, WA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06657222

Phase I-II

135

STEMVAC Experimental Vaccine Plus Hormone Therapy or Capecitabine for Metastatic HR+, HER2- or HER2 Low Breast Cancer

Show Scientific Title

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of an experimental vaccine called STEMVAC in combination with standard hormone therapy or capecitabine (Xeloda®).

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer. You must be receiving hormone therapy and a CDK4/6 inhibitor, or have become resistant to hormone therapy and have received at least one cycle of capecitabine (Xeloda®). View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1: Hormone Therapy Sensitive <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor, by mouth</li> <li class="seamTextUnorderedListItem">STEMVAC, by injection, 5 times within 9 months, then every 6 months</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times</li> </ul> Group 2: Hormone Therapy Resistant <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth</li> <li class="seamTextUnorderedListItem">STEMVAC, by injection, 5 times within 9 months, then every 6 months</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times</li> <li class="seamTextUnorderedListItem">FES PET scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The STEMVAC vaccine targets proteins expressed on breast cancer stem cells and may boost the ability of the immune system to recognize and destroy cancer cells.</li> <li class="seamTextUnorderedListItem">Hormone therapy blocks the effects of estrogen to block the growth of cancer cells.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow. </li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07112053' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/vaccines-mbc/' target='_blank'>Metastatic Trial Talk: Vaccines for MBC</a> </li></ul>

135

STEMVAC Experimental Vaccine Plus Hormone Therapy or Capecitabine for Metastatic HR+, HER2- or HER2 Low Breast Cancer

Show Scientific Title

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Visits:
Number of visits unavailable, up to 3 years

ClinicalTrials.gov: NCT07112053

Phase II

136

AVA6000 Chemotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AVA6000, an experimental chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received standard treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVA6000, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVA6000 is an experimental form of doxorubicin chemotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04969835' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://avacta.com/therapeutics/precision/' target='_blank'>Avacta Life Sciences: AVA6000 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

136

AVA6000 Chemotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Nearest Location from 94107:
682 miles
Fred Hutchinson Cancer Center
Seattle, WA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT04969835

Phase I

137

[18F]FTT Radiotracer to Detect Response to PARP Inhibitors on a PET Scan for Metastatic Breast Cancer

Show Scientific Title

[18F]FTT Positron Emission Tomography (PET) in Patients With Metastatic Breast Cancer

Purpose: To study how well fluorine F 18 fluorthanatrace ([18F]FTT) radiotracer works in a PET scan to detect the response to PARP inhibitors.

Who is this for?: People with metastatic (stage IV) breast cancer who are planning to receive olaparib (Lynparza®) or talazoparib (Talzenna®) PARP inhibitor. View full eligibility criteria

What's involved?

What's being studied?

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06502691' target='_blank'>ClinicalTrials.gov</a> </li></ul>

137

[18F]FTT Radiotracer to Detect Response to PARP Inhibitors on a PET Scan for Metastatic Breast Cancer

Show Scientific Title

[18F]FTT Positron Emission Tomography (PET) in Patients With Metastatic Breast Cancer

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Visits:
5 visits within 6 months or 1 year

ClinicalTrials.gov: NCT06502691

Phase I-II

138

Radiation to Reduce Side Effects for People with Metastatic Breast Cancer with Leptomeningeal Metastases

Show Scientific Title

A Multi-Center Phase 2 Study of Hippocampal Avoidance in Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors

Purpose: To study if radiation to the brain and spinal cord is an effective treatment while also reducing side effects for people with leptomeningeal metastases.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal disease). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation to brain and spinal cord, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times in 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy can reduce symptoms of leptomeningeal metastases.</li> <li class="seamTextUnorderedListItem">However, the type of radiation therapy typically used does not prevent the spread of leptomeningeal disease.</li> <li class="seamTextUnorderedListItem">Craniospinal irradiation (CSI) is radiation therapy directed at the brain and spinal cord. It may be able to target all potential areas of leptomeningeal tumor spread.</li> <li class="seamTextUnorderedListItem">It may also reduce side effects of radiation because it avoids the part of the brain called the hippocampus.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF is typically collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06518057' target='_blank'>ClinicalTrials.gov</a> </li></ul>

138

Radiation to Reduce Side Effects for People with Metastatic Breast Cancer with Leptomeningeal Metastases

Show Scientific Title

A Multi-Center Phase 2 Study of Hippocampal Avoidance in Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Visits:
10 visits within 2 weeks

ClinicalTrials.gov: NCT06518057

Phase II

139

PET/CT Scan to Predict Response to Abemaciclib for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Purpose: To study how well functional imaging PET/CT scans with FFNP can predict your cancer's response to abemaciclib (Verzenio®) CDK4/6 inhibitor with standard of care hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+ or ER low), HER2 negative (HER2-) or HER2 low breast cancer who are planning to receive abemaciclib (Verzenio®). You must have received no more than 1 line of chemotherapy for advanced disease. You must not have liver only metastases. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with FFNP, by IV, 3 times in 1 month, then every 3 months</li> <li class="seamTextUnorderedListItem">Estradiol, by mouth, 1 day</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">FFNP PET/CT imaging is a form of x-ray that uses FFNP as an imaging agent that may provide more precise information about the location of tumors that <q>light up</q> with FFNP than a PET scan alone can provide.</li> <li class="seamTextUnorderedListItem">Estradiol is type of hormone therapy for advanced ER+ breast cancer.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or FISH -.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06179303' target='_blank'>ClinicalTrials.gov</a> </li></ul>

139

PET/CT Scan to Predict Response to Abemaciclib for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Visits:
3 visits in 1 month, then 1 visit every 3 months

ClinicalTrials.gov: NCT06179303

Phase II

140

BGB-21447 Targeted Therapy with Hormone Therapy and CDK4 Inhibitor for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BGB-21447, an experimental targeted therapy, with fulvestrant (Faslodex®) hormone therapy, with or without BGB-43395, an experimental CDK4 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received at least 2 lines of therapy for advanced disease and hormone therapy with a CDK4/6 inhibitor for early stage or advanced disease. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-21447, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-21447, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times in 1 month, then monthly</li> <li class="seamTextUnorderedListItem">BGB-43395, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-21447 is an experimental targeted therapy called a Bcl-2 Inhibitor. Blocking Bcl-2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">BGB-43395 is an experimental targeted therapy called a CDK4 inhibitor. CDK4 is a type of protein that regulates cell growth and division in your body. Blocking CDK4 is believed to have anti-tumor effects.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women and men will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06756932' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: The Latest Research on CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-resistance/' target='_blank'>Metastatic Trial Talk: Overcoming Resistance to CDK4/6 Inhibitors</a> </li></ul>

140

BGB-21447 Targeted Therapy with Hormone Therapy and CDK4 Inhibitor for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

Nearest Location from 94107:
682 miles
Fred Hutchinson Cancer Research Center
Seattle, WA

Visits:
At least 1 visit every month

ClinicalTrials.gov: NCT06756932

Phase I

141

Personalized Vaccine with Immunotherapy for Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of an experimental vaccine with immunotherapy.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Poly ICLC, by injection, weekly for 2 weeks</li> </ul> followed 2 weeks later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized neoantigen peptide vaccine, by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 2-4 weeks for 6 months</li> <li class="seamTextUnorderedListItem">Poly ICLC, by injection, weekly, 3 weeks on, 1 week off</li> </ul> followed 6 months later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 2-4 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized neoantigen peptide vaccines are an experimental type of immunotherapy. The vaccine is designed to target certain proteins (neoantigens) on tumor cells.</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Poly ICLC is an immunotherapy that stimulates your immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05098210' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/breast-cancer-vaccine-explainer/' target='_blank'>Breast Cancer Research Foundation: Breast Cancer Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy' target='_blank'>Breastcancer.org: Nivolumab (Opdivo®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/poly-iclc' target='_blank'>National Cancer Institute: Poly ICLC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li></ul>

141

Personalized Vaccine with Immunotherapy for Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Visits:
1 visit every week for 6 months, then 1 visit every 2-4 weeks

ClinicalTrials.gov: NCT05098210

Phase I

142

BG-75202 in Combination With Other Therapies for HR+, HER2- Advanced Breast Cancer

Show Scientific Title

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BG-75202 KAT6A/B inhibitor alone and in combination with other therapies.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received 1 to 3 prior lines of therapy. You must not have received more than 2 lines that included chemotherapy and/or an antibody-drug conjugate (ADC). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BG-75202, by mouth</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitor, by mouth</li> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BG-75202 is a KAT6A/B inhibitor. KAT6 allows tumor growth to continue.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow. CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor-positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07222267' target='_blank'>ClinicalTrials.gov</a> </li></ul>

142

BG-75202 in Combination With Other Therapies for HR+, HER2- Advanced Breast Cancer

Show Scientific Title

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Nearest Location from 94107:
682 miles
Fred Hutchinson Cancer Research Center
Seattle, WA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07222267

Phase I

143

PET/CT Scan with 18F-Fluciclovine for Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

Purpose: To study the ability of PET/CT scans with 18F-fluciclovine to identify brain metastases.

Who is this for?: People with metastatic (stage IV) breast cancer that is suspected or confirmed to have spread to the brain (brain metastasis) who are planning to receive surgery or radiation for the brain metastases. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-fluciclovine, by IV, 1-3 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine is an experimental tracer for imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">On a brain PET/CT scan, it can be difficult to tell the difference between cancer progression and cancer cells that have been killed by treatment.</li> <li class="seamTextUnorderedListItem">This study is testing whether 18F-fluciclovine, a tracer, can help with this.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06055790' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

143

PET/CT Scan with 18F-Fluciclovine for Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

Nearest Location from 94107:
752 miles
Arizona Cancer Center at UMC North/University Medical Center
Tucson, AZ

Visits:
1-3 visits

ClinicalTrials.gov: NCT06055790

Phase II

144

Ovarian Suppression Following ZOLADEX in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Show Scientific Title

Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer

Purpose: This study is looking at how well ZOLADEX® (goserelin) suppresses ovarian function in premenopausal women with breast cancer.

Who is this for?: Premenopausal women with advanced (stage III) or metastatic (stage IV) breast cancer who are between 18 to 55, and have hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. View full eligibility criteria

What's involved?

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The goal of this study is to better understand how this treatment works in managing hormone levels in HR+, HER2 negative breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07310420' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zoladex.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=22507845007&gbraid=0AAAAA_gRoNBb5XSY7s8DD7IIxTBZtXTv6&gclid=Cj0KCQiAoZDJBhC0ARIsAERP-F-ABUsC3lGhM3VH4Nc4qtBUZY8e6bBS1dm4GjfxXphAdMMFnwMJfWgaAkRAEALw_wcB' target='_blank'>AstraZeneca: Goserelin (Zoladex®)</a> </li></ul>

144

Ovarian Suppression Following ZOLADEX in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Show Scientific Title

Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer

Nearest Location from 94107:
786 miles
San Juan Oncology Associates
Farmington, NM

Visits:
every 4-6 weeks, up to 6 months

ClinicalTrials.gov: NCT07310420

Phase I

145

Registry to Study Cancer Prevention, Detection, and Treatment

Show Scientific Title

Integrated Cancer Repository for Cancer Research

Purpose: To create a registry to study strategies for prevention, screening, early detection, and personalized treatment of cancer.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer, people at high risk for breast cancer, or people who have not been diagnosed with breast cancer. View full eligibility criteria

What's involved?

You will be asked to provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood and urine samples during routine visits</li> <li class="seamTextUnorderedListItem">Provide tissue samples from surgery or biopsy</li> <li class="seamTextUnorderedListItem">Questionnaires, 1 time every year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This registry will compare samples between people with breast cancer, people at high risk for breast cancer, and people who do not have breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02012699' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://icare2project.org' target='_blank'>iCaRe2 Project</a> </li></ul>

145

Registry to Study Cancer Prevention, Detection, and Treatment

Show Scientific Title

Integrated Cancer Repository for Cancer Research

Nearest Location from 94107:
804 miles
Bozeman Health Deaconess Hospital
Bozeman, MT

Visits:
Coincides with routine care, at least 1 visit every year

ClinicalTrials.gov: NCT02012699

Phase NA

146

Palazestrant and Ribociclib Compared to Letrozole and Ribociclib for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of palazestrant oral SERD/CERAN plus ribociclib (Kisqali®) CDK4/6 inhibitor versus letrozole (Femara®) hormone therapy plus ribociclib (Kisqali®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have not yet received treatment for their advanced cancer. You must not have received fulvestrant (Faslodex®) or elacestrant (Orserdu®) at any time. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palazestrant, by mouth, daily</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth, daily, 3 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">Placebo for letrozole (Femara®), by mouth, daily</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for palazestrant, by mouth, daily</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth, daily, 3 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palazestrant is an experimental hormone therapy called a SERD (selective estrogen receptor degrader). SERDs work by binding to and breaking down estrogen receptors. Palazestrant is also a CERAN (complete ER antagonist), meaning that it blocks the function of estrogen receptors. </li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. It is commonly used to treat hormone receptor positive breast cancer.</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07085767' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/new-hormone-therapies/' target='_blank'>Metastatic Trial Talk: Oral SERDs</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://olema.com/pipeline/' target='_blank'>Olema: Palazestrant</a> </li></ul>

146

Palazestrant and Ribociclib Compared to Letrozole and Ribociclib for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

Nearest Location from 94107:
921 miles
Clinical Trial Site
Santa Fe, NM

Visits:
Number of visits unavailable, up to 3.5 years

ClinicalTrials.gov: NCT07085767

Phase III

147

Questionnaires to Measure Satisfaction and Well-Being During Treatment for Women with Stage I-IV Breast Cancer

Show Scientific Title

A Randomized Study of Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey Results

Purpose: To study the experience of women during breast cancer treatment.

Who is this for?: Women newly diagnosed with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete questionnaires, by email or in person, every 3 months until 1 year after surgery</li> <li class="seamTextUnorderedListItem">Receive results of the questionnaires</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete questionnaires, by email or in person, every 3 months until 1 year after surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The questionnaires in this study will be used to understand women's satisfaction with their breasts, psychosocial well-being, physical well-being, sexual well-being, side effects from radiation, and experience with the health care team.</li> <li class="seamTextUnorderedListItem">The questionnaires will also be used to understand the use of social work services, psycho-oncology services, oncology fitness service, nutrition service, and urgent/emergent services including visits to urgent care or the emergency room.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03995082' target='_blank'>ClinicalTrials.gov</a> </li></ul>

147

Questionnaires to Measure Satisfaction and Well-Being During Treatment for Women with Stage I-IV Breast Cancer

Show Scientific Title

A Randomized Study of Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey Results

Nearest Location from 94107:
941 miles
University of Colorado Hospital
Denver, CO

Visits:
1 visit every 3 months until 1 year after surgery

ClinicalTrials.gov: NCT03995082

Phase NA

148

Registry to Study Immune System Response to Breast Cancer in Women Under Age 50

Show Scientific Title

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction

Purpose: To determine how the immune system responds to different types of tumors or to tumors that develop during or after a pregnancy. Some of the breast cancer tissue collected in this study will be used to create models that develop and test new drug treatments.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are 50 years or younger. View full eligibility criteria

What's involved?

All participants will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue, blood, and urine samples, if recently diagnosed</li> <li class="seamTextUnorderedListItem">Tissue donation only, if enrolled after treatment has begun or has ended</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are interested in learning more about the role the immune system plays in cancer. </li> <li class="seamTextUnorderedListItem">This study is looking specifically at the level of immune suppression seen in breast cancer that occurs in women under age 50.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01503190' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/tips/immune/' target='_blank'>Breastcancer.org: Understanding Your Immune System</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.youngsurvival.org/' target='_blank'>Young Survival Coalition</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/faculty/Pages/VirginiaFBorges,MD.aspx' target='_blank'>Lead Researcher: Virginia F. Borges, MD</a> </li></ul>

148

Registry to Study Immune System Response to Breast Cancer in Women Under Age 50

Show Scientific Title

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction

Nearest Location from 94107:
941 miles
University of Colorado Denver
Aurora, CO

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT01503190

Phase NA

149

EIK1004 Targeted Therapy for Advanced Breast Cancer with HRR Mutations

Show Scientific Title

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors (EIK1004-001)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of EIK1004 (IMP1707), an experimental PARP1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have not ever received chemotherapy and hormone therapy (if hormone receptor positive). You must have a BRCA1, BRCA2, PALB2, ATM, or CHEK2 gene mutation. You must not have received more than 1 PARP inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EIK1004 (IMP1707), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EIK1004 is an experimental targeted therapy called a PARP1 inhibitor.</li> <li class="seamTextUnorderedListItem">PARP inhibitors stop the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP).</li> <li class="seamTextUnorderedListItem">BRCA1, BRCA2, PALB2, ATM, and CHEK2 gene mutations are homologous recombination repair (HRR) or homologous recombination deficient (HRD) mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06907043' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

149

EIK1004 Targeted Therapy for Advanced Breast Cancer with HRR Mutations

Show Scientific Title

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors (EIK1004-001)

Nearest Location from 94107:
948 miles
Sarah Cannon Research Institute at HealthOne
Denver, CO

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06907043

Phase I-II

150

DR-0202 Bispecific Antibody for Advanced Triple Negative or HR+ Breast Cancer

Show Scientific Title

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of DR-0202, an experimental bispecific antibody.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor positive (ER+ and/or PR+) breast cancer who have received at least 2 lines of therapy and have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DR-0202, by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DR-0202 is an experimental immunotherapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two different targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06999187' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drenbio.com/pipeline.html' target='_blank'>Dren Bio: DR-0202 Drug Information Page</a> </li></ul>

150

DR-0202 Bispecific Antibody for Advanced Triple Negative or HR+ Breast Cancer

Show Scientific Title

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Nearest Location from 94107:
948 miles
Dren Investigational Site
Denver, CO

Visits:
1 visit every 2 weeks

ClinicalTrials.gov: NCT06999187

Phase I

151

BGB-43395 CDK4 Inhibitor Alone or with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BGB-43395, an experimental CDK4 inhibitor, alone or with fulvestrant (Faslodex®) or letrozole (Femara®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received hormone therapy and a CDK4/6 inhibitor. You must not have received more than 2 lines of chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-43395, by mouth</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-43395, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection or letrozole (Femara®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-43395 is an experimental targeted therapy called a CDK4 inhibitor. It may block the enzymes CDK4 that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Premenopausal women will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06120283' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-resistance/?utm_medium=email&utm_source=subscribers&utm_campaign=Jan2024&utm_content=Email012024' target='_blank'>Metastatic Trial Talk: Overcoming Resistance to CDK4/6 Inhibitors</a> </li></ul>

151

BGB-43395 CDK4 Inhibitor Alone or with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Nearest Location from 94107:
948 miles
Sarah Cannon Research Institute (Scri) At Health One
Denver, CO

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06120283

Phase I

152

MDX2001 Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of MDX2001, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MDX2001, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MDX2001 is an experimental immunotherapy called a tetraspecific antibody. MDX2001 may help target the immune system to help identify and kill tumor cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06239194' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.modextherapeutics.com/pipeline/' target='_blank'>ModeX Therapeutics: MDX2001 Drug Information Page</a> </li></ul>

152

MDX2001 Immunotherapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

Nearest Location from 94107:
948 miles
Sarah Cannon Research Institute
Denver, CO

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06239194

Phase I-II

153

Experimental Immunotherapy for Advanced Breast Cancer that Expresses HLA-G

Show Scientific Title

A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects With Advanced Solid Tumors

Purpose: To study the safety, side effects and anti-tumor activity of the experimental immunotherapy TTX-080.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumor expresses HLA-G. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-080, by IV, every 3 weeks, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-080 is an experimental immunotherapy that researchers believe works by blocking the cancer cell protein HLA-G.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer that expresses HLA-G. </li> <li class="seamTextUnorderedListItem">Targets or mutations: HLA-G</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04485013' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tizonatx.com/science/' target='_blank'>Tizona Therapeutics Drug Information Page: TTX-080</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fimmu.2020.01685/full' target='_blank'>Journal Article: HLA-G Neo-Expression on Tumors</a> </li></ul>

153

Experimental Immunotherapy for Advanced Breast Cancer that Expresses HLA-G

Show Scientific Title

A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects With Advanced Solid Tumors

Nearest Location from 94107:
948 miles
Rocky Mountain Cancer Centers
Denver, CO

Visits:
1 visit every 3 weeks, ongoing

ClinicalTrials.gov: NCT04485013

Phase I

154

Sulforaphane Nutritional Supplement to Reduce Heart Problems from Doxorubicin Chemotherapy

Show Scientific Title

Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)

Purpose: To study if sulforaphane (Avmacol®) reduces heart problems caused by doxorubicin (Adriamycin®) chemotherapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive doxorubicin (Adriamycin®) chemotherapy. You must not have received radiation to your chest, and if your tumor is HER2-positive, you must not be receiving trastuzumab (Herceptin®). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sulforaphane (Avmacol®), by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood tests, 7 times in 1 year</li> <li class="seamTextUnorderedListItem">Heart function tests, 2 times in 1 year</li> <li class="seamTextUnorderedListItem">PET scan, 3 times in 1 year</li> </ul> Group 2: Placebo <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for sulforaphane (Avmacol®), by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood tests, 7 times in 1 year</li> <li class="seamTextUnorderedListItem">Heart function tests, 2 times in 1 year</li> <li class="seamTextUnorderedListItem">PET scan, 3 times in 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®) is a chemotherapy commonly used to treat breast cancer. It can cause injury to the heart in about 10-20% of patients.</li> <li class="seamTextUnorderedListItem">There is a need to develop new strategies that prevent the harmful effects of doxorubicin (Adriamycin®) but maintain its effectiveness as a cancer therapy.</li> <li class="seamTextUnorderedListItem">Sulforaphane (Avmacol®) is an experimental dietary supplement derived from broccoli and other cruciferous vegetables. It may keep normal cells healthy and enhance cancer cell sensitivity to doxorubicin (Adriamycin®).</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03934905' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/adriamycin' target='_blank'>Breastcancer.org: Doxorubicin (Adriamycin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.avmacol.com/' target='_blank'>Nutramax Laboratories: Sulforaphane (Avmacol®)</a> </li></ul>

154

Sulforaphane Nutritional Supplement to Reduce Heart Problems from Doxorubicin Chemotherapy

Show Scientific Title

Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)

Nearest Location from 94107:
1185 miles
Texas Tech University Health Sciences Center
Lubbock, TX

Visits:
At least 7 visits within 1 year

ClinicalTrials.gov: NCT03934905

Phase I-II

155

A Registry for People with Triple Negative or ER Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

Show Scientific Title

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT)

Purpose: To learn more about the relationship between genetic mutations and cancer outcomes.

Who is this for?: People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER Low (1%-10% ER) breast cancer. View full eligibility criteria

What's involved?

This is a data collection (registry) study. You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER Low breast cancer.</li> <li class="seamTextUnorderedListItem">Studies have found a relationship between triple negative breast cancer and inherited BRCA1 and BRCA2 mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PTEN, P53, and PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>ASCO: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Expressions</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ghr.nlm.nih.gov/condition/breast-cancer' target='_blank'>NIH Genetics Home Reference: Breast Cancer</a> </li></ul>

155

A Registry for People with Triple Negative or ER Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

Show Scientific Title

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT)

Nearest Location from 94107:
1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays, KS

Visits:
1 visit

ClinicalTrials.gov: NCT02302742

Phase NA

156

MK-5684 Hormone Therapy for Advanced HR+ Breast Cancer

Show Scientific Title

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Purpose: To compare the anti-cancer activity of MK-5684 hormone therapy to the standard of care hormone therapy treatment.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed during or after at least one line of hormone therapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MK-5684, by mouth, daily</li> <li class="seamTextUnorderedListItem">Fludrocortisone, by mouth</li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth</li> </ul> Group 2: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of fulvestrant (Faslodex®), by injection, monthly or exemestane (Aromasin®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06979596' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: MK-5684</a> </li></ul>

156

MK-5684 Hormone Therapy for Advanced HR+ Breast Cancer

Show Scientific Title

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Nearest Location from 94107:
1298 miles
Mary Lanning Healthcare ( Site 0019)
Hastings, NE

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06979596

Phase II

157

Liver Biopsy to Predict Response to Immunotherapy for Metastatic Breast Cancer That has Spread to the Liver

Show Scientific Title

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Purpose: To collect liver tumor samples to study a possible response to immunotherapy.

Who is this for?: People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that has spread to the liver. You must have not yet started your next line of therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Liver biopsy as part of standard of care</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is collecting samples of breast cancer that has spread to the liver to understand ways to prepare the tissue to predict how a patient may respond to immunotherapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07327489' target='_blank'>ClinicalTrials.gov</a> </li></ul>

157

Liver Biopsy to Predict Response to Immunotherapy for Metastatic Breast Cancer That has Spread to the Liver

Show Scientific Title

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Nearest Location from 94107:
1382 miles
Mercy Hospital - OKC
Oklahoma City, OK

Visits:
Coincides with biopsy

ClinicalTrials.gov: NCT07327489

Phase NA

158

Vagus Nerve Stimulation for Heart Problems in People with Stage I-IV Breast Cancer

Show Scientific Title

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

Purpose: To study if low level vagus nerve stimulation will improve heart function.

Who is this for?: People at least 50 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received doxorubicin (Adriamycin®) and/or anti-HER2 targeted therapy within the last 3 months. You must also meet at least 1 of the following criteria: previous chest radiation, type 2 diabetes, high blood pressure, current smoker, obesity, and/or certain heart conditions. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Heart function tests, 2 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Low level stimulation to one ear with handheld device, 2 weeks</li> </ul> Group 2: Placebo <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Heart function tests, 2 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Low level stimulation to one ear (at a different location than group 1) with handheld device, 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">These medications include some chemotherapy and anti-HER2 targeted therapy drugs.</li> <li class="seamTextUnorderedListItem">Stimulation of a nerve called the vagus nerve can have beneficial effects on the heart. Part of the vagus nerve is in the ear.</li> <li class="seamTextUnorderedListItem">The vagus nerve stimulation sessions are 1 hour.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05921253' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/some-meds-up-heart-risk-in-overweight-women' target='_blank'>Breastcancer.org: Anthracyclines, Anti-HER2 Medications, and Heart Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.parasym.co/about-parasym.html' target='_blank'>Parasym: Vagus Nerve Stimulation</a> </li></ul>

158

Vagus Nerve Stimulation for Heart Problems in People with Stage I-IV Breast Cancer

Show Scientific Title

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

Nearest Location from 94107:
1387 miles
Stephenson Cancer Center
Oklahoma City, OK

Visits:
2 visits within 2 weeks

ClinicalTrials.gov: NCT05921253

Phase I

159

Mindfulness Based Physical Activity Program for People With Metastatic Breast Cancer

Show Scientific Title

Testing the Feasibility and Acceptability of a Remotely Delivered Program to Promote Active Living Among People With Metastatic Breast Cancer

Purpose: To study if a remotely delivered mindfulness and acceptance based physical activity program can support mental, social, and spiritual well-being.

Who is this for?: People with metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acceptance and Mindfulness-Based Program, 2-3 months</li> <li class="seamTextUnorderedListItem">A wearable physical activity tracker</li> <li class="seamTextUnorderedListItem">Questionnaires, at baseline and 9 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers hope the program may help reduce fatigue, emotional stress, and declines in daily functioning that many people with metastatic breast cancer experience.</li> <li class="seamTextUnorderedListItem">A social and supportive part of this program allows you to take part in weekly activities. You’ll be able to share your reflections on these “Weekly Challenges,” see what others have shared, and leave encouraging comments. This is designed to help you feel connected, supported, and mindful as you work on being more active.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07238023' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/metastatic/treatment/exercise-tips' target='_blank'>Breastcancer.org: Making Exercise Part of Your Metastatic Breast Cancer Treatment Plan</a> </li></ul>

159

Mindfulness Based Physical Activity Program for People With Metastatic Breast Cancer

Show Scientific Title

Testing the Feasibility and Acceptability of a Remotely Delivered Program to Promote Active Living Among People With Metastatic Breast Cancer

Nearest Location from 94107:
1387 miles
TSET Health Promotion Research Center
Oklahoma City, OK

Visits:
No visits required

ClinicalTrials.gov: NCT07238023

Phase NA

160

ISM3091 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ISM3091 in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of ISM3091, an experimental USP1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ISM3091, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ISM3091 is an experimental targeted therapy called a USP1 inhibitor. Inhibiting USP1 may stop cancer cells from repairing DNA and growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05932862' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://insilico.com/pipeline_target_usp1' target='_blank'>InSilico Medicine: ISM3091 Drug Information Page</a> </li></ul>

160

ISM3091 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ISM3091 in Patients With Advanced Solid Tumors

Nearest Location from 94107:
1387 miles
Exelixis Clinical Site #13
Oklahoma City, OK

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05932862

Phase I

161

Radiation Therapy for Metastatic HR+, HER2-, GRPR Expressing Breast Cancer

Show Scientific Title

A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of 212Pb-DOTAM-GRPR1, an experimental radiation therapy.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that expresses GRPR who have not received whole body radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">212Pb-DOTAM-GRPR1, every 2 months for 8 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">212Pb-DOTAM-GRPR1 is an experimental radiation therapy called a radioimmunoconjugate, which is a radioactive substance that carries radiation directly to cancer cells.</li> <li class="seamTextUnorderedListItem">A radioimmunoconjugate is a type of radiation therapy that combines an antibody that targets cancer cells with a radiation therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">212Pb-DOTAM-GRPR1 contains a GRPR inhibitor. Inhibiting GRPR may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: GRPR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05283330' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/radioimmunoconjugate' target='_blank'>National Cancer Institute: Radioimmunoconjugate</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oranomed.com/en/pipeline' target='_blank'>Orano Med LLC: 212Pb-DOTAM-GRPR1 Drug Information Page</a> </li></ul>

161

Radiation Therapy for Metastatic HR+, HER2-, GRPR Expressing Breast Cancer

Show Scientific Title

A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Nearest Location from 94107:
1414 miles
XCancer Omaha / Urology Cancer Center
Omaha, NE

Visits:
1 visit every 2 months for 8 months

ClinicalTrials.gov: NCT05283330

Phase I

162

Local Chemotherapy to Prevent a Recurrence of Brain Metastases After Surgery

Show Scientific Title

A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease

Purpose: To compare local chemotherapy (Gliadel Wafer®) with stereotactic radiosurgery (SRS), after surgery, to prevent brain metastases from recurring.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) with at least one tumor requiring surgery. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1: Gliadel <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove the metastatic brain tumor</li> <li class="seamTextUnorderedListItem">Placement of Gliadel Wafers (chemotherapy) in the surgical site after the tumor is removed</li> <li class="seamTextUnorderedListItem">MRIs, before and after surgery</li> </ul> Group 2: Standard care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove the metastatic brain tumor</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS) to the tumor site, within 6 weeks after surgery</li> <li class="seamTextUnorderedListItem">MRIs, before and after surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy. </li> <li class="seamTextUnorderedListItem">Gliadel Wafer® is an implant that dissolves slowly and releases chemotherapy directly into the area where the brain tumor has been removed. It has been approved for certain types of brain tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04222062' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-20903/gliadel-wafer-implant/details' target='_blank'>WebMD: Gliadel Wafer</a> </li></ul>

162

Local Chemotherapy to Prevent a Recurrence of Brain Metastases After Surgery

Show Scientific Title

A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease

Nearest Location from 94107:
1418 miles
University of Nebraska Medical Center
Omaha, NE

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04222062

Phase II

163

Studying Speech, Movement, and Senses During Brain Surgery for Brain Metastasis

Show Scientific Title

Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors

Purpose: To study how brain tumors affect your speech, movement, and senses and to develop new methods of diagnosing brain tumors.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive testing</li> <li class="seamTextUnorderedListItem">MRI and fMRI scans</li> <li class="seamTextUnorderedListItem">DTI tractograms</li> <li class="seamTextUnorderedListItem">MEG studies</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Awake brain mapping and surgery to remove brain tumor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A craniotomy is a type of brain surgery. The surgeon will remove part of your skull (cranium) to access your brain to remove the tumors.</li> <li class="seamTextUnorderedListItem">You will be awake during the craniotomy to monitor how the surgery is affecting your speech, movement, and senses. Your scalp will be anesthetized, so you will not feel the operation or any pain.</li> <li class="seamTextUnorderedListItem">You will receive cognitive testing, MRI and fMRI scans, DTI tractograms, and MEG studies before and after surgery.</li> <li class="seamTextUnorderedListItem">Cognitive tests study your cognition, which is your ability to think.</li> <li class="seamTextUnorderedListItem">Magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI) scans produce brain images created by magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A DTI tractogram is a type of MRI scan that produces brain images created by radio waves and magnetic fields.</li> <li class="seamTextUnorderedListItem">MEG studies measure the magnetic fields produced by your brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01535430' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://braintumorcenter.ucsf.edu/treatments/surgery/awake-brain-mapping-faq' target='_blank'>UCSF Brain Tumor Center: Awake Craniotomy</a> </li></ul>

163

Studying Speech, Movement, and Senses During Brain Surgery for Brain Metastasis

Show Scientific Title

Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors

Nearest Location from 94107:
1418 miles
University of Nebraska Medical Center
Omaha, NE

Visits:
May require hospitalization

ClinicalTrials.gov: NCT01535430

Phase NA

164

Chemotherapy Treatment At Home for People with Advanced Breast Cancer

Show Scientific Title

Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic

Purpose: To compare the safety and effects (good and bad) of receiving paclitaxel (Taxol®) chemotherapy at home and at a clinic.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who are receiving chemotherapy, trastuzumab (Herceptin®), leuprolide (Lupron®), or goserelin (Zoladex®). You must live within 35 miles from Mayo Clinic in Jacksonville, FL. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Treatment At Home <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive paclitaxel (Taxol®) chemotherapy at home, 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Treatment At Clinic and Home <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive paclitaxel (Taxol®) chemotherapy at clinic, 2 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive paclitaxel (Taxol®) chemotherapy at home, 4 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Providing cancer treatment at home, versus in the clinic, may help reduce mental and financial distress and increase treatment compliance, especially for marginalized patients and communities.</li> <li class="seamTextUnorderedListItem">Home health appointments include chemotherapy administration, routine vital sign monitoring, and routine lab tests.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05969860' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/medical-professionals/cancer/news/high-quality-advanced-cancer-care-conducted-at-home/mac-20538184' target='_blank'>Mayo Clinic: Cancer CARE Beyond Walls</a> </li></ul>

164

Chemotherapy Treatment At Home for People with Advanced Breast Cancer

Show Scientific Title

Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic

Nearest Location from 94107:
1454 miles
Altru Cancer Center
Grand Forks, ND

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05969860

Phase II

165

GS-0201 Alone or With ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of GS-0201, an experimental anti-cancer therapy, alone or with sacituzumab govitecan (Trodelvy®) antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2- or HER2 low) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-0201, by mouth</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-0201 is an experimental anti-cancer therapy.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06167317' target='_blank'>ClinicalTrials.gov</a> </li></ul>

165

GS-0201 Alone or With ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors

Nearest Location from 94107:
1471 miles
NEXT Dallas
Irving, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06167317

Phase I

166

Melphalan With Standard Treatment or Standard Treatment Alone for HER2- Metastatic Breast Cancer That Has Spread to the Liver

Show Scientific Title

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients With Metastatic Breast Cancer With Liver Dominant Disease

Purpose: To study the safety, side effects (good and bad), and how well a high-dose of Melphalan chemotherapy delivered directly to the liver works when followed by standard breast cancer treatment, compared to standard treatment alone.

Who is this for?: People with HER2-negative (HER2-) metastatic (stage IV) breast cancer that has spread to the liver. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Melphalan (Alkeran®) chemotherapy (high dose) delivered directly to the liver, by IV, 1-2 times</li> <li class="seamTextUnorderedListItem">Approved standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Complete scans approximately every 2 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Approved standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Complete scans approximately every 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Melphalan (Alkeran®) is a chemotherapy medication used to treat multiple myeloma, ovarian cancer, and other cancers. It works by damaging the DNA of cancer cells, which stops them from growing and dividing.</li> <li class="seamTextUnorderedListItem">Standard chemotherapy includes: eribulin (Halaven®), vinorelbine (Navelbine®), or capecitabine (Xeloda®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06875128' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/liver-metastasis-experts/' target='_blank'>Metastatic Trial Talk: Breast Cancer Liver Metastasis: Highlighting the Experts</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/local-therapies-for-liver-mets/' target='_blank'>Metastatic Trial Talk: Local Therapies for Liver Mets</a> </li></ul>

166

Melphalan With Standard Treatment or Standard Treatment Alone for HER2- Metastatic Breast Cancer That Has Spread to the Liver

Show Scientific Title

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients With Metastatic Breast Cancer With Liver Dominant Disease

Nearest Location from 94107:
1473 miles
UT Southwestern Medical Center
Dallas, TX

Visits:
Clinic visits every 2 weeks; scans every 2 months

ClinicalTrials.gov: NCT06875128

Phase II

167

Rhenium-186 NanoLiposome Radioactive Drug for Leptomeninges Metastases

Show Scientific Title

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases (CA2024-LM-001)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome), an experimental radioactive drug.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges. You must not have received radiation to the whole brain. Other types of radiation to the brain are allowed. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rhenium (186Re) obisbemeda (rhenium-186 nanoliposome), by catheter into the brain, multiple times over 13 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The leptomeninges are the inner layers of tissue that line the brain and spinal cord.</li> <li class="seamTextUnorderedListItem">Rhenium (186Re) obisbemeda (rhenium-186 nanoliposome) is an experimental radiopharmaceutical or radioactive drug.</li> <li class="seamTextUnorderedListItem">Radiopharmaceuticals deliver radiation therapy directly and specifically to cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07098806' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://ir.plustherapeutics.com/static-files/415202a9-4f0f-4478-a604-ea0a183c34b7' target='_blank'>Plus Therapeutics: Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>What Are Radiopharmaceuticals and How Are They Used in MBC?</a> </li></ul>

167

Rhenium-186 NanoLiposome Radioactive Drug for Leptomeninges Metastases

Show Scientific Title

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases (CA2024-LM-001)

Nearest Location from 94107:
1481 miles
The Cancer Therapy and Research Center at UTHSCSA
San Antonio, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07098806

Phase I

168

Avasopasem for Metastatic HR+, HER2- Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormone Therapy

Show Scientific Title

Phase 1 Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy (CTMS# 24-0096)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of avasopasem added to ribociclib (Kisqali®) or abemaciclib (Verzenio®) CDK 4/6 inhibitors and hormone therapy.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are receiving ribociclib (Kisqali®) or abemaciclib (Verzenio®) and one of the following: letrozole (Femara®), anastrozole (Arimidex®), exemestane (Aromasin®), or fulvestrant (Faslodex) and whose cancer has started to progress. You must not have received any other systemic therapies. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Avasopasem</li></ul>

What's being studied?

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07137871' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.galeratx.com/science/' target='_blank'>Galera Therapeutics: Avasopasem</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: CDK 4/6 Inhibitors</a> </li></ul>

168

Avasopasem for Metastatic HR+, HER2- Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormone Therapy

Show Scientific Title

Phase 1 Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy (CTMS# 24-0096)

Nearest Location from 94107:
1481 miles
Mays Cancer Center, UT Health San Antonio
San Antonio, TX

Visits:
Number of visits unavailable, up to 4 months

ClinicalTrials.gov: NCT07137871

Phase I

169

GVV858 in Combination With Fulvestrant for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of GVV858 in combination with fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed on or after hormone therapy in combination with a CDK4/6 inhibitor. You must not have received more than 2 lines of hormone therapy. You must not have received chemotherapy, or an antibody-drug conjugate (ADC) for advanced disease. Your tumor must have an abnormality called CCNE1 amplification. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GVV858</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07288359' target='_blank'>ClinicalTrials.gov</a> </li></ul>

169

GVV858 in Combination With Fulvestrant for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors

Nearest Location from 94107:
1481 miles
START
San Antonio, TX

Visits:
Number of visits unavailable, up to 2 years

ClinicalTrials.gov: NCT07288359

Phase I-II

170

SYS6043 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of SYS6043, an experimental B7-H3 targeted antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that have progressed after standard treatments or who have no standard treatment options available. You must not have received an antibody drug conjugate (ADC). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SYS6043 by IV, once every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SYS6043 is an experimental antibody drug conjugate (ADC) that uses an antibody to deliver chemotherapy directly to cancer cells with the B7-H3 protein.</li> <li class="seamTextUnorderedListItem">B7-H3 is a protein found on some cancer cells that helps them hide from the immune system.</li> <li class="seamTextUnorderedListItem">By blocking or targeting B7-H3, treatments like SYS6043 may make it easier for the immune system to recognize and attack the cancer.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07424547' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>

170

SYS6043 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Nearest Location from 94107:
1481 miles
NEXT Oncology San Antonio
San Antonio, TX

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT07424547

Phase I

171

IDOV-Immune for Advanced Breast Cancer

Show Scientific Title

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of IDOV-Immune, a specially designed virus that targets and destroys cancer cells while helping the immune system recognize and fight the cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose cancer has progressed or who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IDOV-Immune, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Close monitoring for 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IDOV-Immune is a type of oncolytic virus therapy, which means it uses a modified virus designed to enter and destroy cancer cells. </li> <li class="seamTextUnorderedListItem">It may also help the immune system recognize and attack the tumor.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06910657' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oncolytic-viruses/' target='_blank'>Oncolytic Viruses: Using Viruses to Kill Cancer Cells</a> </li></ul>

171

IDOV-Immune for Advanced Breast Cancer

Show Scientific Title

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

Nearest Location from 94107:
1481 miles
South Texas Accelerated Research Therapeutics
San Antonio, TX

Visits:
At least 1 visit

ClinicalTrials.gov: NCT06910657

Phase I

172

ATX-295 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of ATX-295, an experimental KIF18A inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATX-295, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATX-295 is an experimental type of targeted therapy called a KIF18A inhibitor.</li> <li class="seamTextUnorderedListItem">Blocking KIF18A may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">KIF18A is a protein important for cell division, especially in tumors with high chromosomal instability (CIN) and TP53 mutations.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06799065' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://accenttx.com/approach-pipeline/' target='_blank'>Accent Therapeutics: ATX-295 (KIF18A Inhibitor) Drug Information Page</a> </li></ul>

172

ATX-295 Targeted Therapy for Advanced Breast Cancer

Show Scientific Title

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

Nearest Location from 94107:
1481 miles
NEXT Oncology
San Antonio, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06799065

Phase I

173

EP0062 Hormone Therapy for Advanced ER+, HER2- or HER2 Low, AR+ Breast Cancer

Show Scientific Title

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients With Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of EP0062, an experimental hormone therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or HER2 low, androgen receptor positive (AR+) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EP0062, by mouth</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EP0062 is an experimental type of hormone therapy called a selective androgen receptor modulator (SARM) that targets the androgen receptor (AR).</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+/FISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05573126' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ellipses.life/portfolio/' target='_blank'>Ellipses Pharma: EP0062 Drug Information Page</a> </li></ul>

173

EP0062 Hormone Therapy for Advanced ER+, HER2- or HER2 Low, AR+ Breast Cancer

Show Scientific Title

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients With Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Nearest Location from 94107:
1482 miles
Texas Oncology Baylor University Medical Center
Dallas, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05573126

Phase I-II

174

PLN-101095 Immunotherapy with Pembrolizumab for Advanced Breast Cancer

Show Scientific Title

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembro...

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of PLN-101095, an experimental immunotherapy, with pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. You must have received pembrolizumab (Keytruda®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PLN-101095</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PLN-101095 is an experimental immunotherapy. PLN-101095 may help pembrolizumab (Keytruda®) work better.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06270706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://pliantrx.com/oncology/' target='_blank'>Pliant Therapeutics: PLN-101095 Drug Information Page</a> </li></ul>

174

PLN-101095 Immunotherapy with Pembrolizumab for Advanced Breast Cancer

Show Scientific Title

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembro...

Nearest Location from 94107:
1498 miles
NEXT Austin
Austin, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06270706

Phase I

175

Zunsemetinib Targeted Therapy with Chemotherapy for Metastatic HR+, HER2- Breast Cancer with Bone Metastasis

Show Scientific Title

A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Purpose: To study the safety, best dose, and effects (good and bad) of zunsemetinib, an experimental targeted therapy, with chemotherapy compared to standard of care.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has spread to the bone (bone metastasis). You must have received 1 line of hormone therapy with a CDK4/6 inhibitor and no more than 1 line of chemotherapy for metastatic disease. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bisphosphonate (zoledronic acid) or denosumab, every 1-3 months</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zunsemetinib, by mouth, daily</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zunsemetinib is an experimental targeted therapy called an MK2 inhibitor. Blocking MK2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Zunsemetinib targets a molecule that may play a role in inflammation and bone loss.</li> <li class="seamTextUnorderedListItem">Bisphosphonate (zoledronic acid) and denosumab are standard of care drugs that help strengthen bones but have little effect on pain relief and anti-cancer activity.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06374459' target='_blank'>ClinicalTrials.gov</a> </li></ul>

175

Zunsemetinib Targeted Therapy with Chemotherapy for Metastatic HR+, HER2- Breast Cancer with Bone Metastasis

Show Scientific Title

A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Nearest Location from 94107:
1502 miles
The University of Kansas Cancer Center
Westwood, KS

Visits:
Weekly for 3 weeks, then 1 visit every 3 weeks

ClinicalTrials.gov: NCT06374459

Phase I-II

176

Metarrestin (ML-246) for Metastatic Breast Cancer

Show Scientific Title

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors.

Purpose: To find the best dose and study the safety and anti-cancer activity of the experimental targeted therapy metarrestin (ML-246).

Who is this for?: People with metastatic (stage IV) breast cancer who have no standard therapy options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Metarrestin, by mouth, 1 to 5 days a week, ongoing</li> </ul> Two short hospital stays during the first month are required. Additional procedures: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Drug diary</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">CT scan or MRI</li> <li class="seamTextUnorderedListItem">Cognitive tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Metarrestin (ML-246) is an experimental targeted therapy.</li> <li class="seamTextUnorderedListItem">Metarrestin breaks down a part of the cancer cell called the perinucleolar compartment (PNC). </li> <li class="seamTextUnorderedListItem">Breaking down PNCs may reduce cancer progression. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04222413' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/800687' target='_blank'>NCI Drug Dictionary: Metarrestin (ML-246)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.kucancercenter.org/news-room/news/2018/06/metastasis-suppressing-compound' target='_blank'>The University of Kansas Cancer Center: Researchers Identify Metastasis-Suppressing Compound</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nih.gov/news-events/news-releases/nih-northwestern-scientists-develop-potential-new-approach-stop-cancer-metastasis' target='_blank'>NIH News Release: NIH, Northwestern Scientists Develop Potential New Approach to Stop Cancer Metastasis</a> </li></ul>

176

Metarrestin (ML-246) for Metastatic Breast Cancer

Show Scientific Title

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors.

Nearest Location from 94107:
1502 miles
University of Kansas
Fairway, KS

Visits:
2 short hospital stays, then 1 visit a week, ongoing

ClinicalTrials.gov: NCT04222413

Phase I

177

Hormone Therapy or Chemotherapy with Genetic Testing for Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of hormone therapy and capecitabine (Xeloda®) chemotherapy and use MammaPrint® and BluePrint tests to guide treatment decisions.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received treatment with hormone therapy and a CDK4/6 inhibitor. You must not have received chemotherapy or more than 1 line of hormone therapy for advanced disease or have a PIK3CA mutation. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of hormone therapy</li> <li class="seamTextUnorderedListItem">Provide tissue samples for MammaPrint® and BluePrint tests </li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 1 week on, 1 week off</li> <li class="seamTextUnorderedListItem">Provide tissue samples for MammaPrint® and BluePrint tests</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">MammaPrint® and BluePrint are genetic tests that use tumor samples to help guide treatment decisions.</li> <li class="seamTextUnorderedListItem">The tests will also be used to determine if certain mutations are potentially associated with resistance to therapy.</li> <li class="seamTextUnorderedListItem">This trial is for people with non-Luminal A breast cancer. Luminal A breast cancer is ER+, PR+, and HER2- with low Ki-67 levels, which controls how fast cancer cells grow. Luminal A cancers tend to grow more slowly.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05693766' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/xeloda' target='_blank'>Breastcancer.org: Capecitabine (Xeloda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/mammaprint-test' target='_blank'>Breastcancer.org: MammaPrint®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/molecular-subtypes' target='_blank'>Breastcancer.org: Molecular Subtypes of Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing for Breast Cancer</a> </li></ul>

177

Hormone Therapy or Chemotherapy with Genetic Testing for Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)

Nearest Location from 94107:
1509 miles
UT Southwestern Medical Center
Dallas, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05693766

Phase II

178

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Show Scientific Title

Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Purpose: To look at how the metabolism of brain metastases differs from normal tissue.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who have not received prior chemotherapy or radiation for these metastases. View full eligibility criteria

What's involved?

You will undergo the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRSI (a type of MRI), with contrast, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRSI (Magnetic Resonance Spectroscopic Imaging) is a technique used to visualize tumor metabolism in real-time.</li> <li class="seamTextUnorderedListItem">Learning how the metabolism of brain metastases differs from normal tissue may lead to the development of new targeted therapies.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03067467' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

178

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Show Scientific Title

Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Nearest Location from 94107:
1509 miles
UT Southwestern Medical Center
Dallas, TX

Visits:
1-2 visits

ClinicalTrials.gov: NCT03067467

Phase NA

179

Tissue Collection During Surgery for Brain Metastasis

Show Scientific Title

An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

Purpose: To collect brain tumor tissue during surgery and study brain metastasis activity with U-13C-glucose and/or 1,2-13C-acetate.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI and PET scans, 1-2 weeks before surgery</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">U-13C-glucose, by IV and/or 1,2-13C-acetate, by IV</li> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor tissue</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">On the day of surgery, you will receive U-13C-glucose and/or 1,2-13C-acetate naturally occurring chemicals to study brain metastasis activity.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01668082' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

179

Tissue Collection During Surgery for Brain Metastasis

Show Scientific Title

An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

Nearest Location from 94107:
1509 miles
University of Texas Southwestern
Dallas, TX

Visits:
At least 4 visits over 3 weeks including surgery; may require hospitalization

ClinicalTrials.gov: NCT01668082

Phase NA

180

Axelopran for Advanced Breast Cancer in People Using Opioid Pain Medicine

Show Scientific Title

A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of axelopran to see if it can help control cancer growth while also improving symptoms like constipation and overall quality of life.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. If your cancer is hormone receptor positive (ER+ and/or PR+), it must have returned or worsened after treatment with hormone therapy. You must have received at least one line of chemotherapy for advanced breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axelopran alone, by mouth, daily, for 6 weeks</li> <li class="seamTextUnorderedListItem">10 study visits and assessments, 1-2 hours each, over 6 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axelopran is a study medicine that is designed to ease opioid‑related bowel problems while also being studied for its potential to help slow or stabilize cancer growth.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07354919' target='_blank'>ClinicalTrials.gov</a> </li></ul>

180

Axelopran for Advanced Breast Cancer in People Using Opioid Pain Medicine

Show Scientific Title

A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)

Nearest Location from 94107:
1576 miles
HealthPartners Frauenshuh Cancer Research Center
Saint Louis Park, MN

Visits:
10 visits over 6 weeks

ClinicalTrials.gov: NCT07354919

Phase II

181

Ultrasound Compared to MRI to Image Brain Tumors Before Surgery

Show Scientific Title

Feasibility of Transcranial Focused Ultrasound to Measure Brain Tumor

Purpose: To compare the ability of ultrasound and MRI to image brain tumors.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. View full eligibility criteria

What's involved?

You will receive the following during brain surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Ultrasound</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance imaging (MRI) is the standard imaging method for the brain.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">It may be easier to take multiple images at different times with non-invasive ultrasound compared to MRI.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05755399' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

181

Ultrasound Compared to MRI to Image Brain Tumors Before Surgery

Show Scientific Title

Feasibility of Transcranial Focused Ultrasound to Measure Brain Tumor

Nearest Location from 94107:
1584 miles
University of Minnesota
Minneapolis, MN

Visits:
Please contact research site

ClinicalTrials.gov: NCT05755399

Phase NA

182

Registry for People with Metastatic Breast Cancer, Breast Cancer That Has Come Back, or Male Breast Cancer

Show Scientific Title

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Purpose: To create a collection of tissue samples and patient information.

Who is this for?: Women with stage I, stage II, or stage III breast cancer that has come back (recurred) or stage IV (metastatic) breast cancer, and men with breast cancer. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor biopsy sample</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue and blood samples and patient information can be used to improve researchers' understanding of the development, progression, and treatment of breast cancer.</li> <li class="seamTextUnorderedListItem">In this study, information is being collected about metastatic breast cancer, recurrent breast cancer (breast cancer that has come back), and Male Breast Cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06217874' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20309083' target='_blank'>Mayo Clinic: Trial page</a> </li></ul>

182

Registry for People with Metastatic Breast Cancer, Breast Cancer That Has Come Back, or Male Breast Cancer

Show Scientific Title

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06217874

Phase NA

183

The Sarah Nanotechnology System for Metastatic Breast Cancer

Show Scientific Title

Open Label Feasibility Dose Escalation Study to Evaluate the Safety of Sarah Nanotechnology System, With Alternating Magnetic Field (AMF) Application in Patients With Advanced Metastatic Solid Tumors.

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of the Sarah Nanotechnology System.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread within the torso and who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nanoparticles, by IV</li> <li class="seamTextUnorderedListItem">Magnetic radiation treatment </li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">ECG test</li> <li class="seamTextUnorderedListItem">CT scans, 2 times</li> <li class="seamTextUnorderedListItem">Brain MRI scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">For the Sarah Nanotechnology System, the participant receives an injection of nanoparticles that travel to the tumor through the bloodstream. The person is then placed in a machine that produces magnetic radiation that heats up the nanoparticles in the tumor, destroying the tumor while sparing healthy tissue.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07224464' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://newphase.co.il/' target='_blank'>New Phase: The Sarah Nanotechnology System</a> </li></ul>

183

The Sarah Nanotechnology System for Metastatic Breast Cancer

Show Scientific Title

Open Label Feasibility Dose Escalation Study to Evaluate the Safety of Sarah Nanotechnology System, With Alternating Magnetic Field (AMF) Application in Patients With Advanced Metastatic Solid Tumors.

Nearest Location from 94107:
1615 miles
Mayo Clinic
Rochester, MN

Visits:
4 visits within 1 month, remote follow-up for up to 5 years

ClinicalTrials.gov: NCT07224464

Phase NA

184

Registry of CSF Biomarkers from Lumbar Punctures for Brain Metastasis

Show Scientific Title

Cerebrospinal Fluid Biomarkers for Brain Tumors

Purpose: To collect samples of CSF to study brain tumor biomarkers and develop new ways to diagnose, monitor, and treat brain tumors.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF, 2 or more times</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li> </ul> Please contact research site for treatment schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumbar puncture, also known as a spinal tap, is a procedure to collect a sample of fluid that surrounds your brain and spinal cord, called cerebrospinal fluid (CSF).</li> <li class="seamTextUnorderedListItem">Biomarkers can indicate the presence or severity of brain tumors.</li> <li class="seamTextUnorderedListItem">You may choose to undergo additional lumbar punctures to collect additional CSF samples.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692324' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

184

Registry of CSF Biomarkers from Lumbar Punctures for Brain Metastasis

Show Scientific Title

Cerebrospinal Fluid Biomarkers for Brain Tumors

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
2 visits

ClinicalTrials.gov: NCT04692324

Phase NA

185

Ommaya Reservoir Placement to Collect CSF Samples for Brain Metastasis

Show Scientific Title

Ommaya Reservoir Placement for Brain Tumor Biomarker Access

Purpose: To study the safety and effects (good and bad) of Ommaya reservoir placement that will be used to collect and study CSF samples.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to undergo brain surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to place Ommaya reservoir</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of CSF from Ommaya reservoir, 2 or more times</li> </ul> Please contact research site for schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An Ommaya reservoir will be placed during brain surgery.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF), the fluid or liquid surrounding your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">CSF samples will be used to study brain cancer activity and develop new brain cancer treatments.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692337' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/faq-about-ommaya-reservoirs-and-ommaya-taps' target='_blank'>Memorial Sloan Kettering Cancer Center: Ommaya Reservoir</a> </li></ul>

185

Ommaya Reservoir Placement to Collect CSF Samples for Brain Metastasis

Show Scientific Title

Ommaya Reservoir Placement for Brain Tumor Biomarker Access

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
At least 3 visits including surgery; may require hospitalization

ClinicalTrials.gov: NCT04692337

Phase NA

186

Interview About Radiation Dermatitis for People with Stage 0-IV Breast Cancer

Show Scientific Title

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

Purpose: To use interviews to study the experiences of people with radiation dermatitis (burn).

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving or recently completed radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation dermatitis (burn) is a common side effect of radiation.</li> <li class="seamTextUnorderedListItem">It involves itchy skin, skin changing color, and swelling.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06953245' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21995-radiation-burns' target='_blank'>Cleveland Clinic: Radiation Dermatitis</a> </li></ul>

186

Interview About Radiation Dermatitis for People with Stage 0-IV Breast Cancer

Show Scientific Title

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
1 visit

ClinicalTrials.gov: NCT06953245

Phase NA

187

Microdialysis During Surgery for Metastatic Breast Cancer that has Spread to the Brain

Show Scientific Title

Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

Purpose: To study the safety and effects (good and bad) of the use of microdialysis catheters during surgery to collect biomarkers, which may help doctors to develop new strategies to better diagnose, monitor, and treat cancer that has spread to the brain.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery to remove the tumor at Mayo Clinic (Rochester, MN). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Microdialysis during a biopsy or surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A biomarker is a gene, protein, or molecule produced by the body or tumor in a person with cancer that tells a doctor something about the cancer cells. </li> <li class="seamTextUnorderedListItem">Microdialysis is a procedure used for collecting a small volume of liquid during surgery. This liquid contains substances that may provide valuable information to doctors about the nearby cancer.</li> <li class="seamTextUnorderedListItem">Microdialysis will be performed during surgery while your brain tumor is being removed.</li> <li class="seamTextUnorderedListItem">Information collected in this study may help doctors to develop new strategies to better diagnose, monitor, and treat brain tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04047264' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.news-medical.net/life-sciences/What-is-Microdialysis.aspx' target='_blank'>News Medical: What is Microdialysis?</a> </li></ul>

187

Microdialysis During Surgery for Metastatic Breast Cancer that has Spread to the Brain

Show Scientific Title

Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
May require hospitalization

ClinicalTrials.gov: NCT04047264

Phase NA

188

Studying Blood Sugar During Hormone Therapy for Postmenopausal Women with Stage 0-IV HR+ Breast Cancer

Show Scientific Title

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Purpose: To study the effect of hormone therapy on blood sugar.

Who is this for?: Postmenopausal women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving (within 6 months of starting) or planning to receive an aromatase inhibitor or tamoxifen (Nolvadex®), as well as postmenopausal women without breast cancer. You must not have diabetes. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sugar tests, 2 times within 1 year</li> <li class="seamTextUnorderedListItem">Body composition scan</li> <li class="seamTextUnorderedListItem">Phone calls, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Results from people with breast cancer will be compared to people without breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06557057' target='_blank'>ClinicalTrials.gov</a> </li></ul>

188

Studying Blood Sugar During Hormone Therapy for Postmenopausal Women with Stage 0-IV HR+ Breast Cancer

Show Scientific Title

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
At least 2 times within 1 year

ClinicalTrials.gov: NCT06557057

Phase NA

189

Blood Sample Collection to Better Predict Breast Cancer Risk for Healthy Women

Show Scientific Title

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

Purpose: To study genetic and other factors to learn how non-cancerous breast diseases might lead to breast cancer.

Who is this for?: Women who had a breast biopsy at Mayo Clinic between 2002-2022 that was not cancer. You must not have been diagnosed with breast cancer within 6 months of this biopsy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood or saliva (spit) sample</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Features in the blood and breast tissue from people with non-cancerous breast disease may help predict breast cancer risk.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07207564' target='_blank'>ClinicalTrials.gov</a> </li></ul>

189

Blood Sample Collection to Better Predict Breast Cancer Risk for Healthy Women

Show Scientific Title

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
1 visit

ClinicalTrials.gov: NCT07207564

Phase NA

190

A Vaccine Injected Directly Into a Tumor for Metastatic Breast Cancer

Show Scientific Title

Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer

Purpose: To study the best dose, safety, and anti-cancer activity of an experimental vaccine that is injected directly into the tumor.

Who is this for?: People with metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MV-s-NAP vaccine, by injection directly into your tumor, every 3 weeks, 4 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MV-s-NAP is the name of the vaccine used in this trial. It is made from a modified measles virus.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04521764' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/breast-cancer/metastatic-breast-cancer-vaccine-treatment' target='_blank'>WebMD: Vaccine Treatment for Metastatic Breast Cancer</a> </li></ul>

190

A Vaccine Injected Directly Into a Tumor for Metastatic Breast Cancer

Show Scientific Title

Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
1 visit every 3 weeks for 2.5 months

ClinicalTrials.gov: NCT04521764

Phase I

191

Breathing and Walking for Brain and Mental Health for People with Stage 0-IV Breast Cancer and Caregivers

Show Scientific Title

Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)

Purpose: To study the ability of breathing training and walking to improve brain and mental health.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or metastatic (stage IV) breast cancer. Caregivers may also participate. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breathing exercises, with mobile app, daily for 4-6 months</li> <li class="seamTextUnorderedListItem">Breathing exercises, virtual weekly or in-person monthly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking exercises, with mobile app, daily for 6 months</li> <li class="seamTextUnorderedListItem">Walking exercises, in person, weekly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking exercises, with mobile app, daily for 6 months</li> <li class="seamTextUnorderedListItem">Walking exercises, in person, weekly (optional)</li> <li class="seamTextUnorderedListItem">Breathing exercises, by mobile app, daily for 2 months</li> <li class="seamTextUnorderedListItem">Breathing exercises, virtual weekly or in-person monthly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The relationship among breathing, cardiovascular (heart and blood flow) effects in the brain, and mental health is important for people with cancer and their caregivers.</li> <li class="seamTextUnorderedListItem">Breathing training is also called respiratory training and may increase the amount of oxygen that the brain receives.</li> <li class="seamTextUnorderedListItem">Breathing and walking exercises are 30 minutes.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer and multiple sclerosis.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06788886' target='_blank'>ClinicalTrials.gov</a> </li></ul>

191

Breathing and Walking for Brain and Mental Health for People with Stage 0-IV Breast Cancer and Caregivers

Show Scientific Title

Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
At least 2 visits in 6 months

ClinicalTrials.gov: NCT06788886

Phase NA

192

Headband and Meditation for Improving Anxiety and Insomnia for People with Stage I-IV Breast Cancer

Show Scientific Title

Pilot Study of a Wearable EEG Headband as a Meditation Device for Breast Cancer Survivors

Purpose: To study the ability of the MUSE S headband and MUSE phone app to reduce anxiety and insomnia.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who were diagnosed within the last 10 years. You must be experiencing anxiety and insomnia (sleep problems). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MUSE S headband, nightly for 2 months</li> <li class="seamTextUnorderedListItem">Meditation with MUSE phone app, for at least 5 minutes daily, for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Anxiety and insomnia (sleep problems) are among the most common side effects of breast cancer.</li> <li class="seamTextUnorderedListItem">Meditation is an effective tool to decrease stress and anxiety.</li> <li class="seamTextUnorderedListItem">The MUSE S headband sends EEG signals to your brain to improve fatigue, quality of life, and stress.</li> <li class="seamTextUnorderedListItem">You will be asked to wear the MUSE S headband to bed every night and meditate using the MUSE phone app for at least 5 minutes every day.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06274034' target='_blank'>ClinicalTrials.gov</a> </li></ul>

192

Headband and Meditation for Improving Anxiety and Insomnia for People with Stage I-IV Breast Cancer

Show Scientific Title

Pilot Study of a Wearable EEG Headband as a Meditation Device for Breast Cancer Survivors

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Visits:
Number of visits unavailable, over 2 months

ClinicalTrials.gov: NCT06274034

Phase I

193

Studying Language in People with Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

Comparative Analysis of Structural and Functional Characteristics of Brain Regions Measured by Functional Imaging AND Electrophysiology and Hemispheric Laterality Predicted by Structural Connectivity and Fronto-basal-ganglia Circuits for Selective Stopping and Braking and Diffusion Imaging for Seizure Focus Localization AND Representation and Bi...

Purpose: To study brain function in people with brain tumors.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Language tasks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that has spread to the brain can cause various problems, depending on where the tumor is located in the brain.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05989893' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

193

Studying Language in People with Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

Comparative Analysis of Structural and Functional Characteristics of Brain Regions Measured by Functional Imaging AND Electrophysiology and Hemispheric Laterality Predicted by Structural Connectivity and Fronto-basal-ganglia Circuits for Selective Stopping and Braking and Diffusion Imaging for Seizure Focus Localization AND Representation and Bi...

Nearest Location from 94107:
1635 miles
The University of Texas Health Science Center at Houston
Houston, TX

Visits:
1 visit

ClinicalTrials.gov: NCT05989893

Phase NA

194

Tumor Treating Fields Device for Advanced Breast Cancer

Show Scientific Title

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of Tumor Treating Fields (TTF), an experimental wearable device, with targeted therapy or chemotherapy and immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups based on your type of cancer: Group 1: TTF with Targeted Therapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Treating Fields (TTF), daily</li> <li class="seamTextUnorderedListItem">Cabozantinib (Cabometyx® or Cometriq®), by mouth, daily</li> </ul> Group 2: TTF with Chemotherapy and Immunotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Treating Fields (TTF), daily</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Treating Fields (TTF) consists of experimental wearable devices that use electrical fields at different frequencies to stop the growth of tumor cells by interrupting cancer cells' ability to divide.</li> <li class="seamTextUnorderedListItem">Cabozantinib (Cabometyx® or Cometriq®) is a type of targeted therapy called a tyrosine kinase inhibitor. Tyrosine kinase inhibitors work by blocking proteins that signal cancer cells to multiply, which may help keep cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-L1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®) is a type of chemotherapy drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05092373' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verywellhealth.com/tumor-treating-fields-ttf-4584149' target='_blank'>Verywell Health: Tumor Treating Fields (TTF)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a616037.html' target='_blank'>MedlinePlus: Cabozantinib (Cabometyx® or Cometriq®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/abraxane' target='_blank'>Breastcancer.org: Nab-paclitaxel (Abraxane®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/tecentriq' target='_blank'>Breastcancer.org: Atezolizumab (Tecentriq®)</a> </li></ul>

194

Tumor Treating Fields Device for Advanced Breast Cancer

Show Scientific Title

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05092373

Phase I

195

Stereotactic Radiosurgery for People with Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active Systemic Therapy Options

Purpose: To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who have at least 1 brain lesion that has not received radiation. You must be planning to receive chemotherapy or targeted therapy as the first treatment for brain mets. View full eligibility criteria

What's involved?

You will receive the following after receiving chemotherapy or targeted therapy: Group 1: Tumors Completely Disappear (Complete Response) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No radiation</li> <li class="seamTextUnorderedListItem">Brain MRIs</li> </ul> Group 2: Tumors Shrink (Partial Response) or Stay the Same (Stable Disease) You will be randomly assigned to 1 of the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery</li> </ul> or <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No radiation</li> <li class="seamTextUnorderedListItem">Brain MRIs</li> </ul> Group 3: Tumors Grow (Progressive Disease) You will be randomly assigned to 1 of the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery only to brain tumors that have grown (progressed)</li> </ul> or <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery to all brain tumors</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06649058' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526#:~:text=Stereotactic%20radiosurgery%20(SRS)%20uses%20many,sense%20because%20there's%20no%20incision.' target='_blank'>Mayo Clinic: Stereotactic Radiosurgery</a> </li></ul>

195

Stereotactic Radiosurgery for People with Metastatic Breast Cancer with Brain Metastases

Show Scientific Title

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active Systemic Therapy Options

Nearest Location from 94107:
1643 miles
The University of Texas MD Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06649058

Phase II

196

MRI Scans to Improve Brain Surgery for People with Brain Metastases

Show Scientific Title

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain

Purpose: To use MRI scans and CVR mapping to develop a new software to improve brain surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning on receiving a fMRI before brain surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">fMRI scans</li> <li class="seamTextUnorderedListItem">CVR mapping</li> </ul> Please contact research site for trial schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A functional MRI (fMRI) scan measures changes in blood flow that happen during mental activity.</li> <li class="seamTextUnorderedListItem">Cerebrovascular reactivity (CVR) mapping measures changes in blood flow to your brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05342454' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info/fmribrain' target='_blank'>RadiologyInfo.org: Functional MRI (fMRI)</a> </li></ul>

196

MRI Scans to Improve Brain Surgery for People with Brain Metastases

Show Scientific Title

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05342454

Phase NA

197

DM001 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of DM001, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DM001, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DM001 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in DM001 targets 2 proteins (bispecific): TROP2 and EGFR. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06475937' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://aacrjournals.org/cancerres/article/83/8_Supplement/LB215/725224/Abstract-LB215-A-first-in-class-anti-TROP2-EGFR' target='_blank'>AACR Abstract: DM001 for Advanced Cancers</a> </li></ul>

197

DM001 Antibody Drug Conjugate for Advanced Breast Cancer

Show Scientific Title

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors

Nearest Location from 94107:
1643 miles
University of Texas MD Anderson Cancer Center
Houston, TX

Visits:
About 1 visit every 3 weeks

ClinicalTrials.gov: NCT06475937

Phase I

198

Studying the Effects of Tamoxifen in People with ER+ Breast Cancer

Show Scientific Title

Neutrophil Functions in Breast Cancer

Purpose: To study the long-term effects of tamoxifen (Nolvadex®) on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects.

Who is this for?: Pre-menopausal and post-menopausal women with stage I, stage II, stage III, or stage IV (metastatic) estrogen receptor positive (ER+) breast cancer receiving treatment with tamoxifen for at least 6 months. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neutrophil extracellular traps (NET) are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system.</li> <li class="seamTextUnorderedListItem">Treatment with tamoxifen (Nolvadex®) increases the production of NETs.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05056857' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/drugs/9785-tamoxifen' target='_blank'>Cleveland Clinic: Tamoxifen (Nolvadex®)</a> </li></ul>

198

Studying the Effects of Tamoxifen in People with ER+ Breast Cancer

Show Scientific Title

Neutrophil Functions in Breast Cancer

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05056857

Phase NA

199

Developing a Nervous System Exam for People With Leptomeningeal Metastasis

Show Scientific Title

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis (NANO-LM)

Purpose: To develop a nervous system (neurological) exam for people with leptomeningeal metastases.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal metastasis or leptomeningeal disease). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nervous system exam</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The nervous system exam being developed in this study may be used in clinical trials and routine care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06417710' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

199

Developing a Nervous System Exam for People With Leptomeningeal Metastasis

Show Scientific Title

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis (NANO-LM)

Nearest Location from 94107:
1643 miles
MD Anderson Cancer Center
Houston, TX

Visits:
1 visit

ClinicalTrials.gov: NCT06417710

Phase NA

200

AZD8421 CDK2 Inhibitor with Hormone Therapy and CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AZD8421, an experimental CDK2 inhibitor, with camizestrant, an experimental SERD, and a CDK4/6 inhibitor.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received a CDK4/6 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD8421, by mouth</li> <li class="seamTextUnorderedListItem">Camizestrant, by mouth</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), ribociclib (Kisqali®) and/or palbociclib (Ibrance®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD8421 is an experimental type of targeted therapy called a CDK2 inhibitor. CDK2 inhibitors may block the enzyme CDK2 that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Camizestrant is an experimental hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), ribociclib (Kisqali®) and palbociclib (Ibrance®) are a type of targeted therapy called CDK4/6 inhibitors. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06188520' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazeneca.com/our-therapy-areas/pipeline.html' target='_blank'>AstraZeneca: AZD8421 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aacr.org/about-the-aacr/newsroom/news-releases/camizestrant-may-be-superior-to-fulvestrant-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer/' target='_blank'>American Association for Cancer Research: Camizestrant</a> </li></ul>

200

AZD8421 CDK2 Inhibitor with Hormone Therapy and CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

Nearest Location from 94107:
1643 miles
Research Site
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06188520

Phase I-II

201

Cyclophosphamide, Axatilimab, and Retifanlimab for Advanced Triple Negative or Inflammatory Breast Cancer

Show Scientific Title

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cyclophosphamide (Cytoxan®) chemotherapy, axatilimab (Niktimvo®) targeted therapy, and retifanlimab (Zynyz®) immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or hormone receptor positive (ER+ and PR+) inflammatory breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by mouth</li> <li class="seamTextUnorderedListItem">Axatilimab (Niktimvo®), by IV</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Axatilimab (Niktimvo®) is used to treat rejection of transplanted cells and may have anti-cancer activity.</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®) is a PD-1 inhibitor. PD-1 inhibitors are a type of immunotherapy also called a checkpoint inhibitor. They work by getting the immune system to go after cancer cells by blocking the PD-1 protein.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06959537' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.niktimvo.com/niktimvo-patient-information' target='_blank'>Incyte: Axatilimab (Niktimvo®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zynyz.com/scac/?utm_source=google&utm_medium=psearch&utm_campaign=zyn-dtc-br-zynyz-phrase&utm_id=psearchrt9e&gad_source=1&gad_campaignid=22526170965&gbraid=0AAAAABZyZLqUc0VaUPDduSUyY43CjUMIU&gclid=Cj0KCQiAxJXJBhD_ARIsAH_JGjjIq6PGMymOkH7Wnw_GnH' target='_blank'>Incyte: Retifanlimab (Zynyz®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immunotherapy/' target='_blank'>Metastatic Trial Talk: Immunotherapy</a> </li></ul>

201

Cyclophosphamide, Axatilimab, and Retifanlimab for Advanced Triple Negative or Inflammatory Breast Cancer

Show Scientific Title

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Nearest Location from 94107:
1643 miles
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable, 1 year

ClinicalTrials.gov: NCT06959537

Phase I

202

Targeted Therapy and Chemotherapy for Advanced Triple Negative or Metaplastic HER2 Negative Breast Cancer

Show Scientific Title

Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of alpelisib (Piqray®) PI3K inhibitor, L-NMMA experimental iNOS inhibitor, and nab-paclitaxel (Abraxane®) chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or metaplastic HER2 negative (HER2-) breast cancer. You must not have received treatment with everolimus (Afinitor®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> <li class="seamTextUnorderedListItem">L-NMMA, by IV, 2 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Aspirin, by mouth, daily</li> <li class="seamTextUnorderedListItem">Amlodipine, by mouth, daily, 1 week on, 2 weeks off</li> <li class="seamTextUnorderedListItem">Metformin, daily</li> <li class="seamTextUnorderedListItem">Cetirizine, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">L-NMMA is an experimental targeted therapy called a iNOS inhibitor which may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Aspirin and amlodipine help prevent deep venous thrombosis (blood clots) and hypertension (high blood pressure).</li> <li class="seamTextUnorderedListItem">Metformin helps prevent hyperglycemia (high blood sugar).</li> <li class="seamTextUnorderedListItem">Cetirizine is an anti-histamine that helps prevents allergic reactions to alpelisib (Piqray®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05660083' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/abraxane' target='_blank'>Breastcancer.org: Nab-paclitaxel (Abraxane®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0527-x' target='_blank'>Journal Article: iNOS Inhibition for Triple Negative Breast Cancer</a> </li></ul>

202

Targeted Therapy and Chemotherapy for Advanced Triple Negative or Metaplastic HER2 Negative Breast Cancer

Show Scientific Title

Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)

Nearest Location from 94107:
1643 miles
Houston Methodist Neal Cancer Center
Houston, TX

Visits:
2 visits every 3 weeks

ClinicalTrials.gov: NCT05660083

Phase II

203

Anti-HCMV Therapy for Metastatic Breast Cancer with Brain Metastases and CMV Infection

Show Scientific Title

Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of anti-HCMV therapy (Valganciclovir) and to study if it can improve cognition (ability to think) and quality of life.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have a CMV infection. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Valganciclovir, by mouth, higher dose for 2 weeks, lower dose for 4 additional weeks</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, weekly for 6 weeks</li> <li class="seamTextUnorderedListItem">Brain MRI, every 2 months for up to 2 years</li> <li class="seamTextUnorderedListItem">Cognitive testing, every 2 months for up to 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Anti-HCMV therapy is a treatment that fights human cytomegalovirus (HCMV), a common virus, to stop it from growing and causing problems</li> <li class="seamTextUnorderedListItem">Cytomegalovirus (CMV) infection can reactivate in people with brain tumors, and researchers are studying whether it may influence tumor growth or treatment response.</li> <li class="seamTextUnorderedListItem">Valganciclovir is an antiviral medicine that stops the growth of cytomegalovirus (CMV) </li> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that have spread to the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07383649' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

203

Anti-HCMV Therapy for Metastatic Breast Cancer with Brain Metastases and CMV Infection

Show Scientific Title

Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)

Nearest Location from 94107:
1643 miles
Houston Methodist Neal Cancer Center
Houston, TX

Visits:
Weekly for 6 weeks, then every 2 months for up to 2 years

ClinicalTrials.gov: NCT07383649

Phase II

204

Fulvestrant With Abemaciclib for ER+ or ER Low, HER2- Metastatic Breast Cancer

Show Scientific Title

Multicenter Randomized Phase II Trial of Fulvestrant Plus Abemaciclib With or Without Run-in of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer After Failure of a CDK4/6 Inhibitor In Combination With an Aromatase Inhibitor

Purpose: To determine if stopping treatment with abemaciclib (Verzenio®) for 1 month (called a drug holiday) improves the effects (good and bad) and anti-cancer activity of abemaciclib (Verzenio®) with fulvestrant (Faslodex®).

Who is this for?: Women with metastatic (stage IV) ER positive (ER+) or ER Low (1%-10% ER), HER2 negative (HER2-) breast cancer that has progressed on a CDK4/6 inhibitor in combination with an aromatase inhibitor immediately before enrolling in this study. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then once a month </li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, once a month</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). It is approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">SERDs work by binding to and breaking down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">A drug holiday is a planned period of time that you decide with your doctor to stop taking a medication. In some cases, a drug holiday can allow a medication to become effective again.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women will also be given a drug that will put you in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05305924' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verywellhealth.com/drug-holiday-definition-risks-and-benefits-2248870' target='_blank'>Verywell Health: Drug Holiday</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/pathology-report/hormone-receptor-status' target='_blank'>Breastcancer.org: Hormone Receptor Status</a> </li></ul>

204

Fulvestrant With Abemaciclib for ER+ or ER Low, HER2- Metastatic Breast Cancer

Show Scientific Title

Multicenter Randomized Phase II Trial of Fulvestrant Plus Abemaciclib With or Without Run-in of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer After Failure of a CDK4/6 Inhibitor In Combination With an Aromatase Inhibitor

Nearest Location from 94107:
1643 miles
Houston Methodist Cancer Center
Houston, TX

Visits:
2 visits the first month, then 1 visit a month, ongoing

ClinicalTrials.gov: NCT05305924

Phase II

205

Laser Interstitial Thermal Therapy (LITT) or Surgery and Radiation for Recurrent Brain Metastases

Show Scientific Title

Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of stereotactic radiosurgery (SRS) following surgery or LITT.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and has recurred (come back). You must have received prior stereotactic radiosurgery (SRS). View full eligibility criteria

What's involved?

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) (SRS) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Laser interstitial thermal therapy (LITT) is a technique that is done by implanting a laser catheter into the tumor and heating it to temperatures high enough to kill the tumor.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07053033' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/laser-interstitial-thermal-therapy.html' target='_blank'>MD Anderson: Laser Interstitial Thermal Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/stereotactic-radiosurgery.html' target='_blank'>MD Anderson: Stereotactic Radiosurgery</a> </li></ul>

205

Laser Interstitial Thermal Therapy (LITT) or Surgery and Radiation for Recurrent Brain Metastases

Show Scientific Title

Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

Nearest Location from 94107:
1643 miles
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Visits:
n/a

ClinicalTrials.gov: NCT07053033

Phase II

206

Targeted Therapy Avapritinib for Advanced Breast Cancer with a CKIT or PDGFRA Mutation

Show Scientific Title

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

Purpose: To study the safety, side effects and anti-cancer activity of the targeted therapy avapritinib (Ayvakit).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumor tests positive for a CKIT or a PDGFRA mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Avapritinib (Ayvakit), by mouth, daily, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Avapritinib (Ayvakit) is an experimental type of targeted therapy called a tyrosine kinase inhibitor. It works by targeting certain CKIT and PDGFRA kinases.</li> <li class="seamTextUnorderedListItem">Avapritinib (Ayvakit) is approved for use in some people with advanced GIST cancer, but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancers that test positive for CKIT or PDGFRA.</li> <li class="seamTextUnorderedListItem">Targets or mutations: CKIT, PDGFRA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04771520' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/avapritinib' target='_blank'>NCI A to Z List of Cancer Drugs: Avapritinib (Ayvakit)</a> </li><li class='seamTextUnorderedListItem'><a href='https://ayvakit.com' target='_blank'>Blueprint Medicines Drug Information Page: Ayvakit (Avapritinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/january-25-2020/fda-approves-avapritinib-for-pdgfra-mutated-gastrointestinal-stromal-tumor/' target='_blank'>The ASCO Post: FDA Approves Avapritinib for the Treatment of PDGFRA-Mutated Gastrointestinal Stromal Tumor</a> </li></ul>

206

Targeted Therapy Avapritinib for Advanced Breast Cancer with a CKIT or PDGFRA Mutation

Show Scientific Title

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04771520

Phase II

207

PARP Inhibitor Olaparib with Cediranib or Ceralasertib for Women with Advanced, HER2-, Inherited BRCA+ Breast Cancer

Show Scientific Title

Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer

Purpose: To study the anti-cancer activity and safety of combining the PARP inhibitor olaparib (Lynparza®) with an experimental targeted therapy--either cediranib or ceralasertib.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV), HER2 negative (HER2-), inherited BRCA positive (BRCA1/2+) breast cancer. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Cediranib, by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth, daily (one week on, three weeks off)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. It stops the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP) and is already approved for use in women with metastatic, HER2-negative, inherited BRCA1/2 positive breast cancer. </li> <li class="seamTextUnorderedListItem">Cediranib is a tyrosine kinase inhibitor, a type of targeted therapy, that is designed to block the VEGF (vascular endothelial growth factor receptor) protein. </li> <li class="seamTextUnorderedListItem">Tumors use VEGF to grow new blood vessels. </li> <li class="seamTextUnorderedListItem">Research suggests VEGF inhibitors may slow or stop cancer cell growth. Giving cediranib with olaparib may also make the olaparib more effective. </li> <li class="seamTextUnorderedListItem">Ceralasertib is a new type of targeted therapy called an ATR inhibitor. It disrupts a cancer cell's ability to repair its own DNA, which can cause the cancer cells to die.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04090567' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/lynparza' target='_blank'>Breastcancer.org: Lynparza</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Cediranib' target='_blank'>Wikipedia: Cediranib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-azd6738' target='_blank'>NCI Drug Dictionary: Ceralasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nejm.org/doi/full/10.1056/nejmoa1706450' target='_blank'>Journal Article: Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/lynparza-brca-treatment/' target='_blank'>Metastatic Trial Talk: Treating BRCA1/2 Metastatic Breast Cancer</a> </li></ul>

207

PARP Inhibitor Olaparib with Cediranib or Ceralasertib for Women with Advanced, HER2-, Inherited BRCA+ Breast Cancer

Show Scientific Title

Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04090567

Phase II

208

PET/CT Scan for Detecting Metastasis in Lobular Breast Cancer

Show Scientific Title

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Purpose: To determine whether PET/CT scans with piflufolastat F18 (PYLARIFY®) can be used to detect metastasis of breast cancer.

Who is this for?: People with metastatic (stage IV) lobular breast cancer or stage I, stage II, or stage III lobular breast cancer that is suspected to have spread. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piflufolastat F18 (PYLARIFY®), by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piflufolastat F18 (PYLARIFY®) is a tracer that is used to detect metastasis in people with prostate cancer. This trial will determine if it can also be used for breast cancer.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05394259' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/piflufolastat-f-18-intravenous-route/description/drg-20516701' target='_blank'>Mayo Clinic: Piflufolastat F18 (PYLARIFY®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li></ul>

208

PET/CT Scan for Detecting Metastasis in Lobular Breast Cancer

Show Scientific Title

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Nearest Location from 94107:
1643 miles
MD Anderson Cancer Center
Houston, TX

Visits:
1 visit

ClinicalTrials.gov: NCT05394259

Phase I

209

Virtual Health Coaching for People with Stage 0-IV Breast Cancer

Show Scientific Title

Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors

Purpose: To study the use of virtual health coaching to improve well-being, including management of other health conditions, mental and social wellness, and healthy lifestyle behaviors.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer, and people without a history of breast cancer. If you have stage 0-III breast cancer, you must have completed treatment within the last year. If you have metastatic (stage IV) breast cancer, you must have been diagnosed with metastatic disease within the past year. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Immediately Start Coaching <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual health coaching, up to 4 times weekly, during first 6 months</li> <li class="seamTextUnorderedListItem">Provide stool samples, 2 times within 6 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires during second 6 months</li> <li class="seamTextUnorderedListItem">Wear a FitBit, 1 year</li> </ul> Group 2: Delayed Start Coaching <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires during first 6 months</li> <li class="seamTextUnorderedListItem">Provide stool samples, 2 times within 6 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual health coaching, up to 4 times weekly, during second 6 months</li> <li class="seamTextUnorderedListItem">Wear a FitBit, 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This program aims to support people's ability to manage their symptoms and their general wellness (including physical, mental, and social well-being, as well as following healthcare recommendations).</li> <li class="seamTextUnorderedListItem">Coaching consists of weekly calls and information about exercise, physical health, emotional health, and financial health.</li> <li class="seamTextUnorderedListItem">This study is also studying the relationship between symptoms and gut health and if coaching improves gut health.</li> <li class="seamTextUnorderedListItem">People that live in your household who do not have cancer will also be eligible to participate in this study.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05349227' target='_blank'>ClinicalTrials.gov</a> </li></ul>

209

Virtual Health Coaching for People with Stage 0-IV Breast Cancer

Show Scientific Title

Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors

Nearest Location from 94107:
1643 miles
UT Health Houston
Houston, TX

Visits:
At least 2 visits within 1 year

ClinicalTrials.gov: NCT05349227

Phase NA

210

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Show Scientific Title

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT

Purpose: To study the safety and effectiveness of using a PET/CT scan with the experimental tracer F-18.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or DCIS. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">F-18 tracer, by IV, then a PET/CT scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this imaging trial is called fluorine F 18 fluorthanatrace (F-18)--it binds to PARP expressing tumor cells (PARP is a protein over expressed in certain cancers). </li> <li class="seamTextUnorderedListItem">You do not need to have an inherited BRCA1/2 mutation to enroll in this trial but researchers are studying whether F-18 works better in inherited BRCA1/2+ cancers. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of solid tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03604315' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/10123-pet-scan' target='_blank'>Cleveland Clinic: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluorthanatrace' target='_blank'>NCI Drug Dictionary: Fluorine F 18 Fluorthanatrace</a> </li></ul>

210

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Show Scientific Title

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
1 to 2 visits

ClinicalTrials.gov: NCT03604315

Phase I

211

Data Collection to Study Proton Therapy Side Effects

Show Scientific Title

Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults

Purpose: To help researchers predict the risk of side effects of proton therapy and understand the long-term benefit of proton therapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive proton therapy at University of Texas M. D. Anderson Cancer Center. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Review of side effects, weekly during proton therapy, then 1-4 visits every year</li> <li class="seamTextUnorderedListItem">Questionnaires, weekly during proton therapy, then every 2 weeks for 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will be monitored for safety and side effects during the visits.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00991094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/radiation-therapy/proton-therapy' target='_blank'>American Society for Clinical Oncology: Proton Therapy</a> </li></ul>

211

Data Collection to Study Proton Therapy Side Effects

Show Scientific Title

Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
1 visit every week until end of proton therapy, then 1-4 visits every year

ClinicalTrials.gov: NCT00991094

Phase NA

212

BTX-A51 Targeted Therapy for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BTX-A51, an experimental multi-kinase inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BTX-A51, by mouth, 5 days on, 2 days off</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BTX-A51 is an experimental targeted therapy called a multi-kinase inhibitor that blocks CK1α and CDK7/9.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04872166' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.edgewoodoncology.com/science' target='_blank'>Edgewood Oncology: BTX-A51 Drug Information Page</a> </li></ul>

212

BTX-A51 Targeted Therapy for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer

Nearest Location from 94107:
1643 miles
The University of Texas MD Anderson Cancer Center
Houston, TX

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04872166

Phase I

213

Stereotactic Radiosurgery (SRS) Before or After Surgery For Brain Metastases

Show Scientific Title

A Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases

Purpose: To compare how well stereotactic radiosurgery (SRS) works before or after surgery in cancer that has spread to the brain.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have not received prior treatment (surgery or radiation) for brain mets. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS), once, followed by surgery within 2 weeks</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery followed by Stereotactic Radiosurgery (SRS), once, within 1 month</li> </ul> Participants may undergo additional SRS if disease returns after treatment.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS) is the delivery of focused, high-dose radiation given in a single session to the tumors, with a minimal dose given to uninvolved areas of the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03741673' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0552.html' target='_blank'>MD Anderson Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/local/brain/radiosurgery' target='_blank'>Breastcancer.org: Stereotactic Radiosurgery for Brain Metastasis</a> </li></ul>

213

Stereotactic Radiosurgery (SRS) Before or After Surgery For Brain Metastases

Show Scientific Title

A Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
1 visit 2 weeks before or 1 month after surgery

ClinicalTrials.gov: NCT03741673

Phase III

214

Brain Surgery and Electrocorticography for Brain Metastasis

Show Scientific Title

Pilot Investigation of Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Operative Functional Outcomes in Patients With Brain Tumors

Purpose: To identify which areas of the brain are active during brain surgery and to improve the safety of brain surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) that are planning to receive brain surgery at the University of Texas M. D. Anderson Cancer Center. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> <li class="seamTextUnorderedListItem">Electrocorticography</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">During brain surgery, you will complete various tasks to allow doctors to identify which areas of the brain are active during brain surgery, which is called electrocorticography.</li> <li class="seamTextUnorderedListItem">Tasks include speaking and moving parts of your body.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02754544' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

214

Brain Surgery and Electrocorticography for Brain Metastasis

Show Scientific Title

Pilot Investigation of Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Operative Functional Outcomes in Patients With Brain Tumors

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
May require hospitalization

ClinicalTrials.gov: NCT02754544

Phase NA

215

Fecal Microbiota Transplantation for Immunotherapy-Related Diarrhea or Colitis in People with Stage I-IV Breast Cancer

Show Scientific Title

Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients

Purpose: To study the ability of a fecal microbiota transplantation to improve immune checkpoint inhibitor-related diarrhea and colitis.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who developed diarrhea and/or colitis after receiving treatment with dostarlimab (Jemperli®) or pembrolizumab (Keytruda®) immune checkpoint inhibitors. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Loperamide, by mouth, 1 time</li> </ul> followed 4 hours later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fecal microbiota transplantation during colonoscopy, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A fecal microbiota transplantation consists of taking healthy bacteria (microbiota or microbiome) from the feces or stool of a healthy donor and transferring them to the colon of the recipient during a colonoscopy.</li> <li class="seamTextUnorderedListItem">A colonoscopy is a procedure in which a flexible camera is inserted through the anus to examine the colon/intestines.</li> <li class="seamTextUnorderedListItem">Loperamide is a drug used to treat diarrhea.</li> <li class="seamTextUnorderedListItem">Colitis is inflammation of the colon/intestines.</li> <li class="seamTextUnorderedListItem">Your body is home to many bacteria, viruses, and fungi, which are collectively called the microbiome.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04038619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0663.html' target='_blank'>MD Anderson Cancer Center: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/fecal-transplant' target='_blank'>Johns Hopkins Medicine: Fecal Microbiota Transplantation</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a682280.html' target='_blank'>MedlinePlus: Loperamide</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy' target='_blank'>Breastcancer.org: Immune Checkpoint Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li></ul>

215

Fecal Microbiota Transplantation for Immunotherapy-Related Diarrhea or Colitis in People with Stage I-IV Breast Cancer

Show Scientific Title

Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Visits:
5 visits within 3 months

ClinicalTrials.gov: NCT04038619

Phase I

216

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- Lobular Breast Cancer

Show Scientific Title

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer

Purpose: To identify possible biomarkers of response to hormone therapy for advanced lobular breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2-) lobular breast cancer (LBC) who are planning to receive hormone therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scans with 18F-FFNP, by IV, 2 times, at baseline and at 1 month</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times, at baseline and at 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person, including in a person’s tumor, that tell doctors something about a person’s health condition.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this study is 18F-FFNP.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy. MRI scans study the blood vessels in the tumor. PET/CT scans study if the tumor cells are growing.</li> <li class="seamTextUnorderedListItem">The blood samples will be used to conduct DNA and circulating tumor cell (CTC) testing.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06067503' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment' target='_blank'>National Cancer Institute: Biomarker Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/pet-scans' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/ct-scan' target='_blank'>Breastcancer.org: CT Scans</a> </li></ul>

216

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- Lobular Breast Cancer

Show Scientific Title

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer

Nearest Location from 94107:
1678 miles
UW Carbone Cancer Center
Madison, WI

Visits:
2 visits within 1 month

ClinicalTrials.gov: NCT06067503

Phase II

217

Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation

Show Scientific Title

A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations

Purpose: To study if FES-PET/CT scans can help find a personalized dose of tamoxifen (Nolvadex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV), estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that tests positive for a ESR1 mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">FES PET/CT scan, every 3 to 4 weeks, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is an anti-estrogen therapy used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">ESR1 mutations in breast cancer may affect how well tamoxifen works against tumor cells. </li> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body during a PET scan. The imaging trial will use the tracer fluoroestradiol (FES)--it finds estrogen receptors in breast tumors. </li> <li class="seamTextUnorderedListItem">The FES tracer may also show how tamoxifen is affecting your tumors. Researchers may use this information to increase your dose of tamoxifen.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/hormonal-therapy-metastatic-breast-cancer' target='_blank'>ASCO Cancer.net: Hormonal Therapy for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/more-effective-therapies-needed-for-patients-with-esr1mutated-breast-cancer' target='_blank'>Targeted Oncology: More Effective Therapies Needed For Patients With ESR1-Mutated Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.karger.com/Article/FullText/481428' target='_blank'>Journal Article: Are We Ready to Use ESR1 Mutations in Clinical Practice</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ijcem.com/files/ijcem0076055.pdf' target='_blank'>Journal Article: The Role of PET Imaging Probes for Early Monitoring the Response to Tamoxifen</a> </li></ul>

217

Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation

Show Scientific Title

A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations

Nearest Location from 94107:
1678 miles
University of Wisconsin Carbone Cancer Center
Madison, WI

Visits:
1 visit every 3 to 4 weeks, ongoing

ClinicalTrials.gov: NCT04174352

Phase I

218

Improving Communication and End-of-Life Care for People With Metastatic Breast Cancer Near the End of Life

Show Scientific Title

Randomized Trial of a Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

Purpose: To study a palliative care intervention designed to improve communication with the care team and the quality of end-of-life care.

Who is this for?: People with metastatic (stage IV) breast cancer who are at risk of dying within 1 year. You must not have received an outpatient palliative care visit within the last 6 months or be receiving hospice care. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TARGET-PC, monthly for 5 months</li> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People with MBC who are nearing the end of their life often have distressing symptoms and may be in the hospital.</li> <li class="seamTextUnorderedListItem">Sometimes, communication with care teams about their wishes is poor. Patients may not receive palliative or hospice services.</li> <li class="seamTextUnorderedListItem">The program in this study is called TARGET-PC. It focuses on coping with advanced cancer, understanding the illness, treatment decision-making, and end-of-life care planning. TARGET-PC includes 5 monthly visits from a palliative care specialist.</li> <li class="seamTextUnorderedListItem">For usual care, doctors will receive an electronic message to encourage them to discuss their patients' health care preferences.</li> <li class="seamTextUnorderedListItem">This study is also enrolling caregivers.</li> <li class="seamTextUnorderedListItem">Participants will be followed for up to 5 years.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06795529' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/palliative-care-2/' target='_blank'>Metastatic Trial Talk: Palliative Care</a> </li></ul>

218

Improving Communication and End-of-Life Care for People With Metastatic Breast Cancer Near the End of Life

Show Scientific Title

Randomized Trial of a Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

Nearest Location from 94107:
1711 miles
Duke University
Durham, NC

Visits:
Up to 5 visits within 5 months

ClinicalTrials.gov: NCT06795529

Phase NA

219

Cryoablation for Breast Cancer

Show Scientific Title

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cryoablation.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer, or people with stage I, stage II, or stage III breast cancer who refuse or are unable to receive surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation, 1 time</li> <li class="seamTextUnorderedListItem">Imaging scans, 4 times in 3 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation is a procedure in which an extremely cold liquid or device is used to freeze and destroy cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05972343' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cryoablation' target='_blank'>National Cancer Institute: Cryoablation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/cryotherapy' target='_blank'>Breastcancer.org: Cryotherapy</a> </li></ul>

219

Cryoablation for Breast Cancer

Show Scientific Title

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry

Nearest Location from 94107:
1739 miles
Washington University School of Medicine
St Louis, MO

Visits:
At least 5 visits within 3 years

ClinicalTrials.gov: NCT05972343

Phase NA

220

Surgery to Improve Lymphedema for People with Stage I-IV Breast Cancer

Show Scientific Title

The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial

Purpose: To study the ability of lymphatic surgery to improve quality of life compared to standard of care treatment.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are experiencing lymphedema for at least 3 months. You must have received lymphedema treatment for at least 3 months. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphatic surgery, 1-2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conservative complex physical decongestion therapy</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that develops as a side effect of breast cancer treatments like surgery and radiation therapy.</li> <li class="seamTextUnorderedListItem">Standard of care treatment for lymphedema is called conservative complex physical decongestion therapy.</li> <li class="seamTextUnorderedListItem">This includes manual massage to increase lymph drainage, local compression with bandages and garments, physical exercise, and careful skin care. However, these treatments are not always successful and only address symptoms.</li> <li class="seamTextUnorderedListItem">Lymphatic surgery may be able to address the cause of lymphedema to drain and restore the flow of lymph fluid.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05890677' target='_blank'>ClinicalTrials.gov</a> </li></ul>

220

Surgery to Improve Lymphedema for People with Stage I-IV Breast Cancer

Show Scientific Title

The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial

Nearest Location from 94107:
1739 miles
Washington University School of Medicine in St. Louis
St Louis, MO

Visits:
Coincides with surgery or routine care

ClinicalTrials.gov: NCT05890677

Phase NA

221

DiviTum Blood Test to Determine Additional Testing for People with Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study

Purpose: To study whether the DiviTum® blood test affects your doctor's decision to conduct additional tumor tests or imaging.

Who is this for?: People with metastatic (stage IV) hormone positive (HR+), HER2 negative (HER2-) breast cancer receiving or planning to receive their first line of therapy for metastatic disease with hormone therapy and a CDK 4/6 inhibitor at Washington University School of Medicine Siteman Cancer Center. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, every 2-4 weeks for 6 months, then every 3 months for 2.5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The DiviTum® TKa test measures TK1 activity in your blood, which may indicate the rate your cancer is growing and the need for additional tests.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women and men will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04968964' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://biovica.com/divitum/' target='_blank'>Biovica: DiviTum® Test</a> </li></ul>

221

DiviTum Blood Test to Determine Additional Testing for People with Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study

Nearest Location from 94107:
1739 miles
Washington University School of Medicine
St Louis, MO

Visits:
9 visits within 6 months, then every 3 months for 2.5 years

ClinicalTrials.gov: NCT04968964

Phase NA

222

Biomarker Test to Change or Continue Treatment for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Purpose: To use the DiviTum® TKa blood test to determine if people with advanced HR+, HER2- breast cancer should continue or switch treatments.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have not yet received treatment for advanced disease. You must be planning to receive hormone therapy with a CDK4/6 inhibitor. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups depending on results of the DiviTum® TKa blood tests: Group 1: Suppressed (Low) TKa Levels <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum® TKa blood test, 4 times within 4 months</li> <li class="seamTextUnorderedListItem">Continue on endocrine therapy and CDK4/6 inhibitor (i.e., Ribociclib)</li> <li class="seamTextUnorderedListItem">Imaging scans</li> </ul> Group 2: Unsuppressed (Not Low) TKa Levels <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum® TKa blood test, 4 times within 4 months</li> <li class="seamTextUnorderedListItem">Switch treatment</li> <li class="seamTextUnorderedListItem">Imaging scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum® TKa blood test is a blood test that measures thymidine kinase activity (TKa) which may predict how well tumors respond to treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05977036' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://biovica.com/divitum/' target='_blank'>Biovica: DiviTum® Test</a> </li></ul>

222

Biomarker Test to Change or Continue Treatment for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Nearest Location from 94107:
1739 miles
Washington University School of Medicine
St Louis, MO

Visits:
At least 4 visits within 4 months

ClinicalTrials.gov: NCT05977036

Phase NA

223

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Show Scientific Title

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT

Purpose: To evaluate prostate specific membrane antigen (PSMA) expression in breast cancer to determine people most likely to benefit from anti-androgen therapies.

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-), androgen receptor positive (AR+) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-DCFPyL</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTC) test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prostate specific membrane antigen (PSMA) expression may correlate with resistance to anti-androgen therapies, which has been documented in prostate cancer.</li> <li class="seamTextUnorderedListItem">Evaluating PSMA expression may be used to select people most likely to benefit from anti-androgen therapies, such as bicalutamide (Casodex®), in future clinical trials.</li> <li class="seamTextUnorderedListItem">18F-DCFPyL is a tracer that is used to visualize PSMA expression during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are breast cancer cells that leave the tumor and move through the bloodstream.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PSMA, AR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04573231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/psma-new-target-prostate-cancer-treatment' target='_blank'>Memorial Sloan Kettering Cancer Center: PSMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/#:~:text=A%20circulating%20tumor%20cell%20(CTC,test%20for%20metastatic%20breast%20cancer.' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li></ul>

223

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Show Scientific Title

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT

Nearest Location from 94107:
1761 miles
University of Wisconsin School of Medicine and Public Health
Madison, WI

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04573231

Phase II

224

PET/MRI for Metastatic Breast Cancer With Brain Metastases

Show Scientific Title

Use of 18F-Fluciclovine PET for Discerning Tumor From Treatment Change in Patients With Brain Metastases Undergoing Immunotherapy

Purpose: To study whether newer types of imaging scans can find cancer more accurately than current imaging methods.

Who is this for?: People with metastatic (stage IV) breast cancer with brain metastasis. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/MRI scan, 1 time</li> <li class="seamTextUnorderedListItem">Separate MRI scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain.</li> <li class="seamTextUnorderedListItem">This study is looking at two types of scans, PET and MRI, to see if they can find cancer more accurately than the imaging tests that are usually used today.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A PET/MRI scan gives detailed pictures of the brain (MRI) while also showing cancer cell activity (PET) at the same time. This helps doctors see where cancer may be more clearly than using either scan alone.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06159335' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/mri/' target='_blank'>Metastatic Trial Talk: Different Types of Imaging Scans: MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/imaging-2/' target='_blank'>Metastatic Trial Talk: Different Types of Imaging Scans: How, When, and Why They are Used</a> </li></ul>

224

PET/MRI for Metastatic Breast Cancer With Brain Metastases

Show Scientific Title

Use of 18F-Fluciclovine PET for Discerning Tumor From Treatment Change in Patients With Brain Metastases Undergoing Immunotherapy

Nearest Location from 94107:
1761 miles
University of Wisconsin
Madison, WI

Visits:
1 visit

ClinicalTrials.gov: NCT06159335

Phase III

225

Every Day Counts Lifestyle Program to Improve Quality of Life for Women with Metastatic Breast Cancer

Show Scientific Title

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

Purpose: To study whether the Every Day Counts lifestyle program improves the quality of life of women with metastatic breast cancer.

Who is this for?: Women with metastatic (stage IV) breast cancer that is currently stable and who live in Milwaukee, Wisconsin or Chicago, Illinois. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Every Day Counts lifestyle program, 4 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Home/work organization intervention, 4 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Every Day Counts lifestyle program</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Every Day Counts lifestyle program promotes nutritional and physical activity changes based on the American Cancer Society nutrition and physical activity guidelines.</li> <li class="seamTextUnorderedListItem">The Every Day Counts lifestyle program consists of: 1) a curriculum binder covering weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 16-weeks, with in-person or virtual supervised exercise sessions and telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to cooking classes emphasizing plant-based eating.</li> <li class="seamTextUnorderedListItem">The home/work organization intervention consists of: 1) a book with overview of home/work organization program with 16 weekly topics with an overview of each chapter, 2) virtual or weekly phone calls with a home organization coach with standard prompts, 3) text messages supporting home/work organization.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03824145' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://redcap.mcw.edu/surveys/?s=84MA4DRTTTA8FRCD' target='_blank'>Medical College of Wisconsin: Trial Information Brochure</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention/guidelines.html' target='_blank'>American Cancer Society: Guideline for Diet and Physical Activity</a> </li></ul>

225

Every Day Counts Lifestyle Program to Improve Quality of Life for Women with Metastatic Breast Cancer

Show Scientific Title

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

Nearest Location from 94107:
1832 miles
Medical College of Wisconsin
Milwaukee, WI

Visits:
3 visits in 1 year

ClinicalTrials.gov: NCT03824145

Phase NA

226

Memantine for Cognition with Whole Brain Radiation Therapy for Brain Metastasis

Show Scientific Title

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases

Purpose: To study the effects (good and bad) of memantine and whole brain radiation therapy (WBRT) on your cognition (ability to think).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) with pulsed reduced dose rate (PRDR), daily for 10 days</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive testing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li> <li class="seamTextUnorderedListItem">WBRT with pulsed reduced dose rate (PRDR) uses a slower rate of radiation to improve safety and anti-cancer activity.</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®) is a medication that treats cognition (ability to think).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05045950' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-77932-377/memantine-oral/memantine-oral/details' target='_blank'>WebMD: Memantine</a> </li></ul>

226

Memantine for Cognition with Whole Brain Radiation Therapy for Brain Metastasis

Show Scientific Title

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases

Nearest Location from 94107:
1832 miles
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, WI

Visits:
Daily for 10 days

ClinicalTrials.gov: NCT05045950

Phase II

227

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

Show Scientific Title

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Purpose: To collect information to develop a Guardant360 blood test that can measure treatment response.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) who have received 0-1 lines of therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 is a blood test that identifies genomic biomarkers and mutations to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">This trial is collecting information to develop a future version of Guardant360 that can measure treatment response.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05935384' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/tumor-marker-tests' target='_blank'>Breastcancer.org: Breast Cancer Biomarkers and Biomarker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://guardanthealth.com/products/tests-for-patients-with-advanced-cancer/' target='_blank'>Guardant Health: Guardant360 Test Information Page</a> </li></ul>

227

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

Show Scientific Title

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Nearest Location from 94107:
1849 miles
Orchard Healthcare Research Inc.
Skokie, IL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05935384

Phase NA

228

Elacestrant Compared to Elacestrant Plus a CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of elacestrant (Orserdu®) hormone therapy alone or combined with a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer with an ESR1 mutation. You must have received at least 2 types of hormone therapy, at least one of which was received in combination with a CDK4/6 inhibitor for your advanced or metastatic cancer. You must not have received elacestrant (Orserdu®). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth, daily</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitor, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">You will receive a CDK4/6 inhibitor that you have not previously received.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®). In this study, abemaciclib (Verzenio®) is received daily. Palbociclib (Ibrance®) and ribociclib (Kisqali®) are received daily, 3 weeks on, 1 week off.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06062498' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.orserdu.com/' target='_blank'>Menarini: Elacestrant (Orserdu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/hormone-therapy-resistance/' target='_blank'>Metastatic Trial Talk: Treatments to Overcome Resistance to Hormone Therapy</a> </li></ul>

228

Elacestrant Compared to Elacestrant Plus a CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

Nearest Location from 94107:
1856 miles
Northwestern University
Chicago, IL

Visits:
5 visits within 5 years

ClinicalTrials.gov: NCT06062498

Phase II

229

Comparing Two Doses of Stereotactic Radiosurgery for the Treatment of Brain Metastases

Show Scientific Title

The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins

Purpose: To study the safety, anti-cancer activity, and side effects of giving a reduced dose of stereotactic radiation to metastatic tumor sites in the brain.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). The metastases must be located in the cerebrum of the brain and be no larger than 3.0 centimeters in diameter. View full eligibility criteria

What's involved?

You will be assigned to one of two groups: Group 1 Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery using a reduced dose of radiation delivered to the tumor sites.</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"> Stereotactic radiosurgery using the standard dose of radiation delivered to tumor sites.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02747303' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info/stereotactic' target='_blank'>Stereotactic Radiosurgery</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/conditions-and-diseases/anatomy-of-the-brain' target='_blank'>Anatomy of the Brain</a> </li></ul>

229

Comparing Two Doses of Stereotactic Radiosurgery for the Treatment of Brain Metastases

Show Scientific Title

The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins

Nearest Location from 94107:
1857 miles
University of Chicago
Chicago, IL

Visits:
At least 1 visit

ClinicalTrials.gov: NCT02747303

Phase II

230

Exercise for People with Metastatic Breast Cancer

Show Scientific Title

Exercise in Metastatic Breast Cancer: EMBody

Purpose: To study if a virtual exercise program improves fitness, muscle mass, and quality of life.

Who is this for?: People with metastatic (stage IV) breast cancer that has not progressed within the last year or who have no evidence of disease (NED). You must be participating in less than 2.5 hours of exercise per week. You must not have received chemotherapy within the last year. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual exercise program, 3 times per week for 4 months</li> <li class="seamTextUnorderedListItem">Classes on creating and maintaining behavior changes</li> </ul> Group 2: Standard of Care' <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">American College of Sports Medicine handouts</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise.</li> <li class="seamTextUnorderedListItem">During sessions, you will wear a provided heart rate monitor with a training goal of moderate intensity.</li> <li class="seamTextUnorderedListItem">Each exercise session is 1 hour.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05468034' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/metastatic/treatment/exercise-tips' target='_blank'>Breastcancer.org: Exercise and MBC</a> </li></ul>

230

Exercise for People with Metastatic Breast Cancer

Show Scientific Title

Exercise in Metastatic Breast Cancer: EMBody

Nearest Location from 94107:
1946 miles
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, IN

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05468034

Phase NA

231

AND019 for Postmenopausal Women with Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AND019, an experimental hormone therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received standard treatment with at least 1 line of hormone therapy and no more than 1 line of chemotherapy for advanced/metastatic disease. You must not have received treatment with fulvestrant (Faslodex®) or any other SERD. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AND019, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AND019 is an experimental hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05187832' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/selective-estrogen-receptor-degrader-and019' target='_blank'>National Cancer Institute: AND019</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oral-serds/' target='_blank'>Metastatic Trial Talk: Update on Oral SERDs for Estrogen Receptor-Positive MBC</a> </li></ul>

231

AND019 for Postmenopausal Women with Advanced ER+, HER2- Breast Cancer

Show Scientific Title

A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer

Nearest Location from 94107:
1959 miles
Sarah Cannon Research Institute
Nashville, TN

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05187832

Phase I

232

HLD-0117 Targeted Therapy for ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study of HLD-0117 in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of HLD‑0117, an experimental targeted therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+), HER2 negative (HER2‑) breast cancer. You must have received at least one hormone (endocrine) therapy, a CDK4/6 inhibitor and up to two prior lines of therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HLD‑0117, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This drug is an oral targeted therapy designed to hold onto and kill cancer cells in a new way, even when the cancer has stopped responding to other treatments, with the goal of helping people whose tumors have developed drug resistance.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07524855' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://haldatx.com/our-science/' target='_blank'>Halda Therapeutics</a> </li></ul>

232

HLD-0117 Targeted Therapy for ER+, HER2- Breast Cancer

Show Scientific Title

A Phase 1 Study of HLD-0117 in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)

Nearest Location from 94107:
1959 miles
SCRI Oncology Partners
Nashville, TN

Visits:
At least 1 visit every month

ClinicalTrials.gov: NCT07524855

Phase I

233

MRI and PET Scans to Predict Resistance to Radiation for People with Metastatic Breast Cancer

Show Scientific Title

Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Purpose: To study whether a new type of MRI scan with PET scans can predict resistance to radiation.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive stereotactic radiation before brain surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 2 times</li> <li class="seamTextUnorderedListItem">PET scan, 2 times</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistance to radiation is a tumor coming back or growing after radiation, as seen on imaging scans.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05996432' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/22966-brain-mri' target='_blank'>Cleveland Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/pet-scans' target='_blank'>Breastcancer.org: PET Scans</a> </li></ul>

233

MRI and PET Scans to Predict Resistance to Radiation for People with Metastatic Breast Cancer

Show Scientific Title

Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Nearest Location from 94107:
1959 miles
Vanderbilt University/Ingram Cancer Center
Nashville, TN

Visits:
2 visits within up to 4 years

ClinicalTrials.gov: NCT05996432

Phase I

234

Surgery for Breast Cancer that has Spread to the Brain Without Dexamethasone

Show Scientific Title

MeDex: No Perioperative Dexamethasone in Brain Metastases

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of surgery for brain metastasis without dexamethasone before, during, or up to 3 weeks after surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). The cancer in your brain must have been recently diagnosed, and you must be planning to receive brain surgery to remove the cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove the tumor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone is a steroid used during brain surgery to prevent brain swelling. Because it is an anti-inflammatory drug, it may also reduce the effect of immunotherapies used to treat cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07044557' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

234

Surgery for Breast Cancer that has Spread to the Brain Without Dexamethasone

Show Scientific Title

MeDex: No Perioperative Dexamethasone in Brain Metastases

Nearest Location from 94107:
1984 miles
University of Louisville Hospital
Louisville, KY

Visits:
Coincides with surgery

ClinicalTrials.gov: NCT07044557

Phase NA

235

Palliative Radiation and Immunotherapy for People with Metastatic Breast Cancer

Show Scientific Title

A Phase 2 Study of Palliative Radiation in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of stereotactic radiation with pembrolizumab (Keytruda®) immunotherapy.

Who is this for?: Women with stage IV (metastatic) breast cancer who have received at least 2 lines of therapy, including 1 line of chemotherapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation, 1-5 sessions</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Palliative radiation reduces side effects of metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04990921' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncolink.org/support/hospice-and-palliative-care/palliative-radiation-treatment#:~:text=Palliative%20radiation%20is%20the%20use,doses)%20than%20traditional%20radiation%20treatment.' target='_blank'>OncoLink: Palliative Radiation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>

235

Palliative Radiation and Immunotherapy for People with Metastatic Breast Cancer

Show Scientific Title

A Phase 2 Study of Palliative Radiation in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink

Nearest Location from 94107:
1984 miles
James Graham Brown Cancer Center
Louisville, KY

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT04990921

Phase II

236

STRATAFIX Absorbable Sutures for Closure of Surgical Wounds for Surgery to Remove Brain Metastases

Show Scientific Title

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Purpose: To study the safety and effects (good and bad) of STRATAFIX sutures to close a surgical wound.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery to remove the tumor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">STRATAFIX sutures to close the surgical wound.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">STRATAFIX sutures are FDA-approved absorbable sutures for closing surgical wounds.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer and people with non-cancerous conditions.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07225101' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

236

STRATAFIX Absorbable Sutures for Closure of Surgical Wounds for Surgery to Remove Brain Metastases

Show Scientific Title

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Nearest Location from 94107:
2011 miles
University of Michigan Health Sparrow
Lansing, MI

Visits:
Coincides with surgery

ClinicalTrials.gov: NCT07225101

Phase IV

237

Comparing Radiosurgery Margins for People with Breast Cancer Brain Metastases

Show Scientific Title

UAB 2507 - Randomized Phase II Study of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

Purpose: To compare the anti-cancer activity of giving radiosurgery (radiation) with no margin vs. a 2 millimeter margin.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have at least 1 lesion that has not received stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) (targeted radiation). You are still eligible if you received prior whole brain radiation alone. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: No Margin <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiosurgery with 0 millimeter (mm) margin</li> </ul> Group 2: 2 mm Margin <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiosurgery with 2 millimeter (mm) margin</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiosurgery (also called stereotactic radiation) uses a high dose of radiation to destroy or kill a tumor.</li> <li class="seamTextUnorderedListItem">In this study, margins refer to the area around the brain tumor where radiation is given.</li> <li class="seamTextUnorderedListItem">This trial will compare giving radiation with no margin (0 millimeters) vs. a 2 millimeter margin.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06857006' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

237

Comparing Radiosurgery Margins for People with Breast Cancer Brain Metastases

Show Scientific Title

UAB 2507 - Randomized Phase II Study of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

Nearest Location from 94107:
2013 miles
University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center
Birmingham, AL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06857006

Phase NA

238

Low Dose Capecitabine Chemotherapy for People with Advanced HR+, HER2- or Triple Negative Breast Cancer

Show Scientific Title

Phase II Single Arm Trial of Low Dose Capecitabine in Patients with Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a lower dose of capecitabine (Xeloda®) chemotherapy for older or frail (weak) people with advanced breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2- or HER2 low) or triple negative (ER-, PR-, HER2- or HER2 low) breast cancer who have received at least 1 line of therapy for advanced disease. You must be frail (weak) or at least 60 years old. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low dose capecitabine (Xeloda®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In this trial, frail is defined as having a greater risk of complications and poorer outcomes because of illness, injury, or age.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">A lower dose of capecitabine (Xeloda®) may be better for frail and older people.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06105684' target='_blank'>ClinicalTrials.gov</a> </li></ul>

238

Low Dose Capecitabine Chemotherapy for People with Advanced HR+, HER2- or Triple Negative Breast Cancer

Show Scientific Title

Phase II Single Arm Trial of Low Dose Capecitabine in Patients with Advanced Breast Cancer

Nearest Location from 94107:
2013 miles
University of Alabama at Birmingham
Birmingham, AL

Visits:
At least 2 times in 3 months

ClinicalTrials.gov: NCT06105684

Phase II

239

Leuprolide or Goserelin to Reduce Estrogen for Pre- or Peri-Menopausal Women With Stage I-IV Breast Cancer

Show Scientific Title

Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS)

Purpose: To compare a low dose of leuprolide (Lupron®), a high dose of leuprolide (Lupron®), and goserelin (Zoladex®) for their ability to reduce estrogen production.

Who is this for?: Pre-menopausal or peri-menopausal women with stage I, stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to receive a gonadotropin releasing hormone (GnRH) agonist plus hormone therapy. You must have completed chemotherapy if recommended. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leuprolide (Lupron®), low dose, by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leuprolide (Lupron®), high dose, by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, monthly for 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leuprolide (Lupron®) and goserelin (Zoladex®) are given to pre-menopausal and peri-menopausal women with HR+ breast cancer. These drugs block the ability of the ovaries to make estrogen, which causes HR+ breast cancer to grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07158021' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zoladex.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=22507845007&gbraid=0AAAAA_gRoNBb5XSY7s8DD7IIxTBZtXTv6&gclid=Cj0KCQiAoZDJBhC0ARIsAERP-F-ABUsC3lGhM3VH4Nc4qtBUZY8e6bBS1dm4GjfxXphAdMMFnwMJfWgaAkRAEALw_wcB' target='_blank'>AstraZeneca: Goserelin (Zoladex®)</a> </li></ul>

239

Leuprolide or Goserelin to Reduce Estrogen for Pre- or Peri-Menopausal Women With Stage I-IV Breast Cancer

Show Scientific Title

Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS)

Nearest Location from 94107:
2054 miles
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Visits:
Monthly for 6 months

ClinicalTrials.gov: NCT07158021

Phase II

240

Virtual Platform to Track Medication Safety and Concerns for Stage 0-IV Breast Cancer

Show Scientific Title

Patient Engagement in Using the Technology for Self-Tracking Medication Safety Events

Purpose: To study the usefulness of a self-monitoring platform for tracking medication safety events and concerns.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving treatment for their cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use of the online platform to track your experiences or concerns about taking your medications, including symptoms, for 6 months</li> <li class="seamTextUnorderedListItem">Educational materials and resources, virtual, for 6 months</li> <li class="seamTextUnorderedListItem">Follow-up from a nurse practitioner, virtual, as needed over the 6 months</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patients receiving cancer treatment by mouth often have challenges with managing complex treatments, side effects, and interactions with food or other drugs at home.</li> <li class="seamTextUnorderedListItem">In this study, patients go online to track their experiences or concerns about taking their medications, including symptoms. This online platform may help people take better care of their health.</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07291414' target='_blank'>ClinicalTrials.gov</a> </li></ul>

240

Virtual Platform to Track Medication Safety and Concerns for Stage 0-IV Breast Cancer

Show Scientific Title

Patient Engagement in Using the Technology for Self-Tracking Medication Safety Events

Nearest Location from 94107:
2054 miles
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Visits:
Number of visits unavailable, up to 1 year

ClinicalTrials.gov: NCT07291414

Phase NA

241

PET/CT Scan with 18F-FETrp Tracer for Stage I-IV Breast Cancer

Show Scientific Title

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

Purpose: To study whether an experimental tracer called 18F-FETrp can distinguish between tumor and non-tumor tissue on a PET/CT scan.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FETrp, by injection, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FETrp (1-(2-(18F)fluoroethyl)-L-tryptophan) is an experimental tracer for PET imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic (body processes) information obtained from the PET scan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05556473' target='_blank'>ClinicalTrials.gov</a> </li></ul>

241

PET/CT Scan with 18F-FETrp Tracer for Stage I-IV Breast Cancer

Show Scientific Title

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

Nearest Location from 94107:
2088 miles
Karmanos Cancer Institute
Detroit, MI

Visits:
1 visit

ClinicalTrials.gov: NCT05556473

Phase I

242

Temporary Tattoo Ink to Mark the Area for Radiation for Women with Stage 0-III Breast Cancer

Show Scientific Title

A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery

Purpose: To study the safety and effects (good and bad) of Magic Ink for marking the site for radiation.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive radiation after surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magic Ink, by injection</li> <li class="seamTextUnorderedListItem">Skin assessment, 2 times</li> <li class="seamTextUnorderedListItem">Survey</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typically, tattoos are placed on the breast to mark the area for radiation. These tattoos are permanent.</li> <li class="seamTextUnorderedListItem">Magic Ink is a temporary skin marker that can only be seen with ultraviolet light.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07095114' target='_blank'>ClinicalTrials.gov</a> </li></ul>

242

Temporary Tattoo Ink to Mark the Area for Radiation for Women with Stage 0-III Breast Cancer

Show Scientific Title

A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery

Nearest Location from 94107:
2088 miles
Karmanos Cancer Institute
Detroit, MI

Visits:
3 visits within 3 months

ClinicalTrials.gov: NCT07095114

Phase NA

243

Tango Dance Lessons to Reduce Nerve Pain for People with Stage I-IV Breast Cancer

Show Scientific Title

DANCE-BASED AVENUES to ADVANCE NONPHARMACOLOGIC TREATMENT of CHEMOTHERAPY EFFECTS (DAANCE): a MULTICENTER TRIAL

Purpose: To study if tango dance lessons can reduce nerve pain caused by chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who completed treatment with paclitaxel (Taxol®) or docetaxel (Taxotere®) chemotherapy at least 3 months ago. You must have nerve pain (neuropathy). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tango dance lessons, 2 times every week for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 3 months</li> <li class="seamTextUnorderedListItem">Body function tests, 3 times in 3 months</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care, 1 month</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 3 months</li> <li class="seamTextUnorderedListItem">Body function tests, 3 times in 3 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tango dance lessons, 2 times every week for 2 months (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 80% of people with cancer who receive some chemotherapy drugs called taxanes experience neuropathy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain in your hands and feet from nerve damage as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy decreases quality of life and increases the risk of falling. Treatment options are limited.</li> <li class="seamTextUnorderedListItem">Taxanes are paclitaxel (Taxol®) and docetaxel (Taxotere®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06749210' target='_blank'>ClinicalTrials.gov</a> </li></ul>

243

Tango Dance Lessons to Reduce Nerve Pain for People with Stage I-IV Breast Cancer

Show Scientific Title

DANCE-BASED AVENUES to ADVANCE NONPHARMACOLOGIC TREATMENT of CHEMOTHERAPY EFFECTS (DAANCE): a MULTICENTER TRIAL

Nearest Location from 94107:
2105 miles
The Ohio State University
Columbus, OH

Visits:
2 visits every week for 2 months

ClinicalTrials.gov: NCT06749210

Phase II

244

HyperSight CT Imaging Scans to Improve Radiation for People with Stage I-IV Breast Cancer

Show Scientific Title

A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients

Purpose: To study if HyperSight CBCT imaging scans can improve the speed and accuracy of radiation.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who planning to receive or are receiving radiation. View full eligibility criteria

What's involved?

You will receive the following during radiation sessions: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HyperSight cone beam CT (CBCT) imaging scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">CT scans can be used to help plan radiation.</li> <li class="seamTextUnorderedListItem">HyperSight cone beam CT (CBCT) imaging scans may be faster and more accurate than standard of care CT scans.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06681233' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tanner.org/cancer-care/what-we-offer/diagnosis-and-treatment/radiation-therapy/hypersight-radiation-therapy-clearly-an-advantage-in-cancer-care' target='_blank'>Tanner Health: HyperSight Imaging</a> </li></ul>

244

HyperSight CT Imaging Scans to Improve Radiation for People with Stage I-IV Breast Cancer

Show Scientific Title

A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients

Nearest Location from 94107:
2107 miles
Stefanie Spielman Comprehensive Breast Center
Columbus, OH

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT06681233

Phase NA

245

Stereotactic Radiation, Abemaciclib, and Hormone Therapy for HR+, HER2- Breast Cancer Brain Metastases

Show Scientific Title

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Purpose: To study the anti-cancer activity and side effects of giving the CDK 4/6 inhibitor abemaciclib (Verzenio®), hormone therapy, and stereotactic radiation therapy together to treat brain metastases.

Who is this for?: People with metastatic (stage IV) hormone receptor-positive, HER2 negative (HER2-) breast cancer that has spread to the brain. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Doctor's choice of anti-estrogen therapy, ongoing</li> <li class="seamTextUnorderedListItem">Stereotactic Radiation Therapy to each brain met</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor -- it blocks two enzymes, CDK4 and CDK6, that help cancer grow. It is already approved to treat some metastatic breast cancer, but its use in this trial is experimental.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. This stops cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Anti-estrogen therapies are commonly used to treat hormone receptor-positive breast cancer. These drugs are also called endocrine or hormone therapy and include tamoxifen, aromatase inhibitors, fulvestrant, and others. </li> <li class="seamTextUnorderedListItem">The hormone therapies used in this trial are fulvestrant and aromatase inhibitors.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04923542' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/?s=brain+mets' target='_blank'>Metastatic Trial Talk: Topics for Breast Cancer Brain Mets</a> </li></ul>

245

Stereotactic Radiation, Abemaciclib, and Hormone Therapy for HR+, HER2- Breast Cancer Brain Metastases

Show Scientific Title

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04923542

Phase I-II

246

Minoxidil for Hormone Therapy-Induced Hair Loss in People with Stage I-IV Breast Cancer

Show Scientific Title

A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients

Purpose: To study the safety and ability of 2 methods of administering minoxidil to treat hair loss (alopecia) caused by hormone therapy.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving treatment with tamoxifen (Nolvadex®) or an aromatase inhibitor and are experiencing hair loss. You must not have received chemotherapy within the last 2 years. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Topical Administration <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minoxidil, by foam to scalp, daily for 1 year</li> </ul> Group 2: Oral Administration <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minoxidil, by mouth, daily for 1 year</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People receiving endocrine therapy, also called hormone therapy, commonly report hair loss or thinning. This side effect is called endocrine therapy-induced alopecia (EIA).</li> <li class="seamTextUnorderedListItem">Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early termination of hormone therapy in women with breast cancer.</li> <li class="seamTextUnorderedListItem">Minoxidil, sometimes called Rogaine®, is a drug that may promote hair growth and reduce hair loss.</li> <li class="seamTextUnorderedListItem">Oral minoxidil may work the same as topical minoxidil in treating EIA in people with breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05417308' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss' target='_blank'>Breastcancer.org: Hair Loss (Alopecia)</a> </li></ul>

246

Minoxidil for Hormone Therapy-Induced Hair Loss in People with Stage I-IV Breast Cancer

Show Scientific Title

A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05417308

Phase I

247

Studying Immune Cells in Women with Stage I-IV Breast Cancer

Show Scientific Title

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Purpose: To study immune cells involved in breast cancer.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who have not yet received surgery, or women with stage IV (metastatic) breast cancer. You must be receiving care at the Ohio State Comprehensive Cancer Center or Stefanie Spielman Comprehensive Breast Center. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor and/or lymph node samples (if removed during surgery)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Natural killer (NK) cells are immune cells that identify and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Myeloid derived suppressor cells (MDSC) are immune cells that kill NK cells, which helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this study, researchers will look for and study these types of immune cells in the blood, tumor, and/or lymph node samples.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04022616' target='_blank'>ClinicalTrials.gov</a> </li></ul>

247

Studying Immune Cells in Women with Stage I-IV Breast Cancer

Show Scientific Title

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Visits:
At least 1 visit

ClinicalTrials.gov: NCT04022616

Phase NA

248

Gemcitabine Chemotherapy and NK Cell Therapy for Metastatic HER2 Negative Breast Cancer

Show Scientific Title

Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of gemcitabine (Gemzar®) chemotherapy and NK cell therapy with or without naxitamab (Danyelza®) targeted therapy.

Who is this for?: People with stage IV (metastatic) HER2 negative (HER2-) breast cancer who have received at least 1 line of therapy for metastatic disease. View full eligibility criteria

What's involved?

You will be assigned to 1 of 4 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV, 3 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">TGFBi NK cell therapy, by IV, monthly, up to 1 year</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV, 3 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">TGFBi NK cell therapy, by IV, 2 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV, 3 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">Naxitamab (Danyelza®), by IV, 3 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">TGFBi NK cell therapy, by IV, monthly, up to 1 year</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV, 3 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">Naxitamab (Danyelza®), by IV, 3 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">TGFBi NK cell therapy, by IV, 2 times every month, up to 1 year</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®) is a chemotherapy drug that blocks cancer cells from making DNA which may kill cancer cells.</li> <li class="seamTextUnorderedListItem">Naxitamab (Danyelza®) is a type of targeted therapy called a GD2 inhibitor. GD2 inhibitors help your immune system attack tumor cells.</li> <li class="seamTextUnorderedListItem">Naxitamab (Danyelza®) is approved to treat people with other types of cancer. Its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">TGFBi NK cell therapy is an experimental immunotherapy. NK cells are part of your natural immune system and can identify cancer cells and help your immune system kill cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06026657' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/gemzar' target='_blank'>Breastcancer.org: Gemcitabine (Gemzar®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a621005.html#:~:text=Naxitamab%2Dgqgk%20injection%20is%20used,have%20responded%20to%20other%20treatments.' target='_blank'>Medline Plus: Naxitamab (Danyelza®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/body/24898-natural-killer-cells' target='_blank'>Cleveland Clinic: NK Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapy-2-2/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies: A Type of Immunotherapy for MBC</a> </li></ul>

248

Gemcitabine Chemotherapy and NK Cell Therapy for Metastatic HER2 Negative Breast Cancer

Show Scientific Title

Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Visits:
May require hospitalization; 4-7 visits every month

ClinicalTrials.gov: NCT06026657

Phase I-II

249

MIND Diet and Nutrition Counseling to Improve Brain Function for People with Stage II-IV HR+ Breast Cancer

Show Scientific Title

Protecting the Brain From Toxic Side Effects of Chemotherapy: a Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

Purpose: To study the impact of the Neurodegenerative Delay (MIND) diet on your cognition (ability to think).

Who is this for?: Postmenopausal women 45 to 75 years old with stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+) breast cancer who are planning to begin treatment within 1 month. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nutrition counseling about the MIND diet, 8 in-person sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General health (non-diet) counseling, 8 in-person sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer treatment can lead to cognition (ability to think) problems and low quality of life.</li> <li class="seamTextUnorderedListItem">The Neurodegenerative Delay (MIND) diet is high in anti-inflammatory nutrients (omega-3, carotenoids, B vitamins, etc.) and limits foods that are not healthy for the brain (butter, cheese, red meat, fried foods, sugar, etc.).</li> <li class="seamTextUnorderedListItem">The MIND diet may help improve brain function during cancer treatment.</li> <li class="seamTextUnorderedListItem">Cognition is your ability to think.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05984888' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.osu.edu/wellness/exercise-and-nutrition/the-mind-diet' target='_blank'>Ohio State University: The MIND Diet and Brain Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21032-chemo-brain' target='_blank'>Cleveland Clinic: Chemotherapy and Brain Function Problems</a> </li></ul>

249

MIND Diet and Nutrition Counseling to Improve Brain Function for People with Stage II-IV HR+ Breast Cancer

Show Scientific Title

Protecting the Brain From Toxic Side Effects of Chemotherapy: a Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Visits:
8 visits within 9 months

ClinicalTrials.gov: NCT05984888

Phase NA

250

Interview and Survey About a Support Program for People With Advanced Breast Cancer

Show Scientific Title

Living Well With Advanced Breast Cancer

Purpose: To study the use of supportive care to better understand what has helped people, what has been hard, and what kind of help they still need.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer and their caregivers. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Survey</li> <li class="seamTextUnorderedListItem">Interview</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Living Well with Advanced Breast Cancer is a program at Ohio State that aims to address the physical, social, emotional and spiritual concerns of people living with advanced breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07227038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/cancers-conditions-and-treatment/cancer-types/breast-cancer/specialty-clinics-and-programs/living-well-with-advanced-breast-cancer' target='_blank'>Ohio State University: Living Well with Advanced Breast Cancer</a> </li></ul>

250

Interview and Survey About a Support Program for People With Advanced Breast Cancer

Show Scientific Title

Living Well With Advanced Breast Cancer

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Visits:
1 day

ClinicalTrials.gov: NCT07227038

Phase NA

251

Arginine and Whole Brain Radiation Therapy for People with Brain Metastases

Show Scientific Title

Arginine With Whole Brain Radiation Therapy for the Treatment of Brain Metastases

Purpose: To compare the safety and effects (good and bad) of 2 ways to give L-arginine with whole brain radiation therapy.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive whole brain radiation therapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: L-arginine By IV <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">L-arginine, by IV, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">CT scan, 1 time</li> <li class="seamTextUnorderedListItem">MRI scan 2 times</li> </ul> Group 2: L-arginine By Mouth <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">L-arginine, by mouth, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">CT scan, 1 time</li> <li class="seamTextUnorderedListItem">MRI scan 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Arginine is an essential amino acid.</li> <li class="seamTextUnorderedListItem">Amino acids are the molecules that join together to form proteins in the body.</li> <li class="seamTextUnorderedListItem">Giving arginine has been shown to improve how brain metastases respond to radiation therapy.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06328686' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

251

Arginine and Whole Brain Radiation Therapy for People with Brain Metastases

Show Scientific Title

Arginine With Whole Brain Radiation Therapy for the Treatment of Brain Metastases

Nearest Location from 94107:
2139 miles
Emory University Hospital/Winship Cancer Institute
Atlanta, GA

Visits:
11 visits within 2 weeks

ClinicalTrials.gov: NCT06328686

Phase I

252

Trastuzumab Deruxtecan Antibody Drug Conjugate for Advanced HER2 Negative Breast Cancer

Show Scientific Title

Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of trastuzumab deruxtecan (Enhertu®, T-DXd) antibody drug conjugate for people with metastatic HER2 negative breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer who have received 1-2 lines of therapy (no anti-HER2 targeted therapies) for advanced disease. Your cancer must have always been considered HER2 negative. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">About half of breast cancers that are considered HER2 negative actually have low expression of HER2 (HER2 low) and may respond to anti-HER2 targeted therapies.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan is effective and increases survival in people with HER2 low breast cancers.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®)'s antibody targets HER2 and delivers an anti-cancer drug called deruxtecan.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06750484' target='_blank'>ClinicalTrials.gov</a> </li></ul>

252

Trastuzumab Deruxtecan Antibody Drug Conjugate for Advanced HER2 Negative Breast Cancer

Show Scientific Title

Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer

Nearest Location from 94107:
2139 miles
Emory Winship Cancer Institute
Atlanta, GA

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT06750484

Phase II

253

Decreasing Doses of Dexamethasone to Reduce Side Effects After Brain Surgery for People with Breast Cancer Brain Metastases

Show Scientific Title

Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)

Purpose: To study the effects (good and bad) of decreasing doses of dexamethasone on side effects after surgery to remove a brain tumor.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. View full eligibility criteria

What's involved?

You will receive the following after surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, decreasing doses every day for up to 2 weeks</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Craniotomy is surgery to remove a brain tumor.</li> <li class="seamTextUnorderedListItem">Steroids are the standard of care treatment to reduce swelling (edema) and reduce symptoms after surgery.</li> <li class="seamTextUnorderedListItem">However, some steroids have side effects including high blood sugar, high blood pressure, and worsened wound healing.</li> <li class="seamTextUnorderedListItem">Dexamethasone is a type of steroid called a corticosteroid. It is used to reduce inflammation, reduce swelling, and lower the body's immune response.</li> <li class="seamTextUnorderedListItem">Reducing the dose of dexamethasone may decrease steroid side effects without increasing the risk of swelling after brain surgery.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06132685' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

253

Decreasing Doses of Dexamethasone to Reduce Side Effects After Brain Surgery for People with Breast Cancer Brain Metastases

Show Scientific Title

Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)

Nearest Location from 94107:
2139 miles
Emory University Hospital/Winship Cancer Institute
Atlanta, GA

Visits:
Coincides with surgery

ClinicalTrials.gov: NCT06132685

Phase II

254

Magnetic Resonance Fingerprinting to Distinguish Between Radiation Damage and Brain Tumor Progression

Show Scientific Title

Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy

Purpose: To study the use of MRI scans with magnetic resonance fingerprinting (MRF) to create high-quality images of the entire brain and distinguish between radiation damage and brain tumor recurrence.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis), and people without breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 types of MRI scans, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">After radiation, brain tumors often increase in size on imaging scans due to radiation damage (radiation necrosis).</li> <li class="seamTextUnorderedListItem">However, this makes it challenging for doctors to determine if brain tumors are growing.</li> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting (MRF) is a type of MRI scan that can be used to achieve high-quality images within a short scan time of 5 minutes for viewing the entire brain.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting (MRF) may be useful to avoid surgery to determine if brain tumors are growing or not after radiation.</li> <li class="seamTextUnorderedListItem">Scan results from people with brain tumors will be compared to people without brain tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06101069' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

254

Magnetic Resonance Fingerprinting to Distinguish Between Radiation Damage and Brain Tumor Progression

Show Scientific Title

Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy

Nearest Location from 94107:
2168 miles
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, OH

Visits:
1 visit

ClinicalTrials.gov: NCT06101069

Phase NA

255

Probiotic Supplement for Women With Breast Cancer

Show Scientific Title

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients

Purpose: To study how well a probiotic can change the mix of microorganisms (like bacteria and fungi) in the gut microbiome and breast tissue in people with breast cancer.

Who is this for?: Women with stage I or stage II or stage III or stage IV (invasive ductal carcinoma [IDC] or invasive lobular carcinoma [ILC]) breast cancer. You must agree to avoid unpasteurized fermented foods and probiotics and to keep your usual diet and activity level before the study starts and while you are in the study. View full eligibility criteria

What's involved?

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The gut microbiome is made up of bacteria, viruses, and other organisms that live in the digestive tract and help keep us healthy.</li> <li class="seamTextUnorderedListItem">A probiotic, called BIOHM, is a food supplement that is believed to balance bacteria and fungi in the body.</li> <li class="seamTextUnorderedListItem">This study is looking at whether taking BIOHM may help change the body’s microbiome in people with breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04362826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/diet-nutrition/dietary-supplements/known/probiotics' target='_blank'>Breastcancer.org: Probiotics and Breast Cancer</a> </li></ul>

255

Probiotic Supplement for Women With Breast Cancer

Show Scientific Title

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients

Nearest Location from 94107:
2172 miles
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, OH

Visits:
At least 2 visits in 6 weeks

ClinicalTrials.gov: NCT04362826

Phase NA

256

Stereotactic Radiosurgery Before Brain Surgery for Brain Metastasis

Show Scientific Title

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Purpose: To study the safety, effects (good and bad), best dose, and anti-cancer activity of stereotactic radiosurgery given before brain surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and 1-4 brain tumors. You must have at least 1 brain tumor that has not been treated with radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01891318' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

256

Stereotactic Radiosurgery Before Brain Surgery for Brain Metastasis

Show Scientific Title

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Nearest Location from 94107:
2193 miles
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, OH

Visits:
May require hospitalization

ClinicalTrials.gov: NCT01891318

Phase I-II

257

X-PACT Radiation For Advanced Breast Cancer

Show Scientific Title

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

Purpose: To study the safety and effects (good and bad) of X-ray Psoralen Activated Cancer Therapy (X-PACT), an experimental type of radiation therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have progressed following standard therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">X-PACT radiation with injection, 5-7 sessions over 1.5-4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">X-PACT stands for X-ray Psoralen Activated Cancer Therapy.</li> <li class="seamTextUnorderedListItem">X-PACT consists of injections inside tumors.</li> <li class="seamTextUnorderedListItem">Injections contain drugs that have anti-cancer properties when activated with x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04389281' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.immunolight.com/cancer' target='_blank'>Immunolight Drug Information Page: X-PACT</a> </li><li class='seamTextUnorderedListItem'><a href='https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162078' target='_blank'>Journal Article: X-PACT</a> </li></ul>

257

X-PACT Radiation For Advanced Breast Cancer

Show Scientific Title

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

Nearest Location from 94107:
2223 miles
Prisma Health
Greenville, SC

Visits:
At least 5 visits over the first 1.5 months, then 2 visits over the next 2-3 months

ClinicalTrials.gov: NCT04389281

Phase I

258

Liquid Biopsy to Monitor Treatment Response for Women with Metastatic Lobular ER+ Breast Cancer

Show Scientific Title

LBC-Monitor: Liquid Biopsy Guided Tailoring of Therapy in Metastatic Lobular Breast Cancer (mILC): a Pilot Study of Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA

Purpose: To study how circulating tumor DNA (ctDNA) changes over time to help monitor treatment response and make treatment decisions.

Who is this for?: Women with metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) lobular breast cancer who have not yet received treatment for metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, 4 times in 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lobular breast cancer can be difficult to see and monitor on scans.</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">A ctDNA test is sometimes called a liquid biopsy.</li> <li class="seamTextUnorderedListItem">ctDNA tests may improve the ability to monitor treatment response in lobular breast cancer and identify changes in the tumor cells that may predict resistance to hormone therapy.</li> <li class="seamTextUnorderedListItem">This information may allow doctors to change treatments when it is most beneficial to patients.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06666439' target='_blank'>ClinicalTrials.gov</a> </li></ul>

258

Liquid Biopsy to Monitor Treatment Response for Women with Metastatic Lobular ER+ Breast Cancer

Show Scientific Title

LBC-Monitor: Liquid Biopsy Guided Tailoring of Therapy in Metastatic Lobular Breast Cancer (mILC): a Pilot Study of Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA

Nearest Location from 94107:
2264 miles
Magee Women's Hospital of UPMC
Pittsburgh, PA

Visits:
4 visits in 3 months

ClinicalTrials.gov: NCT06666439

Phase NA

259

CTC‑EXPRESS: Using Blood Tests to Help Guide Treatment and Monitoring in Advanced Breast Cancer

Show Scientific Title

CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer

Purpose: To find out whether special blood tests, that look for cancer cells and cancer‑related genetic material circulating in the blood, can help doctors make better decisions about breast cancer treatment and monitoring.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HR+/HER2- breast cancer before starting first line of treatment or triple negative breast cancer who are starting any line of treatment, or HER2+ breast cancer after receiving first line of treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, taken during routine appointments</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are studying special blood tests that look for cancer cells and cancer‑related genetic material circulating in the blood. These test results help doctors choose treatments, understand how well treatment is working, and track whether the cancer is changing or progressing.</li> <li class="seamTextUnorderedListItem">Advanced blood tests can count cancer cells (CTC enumeration), check cancer markers on those cells (CTC expression), and look for cancer‑related DNA and RNA floating in the blood (cfDNA/RNA).</li> <li class="seamTextUnorderedListItem">When you can join depends on the type of breast cancer you have: HR+/HER2‑ breast cancer before starting first‑line treatment; Triple negative breast cancer starting any line of treatment, and HER2‑positive breast cancer starting second‑line treatment or later</li> <li class="seamTextUnorderedListItem">This is an observational study, and no experimental drugs are given as part of the study.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06833853' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/liquid-biopsy/' target='_blank'>Metastatic Trial Talk: Understanding Liquid Biopsies for MBC</a> </li></ul>

259

CTC‑EXPRESS: Using Blood Tests to Help Guide Treatment and Monitoring in Advanced Breast Cancer

Show Scientific Title

CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer

Nearest Location from 94107:
2264 miles
UPMC Magee Womens Hospital
Pittsburgh, PA

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT06833853

Phase NA

260

Home-Based Respiratory Muscle Training to Reduce Chemotherapy Side Effects for People with Stage I-IV Breast Cancer

Show Scientific Title

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Purpose: To study how home-based respiratory muscle training is useful for minimizing side effects during chemotherapy treatment.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive chemotherapy. You must not have received radiation to the left chest wall. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care, 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Respiratory muscle training using a respiratory muscle training device, 1.5 months (optional)</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Respiratory muscle training using a respiratory muscle training device, 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Respiratory muscle training is a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training.</li> <li class="seamTextUnorderedListItem">Respiratory muscle training may decrease heart and lung side effects of chemotherapy and improve your quality of life.</li> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05787834' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://umiamihealth.org/en/treatments-and-services/ear,-nose,-and-throat-(ent)/speech-therapy/respiratory-muscle-training#:~:text=Respiratory%20muscle%20training%20(RMT)%20is,%2C%20improve%20respiration%20(breathing).' target='_blank'>University of Miami: Respiratory Muscle Training</a> </li></ul>

260

Home-Based Respiratory Muscle Training to Reduce Chemotherapy Side Effects for People with Stage I-IV Breast Cancer

Show Scientific Title

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Nearest Location from 94107:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05787834

Phase NA

261

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

Show Scientific Title

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors

Purpose: To study how breast cancer develops resistance to treatment with CDK 4/6 inhibitors and how to predict response to treatment with CDK 4/6 inhibitors.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or people with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) node positive breast cancer. You must have completed treatment with or currently be receiving treatment with a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, fluid, and biopsy samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your samples may be used to help your doctor make treatment decisions.</li> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>

261

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

Show Scientific Title

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors

Nearest Location from 94107:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04526587

Phase NA

262

Navigation to Provide Access to Support Services for Women with Stage 0-4 Breast Cancer

Show Scientific Title

Addressing Disparities in Breast Cancer Care: An Approach to Health Equity

Purpose: To study a program that helps women with breast cancer receive and manage breast cancer care.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Support from patient navigator</li> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The patient navigator will help connect you with support services, manage obstacles to care, and support your ability to manage cancer treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06350500' target='_blank'>ClinicalTrials.gov</a> </li></ul>

262

Navigation to Provide Access to Support Services for Women with Stage 0-4 Breast Cancer

Show Scientific Title

Addressing Disparities in Breast Cancer Care: An Approach to Health Equity

Nearest Location from 94107:
2299 miles
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06350500

Phase NA

263

Studying the Relationship Between Heart Rate Variability and Fatigue During Treatment for Stage I-IV Breast Cancer

Show Scientific Title

Wearable Activity Tracker Devices and Cancer-Related Fatigue: A Clinical Utility Pilot Study For Patients Undergoing Anti-Cancer Treatment

Purpose: To study the relationship between heart rate variability (HRV) and fatigue during cancer treatment.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive or are receiving treatment. You must be experiencing fatigue (tiredness). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear activity tracker device, 1 month</li> <li class="seamTextUnorderedListItem">Diary of activity tracker information, 1 month</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The activity tracker device measures your heart rate variability (HRV).</li> <li class="seamTextUnorderedListItem">Heart rate variability (HRV) is the fluctuations in the amount of time between your heartbeats.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06291324' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/symptoms/21773-heart-rate-variability-hrv' target='_blank'>Cleveland Clinic: Heart Rate Variability</a> </li></ul>

263

Studying the Relationship Between Heart Rate Variability and Fatigue During Treatment for Stage I-IV Breast Cancer

Show Scientific Title

Wearable Activity Tracker Devices and Cancer-Related Fatigue: A Clinical Utility Pilot Study For Patients Undergoing Anti-Cancer Treatment

Nearest Location from 94107:
2299 miles
Levine Cancer Institute
Charlotte, NC

Visits:
At least 3 visits within 1 month

ClinicalTrials.gov: NCT06291324

Phase NA

264

Methotrexate in Metastatic Breast Cancer With Leptomeningeal Metastasis

Show Scientific Title

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail

Purpose: To study the effects (good and bad) of using high-dose methotrexate to treat metastases in the cerebrospinal fluid surrounding the brain and spinal cord and/or in the leptomeninges (the lining of the brain and spinal cord).

Who is this for?: People with metastatic (stage IV) breast cancer with leptomeningeal metastases (defined below). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High-dose Methotrexate (HD-MTX), by IV, once every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the cerebrospinal fluid.</li> <li class="seamTextUnorderedListItem">Methotrexate is a chemotherapy approved to treat advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Researchers believe methotrexate can cross the blood-brain barrier, which will allow the drug to reach the leptomeningeal metastases.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02422641' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/cancerwise/2017/04/new-hope-for-leptomeningeal-disease-care.html' target='_blank'>MDAnderson: New Hope for Leptomeningeal Disease Care</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/secondary-cancer/leptomeningeal-metastases/what-are#:~:text=Leptomeningeal%20metastases%20mean%20cancer%20cells,leptomeningeal%20disease' target='_blank'>Cancer Research UK: What are Leptomeningeal Metastases?</a> </li></ul>

264

Methotrexate in Metastatic Breast Cancer With Leptomeningeal Metastasis

Show Scientific Title

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail

Nearest Location from 94107:
2314 miles
Comprehensive Cancer Center at Wake Forest University (CCCWFU)
Winston-Salem, NC

Visits:
1 visit every 2 weeks, ongoing

ClinicalTrials.gov: NCT02422641

Phase II

265

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Show Scientific Title

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of epidiferphane, an experimental nutritional supplement, with chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning on receiving treatment with chemotherapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Docetaxel (Taxotere®), every 3 weeks; paclitaxel (Taxol®), weekly; or nab-paclitaxel (Abraxane®), weekly; 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane is an experimental nutritional supplement that may reduce chemotherapy symptoms.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), paclitaxel (Taxol®), and nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with lobular breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05074290' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epidiferphane' target='_blank'>National Cancer Institute: Epidiferphane</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

265

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Show Scientific Title

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Nearest Location from 94107:
2351 miles
University of Florida
Gainesville, FL

Visits:
1 visit every 1-3 weeks for 3 months

ClinicalTrials.gov: NCT05074290

Phase I-II

266

Neratinib Targeted Therapy with Capecitabine Chemotherapy for Metastatic HER2 Negative Breast Cancer with Abnormally Active HER2 Signaling and Brain Metastases

Show Scientific Title

An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of neratinib (Nerlynx®) anti-HER2 targeted therapy with capecitabine (Xeloda®) chemotherapy.

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) breast cancer with abnormally active HER2 signaling that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 day off</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is an anti-HER2 targeted therapy that stops cancer cells from growing by targeting and blocking the HER2 proteins that help cancer cells grow.</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is an oral drug approved by the U.S. Food and Drug Administration (FDA) to treat HER2 positive breast cancer. It is considered investigational in this study because your breast cancer was determined to be HER2 negative by the standard method of testing. However, the CELsignia test showed that your breast cancer cells have HER2 pathway activity that might respond to HER2-targeted treatment.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug that may slow or stop breast cancer cells from growing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04965064' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/nerlynx' target='_blank'>Breastcancer.org: Neratinib (Nerlynx®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/xeloda' target='_blank'>Breastcancer.org: Capecitabine (Xeloda®)</a> </li></ul>

266

Neratinib Targeted Therapy with Capecitabine Chemotherapy for Metastatic HER2 Negative Breast Cancer with Abnormally Active HER2 Signaling and Brain Metastases

Show Scientific Title

An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Nearest Location from 94107:
2352 miles
University of Rochester
Rochester, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04965064

Phase II

267

University of Florida Brain Tumor Tissue Bank

Show Scientific Title

Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research

Purpose: To collect and store brain tumor tissue samples for brain tumor research.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and are planning to receive brain surgery at the Florida Center for Brain Tumor Research. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples (during surgery)</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The samples will become part of the University of Florida Brain Tumor Tissue Bank/Florida Center for Brain Tumor Research. </li> <li class="seamTextUnorderedListItem">The mission of the Florida Center for Brain Tumor Research is to discover cures and treatments for brain tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00811148' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

267

University of Florida Brain Tumor Tissue Bank

Show Scientific Title

Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research

Nearest Location from 94107:
2354 miles
University of Florida
Gainesville, FL

Visits:
Coincides with routine care and surgery

ClinicalTrials.gov: NCT00811148

Phase NA

268

Digital Tool and Patient Navigators to Improve Access to Healthy Food for Stage 0-IV Breast Cancer

Show Scientific Title

The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)

Purpose: To study whether the MyCarePulse digital tool and ASCENT patient navigator program can help people get access to healthy food.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer whose diagnosis was within the last year, speak English or Spanish, and live in Florida. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Standard of care</li> <li class="seamTextUnorderedListItem">MyCarePulse</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">MyCarePulse</li> <li class="seamTextUnorderedListItem">ASCENT patient navigator</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MyCarePulse is a digital tool that assesses the need for food assistance. </li> <li class="seamTextUnorderedListItem">The ASCENT patient navigator program is designed to improve access to nutritious food, improve one's confidence in eating a healthy diet, and improve diet quality compared to standard of care.</li> <li class="seamTextUnorderedListItem">Patient navigators can provide individualized support and connect people with community resources to promote healthy eating.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07042243' target='_blank'>ClinicalTrials.gov</a> </li></ul>

268

Digital Tool and Patient Navigators to Improve Access to Healthy Food for Stage 0-IV Breast Cancer

Show Scientific Title

The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)

Nearest Location from 94107:
2354 miles
University of Florida
Gainesville, FL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07042243

Phase NA

269

Comparing Two Types of Radiation Therapy for People with Brain Metastases

Show Scientific Title

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of two types of radiation therapy used to treat large brain metastases: staged stereotactic radiosurgery (SSRS) and fractionated stereotactic radiotherapy (FSRT).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). The metastases must be larger tumors (2 to 5 cm). View full eligibility criteria

What's involved?

What's being studied?

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07227610' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>Metastatic Trial Talk: MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/side-effects-of-brain-mets-radiation/' target='_blank'>Metastatic Trial Talk: Side Effects of Radiation Therapy for Brain Mets</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/tag/brain-metastases/' target='_blank'>Metastatic Trial Talk: The Latest in Treatments for MBC With Brain Metastases</a> </li></ul>

269

Comparing Two Types of Radiation Therapy for People with Brain Metastases

Show Scientific Title

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

Nearest Location from 94107:
2377 miles
Medical University of South Carolina Hollings Cancer Center
Charleston, SC

Visits:
2-3 radiation sessions within 2 months

ClinicalTrials.gov: NCT07227610

Phase II

270

Screening for Brain Metastasis for People with Metastatic Breast Cancer

Show Scientific Title

Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer

Purpose: To screen people with metastatic breast cancer for brain metastasis.

Who is this for?: People with metastatic (stage IV) breast cancer who do not have symptoms of brain metastasis. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI scan, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Symptoms of brain mets include headaches, seizures, weakness, numbness, vision changes, memory loss, speech problems, balance problems, nausea, and/or vomiting.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Blood tests will identify biomarkers and circulating tumor DNA (ctDNA), which may indicate people most likely to experience brain metastasis.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05115474' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

270

Screening for Brain Metastasis for People with Metastatic Breast Cancer

Show Scientific Title

Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer

Nearest Location from 94107:
2380 miles
Morton Plant Mease- Baycare
Clearwater, FL

Visits:
2 visits

ClinicalTrials.gov: NCT05115474

Phase II

271

Receiving Cancer Treatment at Home Instead of in the Clinic for Stage I-IV Breast Cancer

Show Scientific Title

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

Purpose: To study whether providing cancer treatment in the home is preferred over the traditional clinic setting.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who live in the Florida panhandle area, who are receiving and tolerating standard treatment for their cancer, and who plan to continue to receive these medications for the next 3 months or more. You must not be receiving all your medications by mouth. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In-home standard of care cancer treatment through CCBW, up to 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times within 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typically, drug-related cancer treatment is provided at a medical center, which causes patients to have to spend time away from their family and friends. Treatment at a medical center may contribute to the physical, emotional, social, and financial burden of having cancer.</li> <li class="seamTextUnorderedListItem">The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team to provide cancer treatment in the patient's home and may be preferred over the traditional clinic setting.</li> <li class="seamTextUnorderedListItem">At the end of the 3 months of the trial, participants may choose to continue to receive in-home treatment for another 3 months or return to the clinic.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07285044' target='_blank'>ClinicalTrials.gov</a> </li></ul>

271

Receiving Cancer Treatment at Home Instead of in the Clinic for Stage I-IV Breast Cancer

Show Scientific Title

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07285044

Phase II

272

Blood Test to Predict Response to Treatment for Women with Metastatic HR+ Breast Cancer

Show Scientific Title

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Purpose: To study the ability of the DiviTum®TKa blood test to predict response to treatment for women with metastatic hormone receptor positive breast cancer.

Who is this for?: Women with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer who are planning to receive or currently receiving hormone therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum®TKa blood test, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DiviTum®TKa is an experimental blood test that measures thymidine kinase activity (TKa) which may predict how well tumors respond to treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06388122' target='_blank'>ClinicalTrials.gov</a> </li></ul>

272

Blood Test to Predict Response to Treatment for Women with Metastatic HR+ Breast Cancer

Show Scientific Title

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Visits:
1 visit every 2 weeks

ClinicalTrials.gov: NCT06388122

Phase NA

273

Studying Tumor Blood Flow to Make Treatment Decisions for People with Stage 0-IV Breast Cancer

Show Scientific Title

Intravital Microscopy (IVM) in Human Solid Tumors

Purpose: To use Human Intravital Microscopy (HIVM) to study tumor blood flow and gather information to make treatment decisions.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Human Intravital Microscopy (HIVM) with fluorescein, by IV, during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Human Intravital Microscopy (HIVM) is a procedure completed during surgery to study tumor blood vessels and blood flow.</li> <li class="seamTextUnorderedListItem">IVM can determine if your blood vessels work well enough to be able to receive some types of cancer treatment.</li> <li class="seamTextUnorderedListItem">Fluorescein is used during HIVM to see how blood flows.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03823144' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/cancer-the-blood-and-circulation' target='_blank'>Cancer Research UK: Cancer and Blood Circulation</a> </li></ul>

273

Studying Tumor Blood Flow to Make Treatment Decisions for People with Stage 0-IV Breast Cancer

Show Scientific Title

Intravital Microscopy (IVM) in Human Solid Tumors

Nearest Location from 94107:
2383 miles
Mayo Clinic Florida
Jacksonville, FL

Visits:
Coincides with surgery

ClinicalTrials.gov: NCT03823144

Phase NA

274

Registry to Study the Impact of the Gut Microbiome on Brain Tumors

Show Scientific Title

Study of Human Brain-Gut Axis and Gut Microbiome In Patients With Brain Lesions - Repository for Neuroscience Research

Purpose: To study the impact of the gut microbiome on the growth and progression of brain tumors.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, saliva, urine and stool samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool samples will be used to study your gut microbiome, which are the microorganisms that live in your digestive system.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06117930' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

274

Registry to Study the Impact of the Gut Microbiome on Brain Tumors

Show Scientific Title

Study of Human Brain-Gut Axis and Gut Microbiome In Patients With Brain Lesions - Repository for Neuroscience Research

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Visits:
Coincides with surgery and routine care

ClinicalTrials.gov: NCT06117930

Phase NA

275

Wearable Device for Metastatic Breast Cancer that has Spread to the Leptomeninges

Show Scientific Title

Pilot Feasibility Study of Tumor Treating Fields in Treatment of Leptomeningeal Metastases From Breast Carcinoma Involving the Spine

Purpose: This trial will study the safety and effects (good and bad) of the Novo TTF-200T device.

Who is this for?: People with stage IV (metastatic) breast cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). You must not be receiving high-dose methotrexate, thiotepa, or cytarabine. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The portable Novo TTF-200T device to wear</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Possible lumbar puncture (also called a spinal tap), 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Novo TTF-200T device is a wearable device that produces electric fields to target areas on the body to stop the growth of tumor cells. </li> <li class="seamTextUnorderedListItem">The device has breakthrough designation from the FDA for advanced liver cancer and is being tested in other advanced cancers including MBC.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05746325' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/novottf-200t-delivery-system-given-a-breakthrough-designation-by-the-fda-for-advanced-liver-cancer' target='_blank'>Cancer Network: The Novo TTF-200T Device</a> </li></ul>

275

Wearable Device for Metastatic Breast Cancer that has Spread to the Leptomeninges

Show Scientific Title

Pilot Feasibility Study of Tumor Treating Fields in Treatment of Leptomeningeal Metastases From Breast Carcinoma Involving the Spine

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05746325

Phase NA

276

Personalized Vaccine with Pembrolizumab for Advanced Breast Cancer

Show Scientific Title

A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a personalized neoantigen peptide vaccine, an experimental type of immunotherapy, with pembrolizumab (Keytruda®), a type of immunotherapy called a PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that have received at least 1 line of standard treatment. If you have triple negative (ER-, PR-, HER2-) breast cancer, you must currently be receiving treatment with pembrolizumab (Keytruda®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, 1 session</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized neoantigen peptide vaccine, by injection, 4 times in 2 weeks, then every 3 weeks</li> <li class="seamTextUnorderedListItem">Sargramostim, by injection, 4 times in 2 weeks, then every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require at least 1 biopsy</li> <li class="seamTextUnorderedListItem">May require 1 additional vaccine</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The neoantigen peptide vaccine will be personalized to your cancer based on your blood and biopsy results.</li> <li class="seamTextUnorderedListItem">Personalized neoantigen peptide vaccines are an experimental type of immunotherapy.</li> <li class="seamTextUnorderedListItem">The vaccine is designed to target certain proteins (neoantigens) on tumor cells.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Before you receive the vaccine, you will be given the chemotherapy drug cyclophosphamide (Cytoxan®) to prepare your immune system to receive the vaccine.</li> <li class="seamTextUnorderedListItem">Sargramostim is a type of immunotherapy that stimulates your body to produce more immune cells to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05269381' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20529594?_ga=2.9537585.506318734.1653082699-1752475516.1651774270' target='_blank'>Mayo Clinic: Clinical Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/breast-cancer-vaccine-explainer/' target='_blank'>Breast Cancer Research Foundation: Breast Cancer Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/cytoxan' target='_blank'>Breastcancer.org: Cyclophosphamide (Cytoxan®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/drugs/20884-sargramostim-gm-csf-injection' target='_blank'>Cleveland Clinic: Sargramostim</a> </li></ul>

276

Personalized Vaccine with Pembrolizumab for Advanced Breast Cancer

Show Scientific Title

A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Visits:
5 visits in 3 weeks, then 1 visit every 3 weeks

ClinicalTrials.gov: NCT05269381

Phase I-II

277

Studying Biomarkers, Immune Cells, and ctDNA in People with Brain Metastasis

Show Scientific Title

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Purpose: To study biomarkers, immune cells, and circulating tumor (ctDNA) in blood samples after radiation.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive or receiving radiation at Duke Cancer Center. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests will be used for genetic testing to indicate the presence of biomarkers, immune cells, and circulating tumor (ctDNA).</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05480644' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

277

Studying Biomarkers, Immune Cells, and ctDNA in People with Brain Metastasis

Show Scientific Title

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Nearest Location from 94107:
2385 miles
Duke Cancer Center
Durham, NC

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT05480644

Phase NA

278

Datopotamab Deruxtecan ADC for HER2- Breast Cancer That Spread to the Brain or Leptomeninges

Show Scientific Title

DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of datopotamab deruxtecan, an experimental antibody drug conjugate (ADC).

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) breast cancer that has spread to the brain (brain metastasis) or leptomeninges (leptomeningeal disease). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV, daily</li> <li class="seamTextUnorderedListItem">CT or MRI scans, every 1-2 months</li> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF (optional), 1 time</li> <li class="seamTextUnorderedListItem">Heart scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd) is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan's antibody targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06176261' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/october-10-2022-supplement-breast-cancer-almanac/datopotamab-deruxtecan-shows-activity-in-advanced-triple-negative-breast-cancer/' target='_blank'>ASCO: Dato-DXd</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastastic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>

278

Datopotamab Deruxtecan ADC for HER2- Breast Cancer That Spread to the Brain or Leptomeninges

Show Scientific Title

DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Nearest Location from 94107:
2385 miles
Duke University Medical Center
Durham, NC

Visits:
At least 1 visit every 1-2 months

ClinicalTrials.gov: NCT06176261

Phase II

279

ENGAGE Telehealth Program to Reduce Symptoms and Improve Quality of Life for People with Metastatic Breast Cancer

Show Scientific Title

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients With Advanced Cancer

Purpose: To study the ability of ENGAGE, a telehealth program, to reduce pain, fatigue, and distress and improve quality of life for people with metastatic breast cancer.

Who is this for?: People with metastatic (stage IV) breast cancer who are experiencing pain, fatigue, and/or distress. You must be receiving care at a Duke Cancer Network (DCN) clinic. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ENGAGE program, virtual, 4 sessions</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 4 months</li> </ul> Group 2: Supportive Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supportive care program, virtual, 4 sessions</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ENGAGE sessions use Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches to manage pain, fatigue, and distress.</li> <li class="seamTextUnorderedListItem">Supportive care sessions focus on education, support, and resources focused on common cancer-related concerns, such as education on symptoms, body image concerns, and financial concerns.</li> <li class="seamTextUnorderedListItem">All sessions (Group 1 and Group 2) are led by trained therapists and are 45-60 minutes long.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06555588' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nami.org/treatment/how-i-use-act-and-cbt-to-help-people-cope-with-health-conditions/' target='_blank'>National Alliance on Mental Illness: Using ACT and CBT to Help People Cope with Health Conditions</a> </li></ul>

279

ENGAGE Telehealth Program to Reduce Symptoms and Improve Quality of Life for People with Metastatic Breast Cancer

Show Scientific Title

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients With Advanced Cancer

Nearest Location from 94107:
2388 miles
Duke Cancer Network
Durham, NC

Visits:
3 visits in 4 months

ClinicalTrials.gov: NCT06555588

Phase NA

280

Dendritic Cell Vaccine and Hormone Therapy for Metastatic HR+, HER2- Breast Cancer with ESR1 Mutations

Show Scientific Title

Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of an experimental dendritic cell vaccine with elacestrant (Orserdu®) hormone therapy.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2- or HER2 low) breast cancer with ESR1 mutations. You must have received a CDK4/6 inhibitor with hormone therapy for metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Apheresis procedure to remove white blood cells, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dendritic cell vaccine, by injection, weekly for 2 months then monthly for 3 months</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The dendritic cell vaccine is an experimental immunotherapy that boosts the immune system to recognize and destroy cancer cells.</li> <li class="seamTextUnorderedListItem">You will receive a dendritic cell vaccine made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The white blood cells, called dendritic cells, are removed from your body during a procedure called apheresis. These cells are processed in a lab so that they will see and go after cancer cells with ESR1 mutations, and then they will be injected as a vaccine.</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is a hormone therapy called a selective estrogen receptor degrader (SERD). SERDs work by binding to and breaking down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is considered standard of care for patients with ESR1 mutated HR+ HER2-metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2/ISH-.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06691035' target='_blank'>ClinicalTrials.gov</a> </li></ul>

280

Dendritic Cell Vaccine and Hormone Therapy for Metastatic HR+, HER2- Breast Cancer with ESR1 Mutations

Show Scientific Title

Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Visits:
Weekly for 2 months then monthly for 3 months

ClinicalTrials.gov: NCT06691035

Phase I

281

Studying a New Order of Giving Currently Approved Drugs for Women with HR+, HER2- Breast Cancer

Show Scientific Title

A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer

Purpose: To study a new order of giving currently approved drugs to treat metastatic breast cancer.

Who is this for?: Women with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received an aromatase inhibitor or tamoxifen (Nolvadex®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®)</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®)</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) or trastuzumab deruxtecan (Enhertu®)</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®)</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®)</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) or abemaciclib (Verzenio®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are continually developing new drugs to treat metastatic breast cancer (MBC) and understanding how to best use drugs already approved for MBC.</li> <li class="seamTextUnorderedListItem">An important question in treatment planning is the order in which drugs are given, called “drug sequencing”.</li> <li class="seamTextUnorderedListItem">All drugs in this trial are approved for metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), docetaxel (Taxotere®), and capecitabine (Xeloda®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) and trastuzumab deruxtecan (Enhertu®) are types of targeted therapy called antibody drug conjugates (ADC).</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) and abemaciclib (Verzenio®) are types of targeted therapy called CDK4/6 inhibitors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06409390' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/drug-sequencing/?utm_medium=email&utm_source=subscribers&utm_campaign=Mar2024&utm_content=Email032024' target='_blank'>Metastatic Trial Talk: What is “Drug Sequencing”?</a> </li></ul>

281

Studying a New Order of Giving Currently Approved Drugs for Women with HR+, HER2- Breast Cancer

Show Scientific Title

A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06409390

Phase II

282

Scheduled Brain MRI Scans to Find Brain Metastases Early in Stage IV Breast Cancer

Show Scientific Title

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Purpose: This trial is studying whether getting a brain MRI every 6 months (before any symptoms appear) can find brain metastases earlier than standard care, which only orders a brain scan if symptoms develop.

Who is this for?: People with metastatic (stage IV) breast cancer of any subtype: hormone receptor positive (ER+ and/or PR+), HER2 positive, or triple negative (ER-, PR-, HER2-). You must join within 60 days of your stage IV diagnosis or within 60 days of starting your first treatment for stage IV disease. You must not have been previously diagnosed with brain metastases or leptomeningeal disease, and you must not currently have neurologic symptoms that would already call for a brain MRI. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI scan at the start of the study, then every 6 months for 2 years (about 5 scans total).</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI scan at the start of the study. After that, you will only have a brain scan if you develop neurologic symptoms.</li> <li class="seamTextUnorderedListItem">Please contact research site for treatment schedule.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain.</li> <li class="seamTextUnorderedListItem">This trial is studying whether looking for brain metastases early leads to better outcomes than the usual approach of scanning the brain only when symptoms appear. </li> <li class="seamTextUnorderedListItem">Both groups get a brain MRI at the start of this study. The trial team will then compare the two groups to see whether earlier detection changes the type of treatment given for brain metastases (such as surgery or whole-brain radiation), how many and how large the metastases are, whether leptomeningeal disease (cancer spread to the fluid and tissue around the brain and spinal cord) is found more often, and whether there are differences in quality of life and survival.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07357298' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

282

Scheduled Brain MRI Scans to Find Brain Metastases Early in Stage IV Breast Cancer

Show Scientific Title

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Visits:
up to 4 years

ClinicalTrials.gov: NCT07357298

Phase III

283

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

Show Scientific Title

HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer

Purpose: To study if genomic testing affects which line of therapy doctors suggest people with metastatic breast cancer receive.

Who is this for?: People with metastatic (stage IV) breast cancer who have received no more than one line of therapy for metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PAM50 (Prosigna®) testing of your breast tumor, 1 time</li> <li class="seamTextUnorderedListItem">Results of the PAM50 test will be given to your treating doctor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard of care for treating metastatic breast cancer is to make treatment decisions based on clinical subtype. </li> <li class="seamTextUnorderedListItem">Clinical subtypes include hormone-positive (ER+ and/or PR+), HER2-positive (HER2+), and triple-negative (ER-, PR-, HER2-).</li> <li class="seamTextUnorderedListItem">The PAM50 (Prosigna®) is a genomic test approved for use in some women with early-stage breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor. This gives your doctor a genetic subtype of your tumor. </li> <li class="seamTextUnorderedListItem">This trial is studying whether knowing a tumor's genetic subtype will affect how doctors treat people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Making treatment decisions based on genetic subtypes is not the standard of care.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03769415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/octr/our-team/' target='_blank'>Study Coordinator Information: Terri Eubanks</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/genomic-tumor-testing/' target='_blank'>Metastatic Trial Talk: Genomic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prosigna.com' target='_blank'>Veracyte Test Information Page: PAM50 (Prosigna®)</a> </li></ul>

283

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

Show Scientific Title

HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer

Nearest Location from 94107:
2402 miles
UNC Rex Healthcare
Raleigh, NC

Visits:
1 visit

ClinicalTrials.gov: NCT03769415

Phase NA

284

Increasing Biomarker-Informed Treatment for Metastatic Breast Cancer

Show Scientific Title

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Purpose: To study whether intervention from a navigator and expert review of results of DNA analysis by a pharmacist will increase ordering of biomarker-informed therapy compared to an estimated historical rate of 15% and enrollment in biomarker-informed clinical trials.

Who is this for?: People with stage IV (metastatic) breast cancer for whom biomarker testing is considered appropriate but who have not received it. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood or tissue samples</li> <li class="seamTextUnorderedListItem">Review of your biomarker results by an expert</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person that tell doctors something about that person’s health.</li> <li class="seamTextUnorderedListItem">Patients with cancer have better outcomes when their treatments are selected with the help of biomarker testing. However, genomic testing, which is a type of biomarker testing, is not used as often as it should be.</li> <li class="seamTextUnorderedListItem">This trial is studying whether making biomarker test ordering and interpretation easier for clinicians will increase the rate of biomarker-informed treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06896162' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/new-biomarkers/' target='_blank'>Metastatic Trial Talk: Biomarkers for Selection of MBC Treatment</a> </li></ul>

284

Increasing Biomarker-Informed Treatment for Metastatic Breast Cancer

Show Scientific Title

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Nearest Location from 94107:
2406 miles
Lineberger Comprehensive Cancer Center, University of North Carolina
Chapel Hill, NC

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06896162

Phase NA

285

Behavioral Program to Improve Communication With Your Healthcare Team for Women With Stage I-IV Breast Cancer

Show Scientific Title

Carolina Breast Cancer Study: Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes in the Carolina Breast Cancer Study, Phase 4

Purpose: To study whether a behavioral intervention increases confidence in a person's ability to communicate with their healthcare team about health concerns.

Who is this for?: Women with newly diagnosed stage I, stage II, stage III, or stage IV (metastatic) breast cancer who live in North Carolina. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Provide blood or saliva sample</li> <li class="seamTextUnorderedListItem">Behavioral program, 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The behavioral program includes self-assessments, symptom reporting tools, interactions with nurses and educators, webinars and newsletters, and educational materials. Participants will learn about the study results.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07214610' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/resources-support/prepare-for-visit/' target='_blank'>Metastatic Trial Talk: Communicating With Your Healthcare Team</a> </li></ul>

285

Behavioral Program to Improve Communication With Your Healthcare Team for Women With Stage I-IV Breast Cancer

Show Scientific Title

Carolina Breast Cancer Study: Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes in the Carolina Breast Cancer Study, Phase 4

Nearest Location from 94107:
2406 miles
University of North Carolina at Chapel Hill
Chapel Hill, NC

Visits:
Number of visits unavailable, up to 15 years

ClinicalTrials.gov: NCT07214610

Phase NA

286

Exercise Program to Improve Well-Being for Metastatic Breast Cancer

Show Scientific Title

Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise

Purpose: To study unmet exercise needs and assess whether participation in the Get Real and Heel (GRH) program can increase physical activity.

Who is this for?: People with metastatic (stage IV) breast cancer whose diagnosis was no more than 2 years ago, who receive their cancer care at UNC's Lineberger Comprehensive Cancer Center, and who speak English. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Get Real and Heel (GRH) program, twice a week for 4 months</li> <li class="seamTextUnorderedListItem">Surveys, 2 times within 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise is recommended, safe, and effective for improving function, strength, fitness, and quality of life, but most people with MBC do not meet exercise guidelines.</li> <li class="seamTextUnorderedListItem">Get Real and Heel (GRH) offers 16 weeks of free, expert-led exercise including aerobic, strength, balance, and flexibility training tailored to participant needs.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07313306' target='_blank'>ClinicalTrials.gov</a> </li></ul>

286

Exercise Program to Improve Well-Being for Metastatic Breast Cancer

Show Scientific Title

Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise

Nearest Location from 94107:
2406 miles
Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill
Chapel Hill, NC

Visits:
Twice a week for 4 months

ClinicalTrials.gov: NCT07313306

Phase NA

287

Video Versus Fact Sheet to Increase Genetic Counseling and Testing for Latina Women With Stage 0-IV Breast Cancer or High-Risk Women

Show Scientific Title

Testing a Narrative Intervention to Enhance Genetic Counseling and Testing (CONTIGO)

Purpose: To compare a culturally targeted video and a Spanish-language fact sheet for enhancing genetic counseling, increasing genetic testing, and improving psychosocial outcomes.

Who is this for?: Latina women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer or healthy women with a family history of cancer that suggests hereditary breast and ovarian cancer who speak Spanish. You must not have received genetic counseling or testing. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch the video: <q>Is My Cancer Hereditary? Rosa Visits a Genetic Counselor,</q> virtual</li> <li class="seamTextUnorderedListItem">Surveys, 3 times within 4 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Read a fact sheet, virtual</li> <li class="seamTextUnorderedListItem">Surveys, 3 times within 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The culturally targeted video is in Spanish with English subtitles. It provides education about genetic counseling and testing and hereditary breast and ovarian cancer to at-risk Latinas.</li> <li class="seamTextUnorderedListItem">The fact sheet includes information about genes, breast cancer, risk factors for hereditary breast and ovarian cancer, genetic counseling and testing, and resources.</li> <li class="seamTextUnorderedListItem">All participants will be offered genetic counseling and testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05130606' target='_blank'>ClinicalTrials.gov</a> </li></ul>

287

Video Versus Fact Sheet to Increase Genetic Counseling and Testing for Latina Women With Stage 0-IV Breast Cancer or High-Risk Women

Show Scientific Title

Testing a Narrative Intervention to Enhance Genetic Counseling and Testing (CONTIGO)

Nearest Location from 94107:
2430 miles
Virginia Commonwealth University
Richmond, VA

Visits:
3 visits within 4 months

ClinicalTrials.gov: NCT05130606

Phase NA

288

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for CD70

Show Scientific Title

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers

Purpose: To study the safety and effects (good and bad) of using a new type of CAR T-cell immunotherapy.

Who is this for?: People with metastatic (stage IV) breast cancer that tests positive for CD70 who have already received at least one standard therapy. View full eligibility criteria

What's involved?

You will receive the following: Hospital stay (at least 1-week): <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis (blood draw for the collection of cells)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide, by IV, once a day, for 2 days</li> <li class="seamTextUnorderedListItem">Fludarabine, by IV, once a day, for 5 days</li> <li class="seamTextUnorderedListItem">Aldesleukin, by IV, 3 times a day, for 3 days</li> <li class="seamTextUnorderedListItem">Anti-hCD70 CAR T-cells, by IV, one time</li> </ul> Post-hospital stay: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Antibiotic for 6 months</li> <li class="seamTextUnorderedListItem">Repeat Leukapheresis (blood draw for the collection of cells)</li> <li class="seamTextUnorderedListItem">1-2 day hospital visits (for lab tests, imaging studies, and a physical exam), every 1-3 months for the 1st year after treatment, every 6 months for the 2nd year, and then as determined by your doctor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR T-cell is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">After your blood cells are removed, they are modified with chimeric antigen receptors (CARs) so they can attack specific proteins. </li> <li class="seamTextUnorderedListItem">The CAR T-cells are then infused back into you while you are hospitalized. </li> <li class="seamTextUnorderedListItem">The CAR T-cell therapy used in this study is designed to get the immune system to see and kill cancer cells that are CD70+. </li> <li class="seamTextUnorderedListItem">Along with the CAR-T immunotherapy, you will receive the chemotherapy drugs fludarabine and cyclophosphamide. These drugs are given to deplete the lymph cells. </li> <li class="seamTextUnorderedListItem">You will also receive aldesleukin, a drug that stimulates the growth and development of T cells.</li> <li class="seamTextUnorderedListItem">Targets or mutations: CD70</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02830724' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drsusanloveresearch.org/videos/chimeric-antigen-receptor-t-cell-car-t-therapy' target='_blank'>Dr Susan Love Research Foundation: CAR-T Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/25368676' target='_blank'>Journal Article Abstract: CD70, A Potential Target in Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/search?contains=false&q=Aldesleukin' target='_blank'>NCI Drug Dictionary: Aldesleukin</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>

288

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for CD70

Show Scientific Title

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers

Nearest Location from 94107:
2432 miles
National Institutes of Health Clinical Center
Bethesda, MD

Visits:
Hospital stay for at least 1 week; follow-up visits for 2 years

ClinicalTrials.gov: NCT02830724

Phase I-II

289

Brain Surgery for Brain Metastasis and Tumor Related Epilepsy

Show Scientific Title

Tumor Related Epilepsy

Purpose: To study if brain surgery reduces the number of seizures and to see how surgery affects seizures.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have no more than one brain tumor and have experienced at least one seizure associated with the tumor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Requires hospitalization for at least one week</li> <li class="seamTextUnorderedListItem">Questionnaires, cognitive assessments, and seizure diary</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. </li> <li class="seamTextUnorderedListItem">Researchers think surgery may improve outcomes for people with tumor-related epilepsy by stopping seizures or reducing the number of seizures.</li> <li class="seamTextUnorderedListItem">Cognitive assessments study your cognition, which is your ability to think.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02639325' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/brain-metastasis/' target='_blank'>MBCBrainMets.org: About Brain Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/treatments-brain-metastasis/#toggle-id-7' target='_blank'>MBCBrainMets.org: Brain Metastasis Treatments</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/brain-mets/' target='_blank'>Metastastic Trial Talk: Treating Breast Cancer Brain Mets</a> </li></ul>

289

Brain Surgery for Brain Metastasis and Tumor Related Epilepsy

Show Scientific Title

Tumor Related Epilepsy

Nearest Location from 94107:
2432 miles
National Institutes of Health Clinical Center
Bethesda, MD

Visits:
Requires hospitalization

ClinicalTrials.gov: NCT02639325

Phase NA

290

Individualized Immunotherapy for Metastatic Breast (and Other) Cancer

Show Scientific Title

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Purpose: To study a new type of immunotherapy in which researchers take TILs from tumors, grow the ones that are most effective in fighting the cancer in the laboratory, and then give the cells back to the patient.

Who is this for?: People with metastatic (stage IV) breast cancer and have a tumor that can be surgically removed. View full eligibility criteria

What's involved?

All participants will undergo the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove tumor sample used to grow the tumor infiltrating lymphocyte</li> <li class="seamTextUnorderedListItem">White blood cells-depleting preparative regimen</li> <li class="seamTextUnorderedListItem">Followed by tumor Infiltrating Lymphocytes, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor infiltrating lymphocytes (TILs) are the white blood cells that are found in tumors. </li> <li class="seamTextUnorderedListItem">The immune system has activated these cells to try to control the cancer's growth. </li> <li class="seamTextUnorderedListItem">This study is investigating a new type of immunotherapy in which researchers take TILs from tumors, grow the ones that are most effective in fighting the cancer in the laboratory, and then give the cells back to the patient. </li> <li class="seamTextUnorderedListItem">Previous studies using TIL in melanoma have shown effectiveness in shrinking the tumor. </li> <li class="seamTextUnorderedListItem">In this study, researchers will study the effectiveness of TIL in shrinking breast (and other) tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01174121' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT01174121' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.esmo.org/Conferences/Past-Conferences/ESMO-2014-Congress/News-Articles/The-Promise-of-Tumour-Infiltrating-Lymphocytes-for-Cancer-Treatment-and-as-Prognostic-Predictive-Indicators' target='_blank'>ESMO: Tumor Infiltrating Lymphocytes in Melanoma</a> </li></ul>

290

Individualized Immunotherapy for Metastatic Breast (and Other) Cancer

Show Scientific Title

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Nearest Location from 94107:
2432 miles
National Institutes of Health Clinical Center
Bethesda, MD

Visits:
Hospital stay for about 4 weeks

ClinicalTrials.gov: NCT01174121

Phase II

291

Using Personalized T-Cells Along with Chemotherapy to Treat Metastatic Breast Cancer

Show Scientific Title

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

Purpose: To study the safety and effects (good and bad) of an immunotherapy that uses personalized T cells.

Who is this for?: People with metastatic (stage IV) breast cancer for which standard treatments have not worked. View full eligibility criteria

What's involved?

You will be in the hospital and receive the following: Before hospital stay: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis (blood draw for the collection of cells), 2-4 months before receiving treatment</li> </ul> Hospital stay for receiving treatment (2-3 weeks): <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, once a day, for 2 days </li> <li class="seamTextUnorderedListItem">Fludarabine (Fludara), by IV, once a day, for 5 days</li> <li class="seamTextUnorderedListItem">Followed by Aldesleukin, by IV, once every 8 hours, for up to 4 days </li> <li class="seamTextUnorderedListItem">TCR-Transduced T-Cells, by IV</li> </ul> After hospital stay: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Antibiotic and antiviral, for at least 6 months</li> <li class="seamTextUnorderedListItem">Screening tests, every few months for the first year, every 6 months for the second year, then as determined</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">To create the personalized T cells, cancer cells will be taken from your tumor and white blood cells will be removed from your blood. </li> <li class="seamTextUnorderedListItem">The cancer cells will be analyzed to learn about the genetic mutations they contain. </li> <li class="seamTextUnorderedListItem">In a lab, your white blood cells will be modified in ways that will help them go after your tumor cells. </li> <li class="seamTextUnorderedListItem">They will then be infused into your body. This will take place in the hospital where the research study is taking place. </li> <li class="seamTextUnorderedListItem">When you receive the infused T cells, you will also be given Aldesleukin, an immune function enhancing drug. </li> <li class="seamTextUnorderedListItem">Your treatment will also include two chemotherapy drugs: cyclophosphamide (Cytoxan), which is used to treat breast cancer, and fludarabine (Fludara), which is approved to treat chronic lymphocytic leukemia (CLL). </li> <li class="seamTextUnorderedListItem">This trial also is enrolling patients with other types of metastatic cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03412877' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/press-releases/2014/ACTepithelial' target='_blank'>National Cancer Institute Press Release: Immunotherapy</a> </li></ul>

291

Using Personalized T-Cells Along with Chemotherapy to Treat Metastatic Breast Cancer

Show Scientific Title

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

Nearest Location from 94107:
2432 miles
National Institutes of Health Clinical Center
Bethesda, MD

Visits:
Hospital stay for up to 9 days; screening test every few months for 2 years

ClinicalTrials.gov: NCT03412877

Phase II

292

Brain Stimulation and Training to Improve Vision for Metastatic Breast Cancer that has Spread to the Brain

Show Scientific Title

Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training

Purpose: To study whether transcranial random noise stimulation (tRNS) plus learning-based training can improve vision.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and who are experiencing vision loss due to brain metastases. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transcranial random noise stimulation (tRNS), three 18-minute sessions per day for 2 days</li> <li class="seamTextUnorderedListItem">Perceptual learning-based training</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sham stimulation, three 18-minute sessions per day for 2 days</li> <li class="seamTextUnorderedListItem">Perceptual learning-based training</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sham stimulation, three 18-minute sessions per day for 2 days</li> <li class="seamTextUnorderedListItem">Perceptual learning-based training</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transcranial random noise stimulation (tRNS), three 18-minute sessions per day for 2 days</li> <li class="seamTextUnorderedListItem">Perceptual learning-based training</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transcranial random noise stimulation (tRNS) is a noninvasive brain stimulation technique for improving vision by targeting the regions of the brain responsible for vision.</li> <li class="seamTextUnorderedListItem">Perceptual learning-based training is a task in which the person judges the direction of moving dots.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling healthy people as controls.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07105358' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

292

Brain Stimulation and Training to Improve Vision for Metastatic Breast Cancer that has Spread to the Brain

Show Scientific Title

Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training

Nearest Location from 94107:
2436 miles
Georgetown University Medical Center
Washington D.C., DC

Visits:
4 visits within 2 weeks

ClinicalTrials.gov: NCT07105358

Phase NA

293

Understanding Barriers to Follow-Up After a Positive Breast Cancer Screening Result

Show Scientific Title

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

Purpose: To study a community-based outreach program for screening, diagnosis, and treatment of breast cancer.

Who is this for?: Women, age 40-74 years, who received a result of "positive" for breast cancer following screening. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Referral for follow-up after receiving a <q>positive</q> breast cancer screening result</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at differences between adults who accept or decline follow-up after a <q>positive</q> cancer screening result. The researchers are looking for factors that prevent or make it easier for someone to receive cancer screening, diagnosis, treatment, and clinical trial screening. They are also seeking to understand people's feelings towards navigators who may help people receive these services.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people who were screened for other cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07231159' target='_blank'>ClinicalTrials.gov</a> </li></ul>

293

Understanding Barriers to Follow-Up After a Positive Breast Cancer Screening Result

Show Scientific Title

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

Nearest Location from 94107:
2437 miles
Adventhealth
Orlando, FL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07231159

Phase NA

294

Blood Test to Detect Breast Cancer

Show Scientific Title

Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach

Purpose: To help develop a blood test to detect breast cancer.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer and people who have not been diagnosed with breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 fasting blood draw</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features in a person that tell doctors something about that person’s health.</li> <li class="seamTextUnorderedListItem">FGF19 is a protein that is a possible biomarker for breast cancer. The amount of FGF19 in blood may be abnormal in people with breast cancer.</li> <li class="seamTextUnorderedListItem">The study will compare the amount of FGF19 in the blood of people with and without breast cancer.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06068257' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis#:~:text=Complete%20blood%20count%20(CBC)&text=It%20can%20help%20diagnose%20some,health%20during%20and%20after%20treatment.' target='_blank'>National Cancer Institute: How Cancer Is Diagnosed</a> </li><li class='seamTextUnorderedListItem'><a href='https://med.ucf.edu/media/2023/03/Participant-Recruitment-Flyer-External_Version-1_Tumor-Derived-FGF19_PI-Deborah-Altomare.pdf' target='_blank'>UCF Study Information</a> </li></ul>

294

Blood Test to Detect Breast Cancer

Show Scientific Title

Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach

Nearest Location from 94107:
2444 miles
Burnett School Biomedical Sciences
Orlando, FL

Visits:
1 visit

ClinicalTrials.gov: NCT06068257

Phase NA

295

Registry of Mammograms to Improve Artificial Intelligence Analysis of Scans

Show Scientific Title

UCF MammoChat: An AI-Driven Platform for Personalized Breast Cancer Patient Support -Image Repository

Purpose: To develop artificial intelligence (AI) models to better read diagnostic mammograms.

Who is this for?: People who have received a mammogram. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide consent to donate your mammogram.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Around half of women will receive a false positive mammogram result (a report of cancer when cancer is not actually present). This creates anxiety.</li> <li class="seamTextUnorderedListItem">Artificial intelligence (AI) may be able to better read mammograms to reduce false positive results. AI models need to be improved for different racial groups, age ranges, ethnicities, and different types of breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07214883' target='_blank'>ClinicalTrials.gov</a> </li></ul>

295

Registry of Mammograms to Improve Artificial Intelligence Analysis of Scans

Show Scientific Title

UCF MammoChat: An AI-Driven Platform for Personalized Breast Cancer Patient Support -Image Repository

Nearest Location from 94107:
2446 miles
University of Central Florida
Orlando, FL

Visits:
No visits required

ClinicalTrials.gov: NCT07214883

Phase NA

296

AG01 Targeted Therapy for Advanced HER2-/HER2 Low Breast Cancer That Expresses GP88

Show Scientific Title

FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AG01, an experimental PGRN/GP88 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) or HER2 low breast cancer that expresses GP88. You must have received standard treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AG01, by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AG01 is an experimental targeted therapy called a PGRN/GP88 inhibitor. Blocking PGRN/GP88 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: GP88</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05627960' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abstractsonline.com/pp8/#!/10462/presentation/1702' target='_blank'>SABCS 2021 Abstract: AG01 Inhibits Growth of Triple Negative Breast Cancer Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubmed.ncbi.nlm.nih.gov/33616772/' target='_blank'>Journal Article: AG01 Inhibits Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li></ul>

296

AG01 Targeted Therapy for Advanced HER2-/HER2 Low Breast Cancer That Expresses GP88

Show Scientific Title

FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma

Nearest Location from 94107:
2452 miles
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, MD

Visits:
1 visit every 2 weeks

ClinicalTrials.gov: NCT05627960

Phase I

297

Registry to Identify Biomarkers and Improve Treatment for Breast Cancer Leptomeningeal Metastasis

Show Scientific Title

A Translational Observational Biorepository and Management Study in Patients With Breast Cancer Leptomeningeal Metastasis: The BioLept Study

Purpose: To identify biomarkers for leptomeningeal metastases and improve treatment options for people with leptomeningeal metastases.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal metastasis or leptomeningeal disease). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and/or CSF samples, at least 1-2 times in 1 month</li> <li class="seamTextUnorderedListItem">Questionnaires, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastasis or leptomeningeal disease (LMD) is difficult to treat.</li> <li class="seamTextUnorderedListItem">This trial will collect information and samples that will be used to study LMD.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06638294' target='_blank'>ClinicalTrials.gov</a> </li></ul>

297

Registry to Identify Biomarkers and Improve Treatment for Breast Cancer Leptomeningeal Metastasis

Show Scientific Title

A Translational Observational Biorepository and Management Study in Patients With Breast Cancer Leptomeningeal Metastasis: The BioLept Study

Nearest Location from 94107:
2453 miles
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

Visits:
At least 1-2 visits in 1 month

ClinicalTrials.gov: NCT06638294

Phase NA

298

Analyzing Tumor Mutations Before and After Treatment with Targeted Therapies

Show Scientific Title

A Basket Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy

Purpose: To compare genetic mutations seen in a tumor sample before and after treatment with a targeted therapy. The study will investigate how tumor mutations can be used to predict a cancer's response to treatment and how they change in response to targeted therapies.

Who is this for?: People who are receiving ongoing care at Memorial Sloan Kettering Cancer Center. View full eligibility criteria

What's involved?

All participants will be asked to provide: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A tube of blood</li> <li class="seamTextUnorderedListItem">Cheek swab (also known as a buccal), or a saliva sample that contains normal genes for comparison</li> </ul> Leftover tumor tissue from a previous surgery or biopsy will be used for genomic testing.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most genetic mutations found in cancer cells are not passed down from parents (inherited), but occur when the cells make mistakes when they divide.</li> <li class="seamTextUnorderedListItem">Most cancers have many mutations.</li> <li class="seamTextUnorderedListItem">Some of these mutations help drive the tumor's growth, while others are just bystanders.</li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket trials enroll people based on the kind of mutations found in their tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01775072' target='_blank'>ClinicalTrials.gov</a> </li></ul>

298

Analyzing Tumor Mutations Before and After Treatment with Targeted Therapies

Show Scientific Title

A Basket Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy

Nearest Location from 94107:
2494 miles
Lehigh Valley Health Network
Allentown, PA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT01775072

Phase NA

299

An Experimental Tracer in PET/CT Scans to Find Breast Cancer Tumors

Show Scientific Title

Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer

Purpose: To study the safety and effectiveness of an experimental PET/CT scan tracer (a radioactive substance that looks for and attaches to cancer cells).

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have at least one tumor 1.5 cm or larger. View full eligibility criteria

What's involved?

You will receive the following 1 to 4 times: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">(18F)F-GLN tracer, by IV, then a PET/CT scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">Cancer cells use a protein called glutamine to grow--they use more of it than healthy cells. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F) F-GLN--it shows which cells in your body are using a lot of glutamine. </li> <li class="seamTextUnorderedListItem">A (18F) F-GLN PET/CT scan may work better than standard of care PET/CT scans in finding cancer tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03863457' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/pet' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/beyond-sugar-what-cancer-cells-need-grow' target='_blank'>Memorial Sloan Kettering Cancer Center: Beyond Sugar, What Cancer Cells Need to Grow</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373500/' target='_blank'>Journal Article: Metabolic Imaging of Glutamine in Cancer</a> </li></ul>

299

An Experimental Tracer in PET/CT Scans to Find Breast Cancer Tumors

Show Scientific Title

Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer

Nearest Location from 94107:
2517 miles
University of Pennsylvania
Philadelphia, PA

Visits:
1 to 4 visits

ClinicalTrials.gov: NCT03863457

Phase I

300

Comparing Neurocognitive Changes Between Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) for Brain Metastases

Show Scientific Title

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study

Purpose: To determine if Stereotactic Radiosurgery (SRS) preserves neurological function better than Stereotactic Body Radiation Therapy (SBRT) in patients with multiple brain metastases.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who are planning to undergo radiation therapy to the brain. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive assessments at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy. </li> <li class="seamTextUnorderedListItem">Stereotactic Body Radiation Therapy (SBRT) treats the whole brain and the spine.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03184038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.everydayhealth.com/cancer/stereotactic-therapy-is-best-for-brain-metastases-and-more-cancer-news-from-day-one-of-astro/' target='_blank'>Everyday Health: Stereotactic Therapy For Brain Metastases</a> </li></ul>

300

Comparing Neurocognitive Changes Between Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) for Brain Metastases

Show Scientific Title

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study

Nearest Location from 94107:
2519 miles
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, PA

Visits:
Please contact the research site

ClinicalTrials.gov: NCT03184038

Phase NA

301

Studying Genetic and Molecular Biomarkers of Breast Cancer in Black Women or Men

Show Scientific Title

African Cancer Genome Cohort to Promote Health Equity Among Patients of African Ancestry: Characterization of Genetic and Molecular Drivers

Purpose: To study genetic and molecular biomarkers of breast cancer in individuals of African ancestry.

Who is this for?: Black women or men with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood and tumor tissues</li> <li class="seamTextUnorderedListItem">Receive genetic testing</li> <li class="seamTextUnorderedListItem">Complete social determinants of health (SDOH) survey</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will also identify the effects of social determinants of health (SDOH) and lifestyle factors on breast cancer mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05754658' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/about/priorities/why-is-addressing-sdoh-important.html#:~:text=Social%20determinants%20of%20health%20(SDOH)%20are%20the%20nonmedical%20factors%20that,live%2C%20worship%2C%20and%20age.' target='_blank'>Centers for Disease Control and Prevention: Social Determinants of Health (SDOH)</a> </li></ul>

301

Studying Genetic and Molecular Biomarkers of Breast Cancer in Black Women or Men

Show Scientific Title

African Cancer Genome Cohort to Promote Health Equity Among Patients of African Ancestry: Characterization of Genetic and Molecular Drivers

Nearest Location from 94107:
2521 miles
Fox Chase Cancer Center
Philadelphia, PA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05754658

Phase NA

302

Sotorasib Targeted Therapy for Metastatic Breast Cancer with KRAS G12C+ Brain Metastases

Show Scientific Title

BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)

Purpose: To find out how safe and effective sotorasib, an experimental targeted therapy, is at treating KRAS G12C+ brain tumors.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. Brain metastases must be KRAS G12C positive (KRAS G12C+). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sotorasib</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sotorasib is an experimental targeted therapy called a KRAS G12C inhibitor. Blocking KRAS G12C may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Sotorasib has been approved for other types of cancer. Its use in this trial is considered experimental.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06807619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/dr-fakih-on-the-fda-approval-of-sotorasib-plus-panitumumab-for-kras-g12c-mutated-mcrc' target='_blank'>OncLive: Sotorasib for KRAS G12C+ Colorectal Cancer</a> </li></ul>

302

Sotorasib Targeted Therapy for Metastatic Breast Cancer with KRAS G12C+ Brain Metastases

Show Scientific Title

BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06807619

Phase I

303

Surveys to Study Using Telehealth in Cancer Care for People with Stage I-IV Breast Cancer

Show Scientific Title

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Purpose: To study the ability of enhanced telehealth to reduce the need to make in-person visits.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving care at Memorial Sloan Kettering Cancer Center. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care in-person visit(s)</li> <li class="seamTextUnorderedListItem">Surveys, 2 times</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enhanced telehealth visit(s)</li> <li class="seamTextUnorderedListItem">Surveys, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care.</li> <li class="seamTextUnorderedListItem">Cancer care can be easier by reducing the need to make in-person visits.</li> <li class="seamTextUnorderedListItem">This could be done using a new option called enhanced telehealth.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06954337' target='_blank'>ClinicalTrials.gov</a> </li></ul>

303

Surveys to Study Using Telehealth in Cancer Care for People with Stage I-IV Breast Cancer

Show Scientific Title

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, NJ

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT06954337

Phase NA

304

Deferoxamine For Leptomeningeal Metastasis

Show Scientific Title

A Phase 1a/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases

Purpose: To study the safety and best dose of deferoxamine to treat metastases in the leptomeninges (the lining of the brain and spinal cord).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to place a device (Ommaya reservoir) similar to a chemotherapy port under your scalp</li> <li class="seamTextUnorderedListItem">Deferoxamine, via the Ommaya reservoir, 2-8 sessions per month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Deferoxamine is an experimental therapy and will be administered through an Ommaya reservoir.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF), the fluid or liquid surrounding your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">Leptomeningeal metastasis occurs when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges).</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that have spread to the leptomeninges.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05184816' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/secondary-cancer/leptomeningeal-metastases/what-are#:~:text=Leptomeningeal%20metastases%20mean%20cancer%20cells,leptomeningeal%20disease' target='_blank'>Cancer Research UK: What are Leptomeningeal Metastases?</a> </li><li class='seamTextUnorderedListItem'><a href='https://moffitt.org/cancers/brain-tumor/leptomeningeal-disease/' target='_blank'>Moffitt Cancer Center: Leptomeningeal Disease</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/deferoxamine-01' target='_blank'>Memorial Sloan Kettering Cancer Center: Deferoxamine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/faq-about-ommaya-reservoirs-and-ommaya-taps' target='_blank'>Memorial Sloan Kettering Cancer Center: Frequently Asked Questions About Ommaya Reservoirs and Ommaya Taps</a> </li></ul>

304

Deferoxamine For Leptomeningeal Metastasis

Show Scientific Title

A Phase 1a/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Visits:
2-8 visits per month

ClinicalTrials.gov: NCT05184816

Phase I

305

Managing High Blood Pressure During Treatment for Women with Stage I-IV Breast Cancer

Show Scientific Title

Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT), A Randomized Controlled Trial

Purpose: To compare the safety and effects (good and bad) of 2 methods of managing high blood pressure during breast cancer treatment.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer and high blood pressure who are planning to receive chemotherapy. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard doses of high blood pressure medication</li> <li class="seamTextUnorderedListItem">Dietary and lifestyle changes</li> <li class="seamTextUnorderedListItem">Echocardiograms, 3 times</li> <li class="seamTextUnorderedListItem">Exercise tests, 3 times</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Higher doses of high blood pressure medication</li> <li class="seamTextUnorderedListItem">Dietary and lifestyle changes</li> <li class="seamTextUnorderedListItem">Echocardiograms, 3 times</li> <li class="seamTextUnorderedListItem">Exercise tests, 3 times</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, such as high blood pressure, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">Dietary changes include limiting salt intake.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06023576' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/side-effects/heart-health' target='_blank'>Living Beyond Breast Cancer: Heart Health</a> </li></ul>

305

Managing High Blood Pressure During Treatment for Women with Stage I-IV Breast Cancer

Show Scientific Title

Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT), A Randomized Controlled Trial

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Visits:
4 visits within 1 year

ClinicalTrials.gov: NCT06023576

Phase II

306

Targeted Therapy and Hormone Therapy for Advanced ER+ or ER Low, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of lenvatinib (Lenvima®) tyrosine kinase inhibitor, pembrolizumab (Keytruda®) PD-1 inhibitor, and fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) breast cancer who have received hormone therapy with a CDK4/6 inhibitor for advanced disease. You must not have received more than 2 lines of chemotherapy for advanced disease or a PD-1/PD-L1 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lenvatinib (Lenvima®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 1.5 months</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by IV, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lenvatinib (Lenvima®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Premenopausal women and men will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06110793' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a615015.html' target='_blank'>MedlinePlus: Lenvatinib (Lenvima®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li></ul>

306

Targeted Therapy and Hormone Therapy for Advanced ER+ or ER Low, HER2- Breast Cancer

Show Scientific Title

A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Visits:
1 visit every month

ClinicalTrials.gov: NCT06110793

Phase I-II

307

Language Translation During Appointments for People With Stage I-IV Breast Cancer

Show Scientific Title

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)

Purpose: To measure 3 different ways of translating medical conversations from English to Spanish or Mandarin.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer that was diagnosed within the last 2 months and whose preferred language is Spanish or Mandarin. You must be receiving care at Memorial Sloan Kettering Cancer Center in New York City, NY. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Translation of medical conversation in real time, audio only</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Translation of medical conversation after the speaker has stopped talking, audio only</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Translation of medical conversation after the speaker has stopped talking, audio and video</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People who do not speak English well can better understand medical conversations that are conducted in or translated to their preferred language.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06721065' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.interprefy.com/resources/how-remote-simultaneous-interpretation-works#:~:text=Remote%20Simultaneous%20Interpretation%20(RSI)%20is,no%20equipment%20and%20no%20barriers.' target='_blank'>Interprefy: Remote Simultaneous Interpretation</a> </li><li class='seamTextUnorderedListItem'><a href='https://interpreter.io/Blog/understanding-consecutive-interpretation-a-simple-guide.html#:~:text=In%20consecutive%20interpretation%2C%20the%20interpreter,to%20jot%20down%20key%20points.' target='_blank'>Interpreter.io: Remote Consecutive Interpretation</a> </li></ul>

307

Language Translation During Appointments for People With Stage I-IV Breast Cancer

Show Scientific Title

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, NJ

Visits:
Coincides with routine care

ClinicalTrials.gov: NCT06721065

Phase NA

308

Abemaciclib CDK4/6 Inhibitor with Radiation for People with Metastatic HR+, HER2- Breast Cancer with Bone Metastases

Show Scientific Title

A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer

Purpose: To test different doses of abemaciclib (Verzenio®) CDK4/6 inhibitor to find the best dose in people receiving radiation.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2-) breast cancer with bone metastases who are planning to receive radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06678269' target='_blank'>ClinicalTrials.gov</a> </li></ul>

308

Abemaciclib CDK4/6 Inhibitor with Radiation for People with Metastatic HR+, HER2- Breast Cancer with Bone Metastases

Show Scientific Title

A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering at Basking Ridge (All protocol activities)
Basking Ridge, NJ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06678269

Phase I

309

Two Types of Radiation Therapy for Metastatic Breast Cancer

Show Scientific Title

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases

Purpose: To study the anti-cancer activity of 2 types of radiation therapy.

Who is this for?: People with metastatic (stage IV) breast cancer with tumors in at least two locations (not including the brain). You must not be taking any anti-cancer medications. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conventional stereotactic body radiotherapy (SBRT) to one tumor</li> <li class="seamTextUnorderedListItem">Lattice radiation therapy (LRT) to a second tumor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conventional stereotactic body radiotherapy (SBRT), also called stereotactic radiosurgery, delivers focused radiation to each tumor.</li> <li class="seamTextUnorderedListItem">Lattice radiation therapy (LRT) is a method of delivering radiation across the tumor. It may spare nearby organs from radiation damage.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05837767' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.betterhealthcaretechnology.org/implementing-spatially-fractionated-radiation-therapy-sfrt-techniques-for-palliative-treatment-of-bulky-tumours/' target='_blank'>Better Healthcare Technology Foundation: Lattice vs. Standard Radiation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/sbrt/pyc-20446794#:~:text=Stereotactic%20body%20radiotherapy%20(SBRT)%20is,tumors%2C%20anywhere%20in%20the%20body.' target='_blank'>Mayo Clinic: SBRT</a> </li></ul>

309

Two Types of Radiation Therapy for Metastatic Breast Cancer

Show Scientific Title

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05837767

Phase NA

310

Studying Bone Changes in Post-Menopausal Women with Stage I-IV Breast Cancer After Treatment with Aromatase Inhibitor and Denosumab

Show Scientific Title

Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation

Purpose: To gather information about changes in the bones after stopping treatment with an aromatase inhibitor and denosumab (Xgeva®).

Who is this for?: Postmenopausal women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have completed treatment with an aromatase Inhibitor before or within 6 months of completing at least 2 doses of denosumab (Xgeva®). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical exam, 5 visits within 2 years</li> <li class="seamTextUnorderedListItem">DEXA scan, 2 times within 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The physical exam will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work.</li> <li class="seamTextUnorderedListItem">Dual-energy X-ray absorptiometry (DEXA) scans use x-ray energy to measure bone density (thickness and strength of bones).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05590949' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/radiation-health/data-research/facts-stats/dexa-scan.html' target='_blank'>CDC: DEXA Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a610023.html' target='_blank'>MedlinePlus: Denosumab (Xgeva®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li></ul>

310

Studying Bone Changes in Post-Menopausal Women with Stage I-IV Breast Cancer After Treatment with Aromatase Inhibitor and Denosumab

Show Scientific Title

Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Visits:
5 visits

ClinicalTrials.gov: NCT05590949

Phase NA

311

Dose Selection of Capecitabine or 5-Fluorouracil According to Genetic Testing for the DYPD Gene for Stage I-IV Breast Cancer

Show Scientific Title

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Purpose: To study the safety and effects (good and bad) of 5-fluorouracil (5-FU) or capecitabine (Xeloda®) chemotherapy when the dose is selected based on testing of the DPYD gene.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive 5-fluorouracil (5-FU) or capecitabine (Xeloda®). You must have received DPYD genetic testing. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups, depending on your DPYD genetic testing results: Group 1: Normal DPYD Gene <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-fluorouracil (5-FU), by injection, standard dose OR </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by injection, standard dose</li> <li class="seamTextUnorderedListItem">Dose will be reduced if needed</li> <li class="seamTextUnorderedListItem">Dose may be increased if tolerated</li> </ul> Group 2: DPYD Gene Variant <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-fluorouracil (5-FU), by injection, half the standard dose OR </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by injection, half the standard dose</li> <li class="seamTextUnorderedListItem">Dose may be increased if tolerated</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-Fluorouracil (5-FU) and capecitabine (Xeloda®) are chemotherapy drugs commonly used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">People can respond differently to these drugs due to genetic variations. The FDA now recommends testing for these genetic variants.</li> <li class="seamTextUnorderedListItem">This trial will test dosing of these drugs guided by genetic testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07158164' target='_blank'>ClinicalTrials.gov</a> </li></ul>

311

Dose Selection of Capecitabine or 5-Fluorouracil According to Genetic Testing for the DYPD Gene for Stage I-IV Breast Cancer

Show Scientific Title

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Nearest Location from 94107:
2541 miles
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, NJ

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT07158164

Phase IV

312

Trastuzumab Deruxtecan ADC for People with Advanced HER2 Negative or HER2 Low Breast Cancer

Show Scientific Title

A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of trastuzumab deruxtecan (T-DXd, Enhertu®) antibody drug conjugate (ADC) for advanced HER2 negative or HER2 low breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with HER2 negative (IHC 0) or HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received 1-2 lines of therapy for advanced disease. You must not have received anti-HER2 targeted therapy for advanced disease or any antibody drug conjugate (ADC). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) is a type of immunotherapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) uses the HER2-targeted antibody trastuzumab to deliver the chemotherapy DM1 directly to the cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05950945' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.destinyclinicaltrials.com/en#DESTINY-breast' target='_blank'>AstraZeneca: DESTINY Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab Deruxtecan (Enhertu®)</a> </li></ul>

312

Trastuzumab Deruxtecan ADC for People with Advanced HER2 Negative or HER2 Low Breast Cancer

Show Scientific Title

A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

Nearest Location from 94107:
2549 miles
Overlook Medical Center
Summit, NJ

Visits:
1 visit every 3 weeks

ClinicalTrials.gov: NCT05950945

Phase III

313

Stereotactic Body Radiation Therapy for Metastatic HER2+, HER2 Low, or ER+, HER2- Breast Cancer

Show Scientific Title

Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of stereotactic body radiotherapy (SBRT).

Who is this for?: People with metastatic (stage IV) HER2 positive (HER2+), HER2 low, or estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer. You must have a small number of metastases (oligometastatic disease) and have received standard treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic body radiotherapy (SBRT), 3-5 sessions</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Oligometastatic breast cancer is metastatic breast cancer with a small number of metastases.</li> <li class="seamTextUnorderedListItem">Stereotactic body radiotherapy (SBRT) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">During this trial, you will continue your current line of therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05534438' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uclahealth.org/departments/radonc/research-technologies/innovation-technology/external-beam-radiation-therapy-ebrt/stereotactic-body-radiation-therapy-sbrt/faqs-sbrt' target='_blank'>UCLA Health: Stereotactic Body Radiation Therapy (SBRT)</a> </li></ul>

313

Stereotactic Body Radiation Therapy for Metastatic HER2+, HER2 Low, or ER+, HER2- Breast Cancer

Show Scientific Title

Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression

Nearest Location from 94107:
2561 miles
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, NJ

Visits:
3-5 visits within 1 week

ClinicalTrials.gov: NCT05534438

Phase II

314

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Show Scientific Title

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases

Purpose: To compare how well multi-disciplinary care and standard care work for managing symptoms and understanding outcomes.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Your brain metastases must be newly diagnosed. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Multi-disciplinary care</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Care for people with brain metastases involves complex medical decision making and requires input for multiple groups (disciplines).</li> <li class="seamTextUnorderedListItem">Multi-disciplinary care includes medical oncology, neurosurgery, radiation oncology, neuro-oncology, and palliative care.</li> <li class="seamTextUnorderedListItem">This process may look different for different patients.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06280300' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

314

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Show Scientific Title

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases

Nearest Location from 94107:
2564 miles
University of Vermont Medical Center
Burlington, VT

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06280300

Phase NA

315

Improving Mental Health for Older Adults with Breast Cancer

Show Scientific Title

Mental Health Care Initiation Intervention for Older Adults With Cancer

Purpose: To study the ability of the Open Door for Cancer (OD-C) approach to improve mental health for older adults with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who were diagnosed at age 65 or older and are currently receiving treatment. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Open Door for Cancer (OD-C) approach, by phone or videoconference, 3 sessions within 1.5 months</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mental health screening</li> <li class="seamTextUnorderedListItem">Referrals to support resources</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Open Door for Cancer (OD-C) approach includes the following: 1) Provide education about depression and treatment options; 2) Identify treatment preferences and a personal goal achievable with mental health care; 3) Assess barriers to starting treatment; 4) Referrals to additional support; 5) Address barriers to accessing care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06037954' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/taking-care-of-mental-health/how-breast-cancer-affects-mental-health' target='_blank'>Breastcancer.org: How Breast Cancer Can Affect Mental Health</a> </li></ul>

315

Improving Mental Health for Older Adults with Breast Cancer

Show Scientific Title

Mental Health Care Initiation Intervention for Older Adults With Cancer

Nearest Location from 94107:
2567 miles
Memorial Sloan Kettering Cancer Center
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06037954

Phase NA

316

Pembrolizumab (Immunotherapy) And Radiosurgery (Radiation) to Treat Brain Metastases

Show Scientific Title

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Purpose: To study the safety and effects (good and bad) of using pembrolizumab (Keytruda®) along with stereotactic radiosurgery (SRS) to treat breast cancer that has spread to the brain.

Who is this for?: Women with metastatic (stage IV) breast cancer and at least two brain metastases. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS), once after the first treatment of pembrolizumab</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor.</li> <li class="seamTextUnorderedListItem">It stimulates the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">It has been approved to treat certain types of cancer, but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery is not surgery. It is a type of radiation therapy that precisely targets metastases in the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03449238' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Metastases</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/local/brain/radiosurgery' target='_blank'>Breastcancer.org: Stereotactic Radiosurgery for Brain Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/what' target='_blank'>Breastcancer.org: What is Immunotherapy?</a> </li></ul>

316

Pembrolizumab (Immunotherapy) And Radiosurgery (Radiation) to Treat Brain Metastases

Show Scientific Title

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Nearest Location from 94107:
2567 miles
Weill Cornell Medicine
New York, NY

Visits:
1 visit every 3 weeks, ongoing

ClinicalTrials.gov: NCT03449238

Phase I-II

317

Radiation Therapy, Anti-Estrogen Therapy, and a CDK 4/6 Inhibitor for Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Purpose: To study the anti-cancer activity, side effects, and changes to ctDNA when giving radiation therapy before the standard of care hormone therapy and a CDK 4/6 inhibitor.

Who is this for?: Postmenopausal women with metastatic (stage IV) hormone-positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with no more than five metastases (mets). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation, for 2 weeks</li> <li class="seamTextUnorderedListItem">followed by</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. It is commonly used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is commonly used with anti-estrogen therapy for metastatic, hormone-positive (ER+ and/or PR+), HER2-negative (HER2-) breast cancer. </li> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery) delivers focused radiation to each metastasis (met/tumor).</li> <li class="seamTextUnorderedListItem">Oligometastatic breast cancer is metastatic breast cancer with a small number of metastases.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04563507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/update-on-hormone-receptor-positive-mbc-2021/' target='_blank'>Metastatic Trial Talk: Update on Hormone Receptor-Positive MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oligometastatic-breast-cancer/' target='_blank'>Metastatic Trial Talk: What is Oligometastatic Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/full/10.14694/EdBook_AM.2015.35.e8' target='_blank'>ASCO: Surgery or Ablative Radiotherapy for Breast Cancer Oligometastases</a> </li></ul>

317

Radiation Therapy, Anti-Estrogen Therapy, and a CDK 4/6 Inhibitor for Metastatic HR+, HER2- Breast Cancer

Show Scientific Title

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Nearest Location from 94107:
2567 miles
Weill Cornell Medicine
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04563507

Phase II

318

MRI Scan to Study Changes in Brain Tumors After Treatment

Show Scientific Title

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases

Purpose: To develop a new MRI scan technique that will study the difference between tumor growth from cancer progression and tumor growth from treatment side effects.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive stereotactic radiosurgery. You must have at least 1 brain tumor that has not received radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting is a type of MRI scan.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05559853' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

318

MRI Scan to Study Changes in Brain Tumors After Treatment

Show Scientific Title

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases

Nearest Location from 94107:
2567 miles
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05559853

Phase NA

319

Stem Cells with Chemotherapy for Metastatic HER2- Breast Cancer with an Inherited BRCA1/2 or PALB2 Mutation

Show Scientific Title

SHARON: Study of Metastatic Cancers in Patients With an Inherited Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of stem cells with melphalan chemotherapy.

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) breast cancer with an inherited (germline) BRCA1, BRCA2, or PALB2 mutation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Granulocyte colony-stimulating factor</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Apheresis procedure to collect stem cells</li> </ul> followed by 2 rounds of: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Melphalan, by IV</li> <li class="seamTextUnorderedListItem">Carmustine (BCNU), by IV</li> <li class="seamTextUnorderedListItem">Vitamin B12b, by IV</li> <li class="seamTextUnorderedListItem">Vitamin C, by IV</li> <li class="seamTextUnorderedListItem">Ethanol, by IV</li> </ul> followed 2 days later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stem cells, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your stem cells will be collected from your body and modified in a lab so they can identify and attack cancer cells. These modified stem cells will then be infused back into your body.</li> <li class="seamTextUnorderedListItem">Apheresis is a procedure to collect your stem cells. </li> <li class="seamTextUnorderedListItem">Granulocyte colony-stimulating factor is a drug that will help prepare your body and stem cells for apheresis.</li> <li class="seamTextUnorderedListItem">Melphalan is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Carmustine (BCNU), vitamin B12b, vitamin C, and ethanol will be given to improve the effectiveness of the stem cell infusion.</li> <li class="seamTextUnorderedListItem">You will receive two rounds of melphalan (Alkeran®) chemotherapy and stem cell infusion approximately 6 weeks apart.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04150042' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sharontrial.com/' target='_blank'>General Oncology: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.facingourrisk.org/research-clinical-trials/study/117/a-study-of-melphalan-bcnu-vitamin-b12b-vitamin-c-and-stem-cell-infusion-in-people-with-advanced-pancreatic-cancer-and-brca-mutations' target='_blank'>Facing Our Risk of Cancer Empowered: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/autologous-stem-cell-transplant/pyc-20384859' target='_blank'>Mayo Clinic: Autologous Stem Cell Transplant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/stem-cell-transplant/process.html' target='_blank'>American Cancer Society: Getting a Stem Cell Transplant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/melphalan-intravenous-route/side-effects/drg-20071590?p=1#:~:text=Melphalan%20injection%20is%20used%20to,alkylating%20agents%20(cancer%20medicines).' target='_blank'>Mayo Clinic: Melphalan</a> </li></ul>

319

Stem Cells with Chemotherapy for Metastatic HER2- Breast Cancer with an Inherited BRCA1/2 or PALB2 Mutation

Show Scientific Title

SHARON: Study of Metastatic Cancers in Patients With an Inherited Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

Nearest Location from 94107:
2567 miles
Memorial Sloan Kettering Cancer Center
New York, NY

Visits:
At least 6 visits, may require hospitalization

ClinicalTrials.gov: NCT04150042

Phase I

320

Abemaciclib With Bicalutamide for Androgen Receptor+, HER2- Advanced Breast Cancer

Show Scientific Title

A Multicenter, Phase IB/II Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Purpose: To study the safety, dose, side effects and anti-cancer activity of giving the CDK 4/6 inhibitor abemaciclib (Verzenio®) together with bicalutamide (Casodex®), an anti-androgen drug.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) androgen receptor positive (AR+) HER2 negative breast cancer. You must have received at least one line of therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Bicalutamide (Casodex®), by mouth, twice daily</li> </ul> Please contact research site for treatment schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor -- it blocks two enzymes, CDK4 and CDK6, that help cancer grow. It is already approved to treat some metastatic breast cancer, but its use in this trial is experimental.</li> <li class="seamTextUnorderedListItem">Bicalutamide (Casodex®) is an anti-androgen drug used to treat prostate cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05095207' target='_blank'>ClinicalTrials.gov</a> </li></ul>

320

Abemaciclib With Bicalutamide for Androgen Receptor+, HER2- Advanced Breast Cancer

Show Scientific Title

A Multicenter, Phase IB/II Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Nearest Location from 94107:
2568 miles
Mount Sinai - West
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05095207

Phase I-II

321

Improving PET/CT Scans with 18F-FES for People with Metastatic ER+ Breast Cancer with Brain Metastasis

Show Scientific Title

Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer

Purpose: To improve PET/CT scans with 18F-FES for people with metastatic ER+ breast cancer with brain metastasis.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-FES, by IV, 1 time</li> </ul> followed up to 1 month later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with FDG, by IV, 1 time</li> </ul> followed up to 1 month later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care imaging includes a PET/CT scan with FDG and a MRI scan.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracers used in this study are 18F-FES (experimental) and FDG (standard of care).</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06072807' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

321

Improving PET/CT Scans with 18F-FES for People with Metastatic ER+ Breast Cancer with Brain Metastasis

Show Scientific Title

Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer

Nearest Location from 94107:
2569 miles
New York-Presbyterian/Weill Cornell Medical Center
New York, NY

Visits:
At least 3 visits within 1 year

ClinicalTrials.gov: NCT06072807

Phase IV

322

Community Navigator to Provide Support Services to Black and Latina Women with Metastatic Breast Cancer

Show Scientific Title

Project ACCESS: A Pilot Randomized Controlled Trial of a Navigator Delivered Model to Enhance Access to Supportive Services for Women of Color With Metastatic Breast Cancer

Purpose: To study the ability of a community navigator to provide supportive care for Black and Latina women with metastatic breast cancer.

Who is this for?: African American/Black and Latina women with stage IV (metastatic) breast cancer who live in New York City, NY. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Coaching sessions with community navigator, in-person or virtual, weekly for 1.5 months</li> <li class="seamTextUnorderedListItem">Phone call check-ins, monthly for 4 months</li> <li class="seamTextUnorderedListItem">Support with scheduling supportive care visits (optional)</li> <li class="seamTextUnorderedListItem">Referrals to community resources (optional)</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Phone calls, weekly for 1.5 months</li> <li class="seamTextUnorderedListItem">Phone call check-ins, monthly for 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Black and Latina women experience unequal access to support services and care.</li> <li class="seamTextUnorderedListItem">If you are in group 1, the navigator sessions will focus on health coaching. You have the choice to receive support with scheduling supportive care visits and/or referrals to support groups, educational workshops, and healthy lifestyle services.</li> <li class="seamTextUnorderedListItem">If you are in group 2, the phone calls will include reviewing breast cancer supportive and palliative care resources in NYC and online.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06405828' target='_blank'>ClinicalTrials.gov</a> </li></ul>

322

Community Navigator to Provide Support Services to Black and Latina Women with Metastatic Breast Cancer

Show Scientific Title

Project ACCESS: A Pilot Randomized Controlled Trial of a Navigator Delivered Model to Enhance Access to Supportive Services for Women of Color With Metastatic Breast Cancer

Nearest Location from 94107:
2569 miles
Mount Sinai Hospital
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06405828

Phase NA

323

Leflunomide for Advanced HER2 Negative and/or PTEN Mutated Breast Cancer

Show Scientific Title

A Phase IA/IB Trial of Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of leflunomide, an experimental drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) and/or PTEN mutated breast cancer who have no standard treatment options available. If you have HER2- breast cancer, you must not have received more than 3 lines of chemotherapy and 2 lines of antibody drug conjugates (ADC) for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leflunomide, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leflunomide is an drug drug that is FDA approved for some types of arthritis.</li> <li class="seamTextUnorderedListItem">Leflunomide may also work for cancer. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04997993' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/leflunomide-oral-route/description/drg-20067158' target='_blank'>Mayo Clinic: Leflunomide</a> </li></ul>

323

Leflunomide for Advanced HER2 Negative and/or PTEN Mutated Breast Cancer

Show Scientific Title

A Phase IA/IB Trial of Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Nearest Location from 94107:
2569 miles
Icahn School of Medicine at Mount Sinai
New York, NY

Visits:
3 visits in 1 month, then 1 visit every month

ClinicalTrials.gov: NCT04997993

Phase I

324

Pain Medication Dispensing Device for People with Stage I-IV Breast Cancer Planning to Receive Surgery

Show Scientific Title

Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills After Cancer-Related Surgery

Purpose: To study the ability of Addinex (ADX-27) pill dispensing system to safely store and dispense pain medication.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Addinex (ADX-27) pill dispensing system with mobile app, 3 months</li> <li class="seamTextUnorderedListItem">Phone interview, 1 time</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Addinex (ADX-27) is a password protected pill dispensing system. It allows for the return and disposal of unused opioids.</li> <li class="seamTextUnorderedListItem">Opioids are pain medications often given after surgery.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05585788' target='_blank'>ClinicalTrials.gov</a> </li></ul>

324

Pain Medication Dispensing Device for People with Stage I-IV Breast Cancer Planning to Receive Surgery

Show Scientific Title

Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills After Cancer-Related Surgery

Nearest Location from 94107:
2569 miles
Columbia University Medical Center
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05585788

Phase NA

325

Brodalumab to Manage Immunotherapy Side Effects for People with Advanced Breast Cancer

Show Scientific Title

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: a Pilot Study

Purpose: To study the safety and ability of brodalumab to manage side effects from immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who are experiencing side effects from immunotherapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brodalumab, by injection, weekly for 3 weeks, then every 2 weeks for 5.5 months</li> <li class="seamTextUnorderedListItem">Steroids (if needed)</li> <li class="seamTextUnorderedListItem">CT scan, 3 times within 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer immunotherapy can cause side effects.</li> <li class="seamTextUnorderedListItem">Side effects from immunotherapy can be similar to symptoms of autoimmune conditions.</li> <li class="seamTextUnorderedListItem">Brodalumab is FDA approved to treat people with autoimmune diseases (diseases where the immune system is activated against normal organs), and safe doses and treatment schedules have been determined in these people.</li> <li class="seamTextUnorderedListItem">Therefore, this trial will study the use of brodalumab to manage immunotherapy side effects.</li> <li class="seamTextUnorderedListItem">In this trial, the use of brodalumab is considered experimental.</li> <li class="seamTextUnorderedListItem">In this trial, visits will be a combination of in-person and virtual.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06673329' target='_blank'>ClinicalTrials.gov</a> </li></ul>

325

Brodalumab to Manage Immunotherapy Side Effects for People with Advanced Breast Cancer

Show Scientific Title

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: a Pilot Study

Nearest Location from 94107:
2569 miles
Columbia University Irving Medical Center
New York, NY

Visits:
1 visit every 1-2 weeks for 6 months

ClinicalTrials.gov: NCT06673329

Phase I

326

Developing Genetic Testing Education for Diverse Groups of People with Breast Cancer

Show Scientific Title

Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients

Purpose: To develop educational materials about genetic testing for people that speak different languages and have diverse cultural backgrounds.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing is a type of test that detects changes to the genes, the DNA instructions that are passed on from the mother and father.</li> <li class="seamTextUnorderedListItem">The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder.</li> <li class="seamTextUnorderedListItem">The information gathered from your interview will be used to develop educational materials about genetic testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04751435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease Control and Prevention: Genetic Testing</a> </li></ul>

326

Developing Genetic Testing Education for Diverse Groups of People with Breast Cancer

Show Scientific Title

Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients

Nearest Location from 94107:
2570 miles
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
New York, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04751435

Phase NA

327

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Show Scientific Title

Global Cardio Oncology Registry

Purpose: To collect information on the diagnosis and treatment of cardiovascular health and risk factors in people with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of health information</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">This study uses clinical, laboratory, imaging, demographic, and socioeconomic information to study cardiovascular (heart and blood vessels) health and risk factors before, during, or after cancer treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05598879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.heart.org/en/news/2020/02/19/what-women-need-to-know-about-breast-cancer-and-heart-disease' target='_blank'>American Heart Association: Breast Cancer and Heart Disease</a> </li></ul>

327

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Show Scientific Title

Global Cardio Oncology Registry

Nearest Location from 94107:
2573 miles
Cleveland Clinic Florida
Weston, FL

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05598879

Phase NA

328

CONVIVO Imaging System During Brain Surgery

Show Scientific Title

A Feasibility Analysis of an in Vivo CONVIVO Endomicroscopy During Brain Surgery.

Purpose: To study the safety and ability of the CONVIVO imaging system to compare healthy tissue and abnormal tissue during brain surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). View full eligibility criteria

What's involved?

You will receive the following during brain surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CONVIVO imaging system</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The CONVIVO imaging system may allow surgeons to maximize the amount of tumor tissue removed and minimize the damage to normal tissue.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06087393' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

328

CONVIVO Imaging System During Brain Surgery

Show Scientific Title

A Feasibility Analysis of an in Vivo CONVIVO Endomicroscopy During Brain Surgery.

Nearest Location from 94107:
2583 miles
Northwell Health
Manhasset, NY

Visits:
Coincides with surgery

ClinicalTrials.gov: NCT06087393

Phase NA

329

PET/CT and MRI Scans After Surgery to Monitor Brain Metastases

Show Scientific Title

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Purpose: To study the ability of PET/CT scans with 18F-Fluciclovine to help doctors monitor brain metastases after surgery compared to MRI scans.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery and radiation. You must not have received whole brain radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan, 4-5 times within 1 year</li> <li class="seamTextUnorderedListItem">18F-Fluciclovine, by IV, 4-5 times within 1 year</li> <li class="seamTextUnorderedListItem">MRI scan, 4 times within 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">18F-Fluciclovine is an experimental radioactive substance called a tracer that can look for and attach to cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05554302' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/health/mri-vs-pet-scan#pet-ct-or-pet-mri' target='_blank'>Healthline: PET/CT Scans vs. MRI Scans</a> </li></ul>

329

PET/CT and MRI Scans After Surgery to Monitor Brain Metastases

Show Scientific Title

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Nearest Location from 94107:
2587 miles
Miami Cancer Institute at Baptist Health South Florida
Miami, FL

Visits:
4-5 visits within 1 year

ClinicalTrials.gov: NCT05554302

Phase II

330

18F-Fluciclovine and PET/CT Scans for Brain Metastasis

Show Scientific Title

Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery

Purpose: To study the ability of 18F-fluciclovine and PET/CT scans to detect responses to radiation therapy and changes in brain metastasis.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive treatment with stereotactic radiosurgery. You must have at least 1 brain tumor that has not received treatment. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine (Axumin®), by IV, 3 times</li> <li class="seamTextUnorderedListItem">PET/CT brain scans, 3 scans</li> </ul> Please contact research site for treatment schedule.

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine is an experimental tracer that may be able to detect your response to staged stereotactic radiosurgery.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scans will be administered before, during, and after treatment with stereotactic radiosurgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04689048' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

330

18F-Fluciclovine and PET/CT Scans for Brain Metastasis

Show Scientific Title

Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery

Nearest Location from 94107:
2587 miles
Miami Cancer Institute
Miami, FL

Visits:
3 visits

ClinicalTrials.gov: NCT04689048

Phase I

331

PET Scan with 18F-Fluciclovine to Monitor Brain Metastases

Show Scientific Title

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery (FACILITATE)

Purpose: To study the ability of PET scans with 18F-fluciclovine to measure response to treatment or progression of brain metastases.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. You must not have received whole brain radiation therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET scan with 18F-fluciclovine, by IV, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">18F-fluciclovine is a tracer that is used to visualize cancer cells.</li> <li class="seamTextUnorderedListItem">The PET scans will take place during the same visit as your standard of care MRI scan that you will receive before radiation.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06048094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

331

PET Scan with 18F-Fluciclovine to Monitor Brain Metastases

Show Scientific Title

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery (FACILITATE)

Nearest Location from 94107:
2587 miles
Miami Cancer Institute
Miami, FL

Visits:
2 visits

ClinicalTrials.gov: NCT06048094

Phase I

332

Fasting and/or Exercise to Reduce Fatigue During Hormone Therapy for Women with Metastatic HR+ Breast Cancer

Show Scientific Title

Prolonged Overnight Fasting And/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer (FastER)

Purpose: To study the ability of fasting and/or exercise to reduce fatigue and improve other outcomes for women with advanced breast cancer who are receiving hormone therapy.

Who is this for?: Women with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer who are planning to receive treatment (starting within 1 month) with a CDK4/6 inhibitor as the first or second line of hormone therapy for metastatic disease. You must not exercise more than 1.5 hours/week or participate in regular structured fasting. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 4 groups: Group 1: Fasting Alone <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fasting diet, daily for 3 months</li> <li class="seamTextUnorderedListItem">Complete food journal, daily for 3 months</li> <li class="seamTextUnorderedListItem">Heath coaching sessions, in-person or virtual, weekly for 3 months</li> <li class="seamTextUnorderedListItem">Blood and physical tests, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">PET and CT scans, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Exercise Alone <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program with health coach, in-person or virtual, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Wear FitBit, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood and physical tests, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">PET and CT scans, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 3: Fasting and Exercise <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fasting diet, daily for 3 months</li> <li class="seamTextUnorderedListItem">Complete food journal, daily for 3 months</li> <li class="seamTextUnorderedListItem">Heath coaching sessions, in-person or virtual, weekly for 3 months</li> <li class="seamTextUnorderedListItem">Exercise program with health coach, in-person or virtual, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Wear FitBit, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood and physical tests, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">PET and CT scans, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 4: No Fasting or Exercise <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General health education sessions with health coach, virtual, every 2 weeks for 3 months</li> <li class="seamTextUnorderedListItem">Wear FitBit, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood and physical tests, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">PET and CT scans, 4 times in 1 year</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">If you are in Group 1 or Group 3, you will be asked to fast (not eat or drink) after 8pm, and wait 12 to 14 hours before eating and drinking the next day. You will be asked to fast 6 nights every week (1 night off every week).</li> <li class="seamTextUnorderedListItem">If you are in Group 4, the sessions focus on general nutrition, healthy lifestyle, and quality of life, with no discussion of fasting or exercise. </li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06123988' target='_blank'>ClinicalTrials.gov</a> </li></ul>

332

Fasting and/or Exercise to Reduce Fatigue During Hormone Therapy for Women with Metastatic HR+ Breast Cancer

Show Scientific Title

Prolonged Overnight Fasting And/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer (FastER)

Nearest Location from 94107:
2591 miles
University of Miami
Miami, FL

Visits:
At least 4 visits within 1 year

ClinicalTrials.gov: NCT06123988

Phase NA

333

Radiation for People who Cannot Receive Surgery for Stage I-IV Breast Cancer

Show Scientific Title

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of adding radiation to routine medications for breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who cannot or do not want to receive surgery. You must not be receiving systemic therapy (except for hormone therapy, HER2-targeted therapy, or immunotherapy). View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups, depending on node status: Group 1: Lymph Nodes Negative for Cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-breast radiation, 5 times</li> <li class="seamTextUnorderedListItem">CT or MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Lymph Nodes Positive for Cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-breast and lymph node radiation, 5 times</li> <li class="seamTextUnorderedListItem">CT or MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patients who cannot receive surgery for breast cancer have limited effective treatment options. Radiation may provide long-lasting control of the tumor in patients who cannot or do not wish to receive surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07122713' target='_blank'>ClinicalTrials.gov</a> </li></ul>

333

Radiation for People who Cannot Receive Surgery for Stage I-IV Breast Cancer

Show Scientific Title

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

Nearest Location from 94107:
2604 miles
Stony Brook University Cancer Center
Stony Brook, NY

Visits:
5 visits, then follow-up for up to 5 years

ClinicalTrials.gov: NCT07122713

Phase NA

334

Radiation for Breast Cancer That Spread to the Spine

Show Scientific Title

A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases

Purpose: To study if receiving stereotactic body radiation therapy (SBRT) to the spine allows people to avoid spine surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the spine (spine metastasis). You must have at least 1 lesion that has not received surgery or radiation. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT)</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06165419' target='_blank'>ClinicalTrials.gov</a> </li></ul>

334

Radiation for Breast Cancer That Spread to the Spine

Show Scientific Title

A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases

Nearest Location from 94107:
2604 miles
Stony Brook University Hospital
Stony Brook, NY

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT06165419

Phase II

335

Hormone Therapy and Targeted Therapy Based on Biomarker Testing for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of hormone therapy and targeted therapy based on biomarker testing.

Who is this for?: Post-menopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) or HER2 low breast cancer. You must have received treatment with palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®) for advanced disease. View full eligibility criteria

What's involved?

You will be assigned to 1 of 4 groups based on biomarker testing results: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth, daily</li> </ul> Group 4 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive treatment based on ERBB2, PIK3CA, AKT1, MTOR, PTEN, and RB1 biomarker testing results.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is an anti-HER2 targeted therapy that stops cancer cells from growing by targeting and blocking the HER2 proteins that help cancer cells grow.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®) is a type of targeted therapy called an mTOR inhibitor. It works by interfering with a cancer cell's ability to divide and grow.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+/FISH -.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05933395' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/nerlynx' target='_blank'>Breastcancer.org: Neratinib (Nerlynx®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/afinitor' target='_blank'>Breastcancer.org: Everolimus (Afinitor®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li></ul>

335

Hormone Therapy and Targeted Therapy Based on Biomarker Testing for Advanced ER+, HER2- Breast Cancer

Show Scientific Title

Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE)

Nearest Location from 94107:
2619 miles
Dartmouth Hitchcock Medical Center
Lebanon, NH

Visits:
1 visit every month

ClinicalTrials.gov: NCT05933395

Phase II

336

Estradiol Hormone Therapy and Olaparib Targeted Therapy for Postmenopausal Women with Advanced ER+, HER2- Breast Cancer

Show Scientific Title

Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)

Purpose: To study the safety, best dose, and effects (good and bad) of olaparib (Lynparza®) PARP inhibitor with estradiol (Estrace®) hormone therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received at least 1 line of hormone therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, daily for 2 months</li> <li class="seamTextUnorderedListItem">17b-estradiol (Estrace®), by mouth, daily for 2 months</li> </ul> followed 2 months later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol (Estrace®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">Estradiol (Estrace®) is a type of hormone therapy for advanced ER+ breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05900895' target='_blank'>ClinicalTrials.gov</a> </li></ul>

336

Estradiol Hormone Therapy and Olaparib Targeted Therapy for Postmenopausal Women with Advanced ER+, HER2- Breast Cancer

Show Scientific Title

Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)

Nearest Location from 94107:
2619 miles
Dartmouth Cancer Center
Lebanon, NH

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05900895

Phase I

337

Understanding the Value of a Meeting Between a Pathologist and Patient for Stage I-IV Breast Cancer

Show Scientific Title

24GUT540: Opportunity for Breast Cancer Patients to Meet With a Pathologist to Review the Pathology Slides of Their Breast Samples

Purpose: To study the usefulness of patient-pathologist visits in which pathologists review pathology slides with patients.

Who is this for?: People with stage I, stage II, stage III, or stage IV breast cancer who have completed their initial diagnosis visit with an oncologist or surgeon. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Meet with pathologist</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Very little is known about the value of patient-pathologist meetings. Patients generally report that the experience was positive and helpful.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07040514' target='_blank'>ClinicalTrials.gov</a> </li></ul>

337

Understanding the Value of a Meeting Between a Pathologist and Patient for Stage I-IV Breast Cancer

Show Scientific Title

24GUT540: Opportunity for Breast Cancer Patients to Meet With a Pathologist to Review the Pathology Slides of Their Breast Samples

Nearest Location from 94107:
2619 miles
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Visits:
2 visits within 2 weeks

ClinicalTrials.gov: NCT07040514

Phase NA

338

Estradiol Hormone Therapy for Postmenopausal Women with Advanced ER+ Breast Cancer

Show Scientific Title

Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of estradiol (Estrace®) hormone therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer who have received at least 1 line of hormone therapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol (Estrace®)</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol (Estrace®) is type of hormone therapy for advanced ER+ breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05716516' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drugs.com/estrace.html#:~:text=Estrace%20is%20used%20to%20treat,natural%20estrogen%20in%20the%20body.' target='_blank'>Drugs.com: Estradiol (Estrace®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>

338

Estradiol Hormone Therapy for Postmenopausal Women with Advanced ER+ Breast Cancer

Show Scientific Title

Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer

Nearest Location from 94107:
2619 miles
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05716516

Phase II

339

Preventing Mouth Sores Due to Dato-DXd With Dexamethasone Mouthwash for Advanced HR+, HER2- or Triple Negative Breast Cancer

Show Scientific Title

Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)

Purpose: To study if a dexamethasone mouthwash can prevent mouth sores following treatment with datopotamab deruxtecan (Dato-DXd; Datroway®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer whose cancer has progressed on at least one line of therapy OR people with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed on hormone therapy and a CDK 4/6 inhibitor and 1 prior line of chemotherapy and/or antibody-drug conjugate (ADC). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd; Datroway®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Dexamethasone mouthwash, 5 days per week for 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd; Datroway®) is an antibody-drug conjugate (ADC), which is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">A common side effect of datopotamab deruxtecan (Dato-DXd; Datroway®) is mouth sores and inflammation of the inside of the mouth, called stomatitis.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06974604' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/digestive-system/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2024&utm_content=Email122024' target='_blank'>Metastatic Trial Talk: Managing Side Effects of Treatment: Digestive System Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://datroway.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=22411693368&gbraid=0AAAAA-nL_-d3XIFfFFEx4zohhCrXvhfIZ&gclid=Cj0KCQiAjJTKBhCjARIsAIMC4481LG5Jq8xB9UdmzCJ1we3heac32-SwjTGI7Na6ktS2O8VU50e0DxoaAjnfEALw_wcB' target='_blank'>Daiichi Sankyo: Datopotamab Deruxtecan (Dato-DXd; Datroway®)</a> </li></ul>

339

Preventing Mouth Sores Due to Dato-DXd With Dexamethasone Mouthwash for Advanced HR+, HER2- or Triple Negative Breast Cancer

Show Scientific Title

Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)

Nearest Location from 94107:
2684 miles
Rhode Island and the Miriam Hospitals (Brown University Health)
Providence, RI

Visits:
Every 3 weeks

ClinicalTrials.gov: NCT06974604

Phase II

340

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Show Scientific Title

Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study

Purpose: To study if using MRIs to screen for brain metastases (breast cancer that has spread to the brain) is safe and finds brain metastases earlier than the standard of care (no screening).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who will be starting their first or second chemotherapy for advanced disease. View full eligibility criteria

What's involved?

You will be assigned to 1 of 3 groups depending upon your cancer subtype: Group 1: Triple negative <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 2: Inflammatory Breast Cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 3: Hormone positive or HER2 positive People in Group 3 will be randomly assigned to receiving screening or no screening Screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> No screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No brain MRIs</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic breast cancer does not include ongoing screening for brain metastases.</li> <li class="seamTextUnorderedListItem">This imaging trial will use regularly scheduled MRIs (magnetic resonance imaging) to look for brain mets.</li> <li class="seamTextUnorderedListItem">Researchers believe adding brain metastases screening to the standard of care will help doctors find brain mets earlier--when they are smaller and potentially easier to manage.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04030507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mri/about/pac-20384768' target='_blank'>Mayo Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologybusiness.com/topics/policy/brain-mri-could-id-metastases-breast-cancer-patients-guidelines-dont-recommend-it' target='_blank'>Radiology Business: Brain MRI Could ID Metastases in Breast Cancer Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/Pages/Spring2019/Looking-for-Brain-Metastases.aspx' target='_blank'>Cancer Today: Looking for Brain Metastases</a> </li></ul>

340

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Show Scientific Title

Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study

Nearest Location from 94107:
2693 miles
Brigham and Women's Hospital
Boston, MA

Visits:
1 visit every 6 months, for 2 years

ClinicalTrials.gov: NCT04030507

Phase NA

341

Proton Radiation Therapy for Brain Metastasis

Show Scientific Title

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of proton radiation therapy.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton radiation therapy, 5 visits per week</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Vision and hearing assessments</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton radiation therapy is a type of radiation therapy that uses protons instead of x-rays.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03286335' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.texascenterforprotontherapy.com/cancers-treated/brain-cancer#:~:text=Proton%20therapy%20can%20be%20used,healthy%20tissue%20surrounding%20the%20brain.' target='_blank'>Texas Center for Proton Therapy</a> </li></ul>

341

Proton Radiation Therapy for Brain Metastasis

Show Scientific Title

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy

Nearest Location from 94107:
2693 miles
Massachusetts General Hospital
Boston, MA

Visits:
5 visits per week

ClinicalTrials.gov: NCT03286335

Phase NA

342

Axatilimab Immunotherapy with Targeted Therapy for Advanced HER2 Negative Breast Cancer with BRCA1/2 or PALB2 Mutations

Show Scientific Title

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of axatilimab, an experimental immunotherapy, with olaparib (Lynparza®) PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) or HER2 low breast cancer with tumor or inherited BRCA1 or BRCA2 mutations or inherited PALB2 mutations. You must not have received more than 2 lines of chemotherapy, antibody drug conjugates (ADC), and/or immunotherapy for advanced disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axatilimab, by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, daily</li> <li class="seamTextUnorderedListItem">MRI and/or CT scans, every 2 months</li> <li class="seamTextUnorderedListItem">Electrocardiograms</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axatilimab is an experimental immunotherapy drug that may help the immune system go after and kill cancer drugs.</li> <li class="seamTextUnorderedListItem">Axatilimab is approved to treat Graft-Versus-Host Disease (GVHD), and its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">An electrocardiogram (ECG) test records electrical signals in your heart.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06488378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/clinical-trials/24-155' target='_blank'>Dana-Farber Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axatilimab' target='_blank'>National Cancer Institute: Axatilimab</a> </li></ul>

342

Axatilimab Immunotherapy with Targeted Therapy for Advanced HER2 Negative Breast Cancer with BRCA1/2 or PALB2 Mutations

Show Scientific Title

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Nearest Location from 94107:
2693 miles
Beth Israel Deaconess Medical Center
Boston, MA

Visits:
1 visit every 2 weeks

ClinicalTrials.gov: NCT06488378

Phase I

343

Screening Women with Breast Cancer for Edema and Lymphedema During Targeted Therapy

Show Scientific Title

Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer

Purpose: To study the onset of edema (swelling) and breast cancer-related lymphedema in women with breast cancer.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving targeted therapy after surgery at Massachusetts General Hospital Breast Cancer Center. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Informational brochure about lymphedema risk</li> <li class="seamTextUnorderedListItem">Lymphedema screening program card</li> <li class="seamTextUnorderedListItem">Measurement of arm volume with perometer and SOZO device, every 3 months up to 5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Edema is swelling of body tissues due to excess fluid.</li> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling that occurs following damage to the lymphatic system, which can happen after breast cancer surgery.</li> <li class="seamTextUnorderedListItem">The perometer uses light sensors to calculate the length and volume of your arms.</li> <li class="seamTextUnorderedListItem">The SOZO device measures the amount of fluid in your arm(s).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05142800' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>

343

Screening Women with Breast Cancer for Edema and Lymphedema During Targeted Therapy

Show Scientific Title

Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer

Nearest Location from 94107:
2693 miles
Massachusetts General Hospital
Boston, MA

Visits:
1 visit every 3 months up to 5 years

ClinicalTrials.gov: NCT05142800

Phase NA

344

Targeted Therapy Palbociclib for Brain Metastases

Show Scientific Title

A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway

Purpose: To study the safety, anti-cancer activity, and side effects of giving the CDK 4/6 inhibitor palbociclib (Ibrance®).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). You may not enroll if you have already received a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is commonly used with anti-estrogen therapy for metastatic, hormone-positive (ER+ and/or PR+), HER2-negative (HER2-) breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that metastasized to the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02896335' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

344

Targeted Therapy Palbociclib for Brain Metastases

Show Scientific Title

A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway

Nearest Location from 94107:
2693 miles
Massachusetts General Hospital
Boston, MA

Visits:
Please contact the research site

ClinicalTrials.gov: NCT02896335

Phase II

345

Scalp Cooling to Prevent Hair Loss During Chemotherapy for People With Metastatic Breast Cancer

Show Scientific Title

Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer

Purpose: To study the ability of the Paxman Scalp Cooling System to prevent hair loss during treatment with chemotherapy.

Who is this for?: People with metastatic (stage IV) breast cancer that are planning to receive chemotherapy. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1: Chemotherapy with Scalp Cooling <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paxman Scalp Cooling System, every 3 weeks</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), sacituzumab govitecan (Trodelvy®), or trastuzumab deruxtecan (Enhertu®), by IV, every 1-3 weeks</li> </ul> Group 2: Chemotherapy without Scalp Cooling <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), sacituzumab govitecan (Trodelvy®), or trastuzumab deruxtecan (Enhertu®), by IV, every 1-3 weeks</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Paxman Scalp Cooling System is FDA-approved for preventing hair loss for people undergoing chemotherapy.</li> <li class="seamTextUnorderedListItem">The Paxman Scalp Cooling System has not been studied to look at its ability to prevent hair loss in patients specifically receiving eribulin (Halaven®), sacituzumab govitecan (Trodelvy®), or trastuzumab deruxtecan (Enhertu®).</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a HER2-targeted antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a Trop-2-targeted antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04986579' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://coldcap.com//?lang=us' target='_blank'>Paxman: Paxman Scalp Cooling System</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/managing-hair-loss-scalp-cooling' target='_blank'>Memorial Sloan Kettering Cancer Center: Scalp Cooling</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/halaven' target='_blank'>Breastcancer.org: Eribulin (Halaven®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/trodelvy' target='_blank'>Breastcancer.org: Sacituzumab govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab deruxtecan (Enhertu®)</a> </li></ul>

345

Scalp Cooling to Prevent Hair Loss During Chemotherapy for People With Metastatic Breast Cancer

Show Scientific Title

Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer

Nearest Location from 94107:
2693 miles
Dana Farber Cancer Institute
Boston, MA

Visits:
1 visit every 1-3 weeks

ClinicalTrials.gov: NCT04986579

Phase II

346

VS-6766 Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Single Arm Phase 1/2 Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of VS-6766, an experimental RAF/MEK inhibitor, with abemaciclib (Verzenio®) CDK 4/6 inhibitor and fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. You must have received treatment with fulvestrant (Faslodex)® for advanced/metastatic disease and a CDK 4/6 inhibitor after surgery (adjuvant) or for advanced/metastatic disease. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">VS-6766, by mouth</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> Please contact research site for treatment schedule

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">VS-6766 is an experimental targeted therapy called a RAF/MEK inhibitor that targets and interrupts a pathway that allows cancer cells to grow.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Premenopausal women and men will also be given a drug that will put women in temporary menopause.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05608252' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verastem.com/research/pipeline/#raf-mek-inhibition' target='_blank'>Verastem: VS-6766 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li></ul>

346

VS-6766 Targeted Therapy for Advanced HR+, HER2- Breast Cancer

Show Scientific Title

A Single Arm Phase 1/2 Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer

Nearest Location from 94107:
2693 miles
Dana Farber Cancer Institite
Boston, MA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT05608252

Phase I-II

347

Capecitabine and Elacestrant Versus Capecitabine Alone for ER+, HER2- Advanced Breast Cancer

Show Scientific Title

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of capecitabine (Xeloda®) chemotherapy and elacestrant (Orserdu®) oral SERD versus capecitabine alone.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer whose cancer has progressed while receiving 1 or 2 lines of hormone therapy and palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®) for at least 6 months. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth, daily</li> <li class="seamTextUnorderedListItem">CT scans, every 2-3 months</li> <li class="seamTextUnorderedListItem">MRI scans, every 2-3 months</li> <li class="seamTextUnorderedListItem">Electrocardiogram (ECG)</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">CT scans, every 2-3 months</li> <li class="seamTextUnorderedListItem">MRI scans, every 2-3 months</li> <li class="seamTextUnorderedListItem">Electrocardiogram (ECG)</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is a SERD received by mouth and is approved for people with MBC and a mutation in the ESR1 gene. SERDs work by binding to and breaking down estrogen receptors. </li> <li class="seamTextUnorderedListItem">Participants in Group 2 with an ESR1 mutation whose cancer progresses on capecitabine have the option to continue in the trial and switch to elacestrant alone.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07222215' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.orserdu.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=23351373547&gbraid=0AAAABCDZCD8fUYjQTaZGVMAaU054fkATE&gclid=Cj0KCQiA4eHLBhCzARIsAJ2NZoKvkcIyFtvHb8DzhEzgbV-3X9vBKzc4Pg_8LyeSkBJe9XXQbH2DowAaAqHTEALw_wcB' target='_blank'>Menarini: Elacestrant (Orserdu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/new-hormone-therapies/' target='_blank'>Metastatic Trial Talk: Oral SERDs and Hormone Therapy</a> </li></ul>

347

Capecitabine and Elacestrant Versus Capecitabine Alone for ER+, HER2- Advanced Breast Cancer

Show Scientific Title

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

Nearest Location from 94107:
2693 miles
Dana-Farber Cancer Institute
Boston, MA

Visits:
Every 2-3 months, up to 5 years

ClinicalTrials.gov: NCT07222215

Phase II

348

MRI-Based Imaging Technique to Distinguish Recurrent Brain Metastases from Radiation Damage

Show Scientific Title

Treatment Response Assessment Maps (TRAMs) in the Delineation of Radiation Necrosis From Tumor Progression After Stereotactic Radiation in Patients With Brain Metastases: A Prospective Study

Purpose: To study whether Treatment Response Assessment Maps, a brain imaging technique, can help distinguish between a metastatic recurrence and tissue damage from prior radiation.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Participants must have had a metastatic recurrence at least 4 months after radiation to the same site in the brain and planning to undergo surgery. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain imaging by MRI and Treatment Assessment Maps followed by</li> <li class="seamTextUnorderedListItem">Brain surgery to remove suspected recurrence of brain metastasis</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Treatment Response Assessment Maps is an MRI-based imaging technique that may be able to distinguish recurrent brain metastases from radiation-damaged, but non-cancerous brain tissue.</li> <li class="seamTextUnorderedListItem">This technique may allow future patients to avoid unnecessary surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04033497' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

348

MRI-Based Imaging Technique to Distinguish Recurrent Brain Metastases from Radiation Damage

Show Scientific Title

Treatment Response Assessment Maps (TRAMs) in the Delineation of Radiation Necrosis From Tumor Progression After Stereotactic Radiation in Patients With Brain Metastases: A Prospective Study

Nearest Location from 94107:
2693 miles
Brigham and Women's Hospital
Boston, MA

Visits:
Number of visits unavailable

ClinicalTrials.gov: NCT04033497

Phase NA

349

2 Types of Whole Brain Radiation Therapy for Brain Metastasis

Show Scientific Title

Randomized Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) Versus Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT) in Patients With Brain Metastases

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of 2 types of whole brain radiation therapy (WBRT).

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) that have not received treatment with memantine (Namenda®). View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Normal tissue sparing whole brain radiation therapy (NTS-WBRT), 5 sessions per week for 2-3 weeks</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hippocampal avoidance whole brain radiation therapy (HA-WBRT), 5 sessions per week for 2-3 weeks</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Cognitive testing</li> <li class="seamTextUnorderedListItem">Hearing assessments</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li> <li class="seamTextUnorderedListItem">Normal tissue sparing whole brain radiation therapy (NTS-WBRT) is a targeted radiation therapy that reduces radiation to tissue that does not need radiation therapy.</li> <li class="seamTextUnorderedListItem">Hippocampal avoidance whole brain radiation therapy (HA-WBRT) is a targeted radiation therapy that avoids the hippocampus (part of the brain that controls learning and memory) during radiation therapy.</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®) is a standard of care medication that treats cognition (ability to think).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05013892' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

349

2 Types of Whole Brain Radiation Therapy for Brain Metastasis

Show Scientific Title

Randomized Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) Versus Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT) in Patients With Brain Metastases

Nearest Location from 94107:
2694 miles
Massachusetts General Hospital Cancer Center
Boston, MA

Visits:
5 visits per week for 2-3 weeks

ClinicalTrials.gov: NCT05013892

Phase II

350

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

Show Scientific Title

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Purpose: To study if a computer that has been taught how to match people to clinical trials (artificial intelligence) can help increase enrollment in clinical trials.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already decided to enroll in a clinical trial. View full eligibility criteria

What's involved?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A clinical trial matching report based on your medical records that you can review with your doctor.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use artificial intelligence and virtual tumor boards to help match people to clinical trials.</li> <li class="seamTextUnorderedListItem">The researchers will also create a registry to study the medical and financial effects of this program. </li> <li class="seamTextUnorderedListItem">This is an international trial that is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03452774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://massivebio.com/' target='_blank'>Massive Bio Study Information Page</a> </li></ul>

350

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

Show Scientific Title

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT03452774

Phase NA

351

Virtual Intervention to Improve the Well-Being of Black Women With Stage 0-IV Breast Cancer

Show Scientific Title

Project SOAR Awakenings: Randomized Controlled Trial for Black American Women Diagnosed With Breast Cancer

Purpose: To promote well-being and decrease depression and fatigue.

Who is this for?: Black women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Project SOAR Gatherings, virtual, 1.5- to 2-hour discussions, weekly for 1 month</li> <li class="seamTextUnorderedListItem">Questionnaires, virtual, 3 times within 3 months</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive materials by mail for use on your own</li> <li class="seamTextUnorderedListItem">Questionnaires, virtual, 3 times within 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Project SOAR sessions are based on books and articles that participants will receive. The sessions aim to help Black women accept their emotions, care for themselves, accept help from others, and manage stress.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07208084' target='_blank'>ClinicalTrials.gov</a> </li></ul>

351

Virtual Intervention to Improve the Well-Being of Black Women With Stage 0-IV Breast Cancer

Show Scientific Title

Project SOAR Awakenings: Randomized Controlled Trial for Black American Women Diagnosed With Breast Cancer

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT07208084

Phase NA

352

Studying the Relationship Between Inherited KRAS Mutations and Breast Cancer Risk

Show Scientific Title

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Purpose: To study the relationship between the KRAS mutation and cancer risk.

Who is this for?: People with stage I, stage II, stage III, and stage IV (metastatic) breast cancer, or people with a family history of breast cancer. You must also have endometriosis or an autoimmune condition. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Saliva sample to test for the KRAS mutation</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An inherited KRAS genetic mutation may increase a person's risk of developing breast or other types of cancer.</li> <li class="seamTextUnorderedListItem">This study will follow participants for 10 years. </li> <li class="seamTextUnorderedListItem">The researchers will also look at the effect that different lifestyle factors have on cancer risk. </li> <li class="seamTextUnorderedListItem">Participants will be able to get their KRAS mutation test results after submitting their sample at a discounted cost ($295).</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02253251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://miradx.com/test/kras-variant/' target='_blank'>MiraKind Research Company: KRAS-Variant</a> </li><li class='seamTextUnorderedListItem'><a href='http://mirakind.org/study-eligibility-questionnaire/' target='_blank'>Research Company: Eligibility Survey</a> </li></ul>

352

Studying the Relationship Between Inherited KRAS Mutations and Breast Cancer Risk

Show Scientific Title

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT02253251

Phase NA

353

Mindfulness Program to Promote Sexual Health after Breast Cancer

Show Scientific Title

Virtual Mindful After Cancer Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors

Purpose: To study the effects of a mindfulness-based program and how it may help improve quality of life and sexual health in women with breast cancer.

Who is this for?: Women with stage I or stage II or stage III or stage IV (metastatic) breast cancer who were diagnosed at least 6 months ago, and have at least one concern related to sexual health or body image. View full eligibility criteria

What's involved?

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing a virtual program called Mindful After Cancer (MAC). The program is designed to help people with breast (and gynecologic) cancer manage concerns about sexual health and body image after treatment.</li> <li class="seamTextUnorderedListItem">Researchers with test how well the program can help in areas such as: sexual well-being and satisfaction, body image, emotional health (including anxiety and mood), mindfulness, self-confidence in managing health, and overall quality of life.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07055854' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/wellness-body-image/how-breast-cancer-impacts-your-body-image' target='_blank'>Living Beyond Breast Cancer: Body Image and Breast Cancer</a> </li></ul>

353

Mindfulness Program to Promote Sexual Health after Breast Cancer

Show Scientific Title

Virtual Mindful After Cancer Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT07055854

Phase I

354

Fasting at Night to Improve Cognition After Chemotherapy for People with Stage I-IV Breast Cancer

Show Scientific Title

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors (RESTORE)

Purpose: To study how fasting at night affects health, quality of life, and cognitive ability.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who completed chemotherapy at least 3 months ago and who are having cognitive (thinking) problems. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fast at night, 6 nights every week for 2 months</li> <li class="seamTextUnorderedListItem">Health education videos, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Cognitive tests, 2 times in 2 months</li> <li class="seamTextUnorderedListItem">Surveys, 2 times in 2 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health education videos, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Cognitive tests, 2 times in 2 months</li> <li class="seamTextUnorderedListItem">Surveys, 2 times in 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">When you are fasting, you are still allowed to drink water, coffee, and tea.</li> <li class="seamTextUnorderedListItem">Cognitive problems are problems with thinking (cognition).</li> <li class="seamTextUnorderedListItem">This trial's enrollment will be racially diverse (at least 50% of participants will be Black, Hispanic, and/or Native American).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06938555' target='_blank'>ClinicalTrials.gov</a> </li></ul>

354

Fasting at Night to Improve Cognition After Chemotherapy for People with Stage I-IV Breast Cancer

Show Scientific Title

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors (RESTORE)

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT06938555

Phase NA

355

Counseling by Phone to Help Manage Side Effects of Immunotherapy for Stage II-IV Breast Cancer

Show Scientific Title

Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors

Purpose: To study whether telephone-based counseling will improve your ability to manage immunotherapy side effects.

Who is this for?: People with stage II, stage III, or stage IV (metastatic) breast cancer who have begun treatment with an immune checkpoint inhibitor within the past 3 months. You must be experiencing at least mild psychological distress. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Counseling, by phone call, weekly</li> <li class="seamTextUnorderedListItem">Handbook about managing side effects</li> <li class="seamTextUnorderedListItem">Assessment of side effects, weekly</li> <li class="seamTextUnorderedListItem">Interviews, 2 times within 4 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Assessment of side effects, weekly</li> <li class="seamTextUnorderedListItem">Interviews, 2 times within 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapies are drugs that trigger the immune system to see, go after, and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Side effects from immunotherapy are common.</li> <li class="seamTextUnorderedListItem">The ability to manage the side effects you experience from immunotherapy may reduce your distress, prevent treatment interruption, and lead to fewer visits to your doctor.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05715255' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/treatment/immunotherapy.html#:~:text=Possible%20side%20effects%20of%20immune,reaction%20while%20getting%20these%20drugs.' target='_blank'>American Cancer Society: Immune Checkpoint Inhibitors for Breast Cancer and Their Side Effects</a> </li></ul>

355

Counseling by Phone to Help Manage Side Effects of Immunotherapy for Stage II-IV Breast Cancer

Show Scientific Title

Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT05715255

Phase NA

356

Studying Alopecia During Hormone Therapy in Women with Breast Cancer

Show Scientific Title

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors

Purpose: To study the incidence, timing, duration, and severity of alopecia (hair loss) during hormone therapy.

Who is this for?: Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">While alopecia (hair loss) is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing hormone therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05612100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss' target='_blank'>Breastcancer.org: Alopecia/Hair Loss</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>

356

Studying Alopecia During Hormone Therapy in Women with Breast Cancer

Show Scientific Title

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT05612100

Phase NA

357

Online Pain and Depression Support Program for Asian Women with Stage I-IV Breast Cancer

Show Scientific Title

Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors (CAI)

Purpose: To study if an online pain and depression management program can support Asian women with breast cancer.

Who is this for?: Chinese, Korean, or Japanese women who were diagnosed with breast cancer in the past and are experiencing pain and depression. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: CAI (Web App Based, Individualized Coaching and Support Program for Cancer Pain) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized information and support program, online</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: CAPA (Web App Based Information and Coaching/Support Program for Cancer Pain Management) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General information and support program, online</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"> The pain and depression management program provides web-based information, coaching, and support that is culturally tailored to Asian American women with breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Mandarin (simplified or traditional), Korean, and Japanese.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06085313' target='_blank'>ClinicalTrials.gov</a> </li></ul>

357

Online Pain and Depression Support Program for Asian Women with Stage I-IV Breast Cancer

Show Scientific Title

Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors (CAI)

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT06085313

Phase NA

358

Susan G. Komen ShareForCures Research Registry

Show Scientific Title

ShareForCures: Susan G. Komen's People-powered, Data-driven Breast Cancer Research Registry

Purpose: To create a research registry of data from people with breast cancer, including minority and marginalized people, to ensure data is as diverse as the people touched by the disease.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue samples</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Saliva samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will have a better understanding of breast cancer and everyone can potentially benefit from scientific advances and improvements in care.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05654246' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/shareforcures/' target='_blank'>Susan G. Komen: ShareForCures</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/npcr/value/registries.htm' target='_blank'>Centers for Disease Control and Prevention: How Cancer Registries Work</a> </li></ul>

358

Susan G. Komen ShareForCures Research Registry

Show Scientific Title

ShareForCures: Susan G. Komen's People-powered, Data-driven Breast Cancer Research Registry

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT05654246

Phase NA

359

Care and Monitoring at Home for People with Brain Metastasis

Show Scientific Title

Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation

Purpose: To study if giving metformin and monitoring can be done at home for people receiving brain radiation or who have previously had brain radiation.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must be planning to receive brain radiation or completed brain radiation within the last 3 years. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Metformin, by mouth, daily, 1 year</li> <li class="seamTextUnorderedListItem">FitBit wearable device</li> <li class="seamTextUnorderedListItem">Cognitive tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care treatment, 1 year</li> <li class="seamTextUnorderedListItem">FitBit wearable device</li> <li class="seamTextUnorderedListItem">Cognitive tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain radiation can result in significant negative effects on cognition (the ability to clearly think, learn, and remember).</li> <li class="seamTextUnorderedListItem">Cognitive tests study your cognition, which is your ability to think.</li> <li class="seamTextUnorderedListItem">Metformin is a drug approved to treat type 2 diabetes (a condition in which the body cannot control the level of sugar in the blood).</li> <li class="seamTextUnorderedListItem">Metformin may also be used to treat cancer and improve your cognition (ability to think) and quality of life.</li> <li class="seamTextUnorderedListItem">In this study, a FitBit wearable device will be used to monitor and detect seizures.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06377696' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20567690' target='_blank'>Mayo Clinic: Trial Information Page</a> </li></ul>

359

Care and Monitoring at Home for People with Brain Metastasis

Show Scientific Title

Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT06377696

Phase II

360

Phone Survey to Improve Telemedicine Visits for Brain Metastasis

Show Scientific Title

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

Purpose: To compare opinions of telemedicine (virtual) visits and in-person visits to improve telemedicine (virtual) visits.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who had at least 2 visits at the MD Anderson Cancer Center Brain and Spine Center. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Survey, by phone</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">During the phone survey, you will be asked about your opinions on the quality of care you received at your telemedicine (virtual) or in-person visits.</li> <li class="seamTextUnorderedListItem">Telemedicine visits are also called virtual visits.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04988009' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

360

Phone Survey to Improve Telemedicine Visits for Brain Metastasis

Show Scientific Title

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT04988009

Phase NA

361

Empowerment and Navigation Sessions for Latina Women Ages 30+ with Breast Cancer or a Family History of Breast/Ovarian Cancer

Show Scientific Title

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

Purpose: To compare the impact of empowerment and navigation sessions with standard of care sessions on whether Latina women decide to receive genetic testing and/or genetic counseling.

Who is this for?: Latina women ages 30+ with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or with a family history of breast or ovarian cancer. You must have one social determinant of health risk factor, such as: perceived financial struggles, transportation difficulties, exposure to violence, housing challenges, social isolation/challenges. You must not have received genetic testing or genetic counseling. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, breast cancer screening, and diet and physical activity for breast cancer prevention.</li> <li class="seamTextUnorderedListItem">Standard of care sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, how to share breast cancer information, and testimonials and include role playing activities and group discussions.</li> <li class="seamTextUnorderedListItem">You can receive up to $100 for participation.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05483283' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/making-the-case-for-health-equity.pdf' target='_blank'>American Cancer Society: Health Equity and Social Determinants of Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health' target='_blank'>US Department of Health and Human Services: Social Determinants of Health</a> </li></ul>

361

Empowerment and Navigation Sessions for Latina Women Ages 30+ with Breast Cancer or a Family History of Breast/Ovarian Cancer

Show Scientific Title

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT05483283

Phase NA

362

Coaching Program to Reduce Stress and Promote Resilience for People with Metastatic Breast Cancer

Show Scientific Title

Promoting Resilience in Stress Management for Metastatic Breast Cancer (PRISM-MBC PRISMMBC)

Purpose: To study the ability of the PRISM program to reduce stress and improve resilience for people with metastatic breast cancer.

Who is this for?: People with stage IV (metastatic) breast cancer who were diagnosed with metastatic disease in the last 6 months. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Promoting Resilience in Women with Breast Cancer (PRISM) program, virtual, 4 sessions in 1-2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Promoting Resilience in Women with Breast Cancer (PRISM) program helps improve 4 areas of resilience: stress management, goal setting, cognitive reframing, and meaning-making.</li> <li class="seamTextUnorderedListItem">This study will compare the resilience of Black women to non-Black women.</li> <li class="seamTextUnorderedListItem">It also includes an optional family session.</li> <li class="seamTextUnorderedListItem">Each session is 30-60 minutes every 1-2 weeks.</li> <li class="seamTextUnorderedListItem">Black women with MBC have worse outcomes than white women with MBC because of social determinants of health (SDOH).</li> <li class="seamTextUnorderedListItem">Social determinants of health (SDOH) describe non-medical factors that influence your health, such as race, gender identity, education, occupation, transportation, food and health access, medication affordability, safety at home, housing, and financial stability.</li> <li class="seamTextUnorderedListItem">Reducing stress and improving resilience during MBC treatment may improve quality of life and even improve disease outcomes.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06855654' target='_blank'>ClinicalTrials.gov</a> </li></ul>

362

Coaching Program to Reduce Stress and Promote Resilience for People with Metastatic Breast Cancer

Show Scientific Title

Promoting Resilience in Stress Management for Metastatic Breast Cancer (PRISM-MBC PRISMMBC)

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT06855654

Phase NA

363

Virtual Tool to Help Make Chemotherapy Decisions for People with Stage I-IV Breast Cancer

Show Scientific Title

CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making

Purpose: To see if a virtual tool that informs people about chemotherapy-induced peripheral neuropathy (CIPN) helps people make decisions about chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), or docetaxel (Taxotere) chemotherapy and are experiencing peripheral neuropathy (nerve pain, discomfort, sensation changes, or weakness). View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual chemotherapy decision tool</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropathy is pain, discomfort, sensation changes, and weakness from nerve damage.</li> <li class="seamTextUnorderedListItem">Chemotherapy-induced peripheral neuropathy (CIPN) is neuropathy in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Around half of people who develop CIPN still have it 3 years later.</li> <li class="seamTextUnorderedListItem">A virtual decision tool that provides information about permanent CIPN and prepares patients for a discussion with their doctor may lead to improvements in treatment decision-making.</li> <li class="seamTextUnorderedListItem">This trial is enrolling virtually and does not require any in person visits.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06915168' target='_blank'>ClinicalTrials.gov</a> </li></ul>

363

Virtual Tool to Help Make Chemotherapy Decisions for People with Stage I-IV Breast Cancer

Show Scientific Title

CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT06915168

Phase NA

364

Mobile App to Reduce Emotional Distress in Women Under Age 45 With Breast Cancer

Show Scientific Title

Utility of a Mobile Application for Young Women With Breast Cancer

Purpose: To study the effects of using a mobile health application (the Mighty Pro app) to understand if it can help reduce cancer‑related emotional distress.

Who is this for?: Women, under age 45, with stage0 (DCIS) or stage I or stage II or stage III or stage IV breast cancer, experiencing moderate to high cancer‑related distress, and who are receiving care at Wake Forest Baptist Cancer Center. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1: Intervention <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use of Mighty Pro mobile application, for 1 year</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at whether using a mobile health application can help reduce cancer‑related distress in young women with breast cancer.</li> <li class="seamTextUnorderedListItem">The Mighty Pro app includes educational content and social connection for people with breast cancer.</li> <li class="seamTextUnorderedListItem">This trial does not require any in‑person visits and participation takes place using a mobile device over a 12‑month period.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07009093' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/emotional-health/managing-emotional-side-effects?utm_source=ppc&utm_medium=search&utm_campaign=in-treatment&utm_id=journey&gad_source=1&gad_campaignid=22665797719&gbraid=0AAAAAoX38tAgGRpQ7upZLxlLw_64Mdgcb&gclid=EAI' target='_blank'>Living Beyond Breast Cancer: Managing emotional side effects</a> </li></ul>

364

Mobile App to Reduce Emotional Distress in Women Under Age 45 With Breast Cancer

Show Scientific Title

Utility of a Mobile Application for Young Women With Breast Cancer

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT07009093

Phase NA

365

Online Portal to Educate and Refer Racially Diverse People to Clinical Trials

Show Scientific Title

Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida

Purpose: To study the tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adults with cancer and their family members through referral to cancer clinical trials.

Who is this for?: People who are Black, African American, Hispanic, and/or Latinx. People with cancer and their family members may enroll in this trial. You must live in Florida. View full eligibility criteria

What's involved?

You will be assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ALEX (Agent Leveraging Empathy for eXams) portal</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care portal</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Racial and ethnic minorities are underrepresented in cancer clinical trials.</li> <li class="seamTextUnorderedListItem">The ALEX (Agent Leveraging Empathy for eXams) Research Portal uses culturally responsive, virtual community health educators to reach diverse populations.</li> <li class="seamTextUnorderedListItem">Clinicians can utilize the ALEX portal to refer patients to trials. Community health educators can use the portal to help provide information to patients and schedule follow-ups. Patients and family members can use the portal to access key information and make referrals.</li> <li class="seamTextUnorderedListItem">The standard of care portal provides participants with access to existing online cancer clinical trial resources in one location.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05655494' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/diversity-in-clinical-trials-2/' target='_blank'>Steps Toward Expanding Eligibility Criteria to Increase Diversity in Clinical Trials</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/diversity-in-clinical-trials/' target='_blank'>The Lack of Diversity in Clinical Trials</a> </li></ul>

365

Online Portal to Educate and Refer Racially Diverse People to Clinical Trials

Show Scientific Title

Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT05655494

Phase NA

366

CSC Online Survey: The Cancer Experience Registry

Show Scientific Title

Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis (CER)

Purpose: To learn more about the emotional and social experiences and needs of people affected by cancer.

Who is this for?: People diagnosed with DCIS, stage I, stage II, stage III, or metastatic (stage IV) breast cancer and people who provide care to individuals diagnosed with cancer. View full eligibility criteria

What's involved?

Participation in this study involves the completion of an online questionnaire. The questionnaire may be accessed at the following link: <a href="http://www.cancersupportcommunity.org/MainMenu/ResearchTraining/Cancer-Experience-Registry.html" target="_blank">www.cancerexperienceregistry.org</a>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers hope to use this information to improve the educational materials and the overall quality of care that cancer patients receive. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people diagnosed with other types of cancer. </li> <li class="seamTextUnorderedListItem">The data collected from this study can be found <a href="https://www.cancersupportcommunity.org/RegistryIndexReport2017" target="_blank">here.</a></li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02333604' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerexperienceregistry.org/' target='_blank'>Cancer Support Community Study Website: Cancer Experience Registry</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancersupportcommunity.org/RegistryIndexReport2017' target='_blank'>Cancer Support Community: Cancer Experience Registry Index Report 2017</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youtube.com/watch?v=SyyUYqyNaCc' target='_blank'>Cancer Support Community YouTube Channel: What is the Cancer Experience Registry?</a> </li></ul>

366

CSC Online Survey: The Cancer Experience Registry

Show Scientific Title

Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis (CER)

No Travel Required

Visits:
Online surveys

ClinicalTrials.gov: NCT02333604

Phase NA

367

Integrative Medicine at Home Program for People With Stage I-IV Breast Cancer

Show Scientific Title

Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)

Purpose: To find out whether the Integrative Medicine at Home program can help reduce symptoms and improve treatment satisfaction.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are currently receiving treatment. View full eligibility criteria

What's involved?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Integrative Medicine at Home program, 3 months</li> </ul> Group 2: Enhanced Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Integrative medicine handout</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Integrative Medicine at Home program offers virtual (online rather than in-person) group classes focusing on mind-body practice.</li> <li class="seamTextUnorderedListItem">Mind-body practice is a health practice that combines mental focus, controlled breathing, and body movements to help relax the body and mind and reduce symptoms such as tiredness (fatigue), pain, or insomnia (sleep problems).</li> <li class="seamTextUnorderedListItem">The classes will be led by an Integrative Medicine Service (IMS) clinical therapist using Zoom video conferencing platform.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will be given a handout to encourage you to visit Memorial Sloan Kettering's Integrative Medicine website to access pre-recorded, on-demand meditation videos and audios.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05053230' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine' target='_blank'>Memorial Sloan Kettering Cancer Center: Integrative Medicine</a> </li></ul>

367

Integrative Medicine at Home Program for People With Stage I-IV Breast Cancer

Show Scientific Title

Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT05053230

Phase NA

368

Saliva Samples and Questionnaires to Study How Genes Affect Breast Cancer Risk

Show Scientific Title

The Rutgers University Genetics Coordinating Center Breast Cancer Study

Purpose: To study how genes impact breast cancer risk.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer, and people who have not been diagnosed with breast cancer. View full eligibility criteria

What's involved?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide saliva (spit) sample, by mail</li> <li class="seamTextUnorderedListItem">Questionnaires, online</li> <li class="seamTextUnorderedListItem">Access to your health records (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">By participating in this study, you will receive information about your genetic risk for free.</li> <li class="seamTextUnorderedListItem">Mutations in genes called BRCA1 and BRCA2 explain only about 25% of the genetic cause of breast cancer. </li> <li class="seamTextUnorderedListItem">Researchers are trying to learn more about the genetic cause of breast cancer, which will help researchers create new treatments and improve current treatment options.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06773897' target='_blank'>ClinicalTrials.gov</a> </li></ul>

368

Saliva Samples and Questionnaires to Study How Genes Affect Breast Cancer Risk

Show Scientific Title

The Rutgers University Genetics Coordinating Center Breast Cancer Study

No Travel Required

Visits:
No visits required

ClinicalTrials.gov: NCT06773897

Phase NA

369

MBC Connect Patient Registry: Sharing MBC History, Experiences, and Quality of Life

Show Scientific Title

MBC Connect -- Patient Powered. Research Driven

Purpose: To collect information about the experiences of people with metastatic breast cancer for researchers and clinicians and to provide personalized information to each participant.

Who is this for?: People with metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will be asked to fill out surveys about your breast cancer diagnosis, treatment history and quality of life.</li> <li class="seamTextUnorderedListItem">Based on information you enter, you will get personalized insights and alerts with MBC news, events, and clinical trial opportunities.</li> </ul> To join the registry, click here: <a href="https://www.mbcconnect.org/" target="_blank">www.mbcconnect.org/</a>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBC Connect is a free, web and mobile-friendly registry that collects information about the experiences of people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Joining the registry allows you to receive personalized information about MBC-related news, events, and clinical trial opportunities. </li> <li class="seamTextUnorderedListItem">Researchers and clinicians will be able to analyze information collected in the registry in research studies. </li> <li class="seamTextUnorderedListItem">MBC Connect is available in English and Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'><a href='https://www.mbcconnect.org/' target='_blank'>MBC Connect</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/' target='_blank'>Metastatic Breast Cancer Alliance</a> </li></ul>

369

MBC Connect Patient Registry: Sharing MBC History, Experiences, and Quality of Life

Show Scientific Title

MBC Connect -- Patient Powered. Research Driven

No Travel Required

Visits:
Mobile or online surveys

ClinicalTrials.gov: NCT00000003

Phase NA

370

MBC Project: Collecting Information About Metastatic Breast Cancer To Further Research

Show Scientific Title

The Metastatic Breast Cancer Project

Purpose: To accelerate research in treating, curing and preventing metastatic breast cancer.

Who is this for?: People with metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

Your participation will include the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete a simple online form about yourself and your cancer</li> <li class="seamTextUnorderedListItem">Fill out an online consent form that gives your permission for the researchers to obtain copies of your medical records and some of your stored tumor tissue</li> <li class="seamTextUnorderedListItem">Provide a saliva sample and send back via U.S. mail </li> </ul> To learn more and/or to participate, click here: <a href="https://www.mbcproject.org/" target="_blank">https://www.mbcproject.org/</a>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The goal of the Metastatic Breast Cancer Project is to accelerate research in treating, curing and preventing metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">If you take part in the project, you will fill out questionnaires, provide a saliva sample, and share a piece of your stored tumor tissue and copies of your medical records with the researchers. </li> <li class="seamTextUnorderedListItem">The researchers believe analyzing this data will help them learn more about metastatic breast cancer and make more research advances. </li> <li class="seamTextUnorderedListItem">The MBC Project was created by a coalition of researchers and breast cancer advocacy organizations.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'><a href='https://www.mbcproject.org/' target='_blank'>The Metastatic Breast Cancer Project</a> </li></ul>

You have matched to 373 trials

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.

Virtual Support and Navigation for People with Stage I-IV Breast Cancer

Virtual Support and Navigation for People with Stage I-IV Breast Cancer

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Alisertib Targeted Therapy with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Alisertib Targeted Therapy with Hormone Therapy for Advanced HR+, HER2- Breast Cancer

Experimental Anti-Estrogen Therapy Alone or with Targeted Therapy or Chemotherapy for Women with Advanced ER+, HER2- Breast Cancer

Experimental Anti-Estrogen Therapy Alone or with Targeted Therapy or Chemotherapy for Women with Advanced ER+, HER2- Breast Cancer

Niraparib Targeted Therapy and Irinotecan Chemotherapy for Advanced Breast Cancer with BRCA1, BRCA2, ATM, and PALB2 Mutations

Niraparib Targeted Therapy and Irinotecan Chemotherapy for Advanced Breast Cancer with BRCA1, BRCA2, ATM, and PALB2 Mutations

Talazoparib in Women With Metastatic Triple Negative or HR+, HER2- Breast Cancer with a Tumor (Not Inherited) BRCA1/2 Mutation

Talazoparib in Women With Metastatic Triple Negative or HR+, HER2- Breast Cancer with a Tumor (Not Inherited) BRCA1/2 Mutation

BBO-10203 Targeted Therapy with Trastuzumab for Advanced HER2+ or HR+, HER2- Breast Cancer

BBO-10203 Targeted Therapy with Trastuzumab for Advanced HER2+ or HR+, HER2- Breast Cancer

Experimental Therapy PF-07248144 for Advanced ER+, HER2- Breast Cancer

Experimental Therapy PF-07248144 for Advanced ER+, HER2- Breast Cancer

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

ASTX727 Targeted Therapy with Olaparib for Advanced Breast Cancer with Certain Mutations

ASTX727 Targeted Therapy with Olaparib for Advanced Breast Cancer with Certain Mutations

AZD9574 Targeted Therapy for Advanced HER2 Negative Breast Cancer With Certain Mutations

AZD9574 Targeted Therapy for Advanced HER2 Negative Breast Cancer With Certain Mutations

MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer

MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer

Capivasertib, Palbociclib, and Fulvestrant for Advanced ER+, HER2- Breast Cancer

Capivasertib, Palbociclib, and Fulvestrant for Advanced ER+, HER2- Breast Cancer

GDC-4198 CDK2/4/6 Inhibitor Plus Giredestrant Oral SERD Versus Abemaciclib Plus Giredestrant for Advanced ER+, HER2- Breast Cancer

GDC-4198 CDK2/4/6 Inhibitor Plus Giredestrant Oral SERD Versus Abemaciclib Plus Giredestrant for Advanced ER+, HER2- Breast Cancer

177Lu-FAP-2286 Radioactive Drug for Advanced Breast Cancer

177Lu-FAP-2286 Radioactive Drug for Advanced Breast Cancer

RLY-2608 PI3Kα Inhibitor Plus Fulvestrant Versus Capivasertib AKT Inhibitor Plus Fulvestrant for Advanced PIK3CA-Mutant HR+, HER2- Breast Cancer

RLY-2608 PI3Kα Inhibitor Plus Fulvestrant Versus Capivasertib AKT Inhibitor Plus Fulvestrant for Advanced PIK3CA-Mutant HR+, HER2- Breast Cancer

MBRC-201 Antibody-Drug Conjugate for Metastatic Breast Cancer

MBRC-201 Antibody-Drug Conjugate for Metastatic Breast Cancer

Studying Cannabis to Improve Symptoms for People with Stage I-IV Breast Cancer

Studying Cannabis to Improve Symptoms for People with Stage I-IV Breast Cancer

OP-1250 Hormone Therapy with Targeted Therapy for Advanced HR+, HER2- Breast Cancer

OP-1250 Hormone Therapy with Targeted Therapy for Advanced HR+, HER2- Breast Cancer

CLSP-1025 Immunotherapy for Advanced HLA-A*02:01 Positive Breast Cancer with p53 R175H Mutations

CLSP-1025 Immunotherapy for Advanced HLA-A*02:01 Positive Breast Cancer with p53 R175H Mutations

STX-478 Targeted Therapy for Advanced HR+, HER2- Breast Cancer with a PI3K Mutation

STX-478 Targeted Therapy for Advanced HR+, HER2- Breast Cancer with a PI3K Mutation

XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer

XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer

ETX-636 Targeted Therapy for Advanced HR+, HER2- Breast Cancer With PIK3CA Mutations

ETX-636 Targeted Therapy for Advanced HR+, HER2- Breast Cancer With PIK3CA Mutations

PLUMB Registry for Metastatic Lobular Breast Cancer

PLUMB Registry for Metastatic Lobular Breast Cancer

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Inavolisib Targeted Therapy with CDK4/6 Inhibitor and Hormone Therapy for HR+, HER2- Advanced Breast Cancer with PIK3CA Mutations

Inavolisib Targeted Therapy with CDK4/6 Inhibitor and Hormone Therapy for HR+, HER2- Advanced Breast Cancer with PIK3CA Mutations

BMS-986500 CDK4/6 Inhibitor for Advanced HR+ Breast Cancer

BMS-986500 CDK4/6 Inhibitor for Advanced HR+ Breast Cancer

Tersolisib PI3Ka Inhibitor For HR+, HER2- or HER2 Low Advanced Breast Cancer with a PIK3CA Mutation

Tersolisib PI3Ka Inhibitor For HR+, HER2- or HER2 Low Advanced Breast Cancer with a PIK3CA Mutation

Giredestrant Hormone Therapy with a CDK Inhibitor for Advanced ER+, HER2- Breast Cancer

Giredestrant Hormone Therapy with a CDK Inhibitor for Advanced ER+, HER2- Breast Cancer

Mobile Health Tools to Help Take Medication as Prescribed for People with Metastatic Breast Cancer

Mobile Health Tools to Help Take Medication as Prescribed for People with Metastatic Breast Cancer

LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer

LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

Usual Radiation Therapy Compared to Longer Radiation Therapy for People with Brain Metastases

Usual Radiation Therapy Compared to Longer Radiation Therapy for People with Brain Metastases

Radioactive Drug for Advanced HR+, HER2- or Triple Negative Breast Cancer

Radioactive Drug for Advanced HR+, HER2- or Triple Negative Breast Cancer

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

Lasofoxifene Hormone Therapy with CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer With an ESR1 Mutation

Lasofoxifene Hormone Therapy with CDK4/6 Inhibitor for Advanced ER+, HER2- Breast Cancer With an ESR1 Mutation

PRO1184 Antibody Drug Conjugate for Advanced HER2- Breast Cancer that Expresses FRA

PRO1184 Antibody Drug Conjugate for Advanced HER2- Breast Cancer that Expresses FRA

RE104 for People with Stage 0-IV Breast Cancer and Adjustment Disorder With Anxiety and Depression

RE104 for People with Stage 0-IV Breast Cancer and Adjustment Disorder With Anxiety and Depression

Genomic Test Studying the Tumor Microenvironment for Advanced Breast Cancer